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8Today there is widespread recognition among Member 
States and United Nations entities that drugs, together 
with organized crime, jeopardize the achievement of the 
Millennium Development Goals. It is increasingly clear 
that drug control must become an essential element of 
our joint efforts to achieve peace, security and develop-
ment. At the same time, we must reinforce our commit-
ment to shared responsibility and the basic principles of 
health and human rights.
The World Drug Report documents developments in 
global drug markets and tries to explain the factors that 
drive them. Its analysis of trends and emerging chal-
lenges informs national and international drug and 
crime priorities and policies, and provides a solid foun-
dation of evidence for counternarcotics interventions. 
Drug markets and drug use patterns change rapidly, so 
measures to stop them must also be quick to adapt. Thus 
the more comprehensive the drug data we collect and 
the stronger our capacity to analyse the problem, the 
better prepared the international community will be to 
respond to new challenges.
Recent trends
Despite increased attention to drug demand reduction 
in recent years, drug use continues to take a heavy toll. 
Globally, some 210 million people use illicit drugs each 
year, and almost 200,000 of them die from drugs. There 
continues to be an enormous unmet need for drug use 
prevention, treatment, care and support, particularly in 
developing countries.
Drug use affects not only individual users, but also their 
families, friends, co-workers and communities. Children 
whose parents take drugs are themselves at greater risk 
of drug use and other risky behaviours. Drugs generate 
crime, street violence and other social problems that 
harm communities. In some regions, illicit drug use is 
contributing to the rapid spread of infectious diseases 
like HIV and hepatitis.
Heroin consumption has stabilized in Europe and 
cocaine consumption has declined in North America – 
the most lucrative markets for these drugs. But these 
gains have been offset by several counter-trends: a large 
increase in cocaine use in Europe and South America 
over the last decade; the recent expansion of heroin use 
to Africa; and increased abuse of synthetic ‘designer 
drugs’ and prescription medications in some regions. 
Meanwhile, new drug use profiles are also emerging: 
consumption of combinations of drugs rather than just 
one illicit substance is becoming more common, and 
this increases the risk of death or serious health conse-
quences.
On the supply side, illicit cultivation of opium poppy 
and coca bush is now limited to a few countries, but 
heroin and cocaine production levels remain high. 
Although 2010 saw a significant decrease in opium pro-
duction, this was largely due to a plant disease that 
affected opium poppies in the major growing regions of 
Afghanistan. Yet between 1998 and 2009, global pro-
duction of opium rose almost 80 per cent, which makes 
the 2010 production decline less significant over the last 
decade.  Meanwhile, the market for cocaine has not 
shrunk substantially, it has simply experienced geo-
graphical shifts in supply and demand. Just a decade 
ago, the North American market for cocaine was four 
times larger than that of Europe, but now we are wit-
nessing a complete rebalancing. Today the estimated 
value of the European cocaine market ($33 billion) is 
almost equivalent to that of the North American market 
($37 billion).
Drug trafficking, the critical link between supply and 
demand, is fuelling a global criminal enterprise valued in 
the hundreds of billions of dollars that poses a growing 
challenge to stability and security. Drug traffickers and 
organized criminals are forming transnational networks, 
sourcing drugs on one continent, trafficking them across 
another, and marketing them in a third. In some coun-
tries and regions, the value of the illicit drug trade far 
exceeds the size of the legitimate economy. Given the 
enormous amounts of money controlled by drug traf-
fickers, they have the capacity to corrupt officials. In 
recent years we have seen several such cases in which 
ministers and heads of national law enforcement agen-
cies have been implicated in drug-related corruption. We 
are also witnessing more and more acts of violence, con-
flicts and terrorist activities fuelled by drug trafficking 
and organized crime. 
A stronger multilateral response to illicit drugs
In the face of such diverse and complex challenges, we 
must improve the performance of our global response to 
illicit drugs. 
This year is the 50th anniversary of the keystone of the 
international drug control system: the 1961 Single Con-
vention on Narcotic Drugs. Its provisions remain sound 
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9and highly relevant, as does its central focus on the pro-
tection of health. The international community must 
make more effective use of all three Drug Conventions 
as well as the Conventions against Transnational Organ-
ized Crime and Corruption. Mobilizing these powerful 
international legal instruments, together with existing 
law enforcement and judicial networks, can strengthen 
transnational cooperation in investigating and prosecut-
ing drug traffickers, combating money-laundering, and 
identifying, freezing and confiscating criminal assets. 
A comprehensive and integrated approach can also help 
us to confront the global threat from drugs more effec-
tively. We must build new partnerships. Governments 
and civil society must work together. States have to join 
forces in promoting regional cooperation. This strategy 
is already having some success against drugs originating 
in Afghanistan. The Paris Pact unites more than 50 
States and international organizations to counter traffic 
in and consumption of Afghan opiates. Regional coun-
ternarcotics information-sharing and joint cooperation 
initiatives like the Triangular Initiative (involving 
Afghanistan, the Islamic Republic of  Iran and Pakistan), 
the Central Asian Regional Information and Coordina-
tion Centre and Operation TARCET (initiative to pre-
vent the smuggling of precursors to Afghanistan) have 
intercepted and seized tons of illicit drugs and precursor 
chemicals. Building on the lessons of the Paris Pact, the 
Group of Eight, under the leadership of the French 
Presidency, recently launched an initiative to create a 
unified response to tackle the global cocaine market.
We also must ensure that supply and demand reduction 
efforts work together rather than in parallel. On the 
supply side, if we are to make real progress against heroin 
and cocaine, we must address illicit cultivation in a more 
meaningful and coordinated way. We have many tools at 
our disposal, including alternative livelihoods. Govern-
ments and aid agencies must invest more in development, 
productive employment and increased security. Crop 
eradication can also play a role, as a national responsibil-
ity with international support and assistance and in com-
bination with programmes that help farmers shift to the 
cultivation of licit crops. We must also develop new strat-
egies for preventing the diversion of chemicals that are 
used to make synthetic ‘designer drugs’ and to turn coca 
bush and opium poppies into cocaine and heroin. 
On the demand side, there is growing recognition that 
we must draw a line between criminals (drug traffickers) 
and their victims (drug users), and that treatment for 
drug use offers a far more effective cure than punish-
ment. We are seeing progress in drug use prevention 
through family skills training, and more attention is 
being paid to comprehensive HIV prevention, treatment 
and care. As an essential part of demand reduction 
efforts, we also need to more vigorously raise public 
awareness about illicit drugs, and facilitate healthy and 
fulfilling alternatives to drug use, which must not be 
accepted as a way of life.
Better data and analysis to enrich policy
A lack of comprehensive data continues to obstruct our 
full understanding of the markets for illicit drugs. The 
gaps are more prominent in some regions, such as Africa 
and Asia, and also around new drugs and evolving con-
sumption patterns. 
More comprehensive data collection allows for more and 
better analysis, which in turn enriches our response to 
the world drug challenge. I urge countries to strengthen 
their efforts to collect data on illicit drugs, and I encour-
age donors to support those countries that need assist-
ance in these efforts. If we can strengthen our research 
and analysis, we can better understand the drug phe-
nomenon and pinpoint areas where interventions are 
most likely to achieve positive results. 
I would like to thank the teams of skilled surveyors who 
gather data on cultivation and production levels of illicit 
crops in the world’s major drug-producing regions. The 
information they collect is of strategic importance to the 
efforts of both the Governments concerned and the 
international community to make our societies safer 
from drugs and organized crime. In addition, their data 
forms the core of this report. These brave individuals 
work in challenging and sometimes dangerous condi-
tions. Sadly, in May 2011 a team of UNODC crop 
surveyors in the Plurinational State of Bolivia lost their 
lives while on the job. I would like to pay tribute to their 
courage and commitment, and dedicate this report to 
their memory.
Yury Fedotov 
Executive Director 
United Nations Office on Drugs and Crime
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EXPLANATORY NOTES
Types of drugs:
ATS – Amphetamine-type stimulants (ATS) refers to a 
group of substances comprised of synthetic stimulants 
from the amphetamines-group of substances, including 
amphetamine, methamphetamine, methcathinone and 
the ecstasy-group substances (MDMA and its ana-
logues). In cases where countries report to UNODC 
without indicating the specific ATS they are referring to, 
the term non-specified amphetamines is used. In cases 
where ecstasy is referred to in enclosed brackets (‘ecstasy’), 
the drug represents cases where the drug is sold as ecstasy 
(MDMA) but which may contain a substitute chemical 
and not MDMA.
Coca paste (or coca base) – An extract of the leaves of the 
coca bush. Purification of coca paste yields cocaine (base 
and hydrochloride). 
Cocaine (base and salts) – Coca paste, cocaine base and 
cocaine hydrochloride referred to in the aggregate.
Crack (cocaine) – Cocaine base obtained from cocaine 
hydrochloride through conversion processes to make it 
suitable for smoking.
Heroin HCl (heroin hydrochloride) – Injectable form of 
heroin, sometimes referred to as ‘Heroin no. 4.’
Heroin no. 3 – A less refined form of heroin suitable for 
smoking.
Opioid – A generic term applied to alkaloids from opium 
poppy, their synthetic analogues, and compounds syn-
thesized in the body.  
Opiate – A subset of opioids comprised of the various 
products derived from the opium poppy plant including 
opium, morphine and heroin.
Poppy straw – All parts (except the seeds) of the opium 
poppy, after mowing.
Terms: Since there is some scientific and legal ambiguity 
about the distinctions between drug 'use', 'misuse' and 
'abuse', this report uses the neutral terms, drug 'use' or 
'consumption'.
Annual prevalence refers to the total number of people 
of a given age range who have used a given drug at least 
once in the past year divided by the number of people 
of a given age. 
Maps: The boundaries and names shown and the desig-
nations used on maps do not imply official endorsement 
or acceptance by the United Nations. A dotted line rep-
resents approximately the line of control in Jammu and 
Kashmir agreed upon by India and Pakistan. The final 
status of Jammu and Kashmir has not yet been agreed 
upon by the parties. Disputed boundaries (China/India) 
are represented by cross hatch due to the difficulty of 
showing sufficient detail. 
Population data: The data on population used in this 
report comes from: United Nations, Department of 
Economic and Social Affairs, Population Division, 
World Population Prospects: The 2008 Revision, 2009.
Regions: In various sections, this report uses a number 
of regional designations. These are not official designa-
tions. They are defined as follows:
 • East Africa: Burundi, Comoros, Djibouti, Eritrea, 
Ethiopia, Kenya, Madagascar, Mauritius, Rwanda, 
Seychelles, Somalia, Tanzania (United Republic of ) 
and Uganda.
 • North Africa: Algeria, Egypt, Libyan Arab Jamahiriya, 
Morocco, Sudan and Tunisia.
 • Southern Africa: Angola, Botswana, Lesotho, Malawi, 
Mozambique, Namibia, South Africa, Swaziland, 
Zambia and Zimbabwe.
 • West and Central Africa: Angola, Benin, Burkina 
Faso, Cameroon, Cape Verde, Central African Repub-
lic, Chad, Congo (Democratic Republic of ), Congo 
(Republic of ), Côte d’Ivoire, Equatorial Guinea, 
Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Li-
beria, Mali, Mauritania, Niger, Nigeria, Sao Tome and 
Principe, Senegal, Sierra Leone and Togo. 
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 • Caribbean: Antigua and Barbuda, Bahamas, Barbados, 
Bermuda, Cuba, Dominica, Dominican Republic, 
Grenada, Haiti, Jamaica, Saint Kitts and Nevis, Saint 
Lucia, Saint Vincent and the Grenadines and Trinidad 
and Tobago.
 • Central America: Belize, Costa Rica, El Salvador, 
Guatemala, Honduras, Nicaragua and Panama.
 • North America: Canada, Mexico and the United 
States of America. 
 • South America: Argentina, Bolivia (Plurinational State 
of ), Brazil, Chile, Colombia, Ecuador, Guyana, Para-
guay, Peru, Suriname, Uruguay and Venezuela (Boli-
varian Republic of ).
 • Central Asia and Transcaucasia: Armenia, Azerbaijan, 
Georgia, Kazakhstan, Kyrgyzstan, Tajikistan, Turk-
menistan and Uzbekistan.
 • East and South-East Asia: Brunei Darussalam, Cam-
bodia, China (including Hong Kong, Macao, and 
Taiwan Province of China), the Democratic People’s 
Republic of Korea, Indonesia, Japan, Lao People’s 
Democratic Republic, Malaysia, Mongolia, Myanmar, 
Philippines, the Republic of Korea, Singapore, Thai-
land, Timor-Leste and Viet Nam. 
 • Near and Middle East/South-West Asia: Afghanistan, 
Bahrain, Iran (Islamic Republic of ), Iraq, Israel, Jor-
dan, Kuwait, Lebanon, Oman, Pakistan, Qatar, Saudi 
Arabia, Syrian Arab Republic, the United Arab Emir-
ates and Yemen. The Near and Middle East refers to 
a subregion which includes Bahrain, Israel, Jordan, 
Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, the 
Syrian Arab Republic, the United Arab Emirates and 
Yemen.
 • South Asia: Bangladesh, Bhutan, India, Maldives, Ne-
pal and Sri Lanka. 
 • East Europe: Belarus, Republic of Moldova, Russian 
Federation and Ukraine.
 • South-East Europe: Albania, Bosnia and Herzegovina, 
Bulgaria, Croatia, Kosovo, Montenegro, Romania, 
Serbia, the former Yugoslav Republic of Macedonia 
and Turkey.
 • West and Central Europe: Andorra, Austria, Belgium, 
Cyprus, the Czech Republic, Denmark, Estonia, Fin-
land, France, Germany, Greece, Hungary, Iceland, 
Ireland, Italy, Latvia, Liechtenstein, Lithuania, Lux-
embourg, Malta, Monaco, the Netherlands, Norway, 
Poland, Portugal, San Marino, Slovakia, Slovenia, 
Spain, Sweden, Switzerland and the United Kingdom. 
 • Oceania: Australia, Fiji, Kiribati, Marshall Islands, 
Micronesia, Nauru, New Zealand, Palau, Papua New 
Guinea, Samoa, Solomon Islands, Tonga, Tuvalu, 
Vanuatu and other small island territories.
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EXPLANATORY NOTES
The following abbreviations have been used in this Report:
AIDS Acquired Immune-Deficiency  
Syndrome
ARQ UNODC annual reports questionnaire
ATS 
CCDAC
amphetamine-type stimulants
Central Committee for Drug Abuse 
Control (Myanmar)
CICAD Inter-American Drug Abuse Control 
Commission
CIS Commonwealth of Independent States
COP Colombian peso
DAINAP Drug Abuse Information Network for 
Asia and the Pacific
DEA United States, Drug Enforcement 
Administration
DELTA UNODC Database on Estimates and 
Long Term Trend Analysis
DIRAN Colombian National Police  
– Antinarcotics Directorate
DUMA Drug Use Monitoring in Australia
EMCDDA European Monitoring Centre for 
Drugs and Drug Addiction
ESPAD European School Survey Project  
on Alcohol and other Drugs
EUROPOL European Police Office
Govt. Government
HIV Human Immunodeficiency Virus
HONLEA Heads of National Drug Law  
Enforcement Agencies
IDS UNODC individual drug seizures 
database
IDU injecting drug use
INCB International Narcotics Control Board
INCSR International Narcotics Control Strat-
egy Report (United States Department 
of State)
INTERPOL/
ICPO
International Criminal Police  
Organization
LSD
LCDC
lysergic acid diethylamide
Lao National Commission for Drug 
Control and Supervision
MDA 3,4-methylenedioxyamphetamine 
(tenamfetamine)
MDE 3,4-methylenedioxyethylamphetamine
MDMA 3,4-methylenedioxymethamphetamine
NGO Non-governmental organization
NIDA National Institute of Drug Abuse 
(USA)
OECD Organization for Economic  
Co-operation and Development 
ONDCP Office of National Drug Control  
Policy (USA)
P-2-P 1-phenyl-2-propanone (BMK)
SACENDU South African Community  
Epidemiology Network on Drug Use
SAMHSA Substance Abuse and Mental Health 
Services Administration (USA)
SRO safrole-rich oils
THC tetrahydrocannabinol
UNAIDS Joint United Nations Programme on 
HIV/AIDS
UNODC United Nations Office on Drugs and 
Crime
WCO World Customs Organization
WDR
WHO 
World Drug Report
World Health Organization
3,4-MDP-2-P 3,4-methylenedioxyphenyl-2-pro-
panone (PMK)
 Weights and measurements:
l litre
g gram
mg milligram
kg kilogram
mt metric ton
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Global developments in illicit drug con-
sumption, production and trafficking
Consumption
Globally, UNODC estimates that, in 2009, between 
149 and 272 million people, or 3.3% to 6.1%  of the 
population aged 15-64, used illicit substances at least 
once in the previous year. About half that number are 
estimated to have been current drug users, that is, having 
used illicit drugs at least once during the past month 
prior to the date of assessment. While the total number 
of illicit drug users has increased since the late 1990s, 
the prevalence rates have remained largely stable, as has 
the number of problem drug users,1 which is estimated 
at between 15 and 39 million.
Cannabis is by far the most widely used illicit drug type, 
consumed by between 125 and 203 million people 
worldwide in 2009. This corresponds to an annual prev-
alence rate of 2.8%-4.5%. In terms of annual prevalence, 
cannabis is followed by ATS (amphetamine-type stimu-
lants; mainly methamphetamine, amphetamine and 
1 While there is no established definition of problem drug users, they 
are usually defined by countries as those that regularly use illicit sub-
stances and can be considered dependent, and those who inject drugs.
ecstasy), opioids (including opium, heroin and prescrip-
tion opioids) and cocaine. Lack of information regarding 
use of illicit drugs – particularly ATS - in populous 
countries such as China and India, as well as in emerging 
regions of consumption such as Africa, generate uncer-
tainty when estimating the global number of users. This 
is reflected in the wide ranges of the estimates.
While there are stable or downward trends for heroin 
and cocaine use in major regions of consumption, this is 
being offset by increases in the use of synthetic and pre-
scription drugs. Non-medical use of prescription drugs 
is reportedly a growing health problem in a number of 
developed and developing countries. 
Moreover, in recent years, several new synthetic com-
pounds have emerged in established illicit drug markets. 
Many of these substances are marketed as ‘legal highs’ 
and substitutes for illicit stimulant drugs such as cocaine 
or ‘ecstasy.’ Two examples are piperazines and mephe-
drone, which are not under international control. A 
similar development has been observed with regard to 
cannabis, where demand for synthetic cannabinoids 
Annual prevalence and number of illicit drug users at the global level, late 1990s-2009/2010
Source: UNODC estimates based on ARQ data and other official sources.
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(‘spice’) has increased in some countries. Sold on the 
internet and in specialized shops, synthetic cannabi-
noids have been referred to as ‘legal alternatives’ to can-
nabis, as they are not under international control. The 
control status of these compounds differs significantly 
from country to country.
In terms of treatment demand, the picture varies between 
regions. Cannabis contributes significantly to treatment 
demand in most regions, but it is particularly prominent 
in Africa and Oceania. Opiates dominate treatment 
demand in Europe and Asia, whereas cocaine is the main 
problem drug in South America. In North America, 
cannabis, opioids and cocaine make up similar shares of 
total treatment demand. ATS does not dominate any 
one region but makes a sizable contribution to treat-
ment demand particularly in Asia and Oceania, but also 
in Europe and North America.
In terms of the health consequences of drug use, the 
global average prevalence of HIV among injecting drug 
users is estimated at 17.9%, or equivalently, 2.8 million 
people who inject drugs are HIV positive. This means 
that nearly one in five injecting drug users is living with 
HIV. The prevalence of Hepatitis C among injecting 
drug users at the global level is estimated at 50% (range: 
45.2%-55.3%), suggesting that there are 8.0 million 
(range: 7.2 – 8.8 million) injecting drug users world-
wide who are also infected with HCV. Deaths related to 
or associated with the use of illicit drugs are estimated 
between 104,000 and 263,000 deaths each year, equiva-
lent to a range of 23.1 to 58.7 deaths per one million 
inhabitants aged 15-64. Over half of the deaths are esti-
mated to be fatal overdose cases.
Production
Global opium poppy cultivation amounted to some 
195,700 ha in 2010, a small increase from 2009. The 
vast bulk - some 123,000 ha - were cultivated in Afghan-
istan, where the cultivation trend remained stable. The 
global trend was mainly driven by increases in Myan-
mar, where cultivation rose by some 20% from 2009. 
There was a significant reduction in global opium pro-
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level, by illicit drug category, 2009-2010
Source: UNODC estimates based on ARQ data and other  
official sources.
Global opium poppy and coca cultivation (ha), 1990-2010*
* For Mexico (opium poppy) and the Plurinational State of Bolivia (coca), in the absence of data for 2010, the estimates for 2009 were 
imputed to 2010.
Sources: UNODC.
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Executive Summary
duction in 2010, however, as a result of disease in opium 
poppy plants in Afghanistan.
The global area under coca cultivation continued to 
shrink to 149,1002 ha in 2010, falling by 18% from 
2007 to 2010. There was also a significant decline in 
potential cocaine manufacture, reflecting falling cocaine 
production in Colombia which offset increases identi-
fied in both Peru and the Plurinational State of Bolivia. 
While it is difficult to estimate total global ampheta-
mine-type stimulants manufacture, it has spread, and 
more than 60 Member States from all regions of the 
world have reported such activity to date. The manu-
facture of amphetamines-group substances is larger 
than that of ecstasy. Methamphetamine - which belongs 
to the amphetamines-group - is the most widely manu-
factured ATS, with the United States of America report-
ing a large number of detected illicit laboratories. 
Cannabis herb cultivation occurs in most countries 
worldwide. Although there was insufficient data availa-
ble to update the global cultivation estimate, the rela-
tively stable seizure trend suggests a stable level of 
production. Indoor cultivation of cannabis herb is still 
largely limited to the developed countries of North 
America, Europe and Oceania. Cannabis resin produc-
tion estimates were not updated this year, but based on 
ARQ replies to UNODC, Afghanistan and Morocco 
were major producers.
Trafficking
Trafficking flows vary according to the drug type 
involved. The most commonly seized drug type, can-
nabis herb, is often locally produced and thus, interna-
2 The figure for the Plurinational State of Bolivia was not available at 
the time of printing of this report. The total area under cultivation 
in 2010 is based on 2009 figures for Bolivia and will be revised when 
the 2010 figure becomes available.
tional trafficking is limited. Cocaine and heroin are 
trafficked both intra- and inter-regionally, though con-
siderable amounts are consumed quite far from the 
countries of cultivation and production. Most ATS-
manufacture occurs in the region of consumption, 
whereas their precursor chemicals are trafficked inter-
regionally.
The long-term trends show increased seizures for all the 
major drug types. Between 1998 and 2009, seizures of 
cocaine, heroin and morphine, and cannabis almost 
doubled. ATS seizures more than tripled over the same 
period.    
Though it is still the most commonly seized drug, by far, 
the relative importance of cannabis in total illicit drug 
seizures has declined, rendering the other drug types – 
particularly ATS - increasingly prominent.
Looking at recent trends, global seizures of ATS rose to 
a record high in 2009, driven by increases in metham-
phetamine seizures. Ecstasy seizures, on the other hand, 
decreased. The predominant type of ATS seized varies 
according to region, with methamphetamine dominat-
ing in Oceania, Africa, North America and much of Asia. 
Seizures of opiates remained stable in 2009, with the 
Islamic Republic of Iran and Turkey continuing to 
account for the largest national seizure totals. Cocaine 
seizures also remained largely stable, at a high level. For 
cannabis, seizures of cannabis herb – the most widely 
consumed variety – increased, whereas resin seizures 
decreased.
For cocaine and cannabis resin, seizures are shifting away 
from the main consumer markets to source regions. 
Both North America and West and Central Europe 
account for declining shares of global cocaine seizures, 
while South America is seizing more. Similarly, cannabis 
resin seizures decreased significantly in Europe but 
increased in North Africa from 2008 to 2009.
The major drug markets
Opiates
Global use of opiates remained largely stable in 2009. 
UNODC estimates that some 12 to 21 million people 
used opiates worldwide; some three quarters of them 
used heroin. In 2009, an estimated 12-14 million global 
heroin users consumed some 375 mt of heroin. Europe 
and Asia remain the key global consumption markets, 
and they are largely supplied by Afghan opium.
In recent years, the non-medical use of various prescrip-
tion opioids has become increasingly problematic in 
some areas of the world, particularly in North America. 
In the United States, many emergency room visits are 
now related to prescription opioid use, and this drug 
class is also responsible for an increasing share of treat-
ment admissions in that country.
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Afghanistan accounts for 63% of the total global area 
under opium poppy cultivation. Cultivation there 
remained stable in 2010. Increases were registered in 
Myanmar in 2010, however, which resulted in an 
increasing global trend (5%). The opium yield is also 
increasing in Myanmar, causing the country’s potential 
opium production to increase by some 75%.
Nonetheless, global opium production dropped to 
4,860 mt in 2010, from to 7,853 mt the year before. 
This was largely due to a drastic reduction in Afghani-
stan’s opium production as a result of disease in opium 
poppy plants. UNODC forecasts for Afghan production 
in 2011 predict a further small decline or at least a sta-
bilization of overall opium poppy cultivation at the 
lower levels. If opium yield returns to the average level, 
opium production is likely to increase in Afghanistan in 
2011. 
Seizures of opium and heroin appeared to stabilize in 
2009, amounting to 653 mt and 76 mt, respectively. An 
estimated 460-480 mt of heroin were trafficked (includ-
ing seizures) worldwide in 2009, of which 375 mt 
reached the consumers. Traffickers’ use of maritime 
transportation and seaports has been identified as a key 
emerging threat.
The global opiate market was valued at US$68 billion 
in 2009, with heroin consumers contributing US$61 
billion of this. Heroin prices vary greatly. Although 
prices in Afghanistan increased in 2010, one gram costs 
less than US$4. In West and Central Europe, users pay 
some US$40-100 per gram, in the United States and 
northern Europe, US$170-200, and in Australia, the 
price is as high as US$230–370. While Afghan farmers 
only earned some US$440 million in 2010, organized 
crime groups in the main countries of consumption reap 
the largest profits.
Cocaine
In 2009, the annual prevalence of cocaine use was esti-
mated between 0.3% and 0.5% of the world population 
aged 15-64, or some 14.2 to 20.5 million people in that 
age range. Though the lower and upper bounds of 
cocaine users in 2009 have widened somewhat, con-
sumption remains essentially stable. Taking qualitative 
information into account, the actual number of cocaine 
users is probably closer to the lower end of the range. 
Despite significant declines in recent years, the largest 
cocaine market continues to be that of the United States, 
with an estimated consumption of 157 mt of cocaine, 
equivalent to 36% of global consumption. The second-
largest cocaine market is that of Europe, notably West 
and Central Europe, where consumption is estimated at 
123 mt. Over the last decade, the volume of cocaine 
consumed in Europe has doubled. In recent years, there 
are some signs of stabilization, though at the higher 
levels. Cocaine use in East Europe is limited.
The area under coca cultivation declined by 18% from 
2007 to 2010. Considering the past decade (2000-
2010), the decrease is even larger, 33%. Global seizures 
of cocaine have been generally stable over the period 
2006-2009, amounting to some 732 mt in 2009. Since 
2006 seizures have shifted towards the source areas in 
South America and away from the consumer markets in 
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North America and West and Central Europe. The role 
of West Africa in cocaine trafficking from South America 
to Europe might have decreased if judged from seizures 
only, but there are other indications that traffickers may 
have changed their tactics, and the area remains vulner-
able to a resurgence in trafficking of cocaine. Some coun-
tries in  the Asia-Pacific, with potentially large consumer 
markets, registered increasing cocaine seizures in 2008 
and 2009. 
The value of the global cocaine market is lower than it 
was in the mid-1990s, when prices were much higher 
and the market in the United States was strong. In 1995, 
the global market was worth some US$165 billion, 
while in 2009, this had been reduced to just over half of 
that, some US$85 billion (range: US$75-US$100 bn). 
As with heroin, almost all the profits are reaped by traf-
fickers. 
Amphetamine-type stimulants (ATS)
Global ATS use levels remained essentially stable in 
2009. ATS can be divided into two main categories: 
Amphetamines-group (mainly amphetamine and meth-
amphetamine) and ecstasy-group (MDMA and its ana-
logues). UNODC estimates that the annual prevalence 
for amphetamines-group substances ranged between 
0.3% and 1.3% in 2009, or some 14 to 57 million 
people aged 15-64 who had used such substances at least 
once in the past year. For the ecstasy-group, global 
annual prevalence was estimated at between 0.2% and 
0.6% of the population aged 15-64, or some 11 to 28 
million past-year users.
The predominant substance used varies between and 
within regions. Amphetamines-group substances domi-
nate in Africa, the Americas and Asia, whereas for 
Europe and Oceania, ecstasy-group prevalence rates are 
higher. In North America, the two groups are nearly on 
par. On aggregate, experts who reported their assessment 
of ATS use in their respective countries perceive that the 
use of amphetamines-group substances is stable or 
increasing, whereas for ecstasy, the trend was most often 
reported as stable (decreasing in Asia).
The manufacture of ATS is not geographically bound, 
and ATS laboratories tend to be located close to the 
illicit markets for these drugs. Precursors and other 
chemicals used in the illicit manufacture of ATS are 
frequently trafficked across regions. 
Some 10,600 ATS-related laboratories were reported 
seized in 2009. The vast bulk of the seized laboratories 
were manufacturing methamphetamine, most of them 
located in the United States. Methamphetamine is the 
most widely manufactured ATS worldwide. Amphet-
amine and ecstasy manufacture operations tend to be 
fewer in number but have more sophisticated operations 
as they require more specialized equipment, precursor 
chemicals and greater skill levels. 
In 2009, global seizures of ATS rose significantly, slightly 
exceeding the high level of 2007. The increase was 
mainly driven by methamphetamine seizures, which 
rose by more than 40% to reach 31 mt. Amphetamine 
seizures rose by some 10% to 33 mt. Ecstasy seizures 
decreased somewhat from the already low 2008 level, 
and amounted to 5.4 mt. 
In East and South-East Asia, ATS markets have expanded 
over the past year. Expert perceptions indicate that 
increases in ATS use – notably use of methamphetamine 
- are significant. Government experts have reported that 
methamphetamine ranks among the top three illicit 
drugs consumed in several countries in this region, 
including China, Japan and Indonesia. 
Africa is a region of concern with regard to the traffick-
ing of ATS. Trafficking of methamphetamine from 
Africa was reported first at the end of 2008 and reports 
have continued since. West Africa, in particular, is 
emerging as a new source of methamphetamine for illicit 
markets in East Asia, with couriers transiting Europe, 
West Asia or East Africa. Precursor chemicals are also 
frequently trans-shipped through the region.
In India, the first clandestine ATS manufacture opera-
tion was detected in May 2003. Since then, several 
additional facilities have been uncovered. Attempts at 
illicit ATS manufacture have also been reported from 
Bangladesh and Sri Lanka. South Asia has become one 
of the main regions used to obtain ephedrine and 
Total ATS (including
non-specified amphetamines; right axis)
Amphetamine (left axis)
Methamphetamine (left axis)
Ecstasy (MDA, MDEA, MDMA; left axis)
Seizures of ATS, by type, 2001-2009
Source: UNODC DELTA.
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pseudoephedrine for the illicit manufacture of metham-
phetamine. India is one of the world’s largest manufac-
turers of precursor chemicals and Bangladesh also has a 
growing chemical industry. Amphetamine, metham-
phetamine and ecstasy have been regularly seized in 
South Asia over the past five years.  
Cannabis
Cannabis remains by far the most widely produced and 
consumed illicit substance globally. In 2009, between 
2.8% and 4.5% of the world population aged 15-64 - 
between 125 and 203 million people - had used canna-
bis at least once in the past year. This is similar to last 
year’s estimates. Cannabis herb is the most common 
type used, produced and seized.
Some increases in cannabis use were reported from the 
Americas, Africa and Asia in 2009, whereas consump-
tion in western Europe and Oceania remained stable or 
declined. Over the past 10 years, experts from an increas-
ing number of countries have been reporting stable can-
nabis use trends. Despite this, cannabis use accounts for 
the bulk of treatment demand in Africa and Oceania.
Recent studies have shown that intensive (long-term 
regular use, high doses) exposure to cannabis products 
with high potency levels may increase the risk of psy-
chotic disorders. The average concentration of the major 
psychoactive substance in cannabis products (THC) 
seems to be higher than it was 10-15 years ago, though 
data for the past five years show a stable trend in some 
countries. The pattern, however, is not consistent for all 
products and all countries.
Cannabis herb cultivation is widely dispersed as it is 
mostly produced for domestic or regional markets. 
Therefore, an estimation of total global production is 
fraught with difficulty. Cannabis resin production is 
more localized and the drug is trafficked over larger 
distances. The countries most often identified as sources 
by the cannabis resin consumer markets are Morocco, 
Afghanistan, Lebanon and Nepal/India.
In Afghanistan, the first UNODC/Government canna-
bis survey in 2009 indicated that Afghanistan is indeed 
among the significant cannabis resin-producing coun-
tries. Moreover, cannabis has become a competitor to 
opium poppy as a lucrative crop for farmers in the coun-
try. The preliminary second survey in 2010 gave no 
indications of major changes in the levels of cultivation 
and production compared to 2009.
Cannabis herb seizures increased somewhat – returning 
to the levels of 2006-2007 following a drop in 2008 - 
and amounted to some 6,000 mt. North America 
accounts for the bulk of herb seizures, and seizures in the 
United States and Mexico increased in 2009. Cannabis 
resin seizures, on the other hand, decreased from their 
peak level in 2008. Resin seizures continued their shift 
away from West and Central Europe – where seizures are 
at their lowest level for the last 10 years - to the promi-
nent source region of North Africa, where seizures have 
increased.
Opioids ,
18.9 %
Cannabis ,
64 %
Methaqualone,
3.7% 
ATS , 5.1 %
Khat, 3.9% 
Cocaine,
5 %
S olvents  and
 inhalants , 3.2% 
S edatives  and 
tranquillizers ,
2.3% 
Africa: Distribution* of primary drug of abuse  
of people entering treatment, 2009
*Total is greater than 100% due to polydrug use. 
Source: UNODC ARQ.
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The following chapter first draws together information 
on the global drug problem in its three main sectoral 
dimensions – production, trafficking and consumption, 
including prevalence, drug-related treatment, drug-
related infectious diseases and drug deaths. This is fol-
lowed by a regional overview. More detailed information 
on specific drug markets (opiates, cocaine, cannabis and 
amphetamine-type stimulants) can be found in subse-
quent chapters. 
2) Global overview
a) Production
The world’s largest illicit drug product – in volume 
terms – is cannabis, that is, the production of cannabis 
herb, followed by cannabis resin. The second largest 
illicit drug production is related to cocaine, followed by 
heroin. Amphetamine-type stimulants production seems 
to be at comparable levels with heroin.
Cannabis – the most widely produced illicit drug 
worldwide 
Cannabis herb production takes place across all conti-
nents and in almost all countries. Indoor production of 
cannabis, in contrast, is concentrated in developed 
countries in North America, Europe and Oceania. No 
reliable trend information of cannabis herb production 
at the global level is available. Cannabis herb seizures 
suggest a stable level of cannabis herb production glo-
bally. 
Cannabis resin production is geographically more lim-
ited. Based on information on the origin of cannabis 
resin, supplied by Member States, this seems to take 
place primarily in Morocco – mainly producing for the 
markets in West and Central Europe and North Africa 
– and Afghanistan – mainly producing for neighbouring 
countries in South-West Asia and for the local market. 
Moroccan authorities report that cannabis resin produc-
tion has declined in recent years. Cannabis production 
in Afghanistan – based on joint surveys conducted by 
UNODC and the Government – seems to show a gener-
ally stable level in 2010, compared to a year earlier 
(which was 1,500-3,500 mt in 2009). 
Opium and cocaine production falling... 
Information on production is more readily available 
when it comes to heroin and cocaine. UNODC and the 
Governments concerned conduct regular opium and 
coca surveys in the main opium and coca producing 
areas. These surveys showed clear declines over the 
2007-2009 period (-21% for opium and -13% for coca). 
The global area under coca cultivation continued to 
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Fig. 1: Global opium poppy and coca cultivation, 1990-2010*
* For Mexico (opium poppy) and the Plurinational State of Bolivia (coca), in the absence of data for 2010, the estimates for 2009 were 
imputed to 2010.
Source: UNODC, Illicit Crop Monitoring Programme (ICMP). 
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shrink further to 149,1001 ha in 2010, thus falling by 
18% from 2007 to 2010. The global area under coca 
cultivation in 2010 was a third lower than in 2000. 
The downward trend for the area under opium poppy 
cultivation did not continue in 2010, mainly due to 
increases in Myanmar. The global area under opium 
cultivation in 2010 amounted to some 195,700 ha, 
which was still some 12% lower than in 2000 and more 
than a quarter lower than in 1990. Afghanistan contin-
ued to account for the bulk of the cultivation with some 
123,000 ha (63% of the global total).
In terms of production, opium output declined strongly 
in 2010 (-38%) due to a massive decline of opium pro-
duction in Afghanistan (-48%) linked to much lower 
yields as a consequence of various plant diseases that 
affected poppy plants. These declines of the yield in 
Afghanistan more than offset the increases in Myanmar. 
Nonetheless, Afghanistan remained the world’s largest 
illicit opium-producing country, accounting for 74% of 
global opium production in 2010, down from 88% in 
2009 and 92% in 2007. In parallel, the importance of 
Myanmar increased, from 5% of total opium produc-
tion in 2007 to 12% in 2010. Given the declines of 
opium production in Afghanistan, global opium pro-
duction declined by 45% between 2007 and 2010.
In parallel, ‘potential’ heroin manufacture, that is, the 
heroin that could have been manufactured from the 
opium produced (less the amounts of opium consumed 
as is), fell from some 760 mt in 2007 to less than 400 
mt in 2010. These calculations, however, do not take 
into account the stock and inventory of opium. Based 
on consumption estimates and the amounts seized, it is 
1 The figure for the Plurinational State of Bolivia was not available at 
the time of printing of this report. The total area under cultivation 
in 2010 is based on 2009 figures for Bolivia and will be revised when 
the 2010 figure becomes available.
estimated that the ‘heroin available in the market’ (prior 
to seizures) was, on average, around 430 mt per year 
over the 2002-2008 period and between 460 and 480 
mt in 2009. 
There has been a significant decline in potential cocaine 
manufacture in recent years. Between 2007 and 2010, 
potential cocaine production shrank by about one sixth, 
reflecting strongly falling cocaine production in Colom-
bia which offset increases identified in both Peru and the 
Plurinational State of Bolivia. 
… while manufacture of ATS appears  
to be increasing 
There is no new global ATS production estimate for the 
year 2009. Available indicators suggest, however, that 
global manufacture of ATS may have increased in 2009. 
Seizures of ATS increased by 16% in 2009. The number 
of ATS laboratory incidents rose by 26% on a year ear-
lier to some 10,600, though this figure was still 46% 
lower than in the peak year of 2004. 
The increase was mainly linked to methamphetamine 
laboratories dismantled in the United States of America. 
Global seizures of the main methamphetamine precur-
sor chemicals (ephedrine and pseudoephedrine), taken 
together, more than doubled in 2009. 
In contrast, the number of amphetamine and ecstasy 
laboratories dismantled globally was lower in 2009 than 
in 2007 and far lower than in 2004. Seizures of the main 
amphetamine and ecstasy precursors fell in 2009. The 
importance of Europe as a key location for the manufac-
ture of ecstasy continued to decline. 
Fig. 2: Global opium production (mt),  
2002-2010
Source: UNODC, Illicit Crop Monitoring Programme (ICMP).
Fig. 3: Global number of dismantled ATS  
laboratories, 2007-2009
Source: UNODC ARQ.
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b) Trafficking 
Trafficking flows continue to show distinct patterns: 
 • Most of the cannabis herb traﬃcking is intra-regional. 
In fact, most cannabis is locally produced and locally 
consumed and thus does not generally leave domestic 
frontiers. 
 • Most of the cannabis resin produced in Morocco is 
destined for consumption in West and Central Eu-
rope and North Africa. Cannabis resin produced in 
Afghanistan is primarily destined for neighbouring 
regions. 
 • Cocaine traﬃcking is both intra-regional and inter-re-
gional. Cocaine produced in the three Andean coun-
tries (Colombia, Peru and the Plurinational State of 
Bolivia) continues to be primarily destined for North 
America and West and Central Europe. Actual exports 
out of Andean countries (after deducting seizures and 
consumption in the Andean region) are estimated at 
788 mt. 378 mt are estimated to have left the Andean 
region for North America in 2009, of which some 
200 mt – purity adjusted – were seized in the process. 
The importance of North America has declined, how-
ever, over the last few years. The next main destina-
tions were the countries of West and Central Europe, 
mostly direct shipments, though some traﬃcking also 
takes place via countries in Africa, notably West Africa 
(around 13% of all traﬃcking to Europe). About 217 
mt of cocaine are thought to have left the Andean 
region for West and Central Europe, of which almost 
100 mt (purity-adjusted) were seized in the process. In 
addition, a signiﬁcant share of the cocaine produced 
is also traﬃcked to the Southern Cone countries of 
South America for domestic consumption.
 • Heroin traﬃcking is both intra-regional and inter-
regional in nature. Heroin produced in Afghanistan 
is consumed within the region and/or traﬃcked to 
Europe. Some 160 mt of Afghan heroin are estimated 
to have entered Pakistan in 2009 of which the bulk 
(some 138 mt) were for ﬁnal destinations in Europe, 
South-East Asia, South Asia and Africa. Some 145 mt 
of heroin is estimated to have been traﬃcked from 
Afghanistan to the Islamic Republic of Iran for local 
consumption and onward traﬃcking in 2009. Some 
75-80 mt of heroin are estimated to have reached 
West and Central Europe, mostly traﬃcked via South-
East Europe. About 90 mt of Afghan heroin are esti-
mated to have been traﬃcked to Central Asia, mainly 
for ﬁnal destinations in the C.I.S countries, notably 
the Russian Federation. Heroin manufactured in 
Myanmar is primarily for the market in other South-
East Asian countries. Heroin produced in Mexico and 
Colombia is mainly destined for the United States and 
some limited local consumption. 
 • Traﬃcking in amphetamines continues to be mainly 
intra-regional, while the traﬃcking in ampheta-
mines precursor chemicals continues to be largely 
inter-regional. 
 • Ecstasy-traﬃcking has – traditionally – been intra-
regional within Europe (as the origin of most of the 
ecstasy used to be Europe) and inter-regional for other 
regions. In recent years, the importance of Europe as 
a source region has clearly declined. Production has 
shifted to other regions, notably North America and 
South-East Asia. Exports from the latter regions to 
other regions are, however, still very limited. 
Seizures of cannabis herb and resin have shown a gener-
ally stable trend over the 2007-2009 period. In 2009, 
cannabis herb seizures increased while resin seizures 
declined. 
Following strong increases over the 2000-2005 period, 
Fig. 4: Global seizures of selected drugs (mt), 2005-2009 
Source: UNODC ARQ. Quantities as reported (not adjusted for purity).
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global cocaine seizures fluctuated, but did not change 
significantly between 2005 and 2009. The high cocaine 
seizures indicate ongoing improvements in the cocaine 
interception rates, given falling cocaine production at 
the global level. 
Opium seizures almost doubled between 2005 and 
2009, while seizures of heroin and morphine, taken 
together, remained generally stable over the 2005-2009 
period. This suggests that the strong increase of opium 
production in Afghanistan (until 2007) led to increasing 
opium exports but was not translated into an equally 
rapid expansion of heroin production at the global level. 
Similarly, the declines of Afghan opium production after 
2007 did not lead to any declines of heroin and mor-
phine trafficking - at least not until 2009. 
Seizures of amphetamines increased over the 2005-2009 
period, mainly reflecting increases in methamphetamine 
seizures.2 Ecstasy seizures, in contrast, declined. Between 
2007 and 2009 they fell by more than two thirds, which 
seems to confirm reports of an ecstasy shortage in several 
markets.
Long-term seizure trends show that cocaine, heroin and 
morphine as well as cannabis seizures – in volume terms 
- almost doubled between 1998 and 2009, while seizures 
of ATS more than tripled over the same period. 
Over the 2005-2009 period, the above-mentioned 
plant-based drug seizures remained largely stable while 
ATS seizures, excluding ecstasy, showed a clear increase. 
2 Seizures of amphetamines and ecstasy shown in this report differ 
from those shown in previous reports. Pills have been converted 
in ‘gross weight’ terms into amphetamines or ecstasy (instead of 
the actual amounts of psychoactive substances contained in such 
pills) as seizures of other substances are also shown in ‘gross weight’ 
terms, and not purity-adjusted. The volume of amphetamines and 
ecstasy, shown in kilogram equivalents, is thus higher than in previ-
ous reports. 
c) Consumption
Drug users 
Globally, UNODC estimates that between 149 and 272 
million people, or, 3.3% to 6.1% of the population aged 
15-64 used illicit substances at least once in the previous 
year. About half that number is estimated to have been 
current drug users, that is, having used illicit drugs at 
least once during the past month prior to the survey. 
Thus, the use of illicit psychoactive substances – for 
which a global control system is in place - continues to 
be substantially lower than the use of a legal psychoac-
tive substance such as tobacco.3 Some 25% of the adult 
population (15 years and above) are current tobacco 
smokers, according to the World Health Organization.4 
Prevalence rates of illicit drug use have remained gen-
erally stable over the last decade 
The overall number of drug users appears to have 
increased over the last decade, from 180 to some 210 
million people (range: 149-272 million). In terms of 
prevalence rate, the proportion of drug users among the 
population aged 15-64, however, remained almost 
unchanged at around 5% (range: 3.4%-6.2%) in 2009/ 
2010. 
Problem drug use remains relatively stable 
Considering only the problem drug users, estimates 
range from 15 to 39 million people, equivalent to 0.3%-
3 The WHO places tobacco in the group of psychoactive substances 
(World Health Organization, Neuroscience of psychoactive substance use 
and dependence, Geneva, 2004.) 
4 World Health Organization, World Health Statistics 2010. Results 
were derived from the WHO report on the global tobacco epidemic, 
2009. Data on male use of tobacco products (41.1% of the male 
population aged 15 and above) and female use of tobacco products 
(8.9% of the female population aged 15 and above) are considered 
by WHO to be the best estimate for the year 2006. 
Fig. 5: Trends in seizures of main drug categories (index: 1998 = 100), 1995-2009 
Source: UNODC ARQ.
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0.9% of the population aged 15-64. While there is no 
established definition of problem drug users, they are 
usually defined by countries as those that regularly use 
illicit substances and can be considered dependent, and 
those who inject drugs. The European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) 
defines problem drug use as “injecting drug use or long 
duration/regular use of opioids, cocaine and/or 
amphetamines.”5 A comparison of problem drug use 
since 2004/2005 shows a fairly stable trend.
5 EMCDDA (2008), Guidelines for Estimating the Incidence of Problem 
Drug Use, Lisbon.
Fig. 6: Annual prevalence of illicit drug use, late 1990s-2009/2010 
Source: UNODC estimates based on UNODC ARQ and other official sources. 
Fig. 7: Prevalence of tobacco and illicit drug 
use among the adult population, in % 
* The calculation of monthly use was based on information from 
35 countries for which ratios of past month to annual drug use 
levels were calculated. In case no total drug use figures were avail-
able, the ratio of past month cannabis to past year cannabis use 
was used as a proxy. The unweighted average showed that past- 
month prevalence was equivalent to 52% of annual prevalence. 
Applying this to a prevalence rate of 4.8% results in a past-month 
prevalence estimate of around 2.5%.
Sources: UNODC estimates for illicit drugs based on UNODC 
ARQ; tobacco statistics: WHO, World Health Statistics 2010.
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Cannabis remains the most widely used illicit drug, 
ahead of ATS, opioids and cocaine
A breakdown of illicit drug use shows that cannabis 
remains by far the most widely used illicit substance. 
The number of cannabis users was estimated between 
125 and 203 million in 2009, equivalent to a prevalence 
rate of 2.8%-4.5% of the population aged 15-64.
The second most widely used group of substances seems 
to be the ATS (including methamphetamine, ampheta-
mine, methcathinone and ecstasy). Within ATS, the 
‘amphetamines’ (methamphetamine, amphetamine and 
methcathinone) is still the most prominent group of 
substances, used by 14-56 million people in 2009, 
equivalent to a prevalence rate ranging from 0.3% to 
1.3% of the population aged 15-64. The broad ranges 
are mainly due to major uncertainties regarding the 
extent of amphetamines consumption in the world’s two 
most populous countries, China and India, as well as 
uncertainties regarding the spread of amphetamines use 
in Africa. The same applies to the broad ranges for 
ecstasy use (11-28 million people, or a prevalence rate 
ranging from 0.2-0.6% of the population aged 15-64). 
The third most widely used group of substances appears 
to be the opioids, with estimates ranging from 24 to 35 
million people, equivalent to a prevalence rate of 0.5%-
0.8% of the population aged 15-64. The most problem-
atic opioids6 at the global level, as reflected in treatment 
demand, are the opiates, that is, the various psychoactive 
substances derived from the opium poppy plant, notably 
opium and heroin. About 12-21 million people are esti-
mated to have consumed illicit opiates in 2009, equiva-
lent to a prevalence rate ranging from 0.3% to 0.5%. 
The most problematic opiate in the world’s illegal drug 
markets continues to be heroin. UNODC estimates that 
there were some 12-14 million heroin users in the world 
in 2009. In recent years, problem drug use has also been 
related to the non-medical use of various prescription 
opioids, such as oxycodone, fentanyl or pethidine.
Cocaine appears to rank fourth in terms of global preva-
lence, with estimates ranging from 14 to 21 million 
people,7 equivalent to an annual prevalence rate ranging 
from 0.3%-0.5% of the population aged 15-64. The 
global use of cocaine seems to be less widespread than 
the use of opioids, similar to the use of opiates, and 
more widespread than the use of heroin. 
6 Opioid is a generic term applied to alkaloids from opium poppy, 
their synthetic analogues, and compounds synthesized in the body. 
In general, a distinction is made between ‘opiates’ (that is, the various 
products derived from the opium poppy plant) and synthetic opioids. 
More detail is available in the chapter on the opium/heroin market. 
7 Taking qualitative information into account (regarding Africa and 
Asia), the best estimate is probably less than 16 million. 
Generally stable trends for use of main drug  
categories at the global level… 
The total number of users for the individual drug cate-
gories mentioned above does not appear to have changed 
significantly over the last few years. All changes occurred 
well within the existing ranges. If there has been a gen-
eral trend, it has been – for most drugs - towards a 
widening of existing ranges (that is, increases of the 
upper level and declines of the lower level of the esti-
mates), reflecting greater uncertainty about the actual 
number of drug users. Some of this is a result of statisti-
cal good practice, whereby prevalence estimates older 
than 10 years are now not being used to estimate preva-
lence. Since a large number of countries in Africa and 
Asia do not have recent data on drug use, the levels of 
uncertainty increase. 
Using a five-point scale from large decrease to large 
increase, most government experts perceived a stabiliza-
tion of drug use in 2009, as reported through the ARQ. 
This applied to cannabis, amphetamines, ecstasy, cocaine 
and the opioids, including heroin. 
… while new drugs are emerging 
The generally positive trends for the ‘traditional’ drugs, 
however, do not apply to all illicit drug markets. These 
markets continue to evolve and every year new products, 
not under control, are manufactured to supply an 
increasingly diversified demand for psychoactive sub-
stances. 
Synthetic drugs are the fastest evolving substances in this 
Fig. 8: Annual prevalence of drug use at the 
global level, in percent of the popula-
tion aged 15-64, 2009/2010 
Source: UNODC estimates based on ARQ and other official 
data.
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context, but products based on cannabis, cocaine and 
opiates are also becoming more diversified. In addition, 
reports of drug-adulterant combinations involving phar-
macologically active substances are increasing.
New psychoactive substances are supplied to the illicit 
market as a response to a number of factors: i) the use of 
different chemicals/precursors to evade an established 
law enforcement pattern; ii) the use of substances which 
are not nationally or internationally regulated and con-
trolled; iii) the replacement of substances whose supply 
is decreasing; and iv) the offer of products which can 
satisfy the evolving requirements of users. 
The fact that new psychoactive substances are emerging 
on the drug markets is not a new development. More 
recently, the market for new substances detected in sei-
zures has been expanding quickly. In Europe, one of the 
most ‘innovative’ regions when it comes to new drugs, 
110 new psychoactive substances were reported to the 
European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) and Europol between 1997 and 
2009. In 2010, more than 40 new substances were noti-
fied in the European early-warning system, compared to 
24 in 2009.8 These included piperazines, cathinones, 
synthetic cannabinoids, tryptamines and phenethyl-
amines. 
In the last few years, a number of new substances entered 
the illicit market imitating either the pharmacological 
properties or chemical structures of existing controlled 
substances such as amphetamines or ecstasy. Some of 
these contain unregulated substances and are known as 
‘legal highs’. The piperazines and the cathinones, for 
example mephedrone, are examples of unregulated sub-
stances which recently entered the markets.
8 EMCDDA, 2010 Annual Report. 
Piperazines
Piperazine was initially developed as an anthelminthic 
used in the treatment of parasitic worms. Its best known 
derivative, benzylpiperazine (BZP), was further devel-
oped as an antidepressant but was not marketed for this 
purpose because it produced similar effects to d-amphet-
amine, though less potent. These amphetamine-like 
effects include a sense of euphoria and stimulant proper-
ties. Piperazine derivatives such as BZP and 3-trifluor-
omethylphenylpiperazine (TFMPP) are often sold as 
‘ecstasy’ to overcome the shortage of MDMA.
Mephedrone 
Mephedrone, also known as 4-methylmethcathinone 
(4-MMC), is chemically related to the internationally 
controlled substance cathinone, one of the psychoactive 
substances in the khat plant. Mephedrone was intro-
duced to the drug markets recently and is often touted 
as a legal alternative to amphetamine or cocaine with 
increasing reports emanating from Europe, North 
America and Australia. Although mephedrone and ana-
logues such as naphyrone produce effects similar to 
those of some internationally controlled substances, 
there are often no legislative restrictions on their manu-
facture and distribution due to the chemical differences.
‘Spice’ 
The cannabis market has diversified with the introduc-
tion of synthetic cannabinoids which emulate the effect 
of using cannabis. Since 2008, several synthetic can-
nabinoids (‘spice’) have been detected in herbal smoking 
blends. These products typically contain about 3 grams 
of finely cut plant material to which one or more syn-
thetic cannabinoids have been added. As they do not 
contain products that are under international control, 
Fig. 9: Government experts’ perceptions of trends in illicit drug use,* 2009 
* based on information from 83 countries and territories. 
Source: UNODC ARQ. 
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these products have often been marketed as ‘legal alter-
natives’ to cannabis. Little is known about the pharma-
cology and toxicology of these compounds, and it is 
believed that a number of these substances may have a 
higher addictive potential than cannabis. In response, a 
number of countries have placed ‘spice’ and similar 
products under control, leading to a decrease in the 
extent of the problem. 
Drug-adulterant combinations: Cocaine adulterated 
with levamisole 
Street dealers have traditionally ‘cut’ cocaine with dilu-
ents such as lactose to increase profits. Recently, there 
have been reports of the use of more pharmacologically 
active adulterants such as atropine, phenacetin and 
methyphenidate. The presence of some of these adulter-
ants may serve to increase the desired effects of the illicit 
substances or even reduce or eliminate some of its 
adverse effects. Data from the Netherlands (confirmed 
by data from several other European and North Ameri-
can countries) show that in 2008 and 2009, an increased 
number of cocaine samples contained levamisole, an 
anthelminthic, effective in infections with the common 
roundworm.
Difficulties in controlling new substances…
The large number of new substances that enter the 
market worldwide is posing a number of challenges to 
public health and law enforcement systems which 
require improved monitoring and a coordinated response 
across countries and regions. While some countries have 
tried to address the problem via the application of ‘emer-
gency scheduling’ mechanisms, others have started to 
experiment with ‘generic scheduling mechanisms’ which 
automatically also put analogue substances under con-
trol. This is, however, difficult to implement in many 
legal systems. Other countries have started to bring the 
rapidly growing number of new substances under imme-
diate control via the ‘Medicines Act’ (instead of the 
‘Narcotics Act’), which typically requires that medicinal 
products need to be properly tested before they can be 
sold to the general public. 
The precursor chemicals for synthetic drugs also con-
tinue to change in response to stricter controls. For 
example, in some countries, traffickers have started to 
use norephedrine as a precursor for the manufacture of 
methamphetamine, instead of ephedrine and pseu-
doephedrine, which have been under increasing govern-
mental scrutiny. 
… and problems related to the non-medical use of pre-
scription drugs increase
While there are stable trends for traditionally used drugs, 
and in major consumption regions even some decline 
for heroin and cocaine, there seems to be an increase in 
the non-medical use of prescription drugs in a number 
of countries. 
Non-medical use of prescription drugs, such as a number 
of synthetic opioids, tranquillizers and sedatives or pre-
scription stimulants is reportedly a growing health prob-
lem in a number of countries. In the United States, 
emergency room visits related to the non-medical use of 
prescription drugs have started to exceed the numbers 
related to the use of illicit drugs. Prescription drugs may 
replace certain illicit drugs since their use is perceived to 
be less harmful, being prescribed by physicians. They are 
legal, cheaper than illicit drugs and their use is more 
socially acceptable. Another factor for the growing pop-
ularity of prescription drugs is that patients who have 
been prescribed medications share or sell them to family 
members, friends or others who approach them. Non-
medical use of prescription drugs is a common phenom-
enon among young adults, women, elderly patients and 
health care professionals. Another issue of concern is 
that the growing numbers of polydrug users among 
illicit drug users also use prescription drugs in combina-
tion with their illicit drug of choice to enhance the 
effects of the main drug. 
Treatment demand
The need to enter treatment reflects problematic drug 
use, associated with adverse effects on the health of 
individuals. In most regions of the world, there continue 
to be clear regional patterns regarding the main problem 
drug types. In Europe and Asia, opioids (basically 
opiates, and in particular heroin) are dominant for 
problematic use. In some of the Asian countries, ATS - 
notably methamphetamine in South-East Asia and 
Captagon (that is, amphetamine, often mixed with 
caffeine) on the Arabian peninsula – has emerged as the 
most problematic drug group. ATS in treatment demand 
is also widespread in Oceania, North America and West 
and Central Europe. The problematic use of cannabis 
makes a significant contribution to treatment demand 
across all regions but is particularly prevalent in Africa. 
In South America (including the Caribbean and Central 
America), cocaine is the primary drug responsible for 
drug treatment. In North America, a more diversified 
pattern has developed where a single, dominant drug 
type does not emerge. Cannabis, opioids and cocaine are 
all equally represented. In Oceania, treatment is linked 
primarily to cannabis, followed by opioids. 
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Opiates are the most harmful drugs as reflected  
in treatment demand 
One way of ‘measuring’ the potential harmfulness of 
drugs is to compare the number of people having to 
undergo treatment with the total number of persons 
using the drug in question. 
The latest US data9 show that, on average, three persons 
per 100 annual drug users had to undergo treatment for 
drug use in 2008. Opiates use is far more problematic 
than the use of other illicit drugs. The rate for heroin is 
much higher than the average, at 22 for 100 users, that 
is, more than one out of five users enters treatment. 
Though treatment demand for prescription opioids has 
been rising far stronger in the USA (460% between 
1998 and 2008) than heroin-related treatment demand 
(8%), only 1 out of 100 people who misuse prescription 
opioids enter treatment. The corresponding rates 
amounted to between four and five per 100 users for 
cocaine and amphetamines (‘stimulants’) and one per 
100 users for cannabis in 2008. Above average treatment 
demand still exists for crack-cocaine users (14 per 100 
users), clearly exceeding overall cocaine-related treat-
ment demand, and for methamphetamine users (14 per 
100 users), clearly exceeding overall amphetamines-
related treatment demand. For users of tranquillizers 
and sedatives, the rates are between 0.6 and 0.7 per 100 
users. 
Based on the number of past-year users in European 
countries and the reported numbers in treatment for the 
9 SAMHSA, Results from the 2009 National Survey on Drug Use and 
Health: Detailed Tables; SAMHSA, Treatment Episode Data Set 
(TEDS), 1998-2008; estimates on the number of opioid and opiate 
users have been derived from ONDCP estimates on the number of 
heroin users and SAMHSA estimates on the number of prescription 
opioid users. 
various drug types, data suggest that between one in 
every four or five opioid users end up in treatment. 
These rates are comparable to those found in the USA, 
as most of the reported opioid use in Europe is linked to 
the abuse of opiates, notably heroin. For cocaine and 
ATS, available data suggest that around one in every 100 
users in Europe end up in treatment, that is, less than in 
the USA. This would suggest that cocaine and stimulant 
use in Europe is still not as problematic as in the USA 
because crack-cocaine and methamphetamine, the two 
most problematic substances in these categories, are still 
small in Europe. While treatment related to cannabis use 
increased in Europe over the last decade, this is still far 
less common than in the USA. Around one in every 230 
cannabis users underwent treatment in Europe, com-
pared to one in every 80 in the USA. Differences in 
treatment policy (notably with regard to compulsory 
cannabis-related treatment schemes) and recording prac-
tices may explain some of the differences. Consequently, 
opioid/opiate users in Europe are 20 times more likely 
to end up in treatment compared to cocaine and ATS 
users, and 50 times more likely compared to cannabis 
users. In the USA, the likelihood for opiate users to end 
up in treatment is about five times higher than for 
cocaine and stimulant users and 20 times higher than 
for cannabis users.10 
The prevalence of opiate use, compared to other drugs, 
is relatively low. However, opiates dominate treatment 
with a disproportionately high percentage of demand. 
This reflects the considerable harm associated with opi-
10 This analysis is based on macro data and does not take into account 
polydrug use.
Fig. 10: Comparison of drug types between treatment demand and relative number of users,*  
by region**
* Percentage of illicit drug users does not consider polydrug use. ** Seven regions are represented: Africa, Asia, East and South-East Asia, 
North America, Oceania, South America, West and Central Europe. Each geometric shape corresponds to one region. 
Source: UNODC ARQ; Government reports.
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ates (notably heroin) and the high probability that 
opiate users will require some form of treatment inter-
vention. As for most regions (except North and South 
America), the opiate and opioid figures are still almost 
identical. 
With the high prevalence rates of ATS in Asia, especially 
in East and South-East Asia, there remain concerns over 
an unmet demand for treatment of ATS use there. With 
most of the treatment services aimed at meeting the 
needs of opioid and cannabis users, ATS treatment serv-
ices are relatively scarce and under-resourced.11
The vast majority of illicit drug users consume cannabis, 
and although the harm associated with its use is rela-
tively small in comparison with the opiates, cannabis 
contributes in no small way to treatment demand. The 
level of treatment demand for cannabis coincides with 
regional prevalence rates, with the highest levels of con-
sumption in Oceania and Africa, followed by the Amer-
icas, Europe and Asia.
Infectious diseases among injecting drug users
A systematic review12 conducted for the Reference 
Group to the UN on HIV and Injecting Drug Use esti-
mated that there are approximately 15.9 million (range 
11.0-21.2 million) injecting drug users worldwide, with 
the largest numbers in China, the United States and the 
Russian Federation. These figures suggest that close to 
60% of all problem drug users worldwide inject drugs, 
and that injecting drug users account for about 7.5% of 
all drug users worldwide. 
Injecting drug use is an extreme form of illicit drug use 
with serious health implications and costs for the indi-
vidual and the community. Risky injecting and sexual 
behaviour among drug users becomes a major public 
health concern because of the high risk for the transmis-
sion of blood-borne infections such as HIV, Hepatitis C 
and B, especially among the marginalized and most at 
risk populations. 
Around one in five injecting drug users  
is HIV positive …
Based on information compiled by UNODC, the global 
average prevalence of HIV among injecting drug users is 
estimated at 17.9%, or equivalently, 2.8 million people 
who inject drugs are living with HIV. This is consistent 
with the estimate of 3.0 million (range 0.8-6.6 million) 
presented by the Reference Group to the UN on HIV 
and injecting drug use.13 High levels of HIV infections 
11 UNODC, Patterns and Trends of Amphetamine Type Stimulants and 
Other Drugs Asia and the Pacific, Global SMART Programme, 2010.
12 Mathers BM, Degenhardt L, Phillips B, et al., (November 2008), 
‘Global epidemiology of injecting drug use and HIV among people 
who inject drugs: a systematic review,’ Lancet 372 (9651): 1733–45.
13 Ibid.
are, in general, found among marginalized populations 
of drug users as well as among those in prison settings.
According to the Reference Group, there are large geo-
graphical variations in the prevalence of HIV among 
injecting drug users, with the largest numbers and high-
est rates in Latin America, East Europe, and East and 
South-East Asia. Combined, these regions account for 
73% of the global number of injecting drug users living 
with HIV. In some countries, the prevalence of HIV 
among injecting drug users is extremely high, such as in 
Estonia (72%), Argentina (50%) and Brazil (48%).
… and around half of all injecting drug users are 
infected with the Hepatitis C virus (HCV) 
Infections with viral hepatitis C and B also pose signifi-
cant public health concerns giving rise to considerable 
morbidity and mortality among drug users.
The hepatitis C virus (HCV) affects around 130-170 
million people worldwide14 (representing 2.2%-3.0% of 
the global population) and is a major cause of liver dis-
ease with the potential for considerable ill health effects 
and premature death. In developed countries, injecting 
drug use is the main route for the transmission of 
HCV.15 Although HCV and HIV have different viral 
properties and clinical outcomes, they share parallel 
risks, and their epidemic follows a similar path. HCV is 
five times more widespread worldwide than HIV, how-
ever, because it is more infectious and has probably been 
present for longer in human populations.
The prevalence of HCV among injecting drug users at 
the global level is high, at 50.3% (45.2%-55.3%), with 
13 out of 51 countries reporting prevalence rates greater 
than 70%. Africa and Oceania have the highest rates at 
73.2% and 63.8% respectively, although the number of 
countries reporting rates from these two regions is very 
low. Applying the estimated global average prevalence 
suggests that there are 8.0 (7.2-8.8) million injecting 
drug users worldwide who are also infected with HCV. 
As with HIV, higher levels of HCV infections are found 
among marginalized populations of drug users and those 
in prison settings. 
Most of the information reported to UNODC comes 
from Europe where the average level of infection of 
HCV among injecting drug users is 47.0%, but eight 
out of the 29 countries have prevalence rates above 60% 
and five over 70%. 
14 Daniel Lavanchy. The global burden of hepatitis C, Liver Interna-
tional, 2009; 29(s1): 74–81.
15 Ibid, and Colin W Shepard, Lyn Finelli, Miriam J Alter. Global 
epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5: 
558–67.
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Deaths associated with illicit drug use
Deaths related to or associated with the use of illicit 
drugs may include: fatal drug overdoses; suicide; acci-
dents (such as motor vehicle accidents) while under the 
influence of illicit drugs; deaths among injecting and 
other drug users from infectious diseases such as HIV/
AIDS and Hepatitis C transmitted through the use of 
contaminated needles; or from medical conditions (such 
as organ failure) associated with long-term drug use. The 
information on the number of drug-related deaths 
reported to UNODC is often based on different criteria 
of classification of diseases and may include some or all 
of these categories. 
Data on drug-related deaths is a measure that provides 
information on the most extreme consequences and the 
health impact of drug use in the community. This can 
also provide essential information on risky patterns of 
drug use, the risk attributed to certain drugs or combi-
nations of substances, the level of risk among the most 
vulnerable population groups, and to monitor the prev-
alence of risks attributed to certain drugs.17 Toxicologi-
cal examinations to identify the cause of death are not 
standard in most countries and even if such examina-
tions are undertaken, they can often only confirm the 
presence of a psychoactive substance in the dead body 
but do not provide information on a causal relationship. 
Thus, drug deaths related to cannabis are often reported, 
though in most cases, the presence of this drug did not 
cause the death. Information on drug-related deaths, 
compiled from different countries using different clas-
sification systems, must be treated with caution. 
Globally, different estimates of drug-related deaths have 
been published by the World Health Organization in 
the past. These estimates include:
 • 194,000 (uncertainty interval 113,494 – 276,584) 
drug-related deaths for the year 2000, based on esti-
mates of the following four causes: AIDS, opioid over-
dose, suicide among opioid users and trauma.18
 • 197,400 (uncertainty interval 101,751 – 322,456) 
for the year 2000, based on all-cause mortality from 
cohort studies and attributable fractions.19
 • 245,000 deaths attributed to illicit drug use in 2004, 
which includes deaths related to heroin and cocaine 
use, and deaths from HIV/AIDS, hepatitis B and C 
resulting from illicit drug use.20 
17 EMCDDA, An overview of the drug-related deaths and mortality 
among drug users (DRD) key indicator, January 2009.
18 Degenhardt L, Hall W, Warner-Smith M, Lynskey M., ‘Chapter 13: 
Illicit drug use,’ In: Ezzati M, Lopez A, Rodgers A, Murray CJL, eds. 
Comparative quantification of health risks: global and regional burden of 
disease attributable to selected major risk factors, Geneva, World Health 
Organization, 2003.
19 Ibid.
20 World Health Organization, Global health risks: mortality and burden 
For 2009, UNODC has compiled information on drug-
related deaths based on data reported through the ARQ. 
The level of reporting on drug-related deaths encom-
passes nearly half (49%) of the world’s population aged 
15-64 - although there are large regional differences in 
coverage: North America - 100%; Europe - 97%; South 
America (including the Caribbean and Central America) 
- 64%; Oceania - 62%; Asia - 42%; and Africa, <1%. 
Since very little data emerged from countries in Africa, 
an alternative source on drug-related deaths has been 
used.21
According to the data compiled by UNODC, it is esti-
mated that globally, there are between 104,000 and 
263,000 deaths each year that are attributable to illicit 
drug use, or equivalently, that there are between 23.1 
and 58.7 deaths per million population aged 15-64 due 
to illicit drug use. These estimates are consistent with 
other previously published estimates by the WHO. As 
reported by Member States, approximately 50% of the 
deaths are fatal overdose cases. Significantly, drug-related 
deaths occur among a young age group. For example, 
EMCDDA reports that the mean age for deaths result-
ing from overdose in Europe is the mid-30s.22
In Europe, drug overdoses account for 4% of all deaths 
for those aged 15-3923 - and the rates in some countries 
exceed 10% in this age group. In a study on drug-related 
mortality in eight European cities, 10–20% of mortality 
within the 15-49 age group is attributable to opioid 
use.24 Data from Europe also suggest that for each drug-
induced death, there are an estimated 20-25 non-fatal 
overdose cases. As such, drug-related deaths are highly 
premature (and preventable) and account for a dispro-
portionate contribution to the burden of disease as 
measured by potential years of life lost. 
of disease attributable to selected major risks, 2009.
21 Darke, S., Degenhardt, L. and Mattick, R., Mortality Amongst Illicit 
Drug Users: Epidemiology, Causes and Intervention, Cambridge Uni-
versity Press, 2007.
22 EMCDDA, Annual report: the state of the drugs problem in Europe - 
2010, Lisbon, November 2010.
23 Ibid.
24 Bargagli, A.M., Hickman, M., Davoli, M., Perucci, C.A., Schifano, 
P. et al. (2006), ‘Drug-related mortality and its impact on adult mor-
tality in eight European countries’, European Journal of Public Health 
16, pp. 198–202.
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3) Regional overview 
This overview highlights some of the main characteris-
tics and illicit drug market trends at the regional level. 
a) North America 
North America continues to be the world’s largest drug 
market, even though it is – according to all estimates – 
now smaller, in economic terms, than a decade or two 
ago. 
Production 
Production of illicit drugs in North America is primarily 
linked to cannabis (mainly cannabis herb), ampheta-
mine-type stimulants (ATS) and opiates. 
Substantial amounts of cannabis are grown in all North 
American countries and important exports are directed 
from Mexico to the United States, and, to a lesser extent, 
from Canada to the United States. Greenhouse cultiva-
tion of cannabis is still limited to the USA and Canada. 
Manufacture of ATS takes place in all three countries 
and is mainly of methamphetamine and, to a lesser 
extent, ecstasy. Some 99% of all methamphetamine 
laboratories worldwide (though mostly ‘kitchen labs’) 
are dismantled in North America, notably in the United 
States. Significant amounts of methamphetamine con-
tinue to be shipped across the border from Mexico to 
the United States. Manufacture of ecstasy is mainly con-
centrated in Canada and the USA. A significant share of 
the Canadian ecstasy production is destined for the US 
market. Asian groups with links to China and South-
East Asian countries are mainly involved in the ecstasy 
production.
Production of opiates in North America only takes place 
in Mexico. Mexico’s opium production accounted for 
5% of the world total in 2009.
Trafficking 
Trafficking of drugs continues to be primarily directed 
towards North America. Trafficking of drugs out of the 
region to other destinations exists, but is limited. Traf-
ficking of cannabis herb is mainly intra-regional, with 
cannabis herb from both Mexico and Canada being 
shipped into the United States, in addition to domestic 
shipments of locally produced cannabis herb across US 
states. Similarly, methamphetamine trafficking is prima-
rily intra-regional, with flows from Mexico into the 
United States, as well as locally produced methampheta-
mine being trafficked domestically in the United States. 
Ecstasy trafficking used to be intra-regional (from west-
ern Europe to North America) but has now become 
mainly intra-regional, with deliveries from Canada into 
the United States. Cocaine trafficking, in contrast, 
remains inter-regional, with shipments of cocaine from 
the Andean region, notably Colombia, to Central Amer-
ica and Mexico for final destination markets in the 
United States and, to a lesser extent, Canada. 
The largest seizures in North America are reported for 
cannabis, followed by cocaine and the amphetamines. 
Expressed as a proportion of the global total, data show 
that 70% of global cannabis herb and 70% of global 
ecstasy seizures took place in North America in 2009, 
followed by amphetamines (21%) [methamphetamine 
only: 44%], cocaine (18%) and heroin (4% of the world 
total). Cannabis resin seizures accounted for less than 
1% of the total, showing that hashish does not play a 
significant role in North America. 
While cocaine seizures declined markedly between 2005 
and 2009 (-43%), reflecting the overall decline of the 
cocaine market in North America, seizures increased 
over this period for amphetamines (87%), ecstasy 
(71%), cannabis herb (32%) and heroin (19%). 
Illicit drug use 
The highest levels of illicit drug use are related to the 
consumption of cannabis, mainly cannabis herb. With a 
prevalence rate of 10.7% among the population aged 
15-64, cannabis use in North America is above the 
global average. The region accounts for about one fifth 
of global cannabis users, far above its share of the global 
population (around 7%). Following years of decline, 
cannabis use increased again in 2009 in the United 
States. The annual prevalence of cannabis use in the 
Table 4: Seizures in North America, in kilogram equivalents, 2005-2009
Source: UNODC ARQ.
2005 2006 2007 2008 2009
In % of global 
total in 2009
Cannabis herb 3,183,053 3,278,467 3,930,620 3,205,334 4,188,620 70%
Cocaine 233,605 193,601 175,316 132,970 132,355  18%
Amphetamines 7,422 9,226 7,047 8,551 13,876 21%
Ecstasy 2,227 3,008 3,981 3,279 3,816 70%
Heroin 2,391 2,432 1,760 2,283 2,853 4%
Memo: Population 458 million 7%
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USA increased from 10.1% of the population aged 12 
and above in 2007 to 11.3% in 2009.
The relative importance of North America is larger 
when it comes to cocaine. Almost 37% of all cocaine 
users worldwide are found in North America. With a 
prevalence rate of 1.9% among the population aged 
15-64, North America – despite declines in recent years 
– still has the highest prevalence rate of any subregion, 
far above the global average (0.4%). The decline was 
most pronounced after 2006, with the annual preva-
lence of cocaine use in the USA falling from 3.0% of the 
population aged 15-64 to 2.4% in 2009. Significant 
declines in cocaine use were also reported from Canada 
in recent years, with the annual prevalence rate falling 
from 2.3% in 2004 to 1.4% in 2009. 
About 1.1% of the population in North America uses 
amphetamines and a similar proportion uses ecstasy. 
These are – in both cases – above the global average. Use 
of amphetamine-type stimulants showed a downward 
trend over the 2006-2008 period and increased again 
slightly in 2009. The increase was mainly related to the 
‘recovery’ of methamphetamine, rising from 0.3% of the 
population aged 12 and above in 2008 to 0.5% in 2009. 
The same applied to the use of ecstasy which rose in the 
USA from 0.9% of the population aged 12 and above in 
2008 to 1.1% in 2009.
If opioids are considered, available estimates suggest that 
more than 40% of global opioid users are found in 
North America. These high levels are mainly due to 
widespread non-medical use of prescription opioids, 
which rose between 2002 and 2006, before falling until 
2008 and rising again in 2009. The abuse of opiates is, 
at 0.4%, close to the global average. Opiate use levels 
have remained stable in recent years.
North America has, in general, a significant problem 
when it comes to the non-medical use of prescription 
drugs. In the United States, such use of prescription 
drugs (‘psychotherapeutics’) has ranked for some years 
second after cannabis, with an annual prevalence of 
6.4% among the population aged 12 and above.25 The 
non-medical use of pain relievers (4.9%) which are pre-
scription opioids and of tranquillizers (2.2%) now show 
higher annual prevalence rates than cocaine (1.9%). The 
non-medical use of easily available prescription opioids 
- oxycodone in particular - appears to have increased 
since 2005. Among the new initiators of drug use in 
2009, around 2.2 million people in the USA initiated 
their drug use with pain relievers, approaching the 
number of those who initiated their drug use with can-
nabis.
25 Substance Abuse and Mental Health Services Administration, Results 
from the 2009 National Survey on Drug Use and Health: Volume I. 
Summary of National Findings, 2010, Rockville, Maryland, USA.
The main pharmaceutical prescription drug categories 
used in Canada are ‘opioid pain relievers’, ‘stimulants’ 
and ‘tranquillizers and sedatives’. In 2009, prescription 
opioid misuse in Canada was reported at 0.5%, the same 
level as 2008, while heroin use was estimated at 0.36%.26
In Mexico, the annual prevalence of non-medical use of 
prescription drugs seems to be much lower. The national 
household survey found prescription opioid prevalence 
to amount to 0.06% of the adult population in 2008, 
compared to 0.04% for heroin.27
Drug-related deaths
North America seems to experience a large proportion 
of drug-related deaths (45,100 deaths) and the highest 
drug-related mortality rate (148 deaths per million pop-
ulation aged 15-64). The United States saw an estimated 
38,400 deaths from illicit drug use in 2006, correspond-
ing to a drug-related mortality rate of 182 deaths per 
one million inhabitants aged 15-64. 
In the United States, overdoses from prescription opio-
ids have been steadily increasing from 4,000 in 2001 to 
11,000 in 2006 (the most recent year available), an 
increase of 175%, primarily as a result of the non-med-
ical use of diverted prescription opioids.28 Similar trends 
in the non-medical use of prescription medicines are 
also emerging in other countries.29 
b) South America, Central America  
 and the Caribbean 
South America continues to be primarily a subregion 
known for large-scale cocaine production and traffick-
ing, though drug use, notably in the Southern Cone 
countries, has also become significant. 
Production 
Notable illicit drug production continues to take place 
in the three Andean countries. Colombia, Peru and the 
Plurinational State of Bolivia are responsible for close to 
100% of global coca leaf production, the raw material 
for the manufacture of cocaine. In 2010, coca was culti-
vated on 149,10030 ha in the Andean countries, down 
26 Estimated by UNODC based on 1% prevalence of injecting drug use 
(estimated 220,690 IDU in 2004) reported by the Reference Group 
to the United Nations on HIV and injecting drug use, 2008.
27 SALUD, Encuesta Nacional de Adicciones 2008, Instituto Nacional de 
Salud Pública, Mexico.
28 U.S. Department of Justice, Drug Enforcement Administration, 
National Drug Intelligence Centre, National Prescription Drug Threat 
Assessment 2009,and National Drug Threat Assessment 2010.
29 Nicholas R., Lee N., and A. Roche, Responding to pharmaceutical drug 
misuse in Australia: A Matter of Balance, NCETA Literature Review 
to support the development of the National Pharmaceutical Drug 
Misuse Strategy, March 2011.
30 The figure for the Plurinational State of Bolivia was not available at 
the time of printing of this report. The total area under cultivation in 
2010 is based on old figures for Bolivia and will be revised once the 
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from 221,300 ha in 2000. Cocaine manufacture in clan-
destine laboratories also takes place, to a large extent, in 
the Andean countries. Since 2007, cocaine production 
has shown a clear downward trend, mainly due to 
declines of production in Colombia, which also contin-
ued in 2010. Cocaine production fell by some one sixth 
over the 2007-2010 period. 
Most of the countries in South America, Central Amer-
ica and the Caribbean have significant levels of cannabis 
production, notably of cannabis herb. In 2009, 70% of 
global cannabis plant seizures, an indirect indicator  of 
cannabis eradication, occurred in this subregion. Three 
quarters of these seizures took place in South America. 
Cannabis production seems to be - in most countries - 
primarily for domestic use. Opium production in South 
America is almost negligible at the global level. 
Manufacture of amphetamine-type stimulants is still 
limited in the region as most of the ATS consumed are 
still diverted prescription stimulants. However, in recent 
years, illicit manufacture of ATS has emerged in several 
countries with little or no previous history of reported 
manufacture. 
Trafficking
Trafficking flows are primarily directed out of the 
cocaine-producing countries in the Andean region 
towards North America, either directly to Mexico and 
then the United States, or via Central America to Mexico 
or via the Caribbean to the United States. Trafficking 
flows to Europe are either directly from the Andean 
region or via neighbouring countries to Europe, via 
countries in the Caribbean region as well as via countries 
in Africa (notably West Africa) to Europe. 
Cannabis trafficking flows are mainly intra-regional. In 
addition, there are limited trafficking flows of heroin 
from Colombia to the United States. 
In contrast, trafficking flows of amphetamines and 
2010 figure becomes available.
ecstasy are still mainly from Europe towards South 
America, though these appear to be declining as they 
start to be substituted by local production. 
The largest seizures, in volume terms, are those of coca 
leaf in South America, which accounts for all global coca 
leaf seizures. Such seizures declined, however, over the 
2007-2009 period by some 25%, partly reflecting a 
decline in coca leaf production. In contrast, cocaine 
seizures, for which the countries of South America, Cen-
tral America and the Caribbean accounted for 74% of 
the world total, showed an increase by 27% over the 
2007-2009 period. Increasing interdiction efforts by the 
Andean countries (notably Colombia) as well as 
improvements in international cooperation – and thus 
more ‘upstream’ interdictions – have been responsible 
for this. 
Seizures of opium and heroin declined markedly between 
2005 and 2009. The decline is in line with reports of 
strong reductions of opium production in South Amer-
ica over the last decade. 
Illicit drug use 
Surveys suggest that about 5% of all cannabis users 
worldwide are found in South America, the Caribbean 
and Central America, slightly less than the region’s share 
of the global population. Nonetheless, cannabis is the 
most widely consumed illicit substance in the region. 
The prevalence rate for cannabis use in South America 
ranged between 2.9%-3.0% of the population aged 
15-64 in 2009, between 1.6%-7.6% in the Caribbean 
and between 2.2%-2.5% in Central America. 
The prevalence of cocaine use in South America, Central 
America and the Caribbean is clearly above the global 
average. About 0.9%-1.0% of the population aged 15-64 
consumes cocaine, equivalent to some 2.6-3.0 million 
people or 17% of the world’s cocaine-using population. 
Following years of increases, the latest data indicate a 
Table 5: Seizures in South America, Central America and the Caribbean, in kilogram equivalents, 
2005-2009
Source: UNODC ARQ.
2005 2006 2007 2008 2009
In % of global 
total in 2009
Cannabis herb  509,265 1,065,673 1,009,470  857,534  619,786 10%
Coca leaf 3,195,757 3,318,645 4,698,820 4,883,732 3,517,918 100%
Cocaine  429,740  400,266  427,685  523,040  541,070 74%
Amphetamines  140  87  519  41  189 0.3%
Ecstasy  141  53  103  46  54 1%
Heroin  1,863  1,689  1,205  1,335  1,159 2%
Opium  2,129  263  259  300  74 0.01%
Memo: Population 473 million 7%
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stabilization at the higher levels. Cocaine continues to be 
the main problem drug in South America, Central 
America and the Caribbean, accounting for some 50% 
of all drug-related treatment demand in the region. 
Use of other drugs is below average. This is true for ATS 
as well as the opioids. Overall opioid use is far more 
prevalent (some 0.4%) than the use of opiates (0.1%). 
The most prevalent prescriptions drugs in the region 
seem to be prescription opioids. High prevalence of the 
non-medical use of prescription opioids has been reported 
by Costa Rica, Brazil and Chile. Most of the ATS use in 
the region is linked to diverted prescription stimulants 
(legally prescribed mainly as anorectics or for the treat-
ment of attention deficit disorders). High levels of con-
sumption have been reported for 2009, in particular 
from Argentina, Brazil and, to a lesser extent, Chile.31 
Drug-related deaths
Countries in South America, including the Caribbean 
and Central America, report relatively few drug-related 
deaths (between 2,200 and 6,300) with a mortality rate 
(between seven and 20 deaths per million aged 15-64) 
well below the global average. Countries consistently 
rank cocaine first as the primary cause of death, which 
is in accordance with high prevalence of cocaine use and 
the dominance of cocaine in treatment demand.
c) Europe
Production 
Illicit drug production in Europe is mainly linked to 
cannabis, amphetamines and ecstasy. 
 • Cannabis production in Europe is believed to be  
increasing, mostly in indoor settings. Twenty-nine 
European countries reported domestic cultivation of 
cannabis herb in 2008.
 • In the past, ecstasy-group substances used to be 
manufactured predominantly in West Europe. The 
Netherlands and Belgium are still the main sources for 
ecstasy in Europe. However, manufacture has shifted 
away from the region and only a few laboratories were 
reported from Europe in 2008 and 2009. 
 • Most amphetamine seized in Europe is manufactured, 
in order of importance, in the Netherlands, Poland 
and Belgium. 
 • The clandestine manufacture of methamphetamine 
is concentrated in the Czech Republic, though some 
production is also taking place in the Baltic countries. 
Methamphetamine production and consumption are, 
however, still the exception in Europe.
 • In Spain, there is some evidence of the reconversion 
of cocaine mixed with other substances back into 
cocaine.
31 INCB, Report for 2010 – Psychotropic Substances.
 • In East Europe, notably in the Russian Federation 
and Ukraine, there is domestic production of opium 
or poppy straw for local consumption purposes 
(‘kompot’). 
Trafficking 
Most cannabis seizures are related to cannabis resin in 
Europe, accounting for 49% of the global total in 2009. 
Cannabis resin found on the European market origi-
nates primarily in Morocco. While cannabis resin sei-
zures declined over the 2005-2009 period, those of 
cannabis herb increased by 88%, confirming reports of 
increasing levels of (often hydroponic) cannabis herb 
production within Europe for local consumption. 
Despite the increasing importance of cannabis herb, 
overall cannabis seizures declined by 19% between 2005 
and 2009. 
Cocaine is trafficked to Europe mainly by sea, though in 
terms of reported seizure cases, deliveries by air are 
higher. The trafficking of cocaine into the EU by mari-
time containers seems to have increased in recent years. 
While the European cocaine market appears to have 
been fairly stable between 2006 and 2009 – following 
strong increases in trafficking over the 1998-2006 period 
– cocaine seizures declined massively over this period 
(-53%). This partially reflects improved cooperation 
with law enforcement counterparts in Latin America 
and thus improved sharing of information, leading to 
seizures in South Americas rather than waiting for the 
cocaine to arrive in Europe. Cocaine seizures are still 
concentrated in western Europe. The countries of West 
and Central Europe accounted for 97% of all European 
cocaine seizures in 2009. In addition to direct shipments 
from South America, shipments via Africa, notably West 
Africa, gained strongly in importance over the 2004-
2007 period, before decreasing over the 2007-2009 
period. Though the Iberian peninsula, followed by the 
Netherlands and Belgium, continue to be main entry 
points for cocaine shipments into Europe, there have 
also been reports of shipping cocaine to the Balkan 
region (by container or air freight) for final destinations 
in the European Union. 
Heroin seizures made in Europe accounted for 38% of 
the world total in 2009. Heroin seizures are mostly con-
centrated in South-East Europe (63% of all heroin sei-
zures in Europe), mainly reflecting the strong seizure 
efforts of Turkey as heroin is shipped via the Islamic 
Republic of Iran to Turkey and then along the various 
branches of the 'Balkan route' to western Europe. While 
heroin seizures in West and Central Europe remained 
largely stable over the 2005-2009 period, they doubled 
in South-East Europe. 
Europe is primarily a region of final consumption - 
except for ecstasy, which is still produced locally and 
shipped to other destinations as well. Ecstasy exports out 
of Europe, however, have declined markedly in recent 
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years, which has been linked to improvements in precur-
sor control and thus shortages of the traditional ecstasy 
precursor. Europe’s share in global ecstasy seizures 
declined from 90% in 1996 to 18% in 2009. 
Europe accounted for 24% of global amphetamine sei-
zures in 2009. Amphetamine seizures remained largely 
stable over the 2005-2009 period. More than 80% of all 
European amphetamine seizures in 2009 took place in 
the countries of West and Central Europe. 
Seizures of benzodiazepines and barbiturates increased 
by more than 50% between 2005 and 2009. Close to 
90% of all benzodiazepines and barbiturate seizures 
worldwide in 2009 were reported from countries in 
Europe. 
Seizures of GHB (gamma-hydroxybutyric acid), fre-
quently known in the illicit drug markets as ‘liquid 
ecstasy’ and as a ‘date rape drug,’ increased four-fold in 
Europe over the 2005-2009 period. European seizures 
accounted for almost 80% of the world total. 
Seizures of LSD, which in volume terms are hardly 
noticeable, have shown a downward trend over the 
2005-2009 period. Europe accounts for 80% all LSD 
seizures made worldwide. 
Illicit drug use 
The most prevalent drug in Europe is cannabis, showing 
an annual prevalence rate of 5.2%-5.3% among the 
population aged 15-64. Around 18% of the total canna-
bis-using population lives in Europe. Following years of 
significant increases, cannabis use appears to have stabi-
lized in Europe. 
Cocaine is the second most prevalent drug (0.8%-
0.9%). With 4.3 - 4.75 million cocaine users, Europe 
accounts for almost 30% of all cocaine users worldwide. 
Cocaine use is still concentrated in West and Central 
Europe, accounting for some 90% of all cocaine users in 
Europe. Cocaine prevalence rates in West and Central 
Europe doubled between 1998 and 2006 but remained 
basically stable over the 2006-2009 period.
The next most prevalent substance is ecstasy (0.7% of 
the population aged 15-64). With 3.7-4 million ecstasy 
users, Europe accounts for about one fifth of the global 
ecstasy-using population. Most European countries 
report stable trends of ecstasy use. 
Use of amphetamines affects some 2.5-3.2 million people 
in Europe, or 0.5-0.6% of the population aged 15-64. 
Most countries report stable trends in amphetamine use. 
Amphetamine remains the main amphetamines-group 
substance used in Europe. Methamphetamine use is 
mainly limited to the Czech Republic, though some 
consumption also occurs in neighbouring Slovakia, some 
of the provinces of Germany and Austria bordering the 
Czech Republic, as well as in the Baltic countries and 
some of the Nordic countries. If ecstasy and ampheta-
mines-group use are combined, use of ATS constitutes 
the second most prominent drug group after cannabis. 
In contrast to other regions, non-medical use of pre-
scription drugs has not been regarded as a major prob-
lem in Europe so far.32 Denmark, Estonia and Finland 
are countries with substantial or higher proportions of 
non-medical use of prescription opioids than heroin. 
The highest levels of non-medical use of prescription 
opioids so far have been reported from Northern Ireland 
(UK). Other countries in Europe reporting a substantial 
proportion of treatment demand for sedatives and tran-
32 EMCDDA, The State of Drugs Problem in Europe, Annual Report 
2010.
2005 2006 2007 2008 2009
In % of global 
total in 2009
Cannabis resin 907,423 618,448 853,654 937,027 623,369 49%
Cannabis herb 105,577 132,558 144,310 178,345 198,841 3%
Cocaine 106,587 121,065 79,864 62,737 56,736 8%
Amphetamines-group 
of which amphetamine
9,906
8,039
11,434
6,019
11,216
8,791
9,771
9,438
9,077
8,117
14%
24%
Ecstasy 4,709 5,649 5,839 1,763 995 18%
Heroin 22,165 22,171 26,394 29,206 28,762 38%
Opium 2,059 1,292 1,445 1,324 1,379 0.2%
Benzodiazepines and  
barbiturates  1,344.25  126.13  452.38  580.54  2,103.22 89%
GHB 156 38 318 383 675 79%
LSD 6.1 0.5 0.4 0.1 0.1 80%
Memo: Population 808 million 12%
Table 6: Seizures in Europe in kilogram equivalents, 2005-2009 
Source: UNODC ARQ.
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quillizers are found among the Nordic countries, nota-
bly Sweden (11.6%), Norway (10.2%) and Finland 
(8.5%). The use of benzodiazepines is common among 
drug users all across Europe, including substitution 
treatment clients. Studies show that between 11% and 
70% of clients report current use of benzodiazepines.33 
Drug-related deaths
For Europe, the best estimates suggest that there are 
between 25,000 and 27,000 drug-related deaths annu-
ally, with a rate between 46 and 48 deaths per one mil-
lion people aged 15-64, though some estimates give 
substantially higher figures (about twice these numbers). 
Drug-related deaths due to overdose amounted to some 
7,000 in the countries of the European Union in recent 
years, down from around 8,000 in 2000.34 Opioids, 
mainly heroin, are predominantly ranked as the primary 
cause of death, followed – at much lower levels – by 
cocaine. Most drug-related deaths seem to occur in 
Ukraine, the Russian Federation, the United Kingdom, 
Spain and Germany. Combined, these five countries 
account for some 80% of all reported drug-related 
deaths in Europe. In terms of mortality rates, Ukraine, 
Iceland, Ireland and Luxembourg seem to experience 
some of the highest levels in Europe, with over 100 
drug-related deaths per one million inhabitants aged 
15-64.
d) Africa
Production 
Illicit drug production in Africa is mainly focused on 
cannabis. While cannabis resin is mainly produced in 
Morocco, cannabis herb is produced all over Africa. 
Small-scale opium production is limited to countries in 
North Africa, notably Egypt, which regularly reports the 
largest eradication of opium poppy among all countries 
in Africa. 
ATS manufacture appears to be emerging in some Afri-
can countries. For some time, methamphetamine and 
methcathinone production has been taking place in 
South Africa, basically for domestic use. Similarly, Egypt 
has reported clandestine manufacture of ATS for some 
years. This production only takes place at low levels and 
is intended for the domestic market. 
In contrast, recent reports of shipments of metham-
phetamine from countries in West Africa (notably 
Nigeria) to various destinations in East and South-East 
Asia is an international concern, and suggest that a more 
professional ATS production has been emerging in West 
Africa. Some equipment and chemicals seized in Guinea 
33 EMCDDA, Polydrug Use: Patterns and responses, Selected issues 2009.
34 EMCDDA, Statistical Bulletin, Number of drug-induced death 
recorded in EU Member States according to national definition, 
Dutal drug-induced deaths, 1995-2008. 
in 2010 might indicate possible ATS manufacture there. 
Finally, khat is cultivated in several East African coun-
tries. Khat is not under international control, though a 
number of countries – including countries in Africa –
have introduced national legislation to prohibit its cul-
tivation and trafficking. 
Trafficking
Most of the cannabis trafficking is for shipments across 
African countries. Only smaller amounts are destined 
for overseas markets, mainly in Europe. Most of the can-
nabis resin production in North Africa is for final con-
sumption in Europe. The largest seizures were reported 
for cannabis herb, followed by cannabis resin. Africa’s 
share of global cannabis herb seizures amounts to 11% 
– and is thus below its share of the global population 
(15%), while its share in global cannabis resin seizures 
– mostly carried out by countries in North Africa – is 
equivalent to 25% of the world total. 
Africa has been affected by significant shipments of 
cocaine from South America to Europe in recent years. 
The amounts trafficked via Africa to Europe, however, 
seem to have decreased in 2008 and 2009, and only 
partly resumed in 2010. Estimates for 2009 suggest that 
some 35 mt of cocaine may have left South America for 
Africa of which some 21 mt actually arrived in Europe. 
Most of the rest appears to have been consumed locally. 
In addition, there are some indications that West Afri-
can countries are being used to stockpile cocaine which 
is later trafficked in small quantities to Europe. 
In addition, African countries are increasingly being used 
by traffickers to ship Afghan heroin to final destinations 
in Europe and other regions. Though East Africa is 
reportedly the main intermediate target for these traf-
ficking activities, African heroin seizures were highest in 
Southern Africa and North Africa. Estimates suggest that 
40-45 mt of Afghan heroin was trafficked to Africa in 
2009. 
Methamphetamine seizures have been reported from 
Nigeria and South Africa. For 2009, however, only 
South Africa reported such seizures, out of a total of four 
African countries reporting any ATS seizures in the 
ARQ. Approximately one half of the ATS seized in 
Africa was amphetamine. The paucity of the data does 
not allow for a reliable characterization for the continent 
as a whole. Several African countries appear to be 
affected by trafficking in, and consumption of, diverted 
or counterfeit prescription drugs containing controlled 
substances whose nature is not always clear, though they 
appear to include ATS as well as sedatives and tranquil-
lizers.
Illicit drug use 
Information on drug use in Africa is extremely limited, 
given the lack of scientific surveys in the region. The 
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Table 7: Seizures in Africa, kilogram equivalents, 2005-2009
Source: UNODC ARQ.
2005 2006 2007 2008 2009
In % of global 
total in 2009
Cannabis herb 865,974 1,220,578 694,177 936,084 639,769 11%
Cannabis resin 121,576 132,784 140,544 165,455 320,600 25%
Khat* 1,522 5,691 2,490 6,219 23,442 12%
Cocaine 2,575 851 5,535 2,551 956 0.1%
Methaqualone 159 773 93 1,586 828 99%
Heroin 325 335 328 311 515 0.7%
Opium 45 33 49 67 57 0.01%
Amphetamines-group 2,085 851 721 3,492 98 0.2%
Ecstasy 3.7 74.5 9.2 0.06 0.02 0.0%
Memo: Population 1,009 million 15%
*Not under international control.
high level of uncertainty is reflected in the broad ranges 
around the best estimates. The available information 
suggests that cannabis use is widespread, and that other 
drugs are used as well, notably in urban areas. 
The limited information on drug-related treatment in 
Africa identified cannabis as the main problem drug, 
accounting for 64% of all treatment demand in the 
region. This is a far higher proportion for cannabis than 
in any other region. Cannabis was followed by opioids 
(19%), cocaine (5%) ATS (5%), methaqualone (4%), 
khat (3%), solvents and inhalants (3%) and sedatives 
and tranquillizers (2%). 
Given the absence of information on overall drug use 
patterns, it is also difficult to estimate the extent of non-
medical prescription drug use in the region. However, 
parallel markets exist in many African countries, where 
prescription drugs are sold outside the control of the 
health authorities. ARQ data suggest frequent non-
medical use of prescription drugs such as buprenor-
phine, pentazocine and benzodiazepines in several 
African countries. In Mauritius, the use of buprenor-
phine was reported to be higher than heroin. In Mada-
gascar, around 38% of the total treatment demand was 
for tranquillizers, second to cannabis (>60%). Similarly 
in South Africa, on average 6.9% of people in treatment 
reported prescription opioids and tranquillizers as either 
their primary or secondary drug of abuse.35 
Drug-related deaths
Information on drug related deaths in Africa is also lim-
ited. The best available estimates suggest that there 
could be between 13,000 and 41,700 drug-related 
deaths, equivalent to between 23 and 74 per one million 
35 South African Community Epidemiology Network on Drug Use 
(SACENDU), Monitoring Alcohol and drug abuse trends in South 
Africa, SACENDU Research Brief Vol 13 (01), 2010.
inhabitants aged 15-64. These figures would suggest 
that drug-related death in Africa is close to the global 
average. Estimates could of course change substantially 
were better data to become available. 
e) Asia
Production
The main illicit drug produced in Asia is opium. The 
two largest opium-producing countries are Afghanistan 
and Myanmar. Though the proportion of Asian opium 
production in the global total declined from 98% in 
2007 to 87% in 2010, Asian opium continues to domi-
nate the world opium and thus also the world heroin 
market. While Afghan opium production declined over 
the 2007-2010 period, production in Myanmar 
increased. 
Cannabis production is widespread across Asia, includ-
ing cannabis resin production in Afghanistan and its 
neighbours in South-West Asia and Central Asia, and 
cannabis herb production in East and South-East Asia, 
and South Asia. The preliminary UNODC/Govern-
ment of Afghanistan cannabis survey found cannabis 
resin production of 1,200-3,700 mt in Afghanistan in 
2010, and Afghanistan was worldwide the second most 
frequently mentioned source country for cannabis resin 
shipments after Morocco. Seizures of cannabis plants – 
an indirect indicator of cannabis eradication – were 
higher in Asia 2009 than in North America, Europe or 
Oceania. Only South America showed higher figures. 
Asia also plays a major role in the clandestine manufac-
ture of ATS, notably of methamphetamine. Metham-
phetamine manufacture is mainly concentrated in East 
and South-East Asia, including the Philippines, China, 
Malaysia and Myanmar. In addition, since 2009, the 
Islamic Republic of Iran appears to have emerged as a 
significant location for the clandestine manufacture of 
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methamphetamine. Limited production of ecstasy also 
takes place in Asia, notably East and South-East Asia, 
including Malaysia, China and Indonesia. ATS produc-
tion is mainly for consumption within the region. 
Exports to other regions (with the exception of a few 
exports to Oceania) hardly take place. 
Trafficking
Trafficking in Asia is dominated by opium and heroin, 
which are smuggled to final destinations within the 
region as well as to Europe (from Afghanistan) and 
China (from Myanmar), though some Afghan opiates 
also find their way to China (up to 30% of Chinese 
demand). Overall, Asian opium exports accounted for 
more than 99% of the world total. Similarly, morphine 
seizures made in Asia accounted for more than 99% of 
the world total. More than half of all heroin seizures 
(56% in 2009) were made by Asian countries. In line 
with the much larger opium production of Afghanistan 
compared to Myanmar, opiate seizures have been far 
larger for the countries surrounding Afghanistan (nota-
bly the Islamic Republic of Iran and Pakistan) than for 
the countries surrounding Myanmar. 
Cannabis herb seizures in Asia amounted to just 6% of 
the world total. In contrast, cannabis resin seizures 
accounted for 24% of the world total in 2009. Cannabis 
herb and resin seizures in Asia both showed upward 
trends over the 2005-2009 period (60% and 30%, 
respectively). A breakdown shows that 98% of Asian can-
nabis resin seizures in 2009 took place in the Near and 
Middle East/South-West Asia. Cannabis herb seizures, in 
contrast, occurred primarily in South Asia (53% of all 
Asian seizures) and in East and South-East Asia (36%).
In addition, Asia has developed into a major production 
and trafficking hub for ATS, accounting for 64% of all 
such seizures worldwide in 2009. Amphetamine seizures 
(mainly Captagon) happen primarily in the Near and 
Middle East, notably the Arabian peninsula, accounting 
for almost all Asian amphetamine seizures. Metham-
phetamine seizures, in contrast, affect primarily East and 
South-East Asia (95% of all Asian methamphetamine 
seizures). Both amphetamine and methamphetamine 
seizures increased in Asia over the 2005-2009 period (by 
59% and 36%, respectively). 
Ecstasy seizures, in contrast, declined over the 2005-
2009 period (-58%), which is also in line with reports 
of improved ecstasy precursor controls. The importance 
of Asian ecstasy seizures in the global total (9%) is much 
lower than for the amphetamines. 
A problem, for countries in East and South-East Asia as 
well as South Asia, is the increasing popularity of keta-
mine, a drug used mainly in veterinary medicine for its 
analgesic properties. It is not under international con-
trol. Ketamine is sometimes sold as ‘ecstasy’ or mixed 
with MDMA. Seizures of ketamine tripled over the 
2005-2009 period and were in 2009 – in volume terms 
– some 20 times larger than ecstasy seizures in Asia. Asia 
accounted for 99% of global ketamine seizures in 2009. 
Most of the ketamine is produced in the region. 
Cocaine seizures reported in Asia accounted for just 
0.1% of the global total. Nonetheless, except for coun-
tries in Central Asia, all other subregions reported sei-
zures of cocaine in recent years. Relative concentrations 
of cocaine trafficking seem to exist in East and South-
East Asia as well as in the Near and Middle East. 
Illicit drug use 
Information on illicit drug use is only slightly better in 
Asia than in Africa, which also results in broad ranges 
around the best estimates. 
2005 2006 2007 2008 2009
In % of 
global total 
in 2009
Opium 337,071 381,741 517,119 643,873 649,449 > 99%
Morphine 31,342 45,787 27,039 17,060 23,655 > 99%
Heroin 31,852 30,442 34,699 40,490 42,512 56%
Cannabis herb 233,808 231,786 201,030 331,322 373,522 6%
Cannabis resin 236,284 227,822 308,410 543,177 306,556 24%
Amphetamines-group
of which amphetamine 
 methamphetamine
29,968
15,572
12,175
32,460
15,690
12,360
31,031
19,296
11,026
32,854
19,711
13,052
41,592
24,772
16,577
64%
74%
53%
Ecstasy 1,202 451 1,998 843 506 9%
Ketamine 3,256 4,455 12,098 7,913 10,693 99%
Cocaine 525 711 568 1,136 676 0.1%
Memo: Population 4,068 million 59%
Table 8: Seizures in Asia, kilogram equivalents, 2005-2009 
Source: UNODC ARQ.
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Cannabis is the most widely consumed drug in Asia. 
Despite national differences, overall cannabis use is, 
however, rather low in Asia, clearly below the global 
average. While cannabis resin is mostly used in Afghan-
istan and Lebanon and their respective neighbouring 
countries, cannabis herb is mainly used in South and 
South-East Asia. 
The second most widely consumed drug type in Asia is 
the amphetamines, that is, methamphetamine in East 
and South-East Asia and amphetamine on the Arabian 
peninsula. Available information suggests that the use of 
amphetamines increased in recent years. 
Asian countries reported mixed trends of ecstasy use. 
Estimates regarding ecstasy, however, must be treated 
with caution. Substances other than MDMA are often 
sold as ‘ecstasy’ in Asia. 
By far the most problematic group of substances for 
most Asian countries are the opiates. It is estimated that 
more than half of the world’s opiate-using population 
lives in Asia. Opiate prevalence rates are particularly 
high in the main opium-producing regions as well as in 
some of their neighbouring countries. The highest esti-
mates of opiate consumption are found in the countries 
of South-West Asia. 
Cocaine use in Asia is still limited, though there are 
regular reports that organized crime groups are trying to 
develop the market, notably in some of the richer parts 
of Asia, where sufficient purchasing power exists.
Due to the absence of regular prevalence studies for the 
majority of countries in Asia, information on non-med-
ical use of prescription drugs is scattered and limited. 
Available reports nonetheless indicate substantial non-
medical use of prescription opioids, tranquillizers and 
amphetamines in many Asian countries. 
In Bangladesh, Nepal and India, buprenorphine is com-
monly injected. In South-West and Central Asia, among 
the regular heroin users, the non-medical use of pre-
scription opioids, barbiturates and sedatives has been a 
commonly observed phenomenon. In Afghanistan, an 
annual prevalence rate of 0.5% for prescription opioids 
and 0.4% for tranquillizers was reported among the 
adult population. The annual prevalence of tranquillizer 
use was about the same among the male and female 
populations, while other drug use is far more male-
dominated.36
In South-East Asia, along with the use of ATS, the non-
medical use of tranquillizers – especially benzodiazepines 
– is widely reported from various countries in the region, 
including Brunei Darussalam, Malaysia, Myanmar, the 
Philippines and Singapore. In the Republic of Korea and 
the Philippines, prescription opiates are the predomi-
36 UNODC, Drug Use in Afghanistan: 2009 Survey.
nantly used opioids. Increased use of synthetic and pre-
scription drugs has also been reported in a number of 
countries, including Jordan, Qatar and the United Arab 
Emirates. In Kuwait, for instance, around 16% of treat-
ment demand was related to the use of sedatives and 
tranquillizers.
Drug-related deaths
Asia has the largest uncertainty in the estimated range of 
drug-related deaths: between 6 and 51 deaths per one 
million persons aged 15-64. This needs to be interpreted 
with caution, considering the lower coverage and report-
ing of mortality data. Nevertheless, due to the consider-
able population in Asia, this translates to between 
15,000 and 140,000 deaths. In Asia, opioids are almost 
exclusively reported as the primary substance in drug-
related deaths.
f) Oceania
Production 
Drug production in Oceania is limited to the cultivation 
of the cannabis plant, mainly for the production of can-
nabis herb. Cannabis production takes place in Aus-
tralia, New Zealand and most of the small island 
countries. Cannabis production is for local consump-
tion and there is no information on exports to other 
regions. 
In addition, ATS production has started to gain promi-
nence over the last decade. This is mainly metham-
phetamine and, to a lesser extent, ecstasy. In addition, 
some amphetamine is also produced. ATS production is 
concentrated in Australia and, to a lesser extent, New 
Zealand. 
Trafficking 
The amounts of drugs seized in Oceania tend to be very 
small by international standards. Seizures of cannabis 
herb continued to decline over the 2005-2009 period 
and account for just 0.02% of the world total – far less 
than the share of the population of the Oceania region 
in the global total (0.5%). This is surprising as Oceania 
has one of the world’s highest cannabis use prevalence 
rates. 
The second largest seizures in volume terms were of 
cocaine, accounting for 0.04% of global seizures. 
Cocaine seizures increased over the 2005-2008 period, 
but declined again in 2009. Cocaine is trafficked from 
South America to Australia, though some recent arrests 
suggest that Mexican drug cartels may have started to 
show an interest in the potentially lucrative Australian 
cocaine market (due to high cocaine prices). 
The proportion of Oceania in the global total is higher 
when it comes to ATS. Seizures of amphetamines-group 
substances accounted for 0.4% of the world total. 
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Amphetamines-group seizures declined by some 85% 
between 2006 and 2009. 
The decline was even more pronounced for ecstasy sei-
zures, falling by 96% between 2005 and 2009, or by 
99% between 2007 and 2009. Nonetheless, with a share 
in global seizures of 1.2%, ecstasy continues to play an 
above-average role in this region. Significant amounts of 
ecstasy – by local standards – are still being smuggled 
into Oceania (notably Australia) from Europe and 
South-East Asia, in addition to domestic supply. 
The importance of heroin seizures in Oceania is also 
modest (0.3% of global seizures). Heroin seizures, how-
ever, showed a clear increase over the 2006-2009 period 
but were nonetheless some 80% lower than in 2000. 
LSD seizures declined by some 95% between 2005 and 
2009, but LSD was the only substance where Oceania 
accounted for a substantial share of global drug seizures 
(16%). 
Illicit drug use
Illicit drug use in Oceania is generally characterized by 
high prevalence rates, notably for cannabis (9.3%-
14.8% of the population aged 15-64), but also for ATS, 
both ecstasy (3.6%-4%) and amphetamines (2%-2.8%), 
as well as for cocaine (1.4%-1.7%). Only the prevalence 
rate for opiates (0.2%) is below the global average – a 
lasting result of the ‘heroin drought’ in 2001. 
At the same time, much progress has been made over the 
last decade in reducing the prevalence rates. This was 
particularly true for the opiates, but also for cannabis. 
Use of ecstasy and cocaine increased. More recently, all 
indicators show a stabilization of drug use. 
Though annual drug use prevalence rates are high, per 
capita consumption of drugs among drug users tends to 
be low in Oceania, notably for cocaine. Very high drug 
prices may explain this. 
Non-medical use of prescription drugs also appears to be 
widespread in Oceania, and it seems to be mainly linked 
to some prescription amphetamines and prescription 
opioids. 
In Australia, there is substantial non-medical use of both 
amphetamines (2.7%) and prescription opioids (0.2%) 
among the general population. Use of tranquillizers is 
also common. Among students aged 12-17, 16.2% had 
used tranquillizers without a doctor’s prescription in 
their lifetime. This compares with a lifetime prevalence 
of 3.8% for amphetamines among students, and 2.3% 
who had used opiates in their lifetime.37 Widespread 
non-medical use of prescription drugs was also reported 
by New Zealand. 
Drug-related deaths
For Oceania, although the total number of drug-related 
deaths is small (approximately 2,800 deaths), the mor-
tality rate seems to be rather high, at 119 deaths per one 
million inhabitants aged 15-64. Since Australia is the 
only reporting country, this rate probably does not 
reflect the situation across Oceania. Moreover, Australia 
has a better drug-death registration system than many 
other countries.
37 White V. and Smith G., Australian secondary school students’ use of 
tobacco, alcohol, and over-the-counter and illicit substance in 2008, 
Drug Strategy Branch, Australian Government Department of 
Health and Ageing, September 2009.
2005 2006 2007 2008 2009
In % of global 
total in 2009
Cannabis herb 3,514 2,845 2,730 1,445 1,389 0.02%
Cocaine 95 285 626 931 290 0.04%
Amphetamines-group 
of which methamphetamine
338
132
1,753
216
198
174
312
48
253
171
0.4%
0.6%
Ecstasy 1,447 541 4,666 58 63 1.2%
Heroin 152 67 65 80 195 0.3%
LSD 0.67 0.13 0.13 0.00 0.03 16%
Memo: Population 36 million 0.5%
Table 9: Seizures in Oceania, kilogram equivalents, 2005-2009 
Source: UNODC ARQ.
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2.1 Introduction 
UNODC estimates that there were between 12 and 21 
million opiate users worldwide in 2009. Heroin remains 
the most commonly used opiate, consumed by a vast 
majority of global opiate users (about 75%). In 2009, an 
estimated 12-14 million heroin users consumed some 
375 mt of heroin. 
Europe and Asia remain the key opiate consumption 
markets. However, a range of opiates are consumed 
worldwide, including raw opium, morphine and local 
types of opiates.1 Consumption of these substances is 
limited and generally confined to certain geographical 
areas. In recent years, problem drug use has also been 
related to the non-medical use of various prescription 
opioids, such as oxycodone, fentanyl or pethidine. 
Global opium poppy cultivation amounted to some 
195,700 ha in 2010, a 5% increase from 2009, mainly 
driven by increased cultivation in Myanmar. Cultivation 
in the Lao People’s Democratic Republic increased in 
2010, but remains at a low level. Over the last three 
years, although cultivation in Afghanistan has declined, 
it remains high (63% of global cultivation). The area 
under opium poppy cultivation in Afghanistan was esti-
mated at some 123,000 ha in 2010, the same level as 
2009. 
Global opium production amounted to 4,860 mt in 
2010, compared to 7,853 mt the year before. This was 
largely due to a drastic reduction in Afghanistan’s opium 
production as a result of a disease in opium poppy 
1 Produced by mixing locally grown opium poppy with acetic anhy-
dride.
plants. Forecasts for Afghan production in 2011, based 
on UNODC’s Winter Rapid Assessment (February 2011), 
project a further small decline or at least a stabilization 
of overall opium poppy cultivation at the lower levels. 
Moreover, if the opium yield returns to the average level, 
it is likely that opium production will increase in 
Afghanistan in 2011.
On the basis of production, seizure and consumption 
data, an estimated 460-480 mt of heroin were trafficked 
(including seizures) worldwide in 2009. Of this, 375 mt 
reached the consumers. Opiate trafficking from produc-
tion countries to consumer markets requires a global 
network of routes as well as facilitation by domestic and 
international criminal groups. In particular, traffickers’ 
use of maritime transportation and seaports has been 
identified as a key emerging threat – one which is largely 
overlooked by international law enforcement. In 2009, 
more than 420 million containers were shipped world-
wide, yet only 2% of these were inspected. Although the 
trafficking routes are constantly changing, the global 
movement of heroin from producers to international 
consumers follows well-established paths. Heroin from 
Myanmar is mainly trafficked to China and Mexican 
heroin is mainly trafficked to the United States of Amer-
ica, while Afghan heroin is trafficked to every region of 
the world, except South and Central America. Opiates 
flow from Afghanistan through Pakistan, the Islamic 
Republic of Iran and Central Asia before moving to the 
main consumer markets in West and Central Europe, 
East Europe, and East and South-East Asia.
Opiate users generated an estimated US$68 billion in 
revenue for traffickers in 2009 – with around US$60 
billion from Afghan opiates. Local anti-government ele-
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ments and criminal networks profit from the opiate 
trade in Afghanistan and neighbouring countries, but 
the bulk of the profits benefit international drug traf-
fickers. According to conservative estimates (with a 10% 
net-profit margin2) organized crime groups made net 
profits of at least US$7 billion from the opiate trade. 
Organized crime is a threat to political stability, public 
security and health in transit and destination countries. 
The underground economy produced by the global 
opiate trade is undermining legal economies and fuel-
ling corruption in some countries. Opiates, especially 
heroin, also cause serious health problems, including the 
transmission of blood-borne infections such as HIV/
AIDS and Hepatitis C. 
2.2 Consumption
UNODC estimates that between 12 and 21 (midpoint: 
16.5) million people used opiates at least once in the 
past year3 in 2009, with an annual prevalence rate 
between 0.3% and 0.5% of the world’s population aged 
15-64. Although this section mainly analyses global 
‘opiate’ consumption (heroin and opium), other opio-
ids4 are also considered as some Member States only 
provide overall opioid statistics rather than individual 
heroin or opium prevalence rates through the Annual 
Reports Questionnaire (ARQ).5 
Heroin is the most commonly used opiate, consumed by 
some three quarters of global opiate users. There were an 
estimated 12-14 million heroin users worldwide in 
2009. A range of opiates are consumed worldwide, how-
ever, including raw opium, morphine and local types of 
opiates, such as kompot or cherniashka.6 Raw opium 
consumption is largely restricted to some parts of Asia, 
kompot or cherniashka are consumed almost exclusively 
in East Europe, and illicit morphine has an extremely 
limited consumer base. In recent years, the non-medical 
use of various prescription opioids7 has increased in 
2 This is a minimum profit margin. It could be much higher, but needs 
to be studied in detail. 
3 This refers to the year prior to which the national estimates were 
derived and not necessarily the year 2009.
4 Opioid is a generic term applied to alkaloids from opium poppy, 
their synthetic analogues, and compounds synthesized in the body. 
In general, a distinction is made between ‘opiates’ (that is, the vari-
ous products derived from the opium poppy plant including opium, 
morphine and heroin) and synthetic opioids. For the purpose of 
description in this section (and in line with the new Annual Report 
Questionnaire), ‘opiates’ in this section only refer to opium and 
heroin while ‘prescription opioids’ include morphine and codeine as 
well as synthetic opioids such as methadone, buprenorphine,  pro-
poxyphene, fentanyl, pentazocine, et cetera. 
5 The ARQ used by Member States until 2010 included the broad cat-
egory of opioids and the sub-categories of heroin, opium and ‘other 
opioids.’ The new ARQ approved by Member States in 2010 added 
the category ‘misuse of prescription opioids’ to the ‘other opioids.’ 
6 Produced by mixing locally grown poppy with acetic anhydride 
7 Such as oxycodone, fentanyl, or pethidine and in some instances the 
use of substitution opioids such as buprenorphine or methadone.
some countries, becoming one of the drug groups affect-
ing problem drug users. 
In terms of absolute numbers of users, most opioid users 
are in the Americas, particularly in North America, fol-
lowed by Asia and Europe. However, if only opiate use 
is considered, more than half of the world’s estimated 
opiate (heroin and opium) users are in Asia, followed by 
Europe and Africa. The global pattern of opioid use 
varies considerably by region. In the Americas and Oce-
ania (New Zealand and Australia, in particular) the use 
of prescription opioids constitutes the main problem, 
while the use of heroin is limited. In Europe, in contrast, 
heroin is the main opiate used, with limited non-medi-
cal use of prescription opioids reported.8
In traditional opium-cultivating countries and some of 
their neighbours, opium use is more common than 
heroin use. This is particularly true in Afghanistan, the 
Lao People’s Democratic Republic, Myanmar and the 
Islamic Republic of Iran. In Africa and Asia, while 
heroin is the main opiate used, there are reports indicat-
ing that non-medical use of prescription opioids is 
increasingly common in some countries. 
In 2009, heroin users worldwide consumed some 375 
mt of pure heroin.9 In Asia, the vast majority of heroin 
consumption occurred in China, Pakistan, the Islamic 
Republic of Iran and India.10 In the Americas, the 
United States of America dominated heroin consump-
tion. In Europe, several countries, including the Russian 
Federation11, the United Kingdom, Italy, France and 
Germany, are key heroin consumption countries. In 
Africa, consumption is mainly concentrated in East, 
West and Central Africa.
Raw opium consumption is much more limited than 
heroin consumption, both in terms of number of users 
and geographic reach. In 2008, there were an estimated 
4 million opium users worldwide, who consumed 1.1 
mt of opium.12 Of the total number of global users, the 
vast majority – accounting for more than 80% of global 
consumption – was in Asia. Cultural practices and tradi-
tion may explain the concentration of opium use in 
Asia. Opium smoking is a traditional practice in some 
South-West Asian and South Asian countries, especially 
the Islamic Republic of Iran, Pakistan, Afghanistan and 
India, as well as in some areas of South-East Asia, nota-
8 The extent of prescription opioid use in Europe needs to be further 
investigated.
9 ‘Pure heroin’ refers to heroin of 70% purity, which is roughly equiva-
lent to 2,600 mt of heroin of 10% purity.
10  UNODC, Addiction, Crime and Insurgency: The transnational threat 
of Afghan opium, 2009.
11 Based on preliminary estimates by UNODC, since there are no 
comprehensive studies on prevalence of opiate use in the Russian 
Federation.
12 UNODC, Addiction, Crime and Insurgency : The transnational threat 
of Afghan opium, 2009.
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Despite far higher levels of non-medical use of prescrip-
tion opioids, treatment data suggest that the USA is still 
facing a serious heroin problem: 71% of all opioid-
related treatment admissions in 2008 were due to heroin 
use. But data also showed that treatment for heroin use 
remained stable over the last decade, while treatment 
admissions related to prescription opioids increased 
strongly, raising its share in total opioid-related treat-
ment admissions from 7% in 1998 to 29% in 2008.
With regard to Emergency Department visits, data for 
2009 suggest that more visits are related to the non-
medical use of prescription opioids (narcotic analgesics: 
129.4 visits per 100,000 people) than to the use of 
heroin (69 visits per 100,000 people).15
However, in 2009, data from the US household survey 
showed a stronger increase in heroin use than non-
medical use of prescription opioids. The number of 
heroin users identified via the household survey rose by 
33% compared to 2008, while the number of users of 
prescription opioids rose by 4%. None of these increases 
15 US Department of Health and Human Services, Highlights of the 
2009 Drug Abuse Warning Network (DAWN) Findings on Drug-
Related Emergency Department Visits, 2009.
Opioids and opiates
There are a number of terms used in this chapter in relation to opiates, opioids, synthetic opioids et cetera. The 
purpose of this box is to clarify the technical definition of these terms and explain the terminology used in present-
ing the data in this chapter. 
Technical definition
Opium is produced by the poppy plants and it contains psychoactive substances including morphine, codeine, 
thebaine, papaverine and noscapine. Opium, together with its psychoactive constituents and their semi-synthetic 
derivatives, for example heroin (derived from morphine) are described as opiates. Opioid is a generic term applied 
to two main sets of substances: opiates and synthetic substances (called synthetic opioids), with actions similar to 
those of morphine, in particular the capacity to relieve pain. The synthetic opioids include substances such as fen-
tanyl, methadone, buprenorphine, propoxyphene, pentazocine and oxycodone. Another group of substances 
included in the generic category of opioids is the endogenous opioids, for example, the endorphins (endogenous 
morphine) and enkephalins. These are naturally produced by the human body and have actions similar to morphine. 
Some of these substances, such as the enkephalins, have been synthesized and are available from commercial sources.
Data presented on drug use in relation to opiates and opioids
Data on drug use provided by Member States, have traditionally included the generic category of opioid users and 
the sub-classification of heroin users, opium users and users of ‘other opiates.’ In 2010, the Commission on Narcotic 
Drugs approved a new questionnaire (Annual Report Questionnaire, ARQ) for future data reporting. The ARQ 
includes the generic category for opioid use and three sub-categories defined as i) use of opiates (heroin and opium), 
ii) non-medical use of prescription opioids (morphine, codeine and synthetic opioids such as methadone, buprenor-
phine, propoxyphene, fentanyl, pentazocine and oxycodone) and iii) use of other illicit opioids. 
While morphine and codeine are technically classified as opiates, it is important to note that these have been placed 
under the sub-category of ‘prescription opioids’ for the purposes of data reporting to UNODC.
Fig. 12: National admissions to substance 
abuse treatment in the USA, 1998-2008
Source: SAMHSA, Treatment Episode Data Set (TEDS),  
1998-2008
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were, however, statistically significant. Nonetheless, the 
number of first-time heroin users also increased strongly. 
Around 180,000 persons aged 12 or older had used 
heroin for the first time within the past 12 months. The 
number of first-time heroin users in 2009 was signifi-
cantly higher than the 2002-2008 average, which was 
slightly above 100,000.16
Furthermore, an estimated 2 million people aged 12 
years or older had initiated their drug use with prescrip-
tion pain relievers. Of these, 55.3% obtained the drug 
from a friend or relative for free, 17.6% from a doctor, 
4.8% from a drug dealer or other stranger, and 0.4% 
bought them on the Internet.17
In 2009, non-medical use of prescription opioids in 
Canada was reported at 0.5%, the same level as 2008, 
16 SAMHSA, National Survey on Drug Use and Health (NSDUH), 2009.
17 Ibid.
Region/subregion
Estimated  
number of users 
annually (lower)
-
Estimated  
number of 
users annually 
(upper)
Percent of 
population 
aged 15-64 
(lower)
-
Percent of 
population 
aged 15-64 
(upper)
Africa
East Africa
North Africa
Southern Africa
West and Central Africa
890,000
140,000
130,000
210,000
410,000
-
-
-
-
-
3,210,000
1,310,000
550,000
280,000
1,070,000
0.2
0.1
0.1
0.3
0.2
-
-
-
-
-
0.6
1.0
0.4
0.3
0.5
Americas
Caribbean
Central America
North America
South America
1,180,000
50,000
20,000
1,000,000
110,000
-
-
-
-
-
1,910,000
80,000
20,000
1,630,000
170,000
0.2
0.2
0.1
0.3
0.0
-
-
-
-
-
0.3
0.3
0.1
0.5
0.1
Asia
Central Asia
East/South-East Asia
Near and Middle East
South Asia
6,440,000
320,000
2,800,000
1,940,000
1,380,000
-
-
-
-
-
12,020,000
320,000
4,990,000
3,540,000
3,170,000
0.2
0.6
0.2
0.8
0.2
-
-
-
-
-
0.4
0.6
0.3
1.4
0.4
Europe
East/South-East Europe
West/Central Europe
3,110,000
2,100,000
1,010,000
-
-
-
3,470,000
2,300,000
1,170,000
0.6
0.9
0.3
-
-
-
0.6
1.0
0.4
Oceania 40,000 - 50,000 0.2 - 0.2
Global 11,660,000 - 20,660,000 0.3 - 0.5
Table 10: Annual prevalence and estimated number of opiate users,* by region, subregion and  
globally, 2009
*Opiate estimates for Europe - where countries reported only opioid estimates - were derived by using the distribution of opiate 
users within the overall number of opioid users in treatment.
Fig. 13: Trends in drug-related emergency  
department visits per 100,000  
inhabitants, USA, 2004-2009
Source: US Department of Health and Human Services, High-
lights of the 2009 Drug Abuse Warning Network (DAWN) 
Findings on Drug-Related Emergency Department Visits, 2009.
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while heroin use was estimated at 0.36%.18 Like in 
many other countries, injecting opioids, including 
heroin, is reportedly common among problem drug 
users in Canada. Of the injecting drug users participat-
ing in a behavioural surveillance study in Canada in 
2006, half of the participants reported injecting non-
prescribed morphine, while 27.6% reported injecting 
heroin in the months prior to the interview.19 In line 
with results in other countries, the seroprevalence for 
HIV among the participants was 13.4% while that of 
Hepatitis C was 65.7%.20
In South America, the annual prevalence of opioid use 
(mainly non-medical use of prescription opioids) is esti-
mated at between 0.3 - 0.4% of the adult population, or 
between 850,000 - 940,000 people aged 15 - 64. The 
Plurinational State of Bolivia (0.6%), Brazil (0.5%) and 
Chile (0.5%) remain countries with high opioid use 
rates. In Central America, Costa Rica’s rate is higher 
than the global average (2.8%). In South and Central 
America, codeine-based preparations are among the 
most commonly used opioids. Treatment demand in the 
entire region has remained stable over the past few years. 
In 2009, 9.6% of treatment cases were related to opioid 
use.
18 Estimated by UNODC, based on 1% prevalence of injecting drug 
use (estimated 220,690 IDU in 2004) reported by the Reference 
group to the UN on HIV and injecting drug use, 2008.
19 Public Health Agency of Canada, Enhanced Surveillance of Risk 
Behaviours among injecting drug users in Canada, Phase I Report, 2006.
20 Ibid.
Despite stabilizing heroin consumption levels in 
Europe, associated social and health problems are 
not diminishing 
Heroin is the main opiate used in Europe. Opiate 
(mainly heroin) prevalence in Europe21 is estimated at 
0.6% of the population aged 15-64, or between 3.1 and 
3.5 million people. At 0.9% - 1.0%, the opiate use 
prevalence in East and South-East Europe is higher than 
in West Europe. Overall, experts from more than half of 
the countries in Europe reporting through the ARQ 
perceived opioid trends to be stable. New or updated 
prevalence estimates for a number of countries in Europe 
were published in 2010, including Austria, Belgium, 
Cyprus, Germany, Greece, Ireland, Italy, Luxembourg 
and Sweden. Among these, Ireland and Sweden reported 
an increase in the annual prevalence rates, while other 
countries reported stable opioid use trends.
The highest opioid use prevalence rates in West and 
Central Europe were reported from the United King-
dom (estimated 350,000 users), Italy (216,000 users) 
and France (190,000 users). In East Europe, the Russian 
Federation (1.7 million opiate users)22 and Ukraine 
(370,000 opiate users) had high opiate prevalence rates 
in 2009. Most of the users in the above-mentioned 
countries are heroin users.
21 Opiate estimates for Europe - where countries reported only opioid 
estimates - were derived by using the distribution of opiate users 
within the overall number of opioid users in treatment.
22 These estimates are preliminary, since there are no comprehensive 
studies on prevalence of opiate users in the Russian Federation. The 
estimate of opiate users ranges from 0.3% - 1.64% of the population 
aged 15-64. The estimate of 1.64% is based on the number of opiate 
users in treatment for 2007, using a treatment multiplier of 5.3% 
taken from a study conducted by the National Addiction Centre of 
the Russian Federation: Dynamics of Drug Related Disorders in the 
Russian Federation, 2007.
Fig. 14: Drugs injected by drug users in  
Canada, 2006
Source: Public Health Agency of Canada, Enhanced Surveil-
lance of Risk Behaviours among injecting drug users in 
Canada, Phase I Report, 2006.
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annual prevalence of opioid use in  
Europe, various years
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Of the 1 million people in Europe who received treat-
ment for illicit drug use in 2007, more than half received 
opioid substitution treatment (mainly methadone, to a 
lesser extent buprenorphine and, in some countries, 
slow-release morphines). Like in the past, heroin and its 
metabolites were reported as the main cause of the 
majority of drug-induced deaths in Europe, accounting 
for more than two thirds of all cases reported from 20 
countries. The average age of those who died due to 
heroin use was the mid-thirties, suggesting a stabiliza-
tion or decrease in the number of young heroin users in 
Europe. The EMCDDA Annual Report 2010 suggests 
that for each drug-induced death, there are an estimated 
20-25 non-fatal overdose cases. 
Heroin use is stabilizing in East and South-East 
Asia, but is perceived to be increasing  
in some other parts of Asia
Asian opiate prevalence estimates range between 0.2 and 
0.5% of the population aged 15-64, or an estimated 6.5 
to 13.2 million people. Most of the opiate users in Asia 
reportedly use heroin or opium, and more than half of 
the world’s estimated opiate users live in Asia. Although 
recent prevalence estimates are not available for most 
countries in Asia, less than half (46%) of the countries 
that responded to the ARQ perceived an increase in 
opioid use. However, 38% of the responding countries, 
mostly in South-East Asia, perceived a decrease in 2009. 
Countries in South-West Asia continue to have high 
prevalence rates for opiate use. Together, these countries 
account for nearly one third of opiate users in Asia. In 
Afghanistan, around 60% of the estimated opiate users 
use opium. In the Islamic Republic of Iran, 40% of the 
estimated opiate users consume opium, and the rest 
mainly consume heroin. In the Islamic Republic of Iran, 
83% of treatment admissions in 2009 were for opiate 
use, in Pakistan, the share was 41% in 2006/2007. Opi-
ates are also the most common cause of drug-related 
deaths reported in these countries. In the Islamic Repub-
lic of Iran, the rate of drug-related deaths was 91 per 1 
million people aged 15-64; the majority of these related 
to opiate use. Moreover, overall opiate use in Afghani-
stan increased from 1.4% in 2005 to 2.7% of the popu-
lation aged 15-64 in 2009. Heroin remains the most 
problematic illicit drug in Central Asia and the Cauca-
sus. Experts in Central Asia perceived a stabilizing trend 
of opioid use, but the proportion of officially registered 
heroin users continued to increase, with 47% of regis-
tered drug users in Kyrgyzstan identifying themselves as 
Fig. 16: Prevalence of opioid use in West and Central Europe, 2009 or most recent year available
Source: UNODC. 
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available
*Based on preliminary estimates by UNODC, since there are 
no comprehensive studies on prevalence of opiate use in the 
Russian Federation. 
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heroin users, and 82% in Tajikistan in 2009.23 Injecting 
drug use is also common, with shares ranging from 46% 
of drug users in Uzbekistan to around 70% in Kyr-
gyzstan and Kazakhstan.24 Opiate prevalence in the 
Caucasus is lower than the world average, ranging from 
0.31% in Georgia to 0.22% in Armenia. With the 
exception of Azerbaijan, opioids is also the main sub-
stance group reported in drug-related death cases in the 
region, with rates ranging from 7 per million people 
aged 15-64 in Uzbekistan to 115 in Kazakhstan. 
Although most of the countries in South Asia lack recent 
opiate use estimates, use levels seem to vary in the region. 
23 UNODC, Compendium of drug related statistics: 2009, Regional 
Office for Central Asia, 2009.
24  Ibid.
A 2006 study of drugs and HIV in South Asia25 found 
that 90% of the drug users interviewed in Bangladesh 
and 2% in Bhutan were currently using heroin (either 
smoking or injecting). Additionally, among the respond-
ents, the use of prescription opioids ranged from 1% in 
Bhutan and Sri Lanka to 20% in India. Heroin injection 
was most common among drug users in Nepal, followed 
closely by those in India.
In East and South-East Asia, opiates continue to be used 
at high rates. In 2009, heroin ranked as the main drug 
used in China, Malaysia, Myanmar, Singapore and Viet 
Nam. Most countries in the region have reported stable 
25 UNODC, Rapid Situation and Response Assessment of Drugs and HIV 
in Bangladesh, Bhutan, India, Nepal and Sri Lanka: A regional Report, 
2006.
Fig. 18:  Treatment demand in Europe, 2009 or most recent year available*
Source : UNODC ARQ. 
* Treatment definitions and data reporting differ from country to country. Therefore, totals may not sum up to, or may exceed, 100%.
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or decreasing trends in opiate use, except the Lao Peo-
ple’s Democratic Republic, Singapore and Viet Nam.26 
Opiate prevalence increased from 0.6% in 2008 to 0.8% 
in Myanmar in 2010.27 As in previous years, the preva-
lence of opium use in the opium-growing villages in 
Myanmar (1.7%) was higher than in the non-opium 
growing villages (0.6%). With an estimated prevalence 
of 0.18% of the population aged 15 and above,28 heroin 
use in Myanmar is less widespread than opium use. 
Treatment demand for heroin dependence remains high 
across East and South-East Asia, ranging from 50% of 
all treatment demand in Singapore to around 80% in 
China and 98% in Viet Nam.
Opiate use remains low in the Middle East
The opiate prevalence rate remains low in countries in 
the Middle East, with heroin being the main opiate 
consumed. In terms of treatment demand, heroin and 
26 UNODC, Patterns and Trends of Amphetamine-Type Stimulants and 
other Drugs: Asia and the Pacific, Global SMART Programme, 2010
27 UNODC, South-East Asia Opium Survey 2010: Lao People’s Demo-
cratic Republic, Myanmar, 2010.
28 Ibid.
prescription opioids are reported as the primary sub-
stances in many countries, including Oman (100%), the 
Syrian Arab Republic (95%), United Arab Emirates 
(64%) and Lebanon (57%). Opiates are also ranked as 
the main substance among drug-related deaths, with 
rates ranging from 4.6 per million people aged 15-64 in 
the United Arab Emirates to 44.3 in Bahrain.29 
Heroin use in Africa is perceived  
to be increasing
In 2009, the annual prevalence of opiate use in Africa 
was estimated at between 0.2% and 0.6% of the popula-
tion aged 15-64, or 890,000-3.2 million people. The 
wide range reflects missing data from most parts of the 
continent. Heroin remains the main opiate used in 
Africa, but there are reports of common non-medical 
use of prescription opioids in some countries. 
The majority of African countries that provided infor-
mation to UNODC reported that opioid use has 
increased. In 2009, 60% of the countries that responded 
to the ARQ reported an increase in the use of opioids in 
29 UNODC ARQ.
  Opium Heroin smoked Heroin injected Propoxyphene Buprenorphine
Bhutan (n=200)      
Ever used 0 37 3 32 28
Current users 0 4 3 3 2
% of current users 0 2 1.5 1.5 1
Bangladesh (n=1073)      
Ever used 140 989 46 3 295
Current users 7 961 6 1 154
% of current users 0.7 89.6 0.6 0.1 14.4
India (n=5732)      
Ever used 1535 3017 1623 1713 1466
Current users 858 2123 1228 1103 1115
% of current users 15 37 21.4 19.2 19.5
Nepal (n=1322)      
Ever used 181 1159 606 149 1013
Current users 117 880 456 97 858
% of current users 8.9 66.6 34.5 7.3 64.9
Sri Lanka (n=1016)      
Ever used 107 558 23 39 6
Current users 36 520 4 14 0
% of current users 3.5 51.2 0.4 1.4 0
Table 11: South Asia: Use of opioids among drug users, 2006
Source: UNODC Rapid Situation and Response Assessment of Drugs and HIV in Bangladesh, Bhutan, India, Nepal and Sir Lanka:  
A regional report, 2006.
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their country, while just 30% reported a decrease.30 The 
annual opiate prevalence rate is higher in East Africa – at 
0.1-1% – than other subregions. 
In East Africa, Mauritius (0.91%) and Kenya (0.73%) 
have high prevalence rates for heroin use. However, at 
1.04%, non-medical use of prescription opioids in Mau-
ritius is higher than heroin use. In 2009, a survey of 
alcohol and drug use was conducted in 4,500 house-
holds in the coastal provinces of Kenya; the prevalence 
of heroin use was reported at 1.9% of the population, 
with a higher prevalence of 2.5% among young adults 
aged 18-25.31 Injecting drug use, especially of heroin, is 
reportedly common among drug users in Kenya, and the 
HIV seroprevalence rate for this group was found to be 
very high, 42.9%.32 
Although there are currently no reliable estimates of 
opiate use in the United Republic of Tanzania, increas-
ing trends of injecting heroin have been reported, espe-
cially from the coastal areas. An HIV seroprevalence 
study conducted in 2006 showed HIV seroprevalence 
levels at 27% among male and 58% among female 
injecting drug users.33 Similarly, in a study of HIV 
among drug users in Zanzibar, injecting drug users 
30 UNODC ARQ.
31 NACADA, Report of Survey on Drugs and Substance Abuse in Coast 
Province, Kenya, March 2010.
32 Mathers, B., Degenhardt, L., Phillips, B., Wiessing, L., Hickman, 
M., Strathdee, A., Wodak, A., Panda, S., Tyndall, M., Toufik, A. and 
Mattick, R., on behalf of the Reference Group to the United Nations 
on HIV and Injecting Drug Use, ‘Global epidemiology of injecting 
drug use and HIV among people who inject drugs: a systematic 
review’, The Lancet, 2008; 372:1733-1745.
33 Timpson, S., et al, ‘Substance abuse, HIV risk and HIV and AIDS in 
Tanzania,’ African Journal of Drug and Alcohol Studies, 5(2), 2006.
accounted for 46% of those interviewed, with 30% HIV 
infected and 22% showing positive Hepatitis C sero-
prevalence.34
In 2009, the opiate prevalence rate (mainly heroin) was 
estimated to have increased from 0.57% to 0.70% in 
Nigeria. This means that Nigeria would host almost 
500,000 – 600,000 heroin users.
34 Dahoma , J., et al,  ‘HIV and substance abuse: the dual epidemics 
challenging Zanzibar,’ African Journal of Drug and Alcohol Studies, 
5(2), 2006.
Fig. 20: Number of injecting drug users and HIV seroprevalence in West, Central and South Asia, 
most recent year available
Source: Reference Group to the United Nations on HIV and Injecting Drug Use.
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Fig. 21: Annual prevalence of opiate use in  
Africa, by region, 2009
Source: UNODC ARQ.
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Opiates already constitute the main drug group users 
seek treatment for in many countries in the region, rang-
ing from 81% of those treated in Mauritius, 55% in 
Mozambique, 45% in Seychelles and 33% in the United 
Republic of Tanzania. Among the limited countries 
reporting mortality data, opiates were also ranked as the 
main substance group responsible for drug-related 
deaths.
Stable trend of heroin use in Oceania 
In 2007, 0.4% of the population aged 15-64 in Aus-
tralia, around 57,000 people, were reported to have used 
heroin, street methadone and/or other opioids in the 
preceding 12 months. In 2008, 1.7% of students aged 
12-17 who participated in the Australian secondary 
school survey had used opioids, other than for medical 
reasons.35
The Illicit Drug Reporting System (IDRS) in Australia 
showed that heroin continues to be the main drug of 
choice among injecting drug users. After a strong decline 
in 2001, the proportion of such users reporting heroin 
as the last drug or the drug injected most often declined 
again over the 2004-2006 period. Since then, however, 
there has been a steady increase in heroin use among 
injecting drug users, from 27% in 2006 to 43% in 
2009, which could be an early indication that the stabi-
lization of heroin use in Australia may be coming to an 
end. The proportions of injecting drug users consuming 
heroin are, however, still substantially lower than in 
35 White V. and Smith, G., Australian secondary school students ’use of 
tobacco, alcohol, and over the counter and illicit substances in 2008, 
Drugs Strategy Branch, Australian Department of Health and 
Ageing.
2000 (58%).36 Furthermore, morphine, followed by 
oxycodone, remained the most commonly injected pre-
scription opioids among injecting drug users. 
The HIV seroprevalence among injecting drug users in 
Australia remained low, at 1.5% over the 2005-2008 
period, while the Hepatitis C (HCV) seroprevalence was 
reported at 63%.37 The rate of HCV seroprevalence was 
even higher among drug users who reported heroin or 
36 Rainsford, C., Lenton, S. and Fetherston, J., ’Indicators of chang-
ing trends in heroin and other opioid use in IDRS data nationally 
and in Western Australia,’ Drug Trends Bulletin, April 2010, Sydney: 
National Drug and Alcohol Research Centre, University of New 
South Wales.
37  UNODC ARQ.
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Fig. 22: Treatment demand in Africa, 2009  
or most recent year available*
* Treatment definitions and data reporting differ from  
country to  country. Therefore totals may not sum up to, or may 
exceed, 100%.
Source: UNODC ARQ. 
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Fig. 23: Drug of choice, Australia, 2000-2009
Source: Illicit Drug Reporting System, Australia.
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In 2010, the total area under opium poppy cultivation 
was some 195,700 ha, a 5% increase from 2009. While 
Afghanistan continued to account for the bulk of the 
cultivation, some 123,000 ha, increased cultivation in 
Myanmar was the main driver behind the global increase. 
In the 3-year period since 2007, opium cultivation in 
Afghanistan has actually declined, although it remains at 
high levels. Cultivation in Myanmar and Mexico has 
increased significantly. In 2006, opium poppy cultiva-
tion in Myanmar was 21,500 ha; the lowest since 1996. 
Since then, it has been steadily increasing. In addition to 
Myanmar, opium cultivation increased by almost 60% 
in the Lao People’s Democratic Republic in 2010, 
although it remains at a low level. 
A 2010 estimate for opium poppy cultivation in Mexico 
was not available at the time of writing. Therefore, the 
2009 estimate was used to calculate the total global cul-
tivation in 2010. Opium poppy cultivation in Mexico 
appears to have been steadily increasing over the 2005-
2009 period, amounting to 19,500 ha in 2009, the third 
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Fig. 26: Global cultivation of opium poppy 
(ha),* 2005-2010
* For Mexico, in the absence of data for 2010, the estimate for 
2009 was imputed to 2010.
Source: UNODC ARQ. 
Map 9: Security map (as of 30 March 2010) and opium cultivation in Afghanistan by province, 2010
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largest area worldwide after Afghanistan and Myanmar. 
In contrast to the other countries mentioned above, 
neither the Government nor UNODC has been directly 
involved in monitoring such cultivation and the esti-
mates thus cannot be confirmed. In 2009, the Mexican 
Government reported eradication of almost 15,000 ha 
of opium poppy, the highest reported total worldwide 
for that year.
In Myanmar, opium poppy cultivation has increased 
every year since 2006. Cultivation is concentrated in the 
Shan State, in the eastern part of the country. At 3,000 
ha in 2010, opium poppy cultivation in the Lao People’s 
Democratic Republic was higher than in any year since 
2005, and has increased significantly since the lowest 
level (1,500 ha) in 2007. Cultivation seems to be increas-
ingly concentrated in a few provinces in the northern 
part of the country.
In Pakistan, opium poppy is mainly grown in the Khyber 
District of the Federally Administered Tribal Area 
(FATA), but smaller pockets were also found in Balo-
chistan and Sindh provinces. Since 2006, cultivation in 
Pakistan has remained below 2,000 ha. 
Aside from these countries, reports of opium poppy 
eradication programmes and seizures of plant material 
indicate the existence of opium poppy cultivation in 
many other countries and regions. A considerable level 
of illegal cultivation is estimated in India, as domestic 
raw opium consumption and half of domestic heroin 
demand are met by local production.41 At least 10,000 
ha of opium poppy cultivation is estimated in other 
countries worldwide, with a 30% increase in 2010. 
41 UNODC ARQ.
Overall, in the last five years, global opium poppy culti-
vation has increased by some 40%. UNODC currently 
implements programmes to monitor the illicit cultiva-
tion of opium poppy in cooperation with the Govern-
ments of Afghanistan, Myanmar and the Lao People’s 
Democratic Republic.
In 2010, potential global opium production dropped by 
at least 38% from 2009, due to significantly reduced 
opium yield as a result of disease on opium poppy plants 
in Afghanistan. Although increases in cultivation (and 
opium yield) in other countries led to an increase in 
potential opium production outside Afghanistan, this 
did not offset Afghanistan’s decrease. However, opium 
production may increase if the opium yield returns to 
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Afghanistan  400  121 21,430 *  5,103  5,300  9,047  5,480  5,351 2,316 
Colombia 6,885  6,988  2,901  8,249  9,254  2,385  3,577  3,266  3,866  2,121  1,929  375  381  546 
Egypt  15  34  65  45  50  98  121  89 
Guatemala  489  720  449  536  1,345  918 
India  29  96  248  153  18  219  494  167  12  247  8,000  624  2,420 1,022 
Lao PDR  4,134  3,556  2,575  1,518  779  575  651  579 
Lebanon  4  67  27  8  21 
Mexico 14,671 17,732 17,449 15,461 15,717 15,350 19,157 20,034 15,926 21,609 16,890 11,046 13,095 14,753 
Myanmar  1,938  3,093  3,172  9,824  1,643  9,317  7,469  638  2,820  3,907  3,970  3,598  4,820  4,087 8,268 
Nepal  19  19  4  1  21  35 
Pakistan  867  654  2,194  1,197  1,704  1,484  4,185  5,200  391  354  614 0 105  68 
Peru  4  18  26  155  14  57  98  92  88  28  23  32  21 
Thailand  886  1,053  716  808  757  832  989  767  122  110  153  220  285  201  278 
Venezuela  51  266  148  137  215  39 0 0  87  154 0 0 0
Viet Nam  1,142  340  439  426 125 100  32  38  99  31 
Table 12: Reported opium poppy eradication in selected countries (ha), 1996 to 2010
* Although eradication took place in 2004, it was not officially reported to UNODC.  
In this table, only eradication reported in area units is considered. Eradication reported as plant seizures can be found in the seizure 
annex of the electronic version of the World Drug Report.  
Sources: UNODC, Annual Reports Questionnaire, Government reports, reports of regional bodies, INCSR.
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Fig. 27: Global opium production*, 2005-2010
* For Mexico, in the absence of data for 2010, the estimate for 
2009 was imputed to 2010.
Source: UNODC.
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Table 13: Global illicit cultivation of opium poppy and potential opium production, 1996-2010
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
 SOUTH-WEST ASIA
   Afghanistan 56,824 58,416 63,674 90,583    82,171 7,606 74,100 80,000 131,000 104,000 165,000 193,000 157,000 123,000 123,000
   Pakistan 873 874 950 284 260 213 622 2,500 1,500 2,438 1,545 1,701 1,909 1,779 1,721
   Subtotal 57,697 59,290 64,624 90,867 82,431 7,819 74,722 82,500 132,500 106,438 166,545 194,701 158,909 124,779 124,721
 SOUTH-EAST ASIA
   Lao PDR (a) 21,601 24,082 26,837 22,543 19,052 17,255 14,000 12,000 6,600 1,800 2,500 1,500 1,600 1,900 3,000
   Myanmar (a) 163,000 155,150 130,300 89,500 108,700 105,000 81,400 62,200 44,200 32,800 21,500 27,700 28,500 31,700 38,100
   Thailand (b) 368 352 716 702 890 820 750
   Viet Nam (b) 1,743 340 442 442
   Subtotal 186,712 179,924 158,295 113,187 128,642 123,075 96,150 74,200 50,800 34,600 24,000 29,200 30,100 33,600 41,100
 LATIN AMERICA
   Colombia 4,916 6,584 7,350 6,500 6,500 4,300 4,153 4,026 3,950 1,950 1,023 715 394 356
   Mexico (c) 5,100 4,000 5,500 3,600 1,900 4,400 2,700 4,800 3,500 3,300 5,000 6,900 15,000 19,500
   Subtotal 10,016 10,584 12,850 10,100 8,400 8,700 6,853 8,826 7,450 5,250 6,023 7,615 15,394 19,856 19,856
 OTHER
   Other countries (d) 3,190 2,050 2,050 2,050 2,479 2,500 2,500 3,074 5,190 5,212 4,432 4,184 8,600 7,700 10,000
 TOTAL 257,615 251,848 237,819 216,204 221,952 142,094 180,225 168,600 195,940 151,500 201,000 235,700 213,003 185,935 195,677
 SOUTH-WEST ASIA
   Afghanistan 2,248     2,804     2,693     4,565     3,276     185        3,400     3,600     4,200 4,100 6,100 8,200 7,700 6,900 3,600
   Pakistan 24          24          26          9            8            5            5            52          40 36 39 43 48 44 43
   Subtotal 2,272 2,828 2,719 4,574 3,284 190 3,405 3,652 4,240 4,136 6,139 8,243 7,748 6,944 3,643
 SOUTH-EAST ASIA
   Lao PDR 140        147        124        124        167        134        112        120        43 14 20 9 10 11 18
   Myanmar 1,760     1,676     1,303     895        1,087     1,097     828        810        370 312 315 460 410 330 580
   Thailand (b) 5            4            8            8            6            6            9            
   Viet Nam (b) 9            2            2            2            
   Subtotal 1,914     1,829     1,437     1,029     1,260     1,237     949        930 413 326 335 469 420 341 598
 LATIN AMERICA
   Colombia 67          90          100        88          88          80          52          50          49          24 13 14 10 9
   Mexico (c) 54          46          60          43          21          91          58          101        73          71 108 149 325 425
   Subtotal 121        136        160        131        109        171        110        151 122 95 121 163 335 434 434
 OTHER
   Other countries (d) 48          30          30          30          38          32 56 50          75 63 16 15 139 134 185
 TOTAL 4,355      4,823      4,346      5,764      4,691      1,630      4,520      4,783      4,850 4,620 6,610 8,890 8,641 7,853 4,860
 NET CULTIVATION OF OPIUM POPPY IN HECTARES 
 POTENTIAL PRODUCTION OF OVEN-DRY OPIUM IN METRIC TONS 
GLOBAL ILLICIT CULTIVATION OF OPIUM POPPY AND PRODUCTION OF OPIATES, 1996-2010
Figures in italics are preliminary and may be revised when updated information becomes available. Information on estimation methodologies and defi-
nitions can be found in the Methodology chapter of this Report.
Sources: Afghanistan: before 2003: UNODC; since 2003: National Illicit Crop Monitoring System supported by UNODC. Pakistan: ARQ, Government 
of Pakistan, US Department of State. Lao PDR: 1996-1999: UNODC; since 2000: National Illicit Crop Monitoring System supported by UNODC. 
Myanmar: before 2001: US Department of State; since 2001: National Illicit Crop Monitoring System supported by UNODC. Colombia: before 2000: 
various sources, since 2000: Government of Colombia. For 2008 and 2009, production was calculated based on regional yield figures and conversion 
ratios from US Department of State/DEA. Mexico: Estimates derived from US Government surveys.
(a)  May include areas which were eradicated after the data of the area survey.
(b)  Due to continuing low cultivation, figures for Viet Nam (as of 2000) and Thailand (as of 2003) were included in the category "Other".
(c)  The Government of Mexico reported a gross opium poppy cultivation of 19,147 hectares (2006) and estimated gross opium production at 211 mt 
(2006), 122 mt (2007), 144 mt (2008), 162 mt (2009) and 170 mt (2010). These gross figures are not directly comparable to the net figures pre-
sented in this table. The Government of Mexico is not in a position to confirm the US figures as it does not have information on the methodology 
used to calculate them.
(d)  Eradication and plant seizure reports from different sources between 2006 and 2010 indicate that illicit opium poppy cultivation also exists in 
the following subregions: North Africa, Central Asia and Transcaucasia, Near and Middle East /South-West Asia, South Asia, East and South-East 
Asia, East Europe, Southeast Europe, Central America and South America. Starting 2008, a new  methodology was introduced to estimate opium 
poppy cultivation and opium/heroin production in these countries. These estimates are higher than the previous figures but have a similar order of 
magnitude. A detailed description of the estimation methodology is available in the Methodology section.
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average levels in Afghanistan in 2011, despite the expec-
tation that overall opium poppy cultivation will remain 
stable there. 
Despite potential global opium production decreasing 
to 4,860 mt – a significant decline compared to the peak 
production from 2006-2009 – this level is similar to 
average production levels over the past two decades. 
Afghanistan remained the largest opium-producing 
country in 2010, with 74% of global potential produc-
tion (down from 88% in 2009). In 2009, Mexico for the 
first time had a higher potential opium production than 
Myanmar. In 2010, potential opium production in 
Myanmar amounted to 580 mt, a 76% increase. This is 
the highest level since 2004 in that country.
As in previous years, UNODC has estimated the total 
potential production of opium and heroin (of unknown 
purity). According to these estimates, the production of 
opium in 2010 amounted to 4,860 mt, a 38% decrease 
from 2009. Potential heroin production amounted to 
396 mt, a 40% decline from the 667 mt estimated in 
2009. ‘Potential heroin production’ refers to the amount 
of heroin that would be produced if all the harvested 
opium would be either introduced to the market as 
opium or processed into heroin.42
The entire amount of opium produced every year may 
not be either consumed or converted into heroin, how-
ever, as seizures of final or intermediate products may 
take place and opiate stockpiling may be occurring 
inside and outside of Afghanistan.43 The amount of 
heroin available in the market is directly linked with 
demand and is likely to be less than the potential pro-
duction levels (which are calculated by multiplying the 
cultivated area with yield per hectare). Thus, it is neces-
sary to estimate global opiate demand, taking into 
42 UNODC estimates heroin production by calculating the proportion 
of opium that is converted into heroin as a function of seizures and 
according to information from key informants.
43 Opium stockpiling by opium farmers is an old tradition in 
Afghanistan.
account seizures as well as consumption. On this basis, 
it is estimated that some 460-480 mt of heroin were 
available in the worldwide market in 2009. Of this, 
some 375 mt reached the consumers, whereas the rest 
was seized. Further details regarding these estimates are 
provided in subsequent sections.
In 2009, there were no reports of laboratories involved 
in manufacturing heroin outside opium-producing 
countries. The highest number of laboratories inter-
cepted were in Afghanistan (4844), three laboratories 
were reported in Myanmar and only one in Mexico, 
although there was a much higher number of metham-
phetamine laboratories – an unspecified number of 
which also manufactured heroin. Other laboratories 
processing heroin were discovered in other countries, 
but these were not involved in manufacturing. One 
laboratory in the Russian Federation was producing 
acetylated opium and seven installations in Greece were 
involved in repackaging and adulterating heroin. 
Afghanistan is currently the only country known to be 
involved in manufacturing heroin from Afghan opium. 
Neighbouring countries and other countries along 
known trafficking routes have not reported domestic 
manufacturing of morphine or heroin from Afghan 
opium. High levels of morphine seizures were reported 
outside of Afghanistan in 2010, however. Morphine is 
primarily used to produce heroin as there is limited 
illicit morphine use worldwide. Thus, it is likely that 
heroin processing is also taking place outside Afghani-
stan. Given the security situation, the vast majority of 
Afghan heroin is estimated to be produced in the coun-
try, especially in the southern provinces. The high 
number of heroin manufacturing laboratories destroyed 
in Afghanistan supports this assumption. 
44 Information from the Ministry of Interior/Counter-Narcotics Police 
of Afghanistan.
Fig. 28: Potential production of opium and manufacture of heroin of unknown purity (mt), 2004-2010
* Although eradication took place in 2004, it was not officially reported to UNODC.  
In this table, only eradication reported in area units is considered. Eradication reported as plant seizures can be found in the seizure 
annex of the electronic version of the World Drug Report. Sources: UNODC, Annual Reports Questionnaire; Government reports; 
reports of regional bodies; INCSR.
2004 2005 2006 2007 2008 2009 2010
Total potential opium  4,850  4,620  6,610  8,890  8,641  7,853 4,860 
Potential opium not 
processed into heroin  1,197  1,169  2,056  3,411  3,080  2,898  1,728 
Potential opium  
processed into heroin  3,653  3,451  4,555  5,479  5,561  4,955  3,132 
Total potential heroin  529  472  629  757  752  667  396 
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Seizures
In 2009, global seizures of opium and heroin appeared 
to stabilize, amounting to 653 mt and 76 mt, respec-
tively. The largest quantities of opiates continued to be 
seized by Turkey and the Islamic Republic of Iran, coun-
tries that serve as transit points for heroin trafficked 
from Afghanistan on the ‘Balkan route’ to West and 
Central Europe.
Although much is known about drug suppliers, con-
sumers, traffickers and routes, interdiction remains dif-
ficult. Law enforcement efforts are frustrated by the fact 
that international traffickers constantly change their 
methods and routes, high profits may fuel high-level 
corruption, and international cooperation initiatives 
take time to become effective. 
The trend in global heroin seizures appears to follow 
that in opium production with a delay of one year. A 
decline in opium production in 2001 resulted in a drop 
in heroin seizures in 2002, the stability in opium pro-
duction over the period 2003-2005 was reflected in a 
relatively stable three-year span in heroin seizure totals 
over the period 2004-2006,45 and a marked increase in 
opium production over the period 2005-2007 was mir-
rored in an increase in heroin seizures over the period 
2006-2008. The trend in morphine seizures, however, is 
more erratic.
Illicit drug seizure totals can be susceptible to two main 
factors: 1) the available supply of the drug, and 2) the 
effectiveness of law enforcement efforts. Since law 
enforcement efforts and practices do not necessarily 
evolve in concert in different countries, at a global level, 
the law enforcement component plays a smaller role in 
determining the trend. The increased heroin seizures 
therefore likely reflect, at least in part, an increased 
supply of heroin in the world. This is in line with the 
45 Heroin seizure totals fell slightly in 2005 and 2006, but only by 3.5% 
and 2.7% respectively.
Map 10: Seizures of heroin and morphine, 2009 (countries and territories reporting seizures* of more 
than 10 kg)
* Seizures as reported (no adjustments made for purity)
Source: UNODC Annual Reports Questionnaires data supplemented by other sources
Note: The boundaries and names shown and the designations used on this map do not imply official endorsement or acceptance by the United Nations.
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Fig. 29: Global seizures of heroin(a) and morphine(b): 1999-2009
(a) Seizures as reported (no adjustment for purity).
Year 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Metric Tons 60        81       66        73         98         100      91         104       92        91        100      
(a) 1 kg of morphine is assumed to be equivalent to 1 kg of heroin.
(b) Seizures as reported (no adjustment for purity).
(c) Data for the United Kingdom for 2009 are based on incomplete data for some jurisdictions for the financial year 2009/10, and adjusted for the missing 
jurisdictions using the latest available complete distribution (relative to the financial year 2006/07)
(d) Data relative to 2008. Data for 2009 from the Netherlands were not available.
(b) 1 kg of morphine is assumed to be equivalent to 1 kg of heroin.
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Fig. 30: Global seizures of opium: 1999-2009
Year 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
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increased levels of opium production. In comparison 
with 1998,46 the growth in heroin seizures has kept pace 
with, and slightly outperformed, the growth in opium 
production. In 2009, heroin seizures stood at 2.3 times 
the level in 1998, while opium production in 2008 
stood at 1.8 times the 1997 level.47
In order to assess the impact of drug seizures on global 
supply, total seizures of a given drug may be expressed as 
a percentage of global production; this percentage is 
often referred to as an ‘interception rate.’ Such a calcula-
tion is subject to a number of caveats, however, the first 
of which is the time lag between cultivation of an illicit 
crop and the resulting effect on the availability of the 
derived drug in the illicit market. Assuming that one 
kilogram of heroin or morphine is equivalent to 7-10 kg 
of opium, and comparing total seizures in 2009 with the 
average opium production in 2008 and 2009,48 a range 
of 16-20% for the interception rate for opiates can be 
46 The year 2008 is chosen as a baseline because, over the period 1996-
1998, seizures of opium and heroin, as well as opium production, 
were all relatively stable, suggesting that the opiates market was close 
to equilibrium.
47 Heroin seizures in a given year are compared to opium production in 
the previous year to allow for the time required for processing opium 
into morphine and heroin, and for the heroin to reach the markets 
where it is seized. 
48 Opium production in 2008 is considered along with that in 2009 to 
allow for the time required for processing and for the opiates to reach 
the markets where they are seized.
derived. Opium seizures in a given year are compared to 
the average opium production in that year and the previ-
ous year. Seizures of opium and morphine are concen-
trated in Afghanistan and neighbouring countries, but 
heroin seizures are much more dispersed.
Map 11: Opium seizures in Asia, 2009
Source: UNODC Annual Reports Questionnaires data supplemented by other sources
Note: The boundaries and names shown and the designations used on this map do not 
imply official endorsement or acceptance by the United Nations
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Fig. 31: Global opiate seizures, 1998-2009
Source: UNODC ARQ.
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Afghanistan and neighbouring countries
Opium and heroin seizures in Afghanistan remained 
limited in 2009, amounting to 36 mt of opium and 2.2 
mt of heroin. These seizures accounted for 5.5% and 
2.9% of global opium and heroin seizures, respectively, 
in 2009.
Neighbouring Islamic Republic of Iran, however, con-
tinued to make large seizures. In 2009, 89% of global 
opium seizures were made by that country. The global 
increase in opium seizures since 2002 is mainly due to 
increasing quantities seized in the Islamic Republic of 
Iran, which since 1996 have accounted for more than 
three quarters of annual global opium seizures. In 2006, 
the Islamic Republic of Iran replaced Turkey as the 
country reporting the largest heroin seizures worldwide. 
Since then, the Islamic Republic of Iran and Turkey have 
seized the largest and second-largest, respectively, annual 
heroin totals worldwide. Over the period 2002-2008, 
heroin seizures in both these countries increased mark-
edly, but in 2009, seizures stabilized both in the Islamic 
Republic of Iran, at 25 mt (compared to 23 mt in 2008) 
and in Turkey, at 16 mt (compared to 15 mt in 2008). 
Heroin seizures in Central Asian and East European 
countries have been erratic in recent years, but over the 
long term, a distinct increase has been observed. Over 
the period 2003-2009, heroin seizures in East Europe 
were much higher than in previous years.  
West and Central Europe
The trend in bulk heroin seizures in West and Central 
Europe does not mirror the increased supply of Afghan 
opium or the increased levels of heroin seizures in the 
Islamic Republic of Iran and Turkey. Indeed, seizures in 
West and Central Europe peaked at 11.6 mt in 2000 
and appear to have stabilized at a lower level, ranging 
between 7.5 mt and 7.9 mt annually over the 2005-
2009 period. 
The Asia-Pacific region
In the past, the supply of heroin in China has been 
mainly sourced from South-East Asia (notably Myan-
mar). However, significant quantities of heroin have 
begun to reach China from Afghanistan.
Heroin from northern Myanmar enters China via 
Yunnan province; according to Chinese authorities, 
heroin seizures in Yunnan province rose from 2.9 mt in 
2008 to 3.3 mt in 2009. Seizures of heroin originating 
in Afghanistan registered a more pronounced increase, 
rising from 390 kg (seized in 234 cases) in 2008 to 1.5 
mt (seized in 333 cases) in 2009.49
Heroin trafficking from Afghanistan to the Asia-Pacific 
region is increasing, also supported by drug seizures 
reported by Pakistan. Among those cases in which the 
destination of the consignment was identified as a coun-
try or region other than Pakistan, the proportion of 
heroin seizures destined for the Asia-Pacific region 
increased from around 12% prior to 2006 to 40-44% 
every year since. The emergence of this new route 
around 2005-2006 also appears to have caused a drop in 
heroin seizures in the region, suggesting that regional 
law enforcement needs time to adapt to the new route. 
This was also concurrent with a sharp increase in opium 
production in Afghanistan. This increase may have led 
to a surplus of opiates, some of which may have found 
their way to the Asia-Pacific region.
49 National Narcotics Control Commission of China, presentation at 
the Twentieth Anti-Drug Liaison Officials’ Meeting for International 
Cooperation (ADLOMICO), October 2010, Seoul, Republic of 
Korea.
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Source: UNODC ARQ.
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Fig. 33: Global seizures of opiates: 1999-2009
*Aggregate of heroin, morphine and opium. Expressed in heroin equivalents assuming 1kg of heroin to be equivalent to 1 kg of morphine and 10 kg of opium.
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The Americas
Heroin seizure totals reported by the United States con-
tinued to be the highest in the Americas by far, rising 
steadily from 1.4 mt in 2007 to 2.4 mt in 2009. The 
results of the Heroin Signature Program (HSP) of the 
US Drug Enforcement Agency pointed to an increase in 
the availability of heroin from Mexico. In 2008, the 
wholesale purity of heroin of Mexican origin was at its 
highest (40%) since 2005, while Mexican heroin repre-
sented 39% (by weight) of all heroin analysed through 
the HSP, the highest percentage since 1987. Seizures of 
heroin by US authorities along the US-Mexico border 
increased from 404 kg in 2007 to 556 kg in 2008, and 
the partial total for 2009 amounted to 642 kg.50 In 
2009, large quantities of heroin were also seized in 
Colombia (735 kg), Mexico (283 kg) and Ecuador (177 
kg). Seizures in the Bolivarian Republic of Venezuela 
have declined significantly since the peak level of 2004 
(658 kg), amounting to 81 kg in 2009.
Heroin seizures also increased sharply in Canada, from 
16 kg in 2007 to 102 kg in 2008 and 213 kg in 2009. 
However, the increase in 2009 can be attributed to a 
single maritime shipment of 108 kg. In contrast with 
the United States, Canada assessed that 98% of heroin 
reaching its market in 2009 originated from South Asia. 
In 2009 Canada also seized 20 mt of a preparation 
50 National Drug Intelligence Center, United States Department of 
Justice, National Drug Threat Assessment 2010, February 2010.
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referred to as ‘dode,’ a fine powder obtained by grinding 
dried seed pods of opium poppy. It is most frequently 
consumed mixed with hot water as a tea. Canada assessed 
that 94% of the ‘dode’ that reached its market originated 
in the United States, with the remaining 6% originating 
in the Netherlands, and that the affordability of ‘dode’ 
had the potential to create a market beyond the tradi-
tional cultural groups.
The United States is also affected by non-medical use of 
prescription opioids, and reported significant seizures of 
oxycodone and hydrocodone.
Africa
Heroin seizures in Africa rose sharply, from 311 kg in 
2008 to 515 kg in 2009. This is the highest level since 
1993. South Africa registered the largest seizure total as 
well as the largest year-on-year increase, with seizures 
rising from 41 kg in 2008 to 198 kg in 2009.
In recent years, heroin seizures have increased signifi-
cantly in Egypt. In 2008, Egypt seized 211 kg of heroin, 
accounting for two thirds of total heroin seizures in 
Africa, and registering the third consecutive year-on-
year increase. In 2009, seizures fell to 159 kg, remaining 
significantly higher than the levels registered in this 
country over the period 1995-2006. In the past, Egypt 
has also reported seizures of opium and opium capsules.
In 2009, significant quantities of heroin were also seized 
in Nigeria, 104 kg. Although this represents a sharp 
increase from the level in 2008 (12 kg), seizures were 
already high in 2007 (121 kg). Reports suggest that 
Nigeria may serve as a transit point for limited quanti-
Heroin seizures  in the Americas , selected countries , 1999 2009
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Fig. 36: Heroin seizures in selected countries in the Americas,1999-2009
Source: UNODC ARQ/DELTA.
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Fig. 37: United States: seizures of hydrocodone and oxycodone, 2001-2009
Note: Seizures quantified in number of pills (left axis) are in addition to those quantified by weight (right axis). 
Source: UNODC ARQ.
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ties of heroin destined for consumer markets in other 
countries. Over the 2004-2008 period, Pakistan reported 
significant, albeit declining, numbers of seized heroin 
consignments intended for Nigeria (36 such seizures in 
2008 and 16 in 2009). According to the United States 
Department of Justice, organizations responsible for 
trafficking heroin originating in South-West Asia into 
the United States included some that were based in West 
Africa. Nigeria has been mentioned as a transit country 
for heroin by Australia and the United States in recent 
years. Nigeria assessed that one half of the heroin traf-
ficked on its territory in 2009 was intended for the 
United States, with 40% intended for Europe and 10% 
for China.
Trafficking routes and volumes 
Global heroin-producing countries supply different 
markets. Heroin from Myanmar is mainly trafficked to 
China and Mexican heroin is mainly trafficked to the 
United States of America. Afghan heroin, however, is 
trafficked to every region of the world except Latin 
America. As such, trafficking routes for Afghan heroin 
are the main focus of this section.
Heroin trafficking routes are complex. Estimating the 
volumes, that is, the global flow of opiates, requires data 
on global opiate demand. Global heroin and opium 
seizures are used to identify opiate trafficking routes and 
to help estimate the size of the flows in each country. In 
addition to seizure data, information was drawn from 
official country reports such as ARQ responses. 
Available demand data was used as the key variable to 
estimate the size of the global heroin and opium flows. 
The robustness of demand data varies considerably, and 
the data are subject to frequent revisions and changes. 
Most countries still lack structured data collection sys-
tems capable of producing scientifically sound demand, 
supply and seizure statistics. Accordingly, the statistics 
and estimates provided on opiate demand and flows 
should be viewed as the best current approximations. 
Heroin flow figures used in this section are indicative 
and should be taken with caution. The purpose of pro-
ducing these statistics is to estimate i) the main flows 
and changes in the routes over time, and ii) provide 
threat and risk analysis for production, transit and des-
tination countries. The volumes and routes discussed are 
not fixed and change according to changes in demand, 
drug availability, or risk perceptions of drug traffickers. 
Therefore, it is essential to monitor flows every year to 
observe changes in the market and routes, which can 
inform global strategies and policies regarding public 
health and security ramifications. 
Heroin trafficking from production countries to con-
sumer markets requires a global network of routes and 
facilitation by domestic and international criminal 
groups. Although the exact routes are constantly chang-
ing, the global movement of heroin from Afghanistan 
and other producers to international consumers follows 
well-established paths. Some routes are chosen for geo-
graphic reasons, while others are preferred due to a lack 
of law enforcement. 
It is estimated that some 460-480 mt of heroin was 
available in the global market in 2009. Of this, some 
375 mt reached consumers and the rest was seized. 
Afghanistan continued to be the main supplier for the 
global heroin market, producing 380 mt (83%). 
Despite the complexity of heroin trafficking routes, 
some global movements can be generalized for Afghan 
heroin, which flows from Afghanistan through Pakistan, 
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the Islamic Republic of Iran and some Central Asian 
countries before moving to the main consumer markets 
in West and Central Europe, East Europe, and East and 
South-East Asia.
Heroin flows from Afghanistan…
Afghanistan continues to dominate global heroin supply. 
In 2009, an estimated 6,900 mt of opium were pro-
duced in Afghanistan. Almost 95% of Afghan opium is 
grown in some of the country’s southern provinces, 
including Hilmand, Kandahar, Farah, Nimroz and 
Uruzgan. Heroin processing laboratories are also con-
centrated in these provinces. 
From the production areas, heroin is trafficked overland 
in three main directions: i) to Nimroz, Farah and Hirat 
provinces along the border with the Islamic Republic of 
Iran, ii) to eastern and northern Afghanistan, or iii) to 
Pakistan’s Balochistan borders. UNODC estimates that 
365 mt of Afghan heroin were trafficked into the inter-
national market in 2009. Afghanistan’s neighbours 
received the largest volumes of heroin. Some 160 mt 
were trafficked to Pakistan, 115 mt to the Islamic 
Republic of Iran and 90 mt to some Central Asian coun-
tries (Tajikistan, Uzbekistan and Turkmenistan).
…to Pakistan
An estimated 160 mt of heroin were trafficked from 
Afghanistan to Pakistan in 2009. The majority is thought 
to have entered overland into Pakistan’s Balochistan 
province from Afghanistan’s Hilmand and Kandahar 
provinces, facilitated by the limited law enforcement 
capacity on both sides and the strong presence of the 
Taliban and other anti-government elements. The bor-
ders of Afghanistan’s Nangarhar and Kunar provinces 
with Pakistan’s Federally Administered Tribal Area also 
figure as prominent heroin crossing areas, although to a 
lesser extent.
Of the 160 mt of heroin that entered Pakistan, 138 mt 
Map 12: Afghan heroin trafﬁcking routes and volumes, 2009
Source: UNODC.
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were trafficked onward. At least 30 mt were trafficked 
from Balochistan to the Islamic Republic of Iran. The 
remaining 108 mt were moved internally to Pakistan’s 
industrial capitals, Karachi and Lahore, as well as to 
other coastal or border locations for onward trafficking 
to Europe, South-East Asia, South Asia and Africa by sea 
and air. The declining opium production in Myanmar 
has increased heroin trafficking via Pakistan to South-
East Asia, especially in 2009.
…to the Islamic Republic of Iran
An estimated 145 mt of heroin were trafficked into the 
Islamic Republic of Iran from Afghanistan and Pakistan 
in 2009. Although the majority of heroin enters from 
Afghanistan, increasing security along the Islamic 
Republic of Iran - Afghanistan border is likely to cause 
an increase in heroin flows through Pakistan.51 Accord-
ing to heroin seizures, once heroin enters the Islamic 
Republic of Iran, it is transported in four main direc-
tions: i) through central parts of the country to the 
border with Turkey, ii) to the seaports and coastline, iii) 
to the border with Iraq, or iv) to the border with Azerba-
ijan.
Despite high levels of domestic consumption, the major-
ity of the heroin that enters the Islamic Republic of Iran 
is trafficked onwards, especially along the ‘Balkan Route’ 
towards West and Central Europe. In 2009, an esti-
mated 82 mt were trafficked to Turkey, 6 mt to Africa, 
3 mt to countries of the Caucasus and small quantities 
directly to Europe.
…to Central Asia
In 2009, 90 mt of Afghan heroin were trafficked into 
Central Asia, namely Tajikistan, Uzbekistan, Turkmeni-
stan, Kyrgyzstan and Kazakhstan from Afghanistan. 
Afghan heroin enters the region mainly via the porous 
Tajikistan-Afghanistan border, delineated by the Pianj 
River.52 Afghan heroin also enters via Uzbekistan, 
although in smaller quantities. Once in Tajikistan, 
heroin generally moves through Uzbekistan and Kyr-
gyzstan before transiting Kazakhstan into the Russian 
Federation. 
Of the 90 mt that entered the region, the majority – 75 
mt – was trafficked onwards to the Russian Federation. 
Given that the only land border between the Russian 
Federation and Central Asia is Kazakhstan, almost the 
entire amount of heroin trafficked by land to the Rus-
sian Federation passed through that country. Central 
Asia forms the gateway for heroin destined for the Rus-
sian Federation and onwards to East Europe, a route 
known as the ‘Northern Route.’
51 According to Pakistan’s ANF, 2010.
52 Drug Control Agency (DCA) of Tajikistan.
Main destination markets
Once Afghan opiates have entered neighbouring Paki-
stan, Islamic Republic of Iran and Central Asia, it is 
trafficked to the main international consumption mar-
kets – West and Central Europe, East Europe, East and 
South-East Asia and South Asia. Limited amounts also 
reach other smaller consumption markets.
West and Central Europe
In 2009, users in West and Central Europe consumed 
some 70 mt of pure heroin. An additional 7.5 mt were 
seized by law enforcement institutions. Thus, an esti-
mated 75-80 mt of heroin were trafficked to West and 
Central Europe. The bulk, some 60 mt, were trafficked 
from the countries of South-East Europe (via the Balkan 
route). Moreover, some 7 mt were trafficked from Africa, 
4 mt from Pakistan, 3 mt from the Near and Middle 
East/South-West Asia (mainly the Islamic Republic of 
Iran, Qatar and Jordan) and 1 mt from South Asia 
(mainly India, Bangladesh and Nepal). The source and 
route of the remaining 3 mt are undetermined.
Heroin is trafficked into West and Central Europe by 
land, sea and air. The Balkan route dominates land and 
sea shipments, while Africa is now emerging as the lead-
ing origin of air shipments. One reason for this is that 
law enforcement capacity in East Africa is scarce and 
trafficking heroin by sea from Pakistan poses few chal-
lenges to experienced traffickers. 
The Balkan route originates in Afghanistan, passes 
through the Islamic Republic of Iran and Turkey, and 
reaches the Balkans via Bulgaria, with a smaller flow 
through Greece. Once the heroin enters Turkey, most is 
trafficked to Istanbul and then onwards to the borders 
with Bulgaria and Greece. Traffickers are able to take 
advantage of the lack of visa requirements between the 
Balkan countries. In 2009, an estimated 65 mt of heroin 
reached the Balkan countries, of which some 60 mt were 
trafficked onwards to West and Central Europe, mainly 
to the United Kingdom, Italy, Netherlands, Germany, 
France and Belgium. Limited heroin trafficking also 
occurred via air directly from Turkey to West and Cen-
tral European countries.
The majority of the heroin trafficked through the 
Islamic Republic of Iran and Turkey is believed to be 
intended for western Europe. Recent seizures at seaports 
indicate that maritime transportation might be used 
more than estimated for heroin trafficking worldwide. 
In the first three months of 2011, there were big heroin 
seizures reported in East Africa (Kenya and the United 
Republic of Tanzania). In addition, recent reports indi-
cate that the average seizure per case has decreased in the 
Islamic Republic of Iran and Turkey, two countries that 
have strengthened their law enforcement capacity in 
recent years. This might force heroin traffickers to find 
alternative routes to Europe. 
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East Europe
In 2009, users in East Europe consumed an estimated 
73 mt of heroin. In the Russian Federation, the opiate 
prevalence rate for the adult population was 1.64% in 
2009.53 This is equivalent to around 1.7 million opiate 
users, who consumed some 70 mt of pure heroin. 
In total, including the 3.1 mt of heroin seized and 2-3 
mt of heroin trafficked onward, an estimated 75-80 mt 
of heroin were trafficked into the Russian Federation in 
2009. The route through Central Asia, the Russian Fed-
eration and into East Europe is known as the ‘Northern 
Route.’ The majority of heroin trafficked to the Russian 
Federation came from Central Asia, and to a lesser 
extent Azerbaijan.54 East Europe received the majority 
of its heroin from the Russian Federation, as well as 
from Turkey and countries of the Caucasus.
53 These estimates are preliminary, since there are no comprehensive 
studies on prevalence of opiate users in the Russian Federation. The 
estimate of opiate users ranges from 0.3% - 1.64% of the population 
aged 15-64. The estimate of 1.64% is based on the number of opiate 
users in treatment for 2007, using a treatment multiplier of 5.3% 
taken from a study conducted by the National Addiction Centre of 
the Russian Federation: Dynamics of Drug Related Disorders in the 
Russian Federation, 2007.
54 UNODC ARQ.
East and South-East Asia
In 2009, opiate demand in East and South-East Asia was 
met by both local production and Afghan supply. Myan-
mar and the Lao People’s Democratic Republic are the 
main producing countries, exporting an estimated 25 
mt of heroin. The total estimated heroin demand was 90 
mt (including seizures and onward trafficking) in East 
and South-East Asia in 2009. 
An estimated 65 mt of pure Afghan heroin was traf-
ficked to the region to fill the gap in local production 
– 25 mt to South-East Asia and 40 mt to China. Given 
that the majority of heroin from Myanmar is trafficked 
Map 13: Heroin ﬂows to West and Central Europe in 2009
Source: UNODC.
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to China, most of the heroin reaching South-East Asia 
was likely transported from Afghanistan via Pakistan. 
However, exact drug trafficking routes and sources in 
2009 are difficult to determine due to a lack of seizures. 
Given the low prices of heroin in Pakistan, it may be 
cheaper for drug trafficking networks to transport 
Afghan heroin to China and South-East Asia rather than 
use heroin from Myanmar.
Heroin trafficking from Afghanistan to the Asia-Pacific 
region is an increasing trend, visible in individual drug 
seizures reported by Pakistan. Among those cases in 
which the destination of the consignment was identified 
as a country or region other than Pakistan, the propor-
tion destined for the Asia-Pacific region underwent a 
distinct change in the transition from 2005 to 2006. 
This proportion (by number of seizure cases) was rela-
tively stable over the period 2002-2005 (ranging between 
11 and 13%), rose distinctly to 44% in 2006, to remain 
relatively stable since then, ranging between 40 and 
44%. It is likely that a significant proportion of these 
consignments was intended for China. The proportion 
of cases in which China was identified as the country of 
destination rose sharply from less than 1% in 2004 to 
28% in 2006, possibly reflecting the route identified by 
Chinese authorities involving direct shipments to north-
western China. Since 2006, these shipments appear to 
have been gradually replaced by shipments to other 
countries in the Asia-Pacific region, possibly for further 
trans-shipment to their final destinations (which may 
include China as well as other countries in South-East 
Asia and Oceania). 
This proportion also reached record levels in the case of 
several other countries in this region, such as Malaysia 
(22% in 2008), Thailand (7% in 2009), Nepal (6% in 
2009) and Sri Lanka (5% in 2009). The shipments may 
reflect the recent trafficking route to south-eastern 
China. Indeed, although limited quantities of Afghan 
heroin were trafficked by air from South-West Asia to 
the north-west of China (notably Urumqi), an increas-
ingly important route went from Afghanistan and 
neighbouring countries to the south-eastern Chinese 
province of Guangdong, via transit countries such as 
Malaysia, Singapore, the Philippines and Viet Nam. Five 
of the seizure cases in Guangdong province in 2009 
together accounted for 1 mt of heroin.55 The emergence 
of this new route around 2005-2006 also appears to 
have caused a drop in heroin seizures in this region, sug-
gesting that law enforcement needed time to adapt.
55 National Narcotics Control Commission of China, presentation at 
the Fifteenth Asia-Pacific Operational Drug Enforcement Confer-
ence, February 2010, Tokyo, Japan, and National Narcotics Control 
Commission of China, presentation at the Twentieth Anti-Drug Liai-
son Officials’ Meeting for International Cooperation (ADLOMICO), 
October 2010, Seoul, Republic of Korea.
Map 14: Heroin flows to the Russian Federation and East Europe, 2009
Source: UNODC.
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Heroin trafficking from East and South-East Asia is 
limited. In 2009, 3-4 mt of heroin were trafficked from 
South-East Asia to Australia and, to a lesser extent, New 
Zealand. There are no reports of onward heroin traffick-
ing from China in 2009.
South Asia
South Asia was an important consumption and transit 
point for Afghan heroin in 2009. Some 25 mt of pure 
heroin were consumed in the region and 15 mt were 
trafficked onwards. Of this, some 6 mt went to South-
East Asia, 6 mt to Africa, 1-2 mt to North America and 
1 mt each to China and Europe. Although the majority 
of users in India use Indian heroin, drug traffickers 
prefer to export Afghan heroin due to its higher purity.
Of the 40 mt of heroin that were available in South Asia, 
an estimated 25 mt were trafficked from Afghanistan to 
South Asia, and a further 15 mt were manufactured 
domestically. Indian heroin supplied regional markets 
including Bangladesh,56 Nepal57 and Sri Lanka.
Africa
In 2009, an estimated 40-45 mt of Afghan heroin were 
trafficked to Africa, of which some 25 mt were likely 
trafficked from Pakistan, 5-6 mt from the United Arab 
Emirates, 5-6 mt from India and 5 mt from the Islamic 
Republic of Iran. The majority of heroin is still smug-
gled into South Africa, mainly from South-West Asia 
and, to a lesser extent, South-East Asia. Major hubs in 
Africa include Nigeria and South Africa.
The majority of heroin that reached the continent was 
56  Interviews with Bangladeshi officials, March 2009.
57  Interviews with Nepalese officials, March 2009. 
consumed there, although Africa is now emerging as a 
heroin trafficking hub. In 2009, an estimated 7 mt of 
heroin were trafficked from Africa to Europe, almost 1 
mt to China and a small amount to Australia.
Heroin flows to other destinations
Aside from the above-mentioned destination markets, 
there are other international consumption markets, 
including the Americas and Oceania.
In 2009, an estimated 40 mt of heroin were available in 
the Americas, the majority of which was grown and 
produced regionally. Only a limited amount of Afghan 
heroin was available in the market, as production in 
Mexico was higher than regional demand. However, the 
heroin market in Canada is mainly supplied by Afghan 
heroin. 
In 2009, Mexico produced 426 mt of opium, which 
may be converted into 40 mt of Mexican (black tar) 
heroin. However, such a level of heroin production in 
Mexico would be equivalent to almost double the esti-
mated consumption in its main destination market of 
North America (22 mt). In the absence of regional 
opiate stocks, either production figures are over-esti-
mated or consumption is under-estimated. 
Production in Colombia is similarly opaque. Almost 
58% of the heroin seized in the United States of Amer-
ica is reportedly of Colombian origin.58 However, 
Colombia’s total opium production was 9 mt in 2009, 
with a maximum yield of 1 mt of heroin. As Colombian 
law enforcement bodies seized 650 kg of heroin in 2009, 
350 kg of heroin were left for trafficking. This would 
58  USA Drug Enforcement Administration, Heroin Signature Program.
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not even satisfy heroin consumption in South America 
(2 mt), and nothing would be left for trafficking to the 
US. The currently available data is insufficient to prop-
erly understand heroin supply and demand in the 
Americas.
In 2009, almost 4 mt of heroin were trafficked to Oce-
ania, mainly to Australia. Of this, 3.2 mt were con-
sumed in Australia and 0.6 mt in New Zealand. Heroin 
use was almost negligible in other countries of the 
region. Afghan heroin dominated the markets in Aus-
tralia and New Zealand, likely trafficked via Pakistan 
and South-East Asian countries. Indeed, Australia regis-
tered a significant diversification in the countries of 
departure for heroin trafficking into the country (of 
which there were 11 in 1999-2000 and 29 in 2008-
2009),59 and identified Cambodia, Malaysia, Pakistan, 
Thailand and Viet Nam as the most common departure 
countries in 2008-2009. Although heroin trafficking 
from South and East Africa to Australia was limited in 
2009, shipments from Africa are emerging as a new 
trend, according to the Australian Government.60 
59  Both reporting periods from July 1 to June 30 of the following year.
60  UNODC ARQ.
Map 15: Heroin trafﬁcking from South Asia, 2009
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The findings in this section were calculated by examin-
ing a range of indicators, including demand statistics, 
opiate seizure databases of the World Customs Organi-
zation and UNODC, ARQ responses and individual 
country reports. Experts from international organiza-
tions, Member States and UNODC field offices have 
been consulted. 
Heroin and opium prices depend on a number of fac-
tors, including purity, supply and demand, distance 
from the source and risk of interception. For example, 
one gram of good quality heroin costs around US$2-3 
in Afghanistan, whereas the price is between US$40 – 
US$400 at consumption markets. Although farmers in 
Afghanistan supply much of the world’s opiates, it is the 
international criminal networks along trafficking routes 
that earn billions of dollars every year. 
Heroin market values for each main consumption coun-
try or region were calculated by using the amount of 
estimated heroin consumption as well as the average 
price. Regional/country-level heroin consumption and 
average prices are detailed elsewhere in this chapter. 
Heroin consumption amounts for each country/region 
were calculated by multiplying the estimated number of 
opiate users by the average heroin consumption per 
capita per year. The average heroin consumption figures 
reported in the 2005 World Drug Report have been 
updated with the help of several Member States, 
UNODC field offices and other relevant organizations 
since 2008.61  
In order to compare the market values between regions 
and countries, all prices were adjusted for purity. This 
information was collected through ARQ responses or 
bilateral meetings with officials. However, there is lim-
ited information available about purity levels.    
To calculate the amount of opiate flows through a coun-
try or a region, analyses of both opiate use and seizure 
data from 2009 were carried out to track the patterns 
and estimate the magnitude of opiate flows. The total 
amount of heroin used was calculated for each country, 
then combined with official seizure data and balanced 
against total manufacture. Manufacture, consumption 
and seizure data were analysed together. For example, 
61 UNODC, Addiction, Crime and Insurgency: The Transnational Threat 
of Afghan Opium, 2009.
the size of estimated heroin flows from Afghanistan or 
Pakistan to country ‘X’ should be similar to the amount 
of heroin used and intercepted in country ‘X’ and the 
destination and transit countries receiving heroin via 
country ‘X’. First, heroin or opium demand in the main 
destination regions or countries was calculated. Then, by 
drawing on seizure statistics from each country, the 
amounts of heroin or opium flowing between the coun-
tries were estimated. 
Regarding the analysis on groups that benefit from the 
heroin trade, arrestee statistics provided by Member 
States were analysed, supplemented by extensive consul-
tations with various Government experts and institu-
tions. 
As this report aims to provide global insights as well as 
orders of magnitude, the flows represented on maps 
should be considered broadly indicative rather than 
definitive. Flows may deviate to other countries along 
the routes and there are numerous secondary flows that 
may not be represented. Moreover, trends respond rap-
idly to changes in law enforcement and demand. Opiate 
flow estimations would, therefore, need to be revised if 
demand statistics were to change. The estimates will be 
updated periodically as new drug use data is provided by 
Member States.
Purity and prices
Both heroin (wholesale) and opium (farm-gate) prices in 
Afghanistan have increased in the last year, despite a 
steady decline from 2006 to 2009. At the end of March 
2011, the national average price for one kilogram of dry 
opium in Afghanistan at the farm-gate level was US$274/
kg, 180% higher than the US$98/kg reported in March 
2010.62 The dry opium price at the farm-gate level has 
been increasing since July 2009. The current farm-gate 
price is the highest price reported since November 2004. 
Similarly, at the end of March 2011, heroin cost 
US$3,815/kg, compared to US$2,506/kg in March 
2010, an increase of 52%.63 Afghan heroin has, on aver-
age, a purity level of around 70%, much higher than 
that what reaches global consumption markets.
62 Ministry of Counter Narcotics Islamic Republic of Afghanistan and 
UNODC, Afghanistan Opium Price Monitoring Monthly Report, Feb-
ruary 2011.
63 Ibid.
2.5 Market analysis
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Heroin prices in western Europe do not show a clear 
response to opiate prices in Afghanistan. A long-term 
comparison of the trader price of opium in Afghanistan 
with heroin prices in Europe shows that, despite a 
marked hike in opium prices between early 2000 and 
late 2002, which coincided with a marked drop in 
opium production in 2001, the retail heroin price, 
measured in euros, did not decrease in western Europe. 
In view of the large mark-up between prices in Afghani-
stan and western Europe (the price per pure gram of 
heroin in Afghanistan is approximately 1% of the retail 
price in western Europe), one possible explanation for 
this is that the impact on the final price of price changes 
at the source is only cumulative, rather than propor-
tional, resulting in a non-discernible effect at the much 
higher order of magnitude of retail prices. For example, 
an increase in the wholesale price of heroin in Afghani-
stan from US$2 to US$3 per gram (a spike of 50%) 
would bring about, if the impact is indeed cumulative, 
an increase of US$1 per gram in the final retail price, 
e.g. from US$70 to US$71 per gram (an increase of 1.4 
%). If the impact were proportional, a 50% hike in the 
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Fig. 43: Average price of dry opium at farm-gate level, September 2004 to March 2011
Source: Afghanistan Ministry of Counter Narcotics and UNODC Country Office in Afghanistan, Afghanistan Opium Price Monitoring 
Monthly Report, March 2011. 
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Fig. 44: Accrual of purity-adjusted heroin prices, 2009 (or latest year available)
Sources: UNODC Country Office in Afghanistan; UNODC DELTA, UNODC Estimates.
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wholesale price of heroin in Afghanistan would lead to 
a similar hike in the final retail price, from US$70 to 
US$105.
Although seizures in West and Central Europe do not 
mirror the increased supply of Afghan opium or the 
increased levels of heroin seizures in the Islamic Repub-
lic of Iran and Turkey, heroin price data for western 
Europe are compatible with increased supply. UNODC 
estimates of purity-adjusted heroin retail prices based on 
12 countries in western Europe indicate a decrease of 
35% between 2003 and 2009 in the price per pure gram 
of heroin, measured in euros and unadjusted for infla-
tion.64 The decrease is less evident in bulk retail prices, 
suggesting that the increase in heroin supply may have 
translated into increased purity. The equivalent average 
purity rose from 23% in 2003 to 28% in 2009.
Heroin from Mexico and heroin from South America 
are rather distinct products in the main consumer 
market, the United States of America. Heroin from 
South America is more expensive and of higher purity. 
In 2009, the US reported typical wholesale purity of 
52% for heroin from South America, compared to 40% 
for heroin from Mexico, and a price range of 44,000-
113,333 US$/kg for heroin from South America, com-
pared to 32,880-70,000 US$/kg for heroin from Mexico. 
Based on all heroin purchases performed by law enforce-
ment in the United States, in the last quarter of 2009, 
the average price per pure gram of heroin was at the 
64 Adjusting for inflation using Eurostat’s euro area index would result 
in a further 11% decrease.
highest level over the period 2006-2009, while the aver-
age purity was the lowest over the same period. 
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The opium/heroin market
Market value and beneficiaries
The global opiate market was valued at US$68 billion 
in 2009, with heroin consumers contributing US$61 
billion. The value of the world heroin market tends to 
increase according to the number of international bor-
ders crossed by traffickers. That is, heroin is generally 
cheaper in Afghanistan, a production country, than in 
West and Central Europe, where the drugs have been 
transported by various means across long distances and 
changed hands a number of times. However, this pattern 
can be deceptive, as heroin prices and consumption 
levels vary significantly across countries and regions. 
Heroin prices fluctuate significantly across the globe, 
and Australia is the starkest example of global price 
variation. Although Australian users represent just 
0.85% of total global heroin consumption, they contrib-
ute 4% of the global market value. The street value per 
gram of heroin is between US$230–370 in Australia 
whereas one gram of heroin was worth around US$170-
200 in the USA and northern Europe, and consumers in 
West and Central Europe paid US$40-100 per gram. 
Overall, the Russian Federation and West and Central 
Europe contributed almost half of the total global 
market value, accounting for US$31 billion in 2009.
Beneficiaries
Given the geographic spread of heroin users and the fact 
that heroin prices increase roughly according to distance 
from the source, it is not surprising that criminal net-
works in Europe, the Russian Federation and South-East 
Asia pocketed most of the profits in 2009. Indeed, ben-
eficiaries in Afghanistan, for example, earned signifi-
cantly less than international criminal networks. 
Although international organized crime groups domi-
nate transnational trafficking, local sales in each country 
are conducted almost entirely by local groups, including 
domestic illegal armed groups and separatist move-
ments.
There is a strong link between insecurity and the opiate 
trade in Afghanistan, as opiates constitute the main 
income source for anti-government elements like the 
Afghan Taliban. Almost all of the opium produced in 
Afghanistan was grown in the provinces of southern 
Afghanistan where anti-government elements are active. 
Although the Afghan Taliban’s role in drug trafficking is 
not clear, opium poppy farmers, drug traffickers and 
heroin lab owners paid the group up to 10% of the value 
of their opiate shipments as ‘tax’ or protection fees. In 
2009, the Taliban’s total income from the opiate trade 
was likely around US$155 million. However, Afghan 
opium farmers likely earned US$44065 million and 
Afghan drug traffickers almost US$2.2 billion.
In total, Pakistan’s opiate market was worth US$1.2 bil-
lion in 2009 – counting both transnational trafficking 
and domestic consumption. The exact beneficiaries of 
the opiate trade through Pakistan are difficult to specify, 
although it appears that extremist groups in the Feder-
ally Administered Tribal Areas (FATA) and criminal 
groups in Balochistan are key recipients. Opiates enter 
Pakistan via these areas, which border Afghanistan.
In 2009, the opiate market in the Islamic Republic of 
Iran was estimated at around US$3 billion. The major-
ity of the profits went to Iranian criminal groups and, to 
a lesser extent, foreign drug traffickers based in the 
country.
Although each Central Asian country has domestic 
criminal groups, it is possible that Tajik and Russian 
criminal groups organize heroin trafficking all the way 
from Afghanistan to the Russian Federation. Russian is 
the common language along this route. In 2009, the 
heroin trafficking market in Central Asia was worth an 
estimated US$1.4 billion, most of which went to 
regional criminal groups. 
In 2009, the total value of the heroin trafficked via 
South-East Europe was around US$2 billion, whereas 
the domestic heroin markets in the region were worth 
US$500 million. Thus, the total value of the opiate 
trade was US$2.5 billion in South-East Europe in 2009. 
Turkish, Kurdish and Balkan-based organized crime 
groups benefited from this trade. 
West and Central Europe remains one of the most lucra-
tive drug markets, worth an estimated US$13 billion in 
2009. The heroin market in the United Kingdom was 
estimated at US$3 billion in 2009, facilitated by British, 
Dutch and Turkish organized crime groups, and, to a 
lesser extent, South Asian groups. The heroin market in 
Italy was worth US$3 billion, which mainly went to 
Italian and Albanian organized crime groups. The value 
of the French heroin market was estimated at US$2 bil-
65 UNODC and Afghanistan Ministry of Counter Narcotics, Afghani-
stan Opium Survey, 2009.
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lion, which was pocketed almost entirely by France-
based distributors. The heroin market in Germany 
yielded a profit of approximately US$1.3 billion, with 
heroin mainly trafficked by Turkish and Balkan groups.
In 2009, Russian criminal networks made an estimated 
US$18 billion from heroin. Based on drug-related 
arrests, the Russian drug market is dominated by Rus-
sian citizens, followed by Tajiks as the most active for-
eign nationals. Drug trafficking in East Europe is most 
likely conducted by local groups; however, the picture 
regarding criminal activity in this region is not very 
clear.
In 2009, China’s 2.3 million opiate users consumed 
some 55-60 mt of pure heroin and paid US$7.3 billion 
to local drug dealers. In other South-East Asian coun-
tries, the total heroin market was worth US$2.4 billion. 
Chinese and other local organized crime groups control 
the South-East Asian heroin market at both retail and 
wholesale levels. The heroin trade in Indonesia is pre-
dominantly controlled and directed by West Africans, 
particularly Nigerians.66
In 2009, the total value of the South Asian heroin 
market – estimated at US$1.9 billion – mostly went to 
Indian local criminal groups. With a value of US$1.4 
billion, the biggest market is in India.  
In 2009, Africa’s drug trafficking market was worth an 
estimated US$3.2 billion – most of which went to Nige-
rian organized crime groups. Nigerian groups likely 
dominate the African drug trade and are active in many 
countries around the world, including destination coun-
tries in Europe. However, drug trafficking in Africa 
involves both African networks, including Nigerians and 
Tanzanians, as well as foreign networks, including Chi-
nese and Pakistanis. 
The United States of America dominated regional 
demand for heroin, with a heroin market worth an esti-
mated US$8 billion in 2009. North America-based 
organized crime groups (such as Mexican drug cartels) 
are the main beneficiaries.
In 2009, Oceania’s heroin market was worth an esti-
mated US$3.5 billion as Australia and New Zealand had 
the highest heroin prices in the world. In 2009, both 
South-East Asian and African – mainly Nigerian – drug 
traffickers were involved in shipping heroin to Australia. 
Although information is limited, domestic sales were 
likely conducted by local groups.
Heroin traffickers continue to adapt their techniques 
and alter trafficking routes to exploit international paths 
of least resistance. Numerous global vulnerabilities 
remain and some new areas are emerging. 
66 US Department of State, Bureau of International Narcotics and Law 
Enforcement Affairs, International Narcotics Control Strategy Report, 
2009.
Removal of trade barriers in many parts of the globe has 
not only facilitated the movement of illicit goods, but 
also closer interaction between organized criminal 
groups from different locations and cultures. In 2009, 
many international borders became more transparent 
due to international trade agreements. Drug traffickers 
are likely to exploit this situation and make connections 
with other criminal networks to facilitate the smooth 
movement of heroin. 
Given the ongoing removal of trade barriers globally, 
traditional methods of border control may become 
increasingly unable to stem the flow of opiates into des-
tination markets. In particular, traffickers’ use of mari-
time transportation and seaports has been identified as 
a key emerging threat. Traffickers are already capitalizing 
on increased global trade along sea routes. In 2009, only 
a tiny fraction of the more than 400 million containers 
that were shipped worldwide were inspected. In 2009, 
just 6% of global heroin seizures made by customs 
departments occurred at seaports. There are indications 
that drug traffickers are utilizing maritime transporta-
tion much more intensively than currently believed. 
Drug trafficking through international seaports must be 
further studied and monitoring mechanisms enacted.
In 2009, Africa emerged as a cost-effective heroin traf-
ficking route to Europe, North America and Oceania. 
Drug seizures and the arrest of traffickers indicated that 
Africans – particularly West African networks – are 
increasingly transporting Afghan heroin from Pakistan 
into East Africa for onward shipment to Europe and 
elsewhere. The emergence of Africa as a heroin traffick-
ing hub is likely due to corruption, limited law enforce-
ment capacity and increased pressure on ‘traditional’ 
drug trafficking routes. The most fragile African states 
are particularly vulnerable. East Africa’s minimal law 
enforcement at ports of entry has encouraged drug traf-
fickers to transit heroin through that region. Increasing 
flows of heroin to Africa have also led to increases in 
drug use across the continent.  
Sporadic reports indicate a heroin shortage in Europe, 
particularly in the United Kingdom, where good-quality 
heroin was in short supply in the market. Indeed, the 
mean purity of heroin seizures made by UK police forces 
and analysed by the UK Forensic Science Service 
dropped from 46.4% in the third quarter of 2009 to 
33.7% in the third quarter of 2010, while the mean 
purity of seizures made by the UK Border Agency fell 
from 58.2% to 46.2%. Anecdotal information points to 
a shortage in some countries, but not in all, suggesting 
that increased law enforcement efforts and decreased 
opium production in Afghanistan have played a role.
3. The coca/cocaine market
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3.1 Introduction
Most indicators and research suggest that cocaine is – 
after heroin – the second most problematic drug world-
wide in terms of negative health consequences and 
probably the most problematic drug in terms of traffick-
ing-related violence. 
The overall prevalence and number of cocaine users 
globally remain at stable levels. There are regional differ-
ences in recent trends, however, with significant decreases 
reported in North America, stable trends in West and 
Central Europe and increases in Africa and Asia. The 
estimated consumption of cocaine in terms of the quan-
tities consumed appears to have declined, mainly due to 
a decrease in the United States and low levels of per 
capita use in the emerging markets. The most developed 
cocaine market outside of the Americas continues to be 
Europe, notably West and Central Europe, while cocaine 
use in East Europe is still limited. While demand in the 
United States was more than four times as high as in 
Europe in 1998, just over a decade later, the volume and 
value of the West and Central European cocaine market 
(US$33 billion) is approaching parity with that of the 
US (US$37 billion). The volume of cocaine consumed 
in Europe, however, has doubled in the last decade, even 
though data for the last few years show signs of stabiliza-
tion at the higher levels. 
Harm associated with cocaine use in terms of treatment 
demand, overdose cases and deaths, complications in 
health status due to polydrug use among cocaine users 
and from adulterants in cocaine, remain substantial in 
the major regions of consumption.
There has been a decline in the area under coca cultiva-
tion, as well as in cocaine production. Global seizures of 
cocaine have been generally stable over the period 2006-
2009. Since 2006, seizures have shifted towards the 
source areas in South America and away from the con-
sumer markets in North America and West and Central 
Europe. Some secondary distribution countries in South 
America seem to have acquired increasing importance as 
cocaine trafficking transit countries. Trafficking through 
West Africa continues to be significant, in spite of a 
reduction of seizures since 2007 (from 25% of European 
cocaine seizures that transited countries of West and 
Central Africa in 2007 to 13% in 2009). The area 
remains vulnerable to a resurgence. Some countries in 
the Asia-Pacific - with large potential consumer markets 
- have registered increasing cocaine seizures in 2008 and 
2009. 
The expansion of the cocaine market across the Atlantic 
and, more recently, in South America and beyond, high-
lights the need to treat cocaine as a global problem, and 
to develop strategies on the scale of the threat. Efforts 
must be increasingly coordinated and integrated into an 
international approach that adapts to new developments 
and trends. 
3.2 Consumption
UNODC estimates the annual prevalence of cocaine use 
in 2009 at between 0.3% and 0.5% of the world popu-
lation aged 15-64, corresponding to some 14.3 to 20.5 
million people in this age range who used cocaine at 
least once in the preceding year. The lower and upper 
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ranges of cocaine users in 20091 have widened, suggest-
ing some increase in the estimated number of users, but 
also the increasing uncertainty in these estimates. The 
main difference from previous years is the widening of 
the ranges, arising from a lack of recent or reliable infor-
mation in Africa - particularly West and Central Africa2 
1 In 2008, the estimated annual prevalence number of cocaine users 
ranged between 0.3% and 0.4% of the population aged 15-64, or 
between 15.1 and 19.4 million people.
2 This is partly due to the fact that in previous years, estimates for the 
Democratic Republic of the Congo were included in the Southern 
- and East and South-East Asia, where starting from low 
levels, the use of cocaine may have increased. There is no 
information on the extent of cocaine use in South or 
Central Asia. In 2009, a substantial decrease in the esti-
mates of cocaine users was recorded for North America, 
while cocaine use in Europe appeared to have stabilized. 
In geographical terms, however, cocaine use appears to 
have spread. In 2009, nearly half of the Member States 
Africa subregion and for consistency were moved to the West and 
Central Africa subregion
Table 15: Annual prevalence and estimated number of cocaine users, by region, subregion  
and globally, 2009
Region/subregion
Estimated 
number of users 
annually (lower)
-
Estimated 
number of 
users annually 
(upper)
Percent of 
population 
age 15-64 
(lower)
-
Percent of 
population 
age 15-64 
(upper)
Africa
East Africa
North Africa
Southern Africa
West and Central Africa
940,000
-
30,000
270,000
550,000
-
-
-
-
-
4,420,000
-
50,000
730,000
2,300,000
0.2
-
0.03
0.3
0.3
-
-
-
-
-
0.8
-
0.04
0.9
1.1
Americas
Caribbean
Central America
North America
South America
8,280,000
110,000
120,000
5,690,000
2,360,000
-
-
-
-
-
8,650,000
330,000
140,000
5,690,000
2,480,000
1.4
0.4
0.5
1.9
0.9
-
-
-
-
-
1.4
1.2
0.6
1.9
1.0
Asia
Central Asia
East/South-East Asia
Near and Middle East
South Asia
400,000
-
400,000
40,000
-
-
-
-
-
-
2,300,000
-
1,070,000
650,000
-
0.02
-
0.03
0.01
-
-
-
-
-
-
0.2
-
0.2
0.3
-
Europe
East/South-East Europe
West/Central Europe
4,300,000
310,000
3,990,000
-
-
-
4,750,000
660,000
4,090,000
0.8
0.1
1.2
-
-
-
0.9
0.3
1.3
Oceania 330,000 - 400,000 1.4 - 1.7
Global 14,250,000 - 20,520,000 0.3 - 0.5
Table 16: Expert perceptions of trends in cocaine use, by region, 2009
Source: UNODC ARQ.
Region
Member 
States  
providing 
perception 
data
Member 
States  
perception 
response 
rate
Use  
problem 
increased*
Percent 
use  
problem 
increased
Use  
problem 
stable
Percent 
use 
problem 
stable
Use  
problem 
decreased*
Percent  
use  
problem 
decreased
Africa 8 15% 4 50% 2 25% 2 25%
Americas 15 43% 5 33% 7 47% 3 20%
Asia 13 29% 7 54% 3 23% 3 23%
Europe 27 60% 14 52% 13 48% 0 0%
Oceania 1 7% 0  1  0  
Global 64 33% 30 47% 26 41% 8 13%
* Identifies increases/ decreases ranging from either some to strong, unweighted by population.
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reporting expert opinion through the ARQ considered 
that cocaine use had increased in their countries. This 
was particularly noticeable in Africa and Asia, where 
increasing seizures of cocaine, though still at low levels, 
have also been reported in countries that had never 
reported any in the past. The long-term trends in expert 
perceptions officially reported to UNODC also point to 
a continuing perceived increase in the use of cocaine in 
Africa and Asia. Experts from half of the countries in 
Europe, especially West and Central Europe, considered 
cocaine use to be stable, while the other half of the coun-
tries perceived an increase. The main stabilization or 
decrease in cocaine use trends is perceived to be taking 
place in the Americas. 
Cocaine use is decreasing in North America –  
one of the major regions of cocaine consumption
North America is still the subregion with the largest 
number of cocaine users worldwide (5.7 million in 
2009), accounting for more than a third of all cocaine 
users worldwide. Household surveys in the countries of 
North America reveal a prevalence rate of annual cocaine 
use affecting 1.9% of the population aged 15-64 in 
2009, down from 2.4% in 2006. 
The United States of America has the highest prevalence 
of cocaine use in the region (2.4% of the population, or 
5 million people aged 15-64), but there are indications 
of cocaine use declining over the past few years. 
Since 2006, among the population aged 12 years and 
older, there has been a continuing decline in the annual 
prevalence of cocaine use (from 2.5% in 2006 to 1.9% 
in 2009), though crack use shows a less rapidly declining 
trend. The reduction coincided with a supply squeeze in 
the US cocaine market as less cocaine arrived via Mexico. 
Purity-adjusted cocaine prices rose by more than 80% 
between 2006 and 2009. 
Fig. 49: Expert perception of trends in cocaine use, 2000-2009
Source: UNODC ARQ.
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Fig. 50: Annual prevalence of cocaine use  
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Sources: UNODC World Drug Report 2010 and previous years; 
update based on ARQ data.
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Fig. 51: United States: Trends in annual preva-
lence of cocaine use in the population 
aged 12 years and older, 2002-2009
Source: Substance Abuse and Mental Health Services Adminis-
tration, Results from the 2009 National Survey on Drug Use 
and Health: Volume I, Summary of National Findings.
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at least once in the past year. As in the United States, 
cocaine use has also been decreasing considerably in 
Canada since 2004, when it was reported as 2.3%. In 
2008, it was 1.9% among the 15-64 age group. The 
past-year prevalence of cocaine use in 2009 was nearly 
the double (3.0%) among young people (15-24 years 
old); a rate that has also declined since 2008, when it 
was reported at 5.9%.7 
In Mexico, compared to Canada and the United States, 
the annual prevalence of cocaine use is much lower, at 
0.4%. Experts in Mexico perceived an increase in cocaine 
7 Health Canada, Canadian Alcohol and Drug Use Monitoring Survey, 
2009.
use from the previous year, whereas the treatment 
demand for cocaine as the primary substance of concern 
has declined to 7.9% of the total demand in 2009 from 
20.6% in 2008.8 
Cocaine use is now generally perceived to be stable 
in South and Central America
The estimated number of annual cocaine users in South 
and Central America and the Caribbean ranges between 
2.6 and 2.9 million people aged 15-64. Cocaine use in 
South and Central America remains at levels higher than 
8 This decline in treatment demand may stem from a change in treat-
ment reporting. 
Fig. 52: Annual prevalence of cocaine use among secondary school students in the United States,  
2000-2010
Source: United States Monitoring the Future: national results on adolescent drug use.
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the global average. The estimated annual prevalence 
among the adult population ranges between 0.9% and 
1% in South America and 0.5% to 0.6% in Central 
America. The prevalence of cocaine use in South Amer-
ica, though much lower than North America, is compa-
rable to that in Europe. The upward trend of cocaine use 
reported in previous years did not continue in 2009. 
Except for Ecuador and Guatemala, which reported 
increases, experts from most of the other South and 
Central American countries perceived stable trends. 
Nearly 50% of all treatment demand reported from 
South and Central America (including the Caribbean) is 
reportedly for cocaine use, while cocaine is also ranked 
as the number one substance causing drug-induced or 
related deaths in the subregion.
There is no update on the extent of cocaine use in South 
and Central America. Argentina (2.6%), Chile (2.4%) 
and Uruguay (1.4%) remain countries with high preva-
lence of cocaine use among the general population in 
these subregions. The three Southern Cone countries, 
Brazil, Argentina and Chile, together account for more 
than two thirds of all cocaine users of South America, 
Central America and the Caribbean. The Caribbean 
countries account for 7% of the total and Central Amer-
ica for 5%. 
Although Brazil has a lower prevalence rate of 0.7% of 
the population aged 15-64, because of its large popula-
tion, the country has the highest number of cocaine 
users (900,000) in South America. According to a 
national survey conducted in 2009 among university 
students in Brazil, the annual prevalence of cocaine use 
was 3% of students aged 18 to 35. Cocaine use was 
much lower among female students than male. Among 
the students aged 18-24 and 25-34, comparable levels of 
recent and current cocaine use were reported, which was 
much higher than compared to cocaine use reported 
among the students 18 or 35 years old.9 
9 Andrade, A.G., Duarte, P. and Oliveira, L.G., I Levantamento Nacio-
nal Sobre O Uso De Álcool, Tabaco E Outras Drogas Entre Os Univer-
sitarios Das 27 Capitais Brasileiras, Secretaria Nacional Politicas sobre 
Drogas, Brasilia, 2010.
Fig. 55: Cocaine use in South and Central 
American and Caribbean countries, in 
million persons and % of total (N = 2.7 
million in 2009)
Source: UNODC ARQ.
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33%
Fig. 56: Brazil: Cocaine use among university students, 2009
Source: Nacional Sobre O Uso De Álcool, Tabaco E Outras Drogas Entre Universitarios Das 27 Capitais Brasileiras, Secretaria Nacional 
Politicas sobre Drogas.
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Polydrug use among cocaine users
Polydrug use – the use of multiple drugs at the same 
time, in combination or consecutively – is commonly 
observed among drug-using populations. In Europe and 
the United States of America, cocaine use is commonly 
reported among polydrug users. 
In Europe, the prevalence of polydrug use has been 
reported as being higher among cocaine users than can-
nabis users, while cocaine users also reported higher rates 
of concurrent stimulant use. A study conducted in 14 
European countries in 2006 revealed that around 62% of 
cocaine users were polydrug users. Alcohol, cannabis and 
heroin were the three main substances reportedly used by 
cocaine users.
Among the clients entering treatment in Europe, the 
most frequently reported secondary drug - by nearly one 
third - was cocaine (including crack). Among cocaine 
users in treatment, two main groups were identified: the 
socially integrated individuals using powder cocaine, 
often during the weekend, at parties or other social occa-
sions. These users typically snort cocaine, sometimes in 
conjunction with alcohol or cannabis. The second group 
is a more marginalized group of clients, often injecting 
and using cocaine or crack-cocaine in combination with 
opioids. The marginalized group of cocaine users also 
presented precarious health and social conditions and 
included former opioid users re-entering treatment for 
cocaine use. 
In a study conducted in the United States, after alcohol, 
cocaine was the second most used substance in combina-
tions. It was included in combinations with alcohol, 
cannabis, alcohol and cannabis, and alcohol and opioids.
Speedballing – the concurrent or simultaneous use of 
cocaine and heroin – has also been commonly reported 
in countries with high prevalence of cocaine use includ-
ing the United States, Canada, the United Kingdom, 
Italy and Spain. In 14 European countries, more than a 
quarter of clients seeking treatment in 2006 reported 
concurrent use of cocaine and heroin. In a Canadian 
study, equal proportions of drug users were using cocaine 
and heroin sequentially, within the same hour or simul-
taneously – as in combination. A Mexican study among 
drug users in prison settings reported that nearly all of 
them (92%) were injecting drugs and less than half were 
speedballing.
Some reasons for speedballing suggested in the literature 
are: 1) when cocaine and heroin are used together, no 
new or novel subjective effect is experienced. Instead it 
simultaneously induces effects that are typical to both 
drugs; 2) using cocaine and heroin in low doses simulta-
neously could mutually reinforce their effects; 3) cocaine 
enhances some effects of opioids (as a group) and reduces 
some adverse effects of heroin or other opioids while 
maintaining the ‘rush’ induced by heroin use; 4) for 
some opioid users, including those on substitution or 
maintenance therapy, the use of opioids would be con-
sidered normal or ‘medicinal’ to prevent withdrawals and 
maintain normalcy while crack would be used to get a 
high. 
As for subsequent use of heroin or cocaine, it is suggested 
that heroin use could occur after cocaine to induce a 
depressant effect to deal with the over-excitement caused 
by cocaine, while cocaine could be used to reduce 
unpleasant side-effects of heroin, such as adverse symp-
toms of withdrawal. 
Risks and consequences
The main consequences of polydrug use, as in the case of 
cocaine use, are higher risks of overdose and chronic 
health damage. Using alcohol with cocaine can increase 
the levels of cocaine in the blood, enabling a longer psy-
choactive effect, but also increasing the risk of cardiovas-
cular problems caused by increased heart rate and blood 
pressure. Cocaine can also decrease the perception of 
alcohol intoxication effects. Suicidal ideation and violent 
behaviour have been linked with the concurrent use of 
alcohol and cocaine. When alcohol and cocaine are com-
bined, the liver produces a third substance called cocae-
thylene which intensifies the euphoric effects of cocaine. 
It has been associated with higher risk of heart attacks in 
users under 40 or even sudden death. 
Similarly, when cocaine is mixed with opioids, the nega-
tive cardiovascular effects of cocaine are expanded, which 
can induce respiratory depression and hide the sedative 
effects related to opioids, thus leading to higher overdose 
risks. In Europe, deaths caused by the use of cocaine with 
other drugs represented 21% of drug-induced deaths, 
with opioids involved in 8% of these cases (2009).
The concurrent use of cocaine and heroin has also been 
related with a higher probability of dropping out from 
treatment, relapse and co-morbidity with psychopathol-
Cocaine users % of total
Alcohol 42
Cannabis 28
Heroin 16
Overall polydrug use among cocaine 
users
62
Cannabis users % of total
Alcohol 65
Cocaine 13
Heroin 12
Overall polydrug use among cannabis 
users
85
Polydrug use among cocaine and  
cannabis users*
* The table compares polydrug use among long-term cocaine 
users and cannabis users entering treatment. 
Source: EMCDDA, Annual report 2009: the state of the 
drugs problem in Europe.
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Most countries in Europe now report a stable  
trend in cocaine use
The annual prevalence of cocaine use in Europe is esti-
mated at between 0.8% and 0.9% of the population 
aged 15-64, corresponding to some 4.3 to 4.8 million 
people who used cocaine at least once in the past year. 
These estimates are slightly lower than those for the 
previous year. Cocaine use is reportedly much higher in 
West and Central Europe (1.2%-1.3%) than in East and 
South-East-Europe (0.1%-0.3%). In 2009, many coun-
tries in Europe - mainly West and Central Europe - that 
provided expert opinion on trends reported a perceived 
stabilization in cocaine use for the year 2009. 
Estimates of the prevalence rate for the 27 EU10 and 4 
EFTA11 countries suggest that the number of cocaine 
users doubled over the 1998-2006 period. Between 
2006 and 2009 consumption appears to have stabilized. 
Despite the increase over the last decade in Europe and 
the decline in North America, overall cocaine use levels 
in the EU/EFTA region (annual prevalence of 1.2%) are 
still only half as high as in the USA (2.4% of the popu-
lation aged 15-64 in 2009).
High prevalence rates of cocaine use limited to a 
number of countries in western Europe
Two thirds of European cocaine users live in just three 
countries: the United Kingdom, Spain and Italy. With 
Germany and France, these countries represent 80% of 
European cocaine consumption. In terms of annual 
10 EU countries: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, 
Denmark, Estonia, Finland, France, Germany, Greece, Hungary, 
Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, 
Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and 
United Kingdom.
11 EFTA countries: Iceland, Liechtenstein, Norway and Switzerland.
ogy than only opioid use. Users of opioids and cocaine 
experience more depression, anxiety and related symp-
toms than users of cocaine only. There is also a higher 
frequency of injecting among heroin and cocaine users 
that may result in more sharing of contaminated inject-
ing equipment. Additionally, the reported use of citric 
acid to prepare the injection, and flushing,*1 increase the 
risk of HIV and other blood-borne infections such as 
hepatitis B and C as well as more soft tissue and vein 
damage at the injecting site.
Polydrug use – particularly with cocaine - and its associ-
ated risks therefore has important public health and 
policy implications in terms of prevention, treatment 
and care for heroin and cocaine users.
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Fig. 57: Annual prevalence of cocaine  
use among EU and EFTA countries, 
1998-2009
Sources: Annual Reports Questionnaire data; Government 
reports; UNODC, World Drug Report 2009; EMCDDA, 
Statistical Bulletin 2009.
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prevalence rates, Denmark, Ireland, Italy, Spain and the 
United Kingdom remain countries with rates higher 
than the West and Central European average. Cocaine 
use is considered to be particularly high among young 
people, especially males aged between 15 and 34. In the 
five high prevalence countries, annual prevalence among 
those aged 15-34 ranged from 4% to 8.4%. In these 
countries, cocaine is also reportedly used by opioid users 
who are undergoing substitution treatment.12
In 2009, Belgium, Cyprus, Germany, Spain and the 
United Kingdom (England and Wales) reported new 
prevalence data on cocaine use. Among these countries, 
12 EMCDDA, Annual Report 2010: The state of the drugs problem in 
Europe, Lisbon, 2010
Cyprus and Spain reported a substantial decrease in 
cocaine use. The overall trend in England and Wales 
over the last few years has been fluctuating, following 
major increases since the late 1990s.
Among the other countries with high cocaine prevalence 
rates, Italy showed a stabilizing trend, but preliminary 
data from a survey undertaken in 2009 may indicate a 
decline. In contrast, older data for Denmark (2008) and 
Ireland (2007) showed rising trends in cocaine use over 
the previous survey period.
The situation in Central Europe is mixed, where coun-
tries such as the Czech Republic, Estonia, Latvia and 
Slovakia showed increases in cocaine use while others, 
such as Hungary and Lithuania, reported decreases in 
the latest surveys.
In West and Central Europe, cocaine was reported as the 
Fig. 58: Europe: Trends in cocaine use in  
countries that reported new data
Source: UNODC ARQ; EMCDDA.
Fig. 59: England and Wales (UK): Trends in  
annual prevalence of cocaine use, 
1996-2009/10
Source: UNODC ARQ; EMCDDA.
Fig. 60: Europe: Trends in cocaine use in  
some high prevalence countries 
Source: UNODC ARQ; EMCDDA.
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Fig. 61: Trends in cocaine use in selected  
Central European countries
Source: UNODC ARQ and EMCDDA.
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primary drug of abuse in 11% of treatment cases, on 
average, compared to just 1% of treatment demand in 
East and South-East Europe. Within West and Central 
Europe, treatment demand for cocaine use also varied 
considerably. The highest treatment demand for cocaine-
related problems was in Spain (46% as a proportion of 
all drug-related treatment) and the Netherlands (30%). 
In Germany, Italy, Switzerland and the United King-
dom, treatment demand for cocaine as a proportion of 
all treatment was around 15%. 
Limited information on the extent of cocaine use is 
reported from Africa, however, experts from the 
countries that have reported information perceive 
increases
Information on the extent of cocaine use is only availa-
ble from a limited number of countries in Africa. The 
annual prevalence of cocaine use is estimated between 
0.2% and 0.8% of the population aged 15-64, corre-
sponding to between 940,000 and 4.4 million people 
estimated to have used cocaine in the past year. The 
actual number of cocaine users in Africa is probably 
close to the lower end of the estimates. The wide range 
in the estimates points to an increase in the uncertainty 
of the data available from Africa. 
Among the eight countries that provided expert opinion 
on trends of cocaine use in Africa, four reported 
increases. In North Africa, where cocaine use is consid-
ered to be low (0.03% - 0.04%), Algeria and Morocco 
reported perceived increases. The other two countries 
that reported an increase in cocaine use in 2009 were 
Côte d’Ivoire and Mozambique. Nigeria and South 
Africa reported decreases in cocaine use as perceived by 
the experts. 
In Kenya, a household survey conducted in the coastal 
provinces of the country in 2009 showed a lifetime 
prevalence of cocaine use of 1.6% and current13 preva-
lence of 1.2% among the population aged 12-51. The 
small difference between current and lifetime use indi-
cates that cocaine use in these coastal provinces might be 
13 Current use of drugs was defined as use in the four weeks prior to the 
interview.
Cocaine adulterants
A general phenomenon in recent years has been the 
decline of cocaine purity in the main consumer markets 
of North America and Europe. This went in parallel 
with an increasing role played by adulterants, which are 
changing the pharmacological properties of the white 
powder that is being sold as ‘cocaine.’
While diluents or cutting agents (such as lactose) are 
simply used to increase the weight of the drugs, adulter-
ants are typically psychoactive substances used to com-
pensate for some of the pharmacological effects of the 
drug lost by lower levels of purity. The mixing of the 
drug with adulterants can lead to additional health 
problems for the users. 
In the case of cocaine, different substances have been 
used as adulterants, including the following: 
One of the adulterants that has been increasingly 
reported in cocaine samples in the United States and 
Europe since 2004 is levamisole. This is an anti-parasitic 
agent used in veterinary medicine in South America. In 
the United States, this was also used for the treatment 
of colon cancer and rheumatoid arthritis, but due to its 
adverse side effects, was removed from the market. 
When levamisole is used for longer period and in high 
doses, it may cause serious adverse effects, one of which 
is agranulocytosis. This is a condition that results in a 
lowering of the white blood cell count, thereby imped-
ing the body’s mechanism to fight infection.
In Europe and the United States, up to 70% of the 
analysed cocaine samples were reported to contain 
levamisole. This led the European Early Warning 
System to issue a warning and initiate additional data 
collection. In 2009, SAMHSA also issued a public 
health warning on the risks of cocaine adulterated with 
levamisole.
References 
SAMHSA, Nationwide public health alert issued concerning life 
threatening risk posed by cocaine laced with veterinary anti para-
sitic drug, 21 September 2009.
EMCDDA, Annual report 2009: the state of the drugs problem 
in Europe, Lisbon 2009.
Common cocaine adulterants
Levamisole Likely stimulatory synergy between cocaine and levamisole
Lidocaine Local anaesthetics, similar  anaesthetic effects to cocaine
Procaine Local anaesthetic
Benzocaine Local anaesthetic
Caffeine Stimulant
Boric acid Looks like cocaine and acts as an anaesthetic
Hydroxyzine Antihistamine
Phenacetin Painkiller related to paracetamol
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a new phenomenon. The extent of current cocaine use 
was comparable among all age groups in the 12-50 years 
age range, but, as in other countries, much higher 
among male (2.7%) than female (0.4%) survey respond-
ents.14
Treatment demand for cocaine-related problems in 
Africa, from the countries that have provided data, is 
reported at around 5% of all treatment admissions. The 
highest treatment demand for cocaine-related problems, 
as a proportion of all treatment, was reported from 
Namibia and Burkina Faso. In South Africa, as reported 
by the South African Community Epidemiology Net-
14 National Campaign Against Drug Abuse Authority (NACADA), 
Report of Survey on Drug and Substance Abuse in Coast Province Kenya 
– Main Report, March 2010.
work on Drug Use, treatment demand for cocaine use 
appears to have declined over the past few years, follow-
ing increases in the previous years. Cocaine was reported 
by 5%-15% of clients in treatment as either a primary 
or secondary drug of abuse in the different reporting 
regions in the first half of 2010.15 
Several countries in Asia - especially in East  
and South-East Asia - perceive cocaine use to be 
increasing
Information on the extent of cocaine use in Asia is scant 
and limited mainly to some countries in East and South-
15 Plüddemann A. et al, Monitoring Alcohol & Drug Abuse Trends in 
South Africa (July 1996 – June 2010), Phase 28, SACENDU research 
brief, Vol. 13 (2), 2010, South African Community Epidemiology 
Network on Drug Use.
Fig. 62: Range of the estimated number of  
cocaine users in Africa, 2009
Source: UNODC.
Fig. 63: Range of the annual prevalence of  
cocaine use in Africa, 2009
Source: UNODC.
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Fig. 64: Kenya (coastal provinces): Lifetime 
and current use of cocaine, by age, 
2009
Source: NACADA, Report of Survey on Drug and Substance 
Abuse in Coast Province Kenya.
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 Year Cocaine
Namibia 2006 24%
Burkina Faso 2008 21%
Mozambique 2004 11%
Kenya 2005 10%
Eritrea 2006 8%
South Africa 2009 8%
Togo 2009 8%
Senegal 2005 2%
Ghana 2008 1%
Swaziland 2004 1%
Nigeria 2004  1%
Table 17: Africa: Cocaine as primary drug of 
abuse as a proportion of all treatment 
admissions, recent years
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East Asia. Nevertheless, with this information gap, the 
annual prevalence of cocaine use in Asia is estimated 
between 0.02% and 0.2% of the population aged 15-64, 
or between 400,000 and 2.3 million people who may 
have used cocaine in the past year. The actual number of 
cocaine users in Asia is probably closer to the lower end 
of the range. 
In Asia, most of the countries that provided expert per-
ception on cocaine use, perceived that use had been 
increasing over the past year. In 2009, 7 out of 13 coun-
tries or territories reported a perceived increase in 
cocaine use. Many of the countries that had previously 
not identified any cocaine use now perceive an increase. 
Most of the countries that have perceived an increasing 
trend (starting from low levels of use) are located in East 
and South-East Asia; notably, China is among them. 
Some countries in other subregions have also perceived 
an increase. 
Hong Kong, China, is one territory - although with a 
very small number of cocaine users - that has been 
reporting continuous decreases in cocaine use over the 
past years. This is also reflected in the decreasing number 
of cocaine users registered by the authorities between 
2007 and 2009, reversing the upward trend noted 
between 2004 and 2007. In a limited study among 
cocaine users and key informants conducted in 2008, 
the pattern of cocaine use in Hong Kong, China, showed 
that nearly two thirds of respondents were using crack-
cocaine. Respondents strongly associated their cocaine 
use with night life and entertainment – clubs, discos and 
karaoke.16
Cocaine use in New Zealand and Australia appears 
to be stable following a period of strong increases
Cocaine use in the Oceania region appears generally 
stable following strong increases over the 2004-2007 
period in Australia and over the 2003-2006 period in 
New Zealand. Information on cocaine use from Oceania 
essentially comprise survey data from Australia and New 
Zealand. The annual prevalence in Oceania is estimated 
to range between 1.4% and 1.7% of the population aged 
15–64. The estimates are still lower than the levels 
reported from North America, but higher than those 
found for West and Central Europe.
In Australia, the annual prevalence of cocaine use in 
2007 was estimated at 1.9% of the population aged 
15-64, which is comparable to the level reported from 
North America. As reported in the Australian Illicit 
Drug Data Report (2008-2009), “recent increases in 
cocaine arrests and reported use, as well as considerable 
seizures of the drug in recent years, indicate a potential 
expansion of the Australian cocaine market.”17 
There are indications that this rise did not continue, 
however. Cocaine use among students has shown a 
decline in recent years. In 2008, among the 12-17 year 
old students, the lifetime prevalence of cocaine use was 
reported at 2.4%, while the past month prevalence was 
1.1%. Among the students who participated in the 
16 Yueying, L., Wing, D. and Fai, J., Study of Cocaine Abuse in Hong 
Kong, Report to the Narcotics Division, Department of Applied 
Social Studies, City University of Hong Kong, November 2008.
17 Australian Crime Commission, Illicit Drug Data Report 2008-2009 
June 2010.
Table 18: Expert perception of trends in  
cocaine use in Asia, 2008 and 2009
Source: UNODC ARQ.
 2008 2009
Armenia 
Bahrain  
China  
Israel  
Indonesia  
Japan 
Republic of Korea 
Hong Kong, China   
Macao, China 
Mongolia 
Pakistan  
Philippines 
Kuwait  
Lebanon  
Syrian Arab Republic  
United Arab Emirates 
Legend: Increase; Decrease; Stable
Fig. 65: Hong Kong, China: Trends for cocaine 
and other registered drug users,  
2000-2009 
Source: Central Registry Drug Abuse, Narcotics Division,  
Security Bureau, Hong Kong, China.
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survey, cocaine use across all time periods, that is, life-
time, last year and past month use, increased by age and 
was highest among the 17-year-old students.18 
Lifetime prevalence of cocaine use among 12-15-year 
-old students in Australia decreased significantly between 
2002 and 2008 as well as between 2002 and 2005. The 
past month prevalence among this group was lower in 
2008, but this was not statistically significant. The life-
time and past month prevalence among 16-17-year-old 
students has been at similar levels and has not signifi-
cantly decreased over the three survey periods.19
In 2008, among the detainees tested for drug use in 
Australia, cocaine was found in 1% of urinalysis results. 
Male detainees were more likely to test positive, while 
the highest rates of positive urinalysis was among detain-
ees aged 21 and 35 years. The prevalence of cocaine use 
among the detainees tested for drug use has remained 
consistently low over the previous years20 which is in 
contrast to the high prevalence of cocaine use among the 
general population. Similarly, among the injecting drug 
users, relatively small proportions (2%-3%) have 
reported cocaine as the last drug injected,21 while 
cocaine accounted for less than 1% of the total treat-
18 White V. and Smith G., Australian secondary school students’ use of 
tobacco, alcohol, and over the counter and illicit substances in 2008, 
Drugs Strategy Branch, Australian Department of Health and 
Ageing.
19 Ibid.
20 Gaffney A., Jones W., Seeney J. amd Payne J., Drug Use monitoring 
in Australia:2008 annual report on drug use among police detainees, 
Monitoring Reports 09, Australian Institute of Criminology.
21 National Centre in HIV Epidemiology and Clinical Research, 
Australian NSP Survey National Data Report 2005-2009, National 
Centre in HIV Epidemiology and Clinical Research, The University 
of New South Wales, Sydney, 2010.
ment demand in 2007-2008.22 This also indicates that 
cocaine use in Australia remains more common among 
the socially integrated groups of mostly recreational 
users. 
The latest information on cocaine use from New Zea-
land dates back to 2008, when it was estimated that 
0.6% (range 0.3% - 0.8%) of the population aged 16-64 
had used cocaine in the year prior to the survey. The 
highest annual prevalence of cocaine use (1.8%) was 
found among youth aged 25-34.23 As reported by New 
Zealand, experts perceive cocaine use to have been stable 
over the past couple of years. 
For the remaining parts of Oceania, there is no recent or 
reliable information on the extent or pattern of cocaine 
use.
22 UNODC ARQ.
23 Drug use in New Zealand, Key Results 2007/08 New Zealand Alcohol 
and Drug Use Survey, Ministry of Health, 2010.
Fig. 66: Australia: Cocaine use among  
secondary school students, 2008
Source: Australian secondary school students’ use of tobacco, 
alcohol, and over the counter and illicit substances in 2008.
Table 19: Trends in cocaine use among  
secondary school students in  
Australia, 2002, 2005 and 2008
* Significantly different from 2008 at p <.01.
Source: Australian secondary school students’ use of tobacco, 
alcohol, and over the counter and illicit substances in 2008.
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Cultivation
The global coca cultivation estimate for 2010 is based 
on the 2009 figures for the Plurinational State of Bolivia 
and the 2010 figures for Colombia and Peru. The 2010 
coca cultivation figure for Bolivia was not yet available 
at the time of printing of this report. 
In 2010, the global area under coca cultivation decreased 
by 6%, mainly due to a significant reduction in Colom-
bia which was not entirely offset by a small increase in 
Peru. The reduction of the global area under coca culti-
vation since 2007 has been driven by significant decreases 
in Colombia, which have been only partially offset by 
increases in the Plurinational State of Bolivia and Peru 
over the same period. 
A major difference between coca and other narcotic 
plants such as opium poppy and cannabis is that the 
coca bush is a perennial plant which can be harvested 
several times per year. This longevity of the coca plant 
should, in principle, make it easier to measure the area 
under coca cultivation. In reality, the area under coca 
cultivation is dynamic, changes all the time and it is dif-
ficult to determine the exact amount of land under coca 
cultivation at any specific point in time or within a given 
year. There are several reasons why coca cultivation is 
dynamic: new plantation, abandonment of fields, reac-
tivation of previously abandoned fields, manual eradica-
tion and aerial spraying. There are different methods to 
measure the area under coca cultivation which can be 
affected by some or all of these factors. From a govern-
ment’s perspective, it may be desirable to monitor illicit 
cultivation in a given year by measuring all coca fields, 
irrespective of whether they were being used for the 
whole year or only part of it (gross cultivation area). For 
estimating potential coca leaf and cocaine production, 
however, it is necessary to measure the productive area. 
This can only be done by determining the period in the 
year that the coca fields were productive before being, 
for example, eradicated or abandoned (net productive 
area). The area under cultivation at a specific cut-off 
date may be chosen for other reasons, for example, to 
monitor the effect of law enforcement activities imple-
mented in a specific period (net area under cultivation 
at date x). 
The national monitoring systems supported by UNODC 
currently in place in the Plurinational State of Bolivia, 
Colombia and Peru have developed different ways of 
tackling the challenge of measuring the dynamics of 
coca cultivation, depending on specific country factors, 
the availability of auxiliary information on eradication, 
as well as practical and financial considerations. While 
this approach helps to adjust the monitoring systems to 
the specificities of each country, it also limits the com-
parability of the area under cultivation across countries. 
3.3 Production
Table 20: Global illicit cultivation of coca bush, 1999-2010
Source: Bolivia: 2002 and before: CICAD and US Department of State, INCSR. Since 2003: National monitoring system supported by 
UNODC. Colombia: National Illicit Crop Monitoring System supported by UNODC. Peru: 1999: CICAD and US Department of State, 
INCSR; since 2000: National Illicit Crop Monitoring System supported by UNODC.
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Bolivia 21,800 14,600 19,900 21,600 23,600 27,700 25,400 27,500 28,900 30,500 30,900 (30,900)*
Colombia(a) 160,100 163,300 144,800 102,000 86,000 80,000 86,000 78,000 99,000 81,000 68,000 57,000
Colombia(b) 73,000 62,000
Peru 38,700 43,400 46,200 46,700 44,200 50,300 48,200 51,400 53,700 56,100 59,900 61,200
Total 220,600 221,300 210,900 170,300 153,800 158,000 159,600 156,900 181,600 167,600 158,800* 149,100*
* The figure for Bolivia was not available at the time of printing of this report. Total area under coca cultivation in 2010 is based on the 2009 figure 
for Bolivia and will be revised once the 2010 figure becomes available. For Colombia, the series without adjustment for small fields was used to keep 
comparability.
(a) Area without adjustment for small fields.
(b) Area with adjustment for small fields.
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Since 1999, when the first coca cultivation survey started 
as a joint activity between UNODC and the Govern-
ment of Colombia, the attention of experts has shifted 
from being primarily concerned with the area under 
coca cultivation to getting a better understanding of 
how much cocaine is being produced. This is partly due 
to more appreciation of the fact that eradication, whether 
carried out manually or by aerial spraying, does not 
necessarily translate into a corresponding reduction of 
the coca area. The impact of eradication carried out 
between date A and date B may or may not be seen by 
comparing the area under coca at these two points in 
time but it will certainly be noticeable in the coca yield 
as farmers lose harvests or have to replant their fields. 
Eradication has evolved from a tool to reduce the area 
under coca to one component of a complex counter-
narcotics intervention system, geared towards reducing 
the productivity of the cocaine production chain from 
coca leaf to cocaine HCl at different levels. 
Such a reduction in yield and production is captured by 
the productive area approach, where each hectare under 
coca cultivation is considered for the number of months 
the field is actually productive. For estimating cocaine 
production, the productive area approach seems to be 
the most appropriate but it is also the most demanding 
in terms of data requirements. Currently, the monitor-
ing systems used in the three coca cultivating countries 
contain elements of both approaches, net area and pro-
ductive area. In the Plurinational State of Bolivia and 
Peru, the area estimated from satellite imagery represents 
the average coca cultivation situation in the second half 
of the year, and it is used directly to estimate produc-
tion. In Colombia, where a cut-off date at the end of the 
year is used for the area estimation, additional informa-
tion is used to model the total productive area that 
contributes to the production of coca leaf and cocaine. 
Efforts are being made in all three countries to improve 
the cocaine production estimates and the concepts of 
the net area and the productive area - detailed below - 
are an important part of that process. 
Colombia
In 2010, the area under coca cultivation in Colombia 
decreased significantly, by 15%. Cultivation of coca 
bush decreased in all major growing regions of the coun-
try. The Pacific region remained the region with the 
largest coca cultivation, representing 42% (25,680 ha) 
of the national total, followed by the Central (25% or 
15,310 ha) and Meta-Guaviare regions (14% or 8,710 
ha).1 
Since the first coca cultivation survey implemented by 
the national monitoring system supported by UNODC, 
the average size of coca fields has decreased from around 
2 ha in 1999 to about 0.7 ha - 0.9 ha since 2006. An 
increasing proportion of coca was cultivated on small 
fields. This raised concerns because the type of satellite 
imagery used to detect coca fields in Colombia works 
best for field sizes over 0.25 ha and is not suitable for 
identifying very small fields. 
Thus, a study using very high resolution imagery was 
conducted to determine the proportion of coca grown 
on fields below the 0.25 ha threshold. Based on this 
1 All figures in this paragraph refer to the area adjusted for small fields. 
Table 21: Reported cumulative eradication of coca bush (ha), 1996-2010
Sources: Governments of Colombia, Peru, the Plurinational State of Bolivia, Ecuador and the Bolivarian Republic of Venezuela. 
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Bolivia* manual 7,512 7,000 11,620 15,353 7,653 9,395 11,839  10,089 8,437 6,073 5,070 6,269 5,484 6,341 8,200 
Colombia manual  4,057  2,262  3,126  1,046  3,495  1,745  2,762  4,219  6,234 31,980 43,051 66,805 95,634 60,544 43,792 
spraying 18,519 41,861 66,029 43,112 58,073 94,153 130,364 132,817 136,552 138,775 172,026 153,134 133,496 104,771 101,939 
Peru** manual 1,259 3,462 7,834 14,733 6,208 6,436 7,134 11,312 10,399 12,237 12,688 12,072 10,143 10,025 12,253 
Ecuador manual  4  18  9  12  12  6 
Venezuela manual  18 0 0 0  38  47 0 0  118  40  0 0 0 0
* Bolivia: Since 2006, voluntary and forced eradication. 
** Peru: includes voluntary and forced eradication. 
 Net cultivation 
on 31 Dec 2010
Productive coca 
area 2010
Bolivia n.a. 30,900*
Colombia(a) 57,000 (a) / 62,000 (b) 62,000-77,000 (b)
Peru n.a. 61,200
Total n.a. 154,100-169,100
Table 22: Approaches to measure coca 
cultivation (ha), 2010
* The 2010 figure for Bolivia was not available at the time of printing 
of this report. Total area under coca cultivation in 2010 is based on the 
2009 figure for Bolivia and will be revised once the 2010 figure becomes 
available. 
(a) Area without adjustment for small fields.
(b) Area with adjustment for small fields.
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study, an adjustment factor for small fields was intro-
duced. This adjustment allows for the inclusion of coca 
cultivated fields that are smaller than the detectable 
threshold, and thereby improves the accuracy of the coca 
area estimate in Colombia. 
In 2010, the area under coca cultivation was estimated 
at 57,000 ha without the adjustment for small fields. 
This was corrected to 62,000 ha after including the small 
field factor. To facilitate a comparison with 2009, the 
2009 figure was also corrected, from 68,000 ha without 
to 73,000 ha with the adjustment for small fields. 
Peru
In Peru, in 2010, the area under coca cultivation 
amounted to 61,200 ha, a 2% increase (+1,300 ha) on 
2009, indicating an overall stable situation. However, 
the coca-growing regions showed diverging cultivation 
trends. Upper Huallaga, the largest growing region in 
recent years, experienced a strong decline of almost 
4,500 ha due to intense eradication. In Apurímac-Ene, 
the second largest growing region until 2009, a signifi-
cant increase in the area under coca of more than 2,200 
ha was registered, and with 19,700 ha, it became the 
largest growing region in 2010. 
Other growing regions such as Palcazú-Pichis-Pachitea 
(+59%) as well as Marañon, Putumayo and some smaller 
growing areas in the Amazon basin grew dramatically 
(+90%) and contributed to the overall increase. 
Some smaller growing regions such as Aguatiya and 
Inambari-Tambopata, which have experienced a signifi-
cant increase in the area under coca in recent years, 
remained relatively stable in 2010. 
Production
Due to the ongoing review of conversion factors, no 
point estimate of the level of cocaine production can be 
provided for 2009 and 2010. Because of uncertainties 
about the level of total potential cocaine production and 
about the comparability of the estimates between coun-
tries, the 2009 and 2010 figures were estimated as ranges 
(842-1,111 mt and 786-1,054 mt, respectively).2
High levels of cocaine seizures worldwide support the 
hypothesis that global cocaine production could be at a 
much higher level than previously estimated, mainly 
because traffickers have found ways to improve the effi-
ciency of clandestine laboratories in extracting cocaine 
alkaloids from coca leaves. The lack of precise measure-
ments of laboratory efficiency in the different countries 
increases the level of uncertainty, but does not affect the 
trend, which shows a clear decline in global cocaine 
production since 2007. A recent study (PRELAC) con-
ducted jointly by UNODC and Governments of the 
coca cultivation countries confirmed that laboratory 
efficiency had improved and indicated that traffickers in 
the Plurinational State of Bolivia and Peru may have 
already reached efficiency levels comparable to Colom-
bia.3 Thus, in other parts of this Report, the upper end 
of the global cocaine production range has been 
used. This, despite the uncertainty associated with the 
estimate, is considered to be a better approximation of 
reality. 
Peru
Cocaine production in Peru has been going up since 
2005 due to an increase in the area under coca cultiva-
tion. It is necessary, however, to add a caveat. Coca leaf 
yields in Colombia have been regularly studied and 
updated since 2005, and part of the decline in Colom-
bian cocaine production is due to declining yields. In 
Peru, on the other hand, information on coca leaf yields 
dates back to 2004, and for some of the smaller cultivat-
ing regions, which experienced significant increases in 
the area under coca, no information on region-specific 
coca leaf yields is available. There are additional chal-
lenges involved in estimating the yield of new or reacti-
vated coca fields as opposed to mature, well-maintained 
ones, as well as the effects of continued eradication pres-
sure. As noted above, there are indications that the level 
of cocaine production in Peru could be higher than 
previously estimated due to improvements in laboratory 
efficiency, but more research is needed to improve the 
cocaine estimate for the country. 
Colombia
Cocaine production in Colombia decreased to 350 mt 
in 2010. The drop since 2005 is the result of a decrease 
in the area under coca cultivation and a reduction of 
2 More information on the review of conversion ratios is available in 
the Methodology chapter of this Report and in the World Drug Report 
2010 (p. 249 ff.).
3 PRELAC (‘Prevention of the Diversion of Drugs Precursors in the 
Latin American and Caribbean Region’) is a project financed by the 
European Commission and implemented by UNODC and Govern-
ments in Latin America and the Caribbean. Within this framework, 
several studies analysed coca leaf to cocaine conversion methods . 
For more information see http://www.prelac.org.
Table 23: Colombia, adjustment of coca area  
for small ﬁelds, 2009-2010 (ha)
Source: National monitoring system supported by UNODC.
 2009 2010
Change 
from 2009
Without  
adjustment for 
small fields
68,000 57,000 -16%
With adjustment 
for small fields 73,000 62,000 -15%
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Table 24:  Global production of coca leaf and cocaine HCl (mt), 2005-2010
Source: Governments of Colombia, Peru and the Plurinational State of Bolivia. 
2005 2006 2007 2008 2009 2010
  Bolivia 28,200 33,200 36,400 39,400 40,200
Range 34,200-38,300 37,300-41,800 37,900-42,500
  Peru 97,000 105,100 107,800 113,300 119,000 120,500
Range 85,400-108,600 91,000-119,200 93,200-122,000 97,600-127,800 102,400-134,200 103,000-136,300
  Colombia 555,400                  528,300                  525,300                  389,600 343,600 305,300
Range 305,300-349,600
  Colombia 164,280 154,130 154,000 116,900 103,100 91,600
Range 91,600-104,880
  Bolivia 80 94 104 113 n.a. n.a.
  Colombia 680 660 630 450 410 350
Range 350-400
  Peru 260 280 290 302 n.a. n.a.
Total 1,020 1,034 1,024 865 * *
The ranges express the uncertainty associated with the estimates. In the case of Bolivia and Peru, the ranges are based on confidence intervals and the 
best estimate is the mid-point between the upper and lower bound of the range. In the case of Colombia, the range represents the two approaches 
taken to calculate the productive area, with the lower bound being closer to the estimation used in previous years. The methodology to calculate 
uncertainty ranges for production estimates is still under development and figures may be revised when more information becomes available. 
POTENTIAL PRODUCTION OF SUN-DRIED COCA LEAF IN METRIC TONS
Source: Bolivia: Potential sun-dry coca leaf production available for cocaine production, National Illicit Crop Monitoring System supported by UNODC. 
Leaf yield source: UNODC (Yungas de Paz), Chapare (DEA scientific studies). The estimated amount of coca leaf produced on 12,000 ha in the Yungas 
of La Paz where coca cultivation is authorized under national law, was deducted. Range: Upper and lower bound of the 95% confidence interval of 
coca leaf yield estimate. 
Peru: Potential sun-dried coca leaf production available for cocaine production, estimated by the National Illicit Crop Monitoring System supported by 
UNODC. 9,000 mt of sun-dry coca leaf were deducted, which, according to Government sources, is the amount used for traditional purposes. Range: 
Upper and lower bound of the 95% confidence interval of coca leaf yield estimate.
POTENTIAL PRODUCTION OF COCA LEAF IN OVEN-DRIED EQUIVALENT IN METRIC TONS
POTENTIAL PRODUCTION OF FRESH COCA LEAF IN METRIC TONS
Source: National monitoring system supported by UNODC. National Illicit Crop Monitoring System supported by UNODC.
Due to the introduction of an adjustment factor for small fields, 2010 estimates are not directly comparable with previous years.
POTENTIAL MANUFACTURE OF 100% PURE COCAINE IN METRIC TONS
Source: Bolivia: UNODC calculations based on UNODC (Yungas of La Paz) and DEA scientific studies (Chapare) coca leaf yield surveys. Colombia: National 
Illicit Crop Monitoring System supported by UNODC and DEA scientific studies. Due to the introduction of an adjustment factor for small fields, 2010 
estimates are not directly comparable with previous years. Peru: UNODC calculations based on coca leaf to cocaine conversion ratio from DEA scientific 
studies. 
Detailed information on the ongoing revision of conversion ratios and cocaine laboratory efficiency is available in the World Drug Report 2010 (p. 249). 
* Due to the ongoing review of conversion factors, no point estimate of the level of cocaine production could be provided for 2009 and 2010. Because 
of the uncertainty about the level of total potential cocaine production and about the comparability of the estimates between countries, the 2009 and 
2010 figures were estimated as ranges (842-1,111 mt and 786-1,054 mt, respectively). 
Figures in italics are being reviewed. Information on estimation methodologies and definitions can be found in the Methodology chapter of this Report. 
coca leaf yields. There are also indications of structural 
changes in the way the processing of coca leaves is organ-
ized. Unlike in the Plurinational State of Bolivia and 
Peru, where farmers sun-dry the coca leaves to increase 
their shelf life and facilitate transport, in Colombia, 
farmers typically process the fresh leaves into coca paste 
or cocaine base immediately after harvest. In 2005, only 
24% of the coca leaf produced in that year was sold as 
fresh leaf, whereas in 2009, this proportion had almost 
doubled and reached 45%. Expressed in absolute terms, 
in 2005, farmers sold about 133,000 mt of fresh coca 
leaf to intermediaries, whereas in 2009, the same figures 
amounted to almost 155,000 mt, an increase by 16%. 
This increase is even more remarkable when considering 
that it happened despite an overall decline in coca leaf 
production in Colombia over this period. 
Studies show that farmers can increase their profit when 
processing coca leaf into coca paste and/or cocaine base 
rather than selling it. What could lead farmers to stop 
processing coca leaves themselves and sell them instead? 
A study on cocaine precursors conducted in 2009/2010 
(PRELAC) in South America and additional studies by 
UNODC and the Government revealed that in Colom-
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bia, quality differences in the coca paste and cocaine 
base provided by coca farmers reportedly became a prob-
lem for clandestine cocaine laboratories in recent years. 
A strategy employed by traffickers to obtain cocaine base 
of better or more homogeneous quality could be to try 
to execute more control over the cocaine alkaloid extrac-
tion process. Skilled ‘cooks’ with better know-how, 
equipment and precursor chemicals may be in a better 
position than farmers to produce cocaine base with the 
sought-after properties. It is not yet known how the 
purchasing of coca leaf from farmers is organized and 
who the actors are. Neither is sufficient information 
available on the chemical properties of coca paste or 
cocaine base produced in Colombia to verify this 
hypothesis. 
What could have caused the apparent quality differences 
in the cocaine base produced by farmers? 
Since 2005, probably due to increased counter-narcotics 
pressure, the per-hectare yields of coca fields went down 
in many growing regions of Colombia and there is a 
tendency towards smaller fields. This may make the 
assembly of amounts of coca leaves large enough for 
cocaine processing more difficult at the farm level. As 
coca leaf is not sun-dried in Colombia, storing the leaves 
until a sufficient amount is accumulated is not an 
option, as fresh coca leaves deteriorate rapidly in quality. 
An additional reason might be that, in 2009, it was 
more risky for farmers to engage in coca-processing in 
areas where the Government has increased its presence 
compared to 2005. Selling coca leaf rather than keeping 
processing chemicals and equipment on the farm may 
be part of a risk-aversion strategy employed by farmers. 
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Source: UNODC/Government of Colombia, Coca cultivation 
surveys 2005 and 2009.
On the other hand, field reports indicate the strong link 
between armed groups and coca cultivation and cocaine 
production. Thus, farmers may also have changed their 
sales strategy because of pressure from these groups. 
Another measure taken by traffickers was the introduc-
tion of a previously unknown process called re-oxidation 
of cocaine base. This process is apparently an additional 
step used to homogenize and improve the quality of 
cocaine base of different quality received from different 
sources and geographic areas by using potassium per-
manganate. According to the information available, re-
oxidation is linked to clandestine laboratories producing 
cocaine HCl, called ‘cristalizaderos’ in Colombia, which 
presumably have a wide geographic area from where 
they source cocaine base. The introduction of this proc-
ess into the clandestine cocaine production chain sug-
gests that differences in the quality of cocaine base 
provided by farmers, and maybe partly also the low 
quality provided, indeed became a problem for traffick-
ers producing cocaine HCl in recent years in Colombia. 
Plurinational State of Bolivia 
It can be assumed that, following the trend in cultiva-
tion, cocaine production in Bolivia increased between 
2005 and 2009. 2010 figures were not available at the 
time of printing of this Report. There are indications 
that since about 2007, clandestine laboratories in Bolivia 
have benefited from a transfer of know-how from 
Colombia. Laboratories using the ‘Colombian’ method 
are much more efficient in extracting cocaine from coca 
leaves. More research is needed to better understand the 
current efficiency of clandestine laboratories in Bolivia.
Clandestine processing installations
In 2009, as in previous years, the extraction of cocaine 
alkaloids and manufacture of cocaine HCl remained 
geographically concentrated in South America. The 
illicit extraction of cocaine alkaloids from coca leaves 
takes place exclusively in the three countries cultivating 
coca bush, namely, the Plurinational State of Bolivia, 
Colombia and Peru. In 2009, the destruction of 8,691 
installations involved in the production of coca paste or 
base was reported. This figure does not include the 
destruction of maceration pits, a typical feature of coca 
paste production in the Plurinational State of Bolivia 
and Peru. 
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Coca leaf: fresh – sun-dried – oven-dried
In this report, coca leaf production is presented in different ways: as fresh coca leaf, as sun-dried coca leaf and as 
coca leaf in oven-dried equivalents. 
There are two main reasons. First, coca leaf is processed or traded in Colombia as fresh coca leaf, immediately after 
the harvest, whereas in Peru and the Plurinational State of Bolivia, farmers dry the fresh coca leaf before selling, by 
spreading the leaves on the ground and exposing them to air. The result is coca leaf with a much reduced moisture, 
which makes transport easier and allows storage of the leaves. Sun-dried leaves are also referred to as air-dried leaf. 
The second reason is that the moisture content of both fresh and sun-dried coca leaf varies considerably, depending 
on the biological properties of the leaf as well as environmental factors such as the humidity of the air. A fresh coca 
leaf harvested in the early morning, for example, will have a different moisture content than leaves from the same 
bush plucked at noon. Coca leaves sun-dried after a heavy rainfall at a low altitude will have a different moisture 
content than leaves sun-dried in the dry season at a high altitude. 
While differences may not matter much to farmers selling coca leaves, it matters from a scientific point of view, 
when comparing coca leaf production in different countries and estimating how much cocaine can potentially be 
extracted from the leaves. In other words, scientists are interested in how much dry plant matter is in the leaves, and 
which proportion of that dry matter consists of cocaine alkaloids. The water content of the leaves is not of interest 
in that context and has to be taken out of the calculation. 
Like other live plant material, fresh coca leaves consist mainly of water (~70%). A kilogram of fresh coca leaves would 
typically lose over half of its weight through sun-drying. Even sun-dried leaves contain residual moisture. When 
drying in a laboratory oven to remove all moisture from the leaves, sun-dried coca leaves would still lose another 
third of their weight. In other words, a kilogram of fresh coca leaves weighs only about 300 grams after leaving the 
drying chamber, which is the weight of dry plant matter. Only a tiny proportion (around 0.5%) of that plant matter 
is actually cocaine. 
Thus, when comparing coca leaf production, the weight in oven-dried coca leaf equivalent is the most appropriate. 
However, currently, not enough information on the moisture content of coca leaf in different regions of coca culti-
vating countries is available. Therefore, a direct comparison between fresh coca leaf in Colombia and sun-dried coca 
leaf in the Plurinational State of Bolivia and Peru by converting all figures into oven-dry equivalents is therefore not 
possible. 
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Fig. 68: Seizures of clandestine installations 
processing coca/cocaine, 2009
Source: UNODC ARQ.
In addition to coca paste or cocaine base processing 
installations, countries reported the destruction of 396 
cocaine HCl production laboratories in 2009, 319 or 
81% of which were located in coca cultivating countries. 
This confirms reports from previous years that most of 
the cocaine base produced in coca cultivating countries 
is converted into cocaine HCl in the same countries. 
There are indications of some cross-border trafficking of 
cocaine base for further processing in other countries in 
the region: Argentina (36 laboratories), Ecuador (10) 
and the Bolivarian Republic of Venezuela (26) all 
reported destruction of cocaine producing facilities. 
Often reports did not to specify if the installations 
detected were involved in producing cocaine base or 
HCl. It is assumed that most installations reported as 
being cocaine-producing were producing cocaine HCl, 
not cocaine base. Only a few installations involved in 
cocaine base or HCl manufacture were reported outside 
Latin America, for example, in Mexico (4) and Spain 
(1). 
Spain also reported the detection of clandestine installa-
tions involved in secondary extraction of cocaine. 
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Cocaine is sometimes dissolved in other substances to 
prevent detection. Traffickers use secondary extraction 
laboratories to revert that process and recover the 
cocaine. Most of the clandestine installations detected in 
Spain in 2008 and 2009 were involved in secondary 
extraction (24 in 2008 and 11 in 2009). Greece also 
reported detection of clandestine installations involved 
in cocaine processing. These installations were involved 
in repackaging and adulterating cocaine. One installa-
tion handled only cocaine and four more were also 
handling heroin (reported under ‘heroin’). 
More information on the detection of clandestine sec-
ondary extraction installations and repackaging and 
adulteration sites from other countries would be useful 
to understand potential changes in trafficking strategies. 
It would also indicate the development of trafficking 
hubs. 
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Global seizures of cocaine, including cocaine salts, 
cocaine base and crack-cocaine, increased strongly 
between 2000 and 2005 and were then generally stable 
over the 2006-2009 period, ranging between a mini-
mum of 690 mt in 2007 and a maximum of 732 mt in 
2009. Since 2006, seizures have shifted towards the 
source area of South America away from the consumer 
markets of North America and West and Central Europe, 
reflecting better international cooperation and exchange 
of information. South America accounted for a total of 
317 mt in 2006 (44% of the global total for that year) 
and 442 mt in 2009 (60% of the global total). Over the 
same period, seizures declined by almost one third in 
North America (from 194 mt in 2006 to 132 mt in 
2009) and by more than one half in West and Central 
Europe (from 121 mt in 2006 to 55 mt in 2009).
Slightly more than 60% of cocaine seizures in 2009 took 
place in South America. North America accounted for 
18% and Europe for 8% of the total. Seizures outside 
the Americas and Europe accounted for just 0.3% of the 
total.  
1 US Department of State, 2011 International Narcotics Control Strat-
egy Report, Washington D.C., 2011. 
2 US Department of Justice, Drug Enforcement Administration, Spe-
cial Testing and Research Laboratory, Cocaine Signature Program 
Report, January 2010, quoted in Inter-American Drug Abuse Control 
Commission (CICAD), DEA Special Testing and Research Labora-
tory and DEA Intelligence Division Briefing, OEA/Ser.L/XIV.2.47, 
CICAD/doc.1802/10, 3 May 2010. 
The three main markets for cocaine – in volume terms 
- are North America, notably the United States of Amer-
ica, followed by Europe, notably the EU and EFTA 
countries, and South America. 
The US authorities have estimated for the last couple of 
years that some 90% of the cocaine consumed in North 
America comes from Colombia,1 supplemented by some 
cocaine from Peru and limited amounts from the 
Plurinational State of Bolivia. For the year 2009, results 
of the US Cocaine Signature Program, based on an 
analysis of approximately 3,000 cocaine HCl samples, 
revealed that 95.5% originated in Colombia2 (down 
from 99% in 20023) and 1.7% in Peru; for the rest 
(2.8%), the origin could not be determined. The traf-
ficking of cocaine into the United States is nowadays 
largely controlled by various Mexican drug cartels, while 
until the mid-1990s, large Colombian cartels domi-
nated these operations. 
The origin of cocaine consumed in Europe seems to be 
more evenly distributed. In terms of cocaine seizure 
3 US Department of Justice, Drug Enforcement Administration, 
Selected Intelligence Brief, ‘Cocaine Signature Program Report,’ 
January 2003, Microgram Bulletin, Vol. XXXVI, February 2003. 
Fig. 69: Global cocaine seizures (mt), 
1999-2009
Source: UNODC DELTA.
Fig. 70: Distribution of global cocaine  
seizures, 1999-2009
Source: UNODC DELTA.
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cases, cocaine from Colombia accounted for 8% of the 
cocaine seized in Europe over the 2008-2010 period, 
Peru for 7% and the Plurinational State of Bolivia for 
5% (based on information from 13 European countries).4 
The rest (80%) can only be traced back to various tran-
sit countries in the Americas (notably Argentina, the 
Dominican Republic, Brazil, Costa Rica, Panama, Ecua-
dor and Paraguay), Africa (notably Senegal, Mali, 
Guinea and Nigeria) and Europe (notably Spain, the 
Netherlands and Portugal). 
The importance of Colombia is more pronounced in 
terms of the origin of the quantities of cocaine seized in 
Europe. Cocaine from Colombia accounted for 25% of 
all cocaine seizures in volume terms in Europe over the 
2008-2010 period, Peru for 6% and the Plurinational 
State of Bolivia for 2%. If cocaine that could be traced 
back to the Bolivarian Republic of Venezuela, Ecuador 
and Panama were added to the cocaine from Colombia, 
the ‘Colombia-linked’ cocaine seizures in Europe would 
rise to 69% of the total (2008-2010 period).5 
Cocaine produced in Colombia is mainly destined for 
consumption in overseas markets. Cocaine produced in 
Peru and the Plurinational State of Bolivia, in contrast, 
is used more within South America, notably in countries 
of the Southern Cone. Even though cocaine produced 
in Peru seems to be playing a growing role in Europe, 
the criminal groups organizing the trafficking from 
South America to Europe are still primarily Colombian 
(notably for trafficking operations targeting Spain, the 
main entry point of cocaine into Europe) and – to a 
lesser extent - from other Latin American countries and 
4 Austria, Belgium, Bulgaria, France, Germany, Ireland, Poland, Portu-
gal, Romania, Spain, Switzerland, Turkey and the United Kingdom. 
5 UNODC, Individual Drug Seizures database. 
from various African and European countries. The influ-
ence of the Mexican drug cartels, which dominate 
cocaine sales to the United States, seems to be limited 
when it comes to trafficking to Europe or trafficking to 
countries in South America. 
The global seizure total of 732 mt in 2009 refers to 
cocaine seizures as reported, that is, unadjusted for 
purity. Although precise purity adjustments at the level 
of individual countries are not feasible with the current 
available data, a range can be calculated for global 
purity-adjusted seizures of cocaine.6 By expressing this 
quantity as a percentage of the global supply of cocaine, 
one obtains the interception rate. In order to account for 
the time lag incurred between cultivation and traffick-
ing, one may consider the average production in the 
preceding two years (2007 and 2008) as a proxy for 
global supply. This calculation yields a range of 46%- 
60% for the interception rate. However, this range 
should be interpreted with caution, as it depends on the 
current estimates of cocaine production, which are cur-
rently being reviewed.
Americas 
In 2008 and 2009, the Americas accounted for more 
than 90% of global seizures of cocaine, with seizures 
amounting to 656 mt in 2008 and 673 mt in 2009. The 
largest seizures continued to be made by Colombia and 
the United States. Large quantities of cocaine continue 
to be trafficked from South America to the United 
States, with Mexico being the key transit country. Over 
6 Considering data for 2009 only, global estimates indicate a range of 
431-562 mt. The upper end of the range is obtained by considering 
purities at wholesale level only, which accounts plausibly for the vast 
majority of seizures by weight, while the lower end is obtained using 
both retail and wholesale purities and assuming that the retail level 
accounts for no more than one half of seizures by weight.
Fig. 71: Distribution of global cocaine seizures by region, 2009
Source: UNODC ARQ. 
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the 2002-2006 period, Colombia and the United States 
seized similar quantities of cocaine; however, the seizure 
totals started to diverge in 2007, with Colombia seizing 
more than twice that seized in the US in 2008 and 2009. 
This can be attributed to intensified efforts by the 
Colombian authorities to fight cocaine trafficking and 
to improved international cooperation, notably with law 
enforcement authorities of key countries such as the 
United States, the United Kingdom and Spain 
Every year from 2002 to 2009, Colombia registered the 
highest national cocaine seizure total worldwide. In 
2009, seizures amounted to 253 mt,7 essentially sustain-
ing the record level of 2008 (256 mt). According to 
Colombian authorities,8 in 2009, 48% of cocaine sei-
zures in Colombia were made in territorial waters. 
Colombia also continued to seize large quantities of 
substances that may be used in the extraction and 
processing of naturally occurring alkaloids.9 
It appears that Ecuador, which shares borders with both 
Colombia and Peru, may have acquired increased impor-
tance as a hub for cocaine trafficking. In 2009, seizures 
in Ecuador reached a record level of 65 mt,10 the second 
7 Data from the Observatorio de Drogas de Colombia, August 2010. 
Excludes seizures of ‘basuco’ (1.9 mt). The replies to the ARQ from 
Colombia for 2009 were not available at the time of preparation of 
the present report.
8 Presentation by Colombia to the Twentieth Meeting of Heads of 
National Drug Law Enforcement Agencies, Latin America and the 
Caribbean, Lima, Peru, 4-7 October 2010.
9 Country report by Colombia to the Twentieth Meeting of Heads of 
National Drug Law Enforcement Agencies, Latin America and the 
Caribbean, Lima, Peru, 4-7 October 2010.
10 Country report by Ecuador to the Twentieth Meeting of Heads of 
National Drug Law Enforcement Agencies, Latin America and the 
Caribbean, Lima, Peru, 4-7 October 2010. The replies to the ARQ 
from Ecuador for 2009 were not available at the time of preparation 
of the present report.
highest level in South America. According to Ecuado-
rian authorities,11 seizures of drugs and precursor chem-
icals by the Ecuadorian law enforcement agencies suggest 
that drug traffickers are increasingly seeking to use Ecua-
dor for the stockpiling, storage and trans-shipment of 
vast quantities of cocaine. Cocaine is trafficked into 
Ecuador across the Colombia-Ecuador border, into the 
provinces of Esmeraldas, Carchi and Sucumbios, as well 
as across the Peru-Ecuador border, into the provinces of 
El Oro, Loja and Zamora Chinchipe,12 and is then traf-
ficked on to the consumer markets in North America 
and Europe. The country’s more prominent role was also 
visible in reports of cocaine consignments seized in 
Europe involving Ecuador in the trafficking route, 
which rose from 6 seizure cases in 2005 (amounting to 
a total of 25 kg of cocaine) to 67 in 2009 (amounting to 
a total of 2.5 mt).
In the Bolivarian Republic of Venezuela, seizures peaked 
at 59 mt in 2005, and have fallen to approximately one 
half that level since then, amounting to 28 mt in 2009. 
According to preliminary data, this trend continued into 
2010, with seizures falling to 20 mt.13 The decrease was 
also reflected in reports of significant individual drug 
seizures made in Europe; considering reports from nine 
countries14 which provided data on the provenance of 
11 Country report by Ecuador to the Twentieth Meeting of Heads of 
National Drug Law Enforcement Agencies, Latin America and the 
Caribbean, Lima, Peru, 4-7 October 2010.
12 Presentation by Ecuador to the Twentieth Meeting of Heads of 
National Drug Law Enforcement Agencies, Latin America and the 
Caribbean, Lima, Peru, 4-7 October 2010.
13 Presentation by the Bolivarian Republic of Venezuela to the Twenti-
eth Meeting of Heads of National Drug Law Enforcement Agencies, 
Latin America and the Caribbean, Lima, Peru, 4-7 October 2010.
14 Austria, Belgium, France, Germany, Ireland, Portugal, Romania, 
Fig. 72: Cocaine seizures in the Americas, 
1999-2009
Source: UNODC DELTA.
Fig. 73: Cocaine seizures in South America,  
by country, 2009
Source: UNODC DELTA.
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individual cocaine seizures in both 2006 and 2009, the 
number of seizures involving the Bolivarian Republic of 
Venezuela in the trafficking route fell from 151 (amount-
ing to a total of 9.4 mt) in 2006 to 59 in 2009 (amount-
ing to a total of 6.6 mt). Expressed as a proportion of 
the total cocaine seizures made in Europe (where infor-
mation on provenance was included), these cases fell 
from 12% to 4% in terms of the number of seizures, but 
increased from 36% to 41% in terms of quantity.
In 2008, seizures of cocaine reached relatively high levels 
in both the Plurinational State of Bolivia and Peru, com-
pared to previous years. Since then, seizures in Bolivia 
essentially sustained the high level, amounting to 27 mt 
in 2009 and 29 mt15 in 2010, while seizures in Peru 
receded to 21 mt (from 28 mt in 2008) and rose back 
to 31 mt16 in 2010. The Plurinational State of Bolivia 
assessed that, in 2009, more than 95% of cocaine traf-
ficking on its territory occurred by land; moreover, 
according to Bolivian authorities,17 cross-border traf-
ficking occurred from Bolivia into Argentina, Brazil and 
Chile and also from Peru into Bolivia. In contrast, 
according to Peruvian authorities,18 international traf-
ficking organizations operating in Peru preferred mari-
time routes, with the ports of Callao, Chimbote and 
Spain and Switzerland.
15 Preliminary data from the Government of the Plurinational State of 
Bolivia.
16 Preliminary data from the Government of Peru.
17 Presentation by the Plurinational State of Bolivia to the Twentieth 
Meeting of Heads of National Drug Law Enforcement Agencies, 
Latin America and the Caribbean, Lima, Peru, 4-7 October 2010.
18 Country report by Peru to the Twentieth Meeting of Heads of 
National Drug Law Enforcement Agencies, Latin America and the 
Caribbean, Lima, Peru, 4-7 October 2010.
Paita being the main points of departure. A variety of 
other trafficking methods are also used in Peru, includ-
ing land routes, rivers, couriers, postal services and 
flights from clandestine airfields.
In recent years, seizures of cocaine have also increased 
significantly in Brazil, going from 8 mt in 2004 to 24 mt 
in 2009, of which 1.6 mt were seized in five aircraft 
interceptions.19 In 2009, Brazil was the most prominent 
transit country in the Americas - in terms of number of 
seizures - for cocaine consignments seized in Europe. The 
number of seizure cases which involved Brazil as a transit 
country rose from 25 in 2005 (amounting to 339 kg of 
cocaine) to 260 in 2009 (amounting to 1.5 mt).
According to the World Customs Organization, in 2009 
the most important secondary distribution countries 
(apart from the Plurinational State of Bolivia, Colombia 
and Peru) were the Bolivarian Republic of Venezuela, 
Ecuador, Brazil and Argentina (ranked in order of the 
total weight of seized consignments departing from a 
given country).20 With regard to cocaine reaching 
Europe, the World Customs Organization also noted 
the high quantity of cocaine arriving from Ecuador and 
the growing significance of Brazil and Suriname. With 
regard to cocaine reaching Africa, WCO noted that 
Brazil was the only South American country mentioned 
as a departure country for customs seizures made in 
Africa in 2009. 
In Argentina, cocaine seizures rose steadily from 1.6 mt 
19 Presentation by Brazil to the Twentieth Meeting of Heads of National 
Drug Law Enforcement Agencies, Latin America and the Caribbean, 
Lima, Peru, 4-7 October 2010.
20 Based on seizures recorded in the Customs Enforcement Network 
database. 
Fig. 74: Cocaine seizures in Europe transiting 
selected countries in the Americas,  
by number of cases, 2005-2009
Source: UNODC IDS.
Fig. 75: Cocaine seizures in Europe transiting 
selected countries in the America, by 
quantity seized, 2005-2009
Source: UNODC IDS.
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in 2002 to 12.1 mt in 2008, and in 2009 sustained the 
increased level, at 12.6 mt. Trafficking of cocaine from 
Argentina to Chile was reported by both countries in 
2009; Argentina also assessed that, in 2009, some of the 
cocaine trafficked on its territory was intended for 
Europe, apart from Argentina itself. Seizures in Chile 
rose markedly in 2007, and have since then declined 
slightly, amounting to 8.4 mt in 2009. Argentina was 
also prominent - in terms of number of seizures - as a 
transit country for cocaine consignments seized in 
Europe, with 194 such cases reported in 2009. However, 
these seizures tended to be small in comparison with 
seizure cases transiting other countries, amounting to a 
total of 217 kg of cocaine. 
Other prominent transit countries included countries in 
Central America and the Caribbean such as the Domin-
ican Republic, Costa Rica and Panama. In 2009, sei-
zures in Panama were the third largest in Latin America 
and the Caribbean (53 mt). The Dominican Republic 
assessed that, in 2009, 18% of cocaine trafficked on its 
territory was intended for Spain, with the majority 
intended for the United States. Although the seizures 
involving the Dominican Republic in Europe were not 
large in comparison with other transit countries, some 
large seizures were made in the Dominican Republic 
itself: five of the seizures in 2009 accounted for almost 
two thirds of the total seized in the country that year 
(4.7 mt). According to Costa Rican authorities,21 in 
21 Country report by Costa Rica to the Twentieth Meeting of Heads of 
recent years, there has been a significant increase in the 
quantities of cocaine seized on the sea route, involving 
Costa Rican nationals mostly working in the fishing 
industry and operating under the direction of Colom-
bian nationals, using fishing boats with Costa Rican 
flags to transport illicit drugs. Seizures in Costa Rica 
reached 21 mt in 2009.
Mexico continued to be a key transit country for cocaine 
trafficked into the United States. Cocaine seizures in 
Mexico fell sharply in 2008 (19 mt, down from 48 mt 
in 2007), in line with the trend in the United States, and 
increased slightly in 2009, amounting to 22 mt. The 
vast bulk - almost three quarters - was seized on the 
maritime route. 
The decreased level of seizures was reflected in cocaine 
seizures by US authorities along the border with Mexico, 
which followed a generally decreasing trend between the 
last quarter of 2005 and the second quarter of 2008.22 In 
2009, seizures along the US-Mexico border rose slightly, 
from 17.8 mt in 2008 to 20.5 mt, but remained below 
the peak level of 28 mt registered in 2006. It appears that 
several factors have contributed to a shift in the traffick-
ing routes from Mexico to the United States, including 
high levels of inter-cartel violence in Mexico and efforts 
by Mexican authorities to confront the drug cartels. 
Seizures by the United States peaked at 201 mt in 2005, 
and have since fallen considerably. In 2009, seizures 
appeared to stabilize at slightly more than half the 2005 
level – 109 mt. Together with other indicators, this sug-
gests that the availability of cocaine in the United States 
has stabilized at a reduced level. 
National Drug Law Enforcement Agencies, Latin America and the 
Caribbean, Lima, Peru, 4-7 October 2010.
22 US Department of Justice, National Drug Intelligence Center, 
National Drug Threat Assessment 2009, December 2008.
Fig. 76: Mean price and purity of all* cocaine 
purchases by law enforcement in the 
United States, 2006-2009
* The values represented here represent averages of all cocaine 
purchases, irrespective of the size of the transaction, and thus may 
correspond neither to wholesale nor to retail price levels. Although 
not collected as a representative sample of the US market, these 
data reflect the best information available on changes in cocaine 
price and purity in the US market. 
Source: UNODC ARQ.
Fig. 77: Cocaine seizures in the United  
States by location and quantity (mt), 
2001-2009
Source: UNODC ARQ.
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The coca/cocaine market
The mean purity-adjusted price of cocaine, calculated 
from all cocaine purchases by law enforcement agencies 
in the United States,23 more than doubled between the 
last quarter of 2006 to the last quarter of 2008 (from 
US$90 to US$199 per pure gram), and have remained 
relatively high since then (amounting to US$170 per 
pure gram in the last quarter of 2009). This was largely 
due to a decline in purity, which fell from an average of 
70% in the last quarter of 2006 to 45% in the last quar-
ter of 2008 and 46% in the last quarter of 2009.
Seizures by the United States include large quantities of 
cocaine seized at sea. They accounted for approximately 
one half of the total for the United States in 2009. In 
terms of seizure cases, the majority continued to be 
smaller domestic cases.
A comparison of purity-adjusted cocaine prices at key 
points along the cocaine trafficking route in the Ameri-
cas confirms that the mark-up in price occurs largely 
towards the end of the supply chain. The price at the 
wholesale level is about one quarter of the price at the 
retail level, while the price in producing countries only 
amounts to 1% of the final (retail) price.
At the global level, the total reported quantity of crack-
cocaine seizures is negligible in comparison with seizures 
of cocaine base and cocaine salts. This may partly be due 
to the fact that some countries do not report seizures of 
crack-cocaine, but also because individual seizures of 
crack-cocaine, possibly made at street levels, tend to be 
much smaller. 
23 This includes all purchases, irrespective of the size of the transaction, 
and thus may correspond neither to retail nor wholesale price levels.
Several countries in the Americas, notably in Central 
America and the Caribbean, as well as Brazil, the United 
States and the Bolivarian Republic of Venezuela, report 
seizures of crack-cocaine as well as cocaine base or 
cocaine salts. In 2009, seizures of crack-cocaine 
amounted to 194 kg in Panama, 163 kg in the United 
States and 80 kg in the Bolivarian Republic of Vene-
zuela; in 2008, the largest quantity was seized in Brazil 
(374 kg).24 In 2009, the largest number of such seizures 
worldwide were reported by the Dominican Republic 
(4,173 seizure cases), Canada (1,822) and the Bolivarian 
Republic of Venezuela (1,643).
Europe
Europe is the world’s second largest consumer market 
for cocaine and continues to account for the majority of 
cocaine seizures made outside the Americas. Seizures 
peaked at 121 mt in 2006, then declined for three years 
in a row, falling to less than half this level – 57 mt – in 
2009. The decreasing trend was observed in the West 
European countries that account for the biggest seizures 
in Europe, though several other countries have regis-
tered increases. 
 
24 A breakdown of cocaine seizures in Brazil for 2009 was not available. 
Fig. 78: Cocaine seizures in the United  
States by location and number of  
seizures, 2001-2009
Source: UNODC ARQ.
Fig. 79: Accrual of purity-adjusted cocaine 
prices in the Americas, 2009
* For these countries, the calculation assumes a wholesale purity 
of 70%-90%; the vertical bars represent the midpoint of the 
resulting range.
** The value for Peru represens the price in producing regions, 
while the values for Bolivia and Colombia represent the price in 
major cities
Source: Data from UNODC field offices; UNODC ARQ.
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The Iberian peninsula is an important point of entry for 
cocaine reaching continental Europe. Spain consistently 
reports the highest cocaine seizures in Europe, though 
seizures fell from 50 mt in 2006 to 25 mt in 2009. In 
neighbouring Portugal, the decrease has been more pro-
nounced, from 34 mt in 2006 (the second largest in 
Europe for that year) to 2.7 mt in 2009 (the seventh 
largest). Significant declines have also been registered in 
the Netherlands, where seizures fell from the peak level 
of 14.6 mt in 2005 to 6.8 mt in 2008.25 
In relative terms, seizure trends across Europe in recent 
years appear to fall broadly along a continuum ranging 
from strong declines close to the trafficking hubs that 
serve as the major points of entry or distribution in 
Europe to strong increases in countries, notably further 
east, that historically have not been associated with traf-
ficking of cocaine in large amounts. When comparing 
average seizures over 2005-2006 with 2008-2009, 
marked declines (in both relative and absolute terms) 
were registered in Portugal, Spain, Belgium and the 
Netherlands;26 more moderate declines were registered 
in the United Kingdom and France, while seizures were 
essentially stable in Italy and Germany. On the other 
hand, increases of more than 30% were observed in 
25 Seizure data for the Netherlands for 2009 were not available. 
26 Considering data for 2008 only for the Netherlands.
several countries further east, including the Russian 
Federation, Turkey, Poland, Greece, Ukraine and Roma-
nia. In Ireland, seizures peaked in 2007, and have also 
declined significantly since then. This pattern suggests 
that, while the established trafficking routes for cocaine 
entering Europe continue to be important, cocaine may 
be entering Europe along new routes. 
Romania reported cocaine seizures of 1.3 mt in 2009; 
this appears to include a single seizure of 1.2 mt at the 
port of Constanta, from two containers that arrived 
from the port city of Paranagua, Brazil in January 2009. 
The ensuing investigation also led to the seizure of 3.8 
mt of cocaine in Paranagua in February 2009, also des-
tined for Romania.27
Purity-adjusted cocaine retail prices in West and Central 
Europe rose markedly in 2006, the year when seizures 
peaked; this was mainly due to a drop in purity. One pos-
sible explanation could be that heightened law enforce-
ment efforts impacted on the availability of cocaine in the 
European cocaine market, and traffickers responded to 
this by selling the drug at reduced purities rather than 
raising the bulk price. Since 2006, the purity has remained 
relatively low, with adjusted prices. The purity-adjusted 
price – expressed in euros - declined between 2006 and 
2008, and appeared to stabilize in 2009. 
When adjusted for inflation, the purity-adjusted retail 
price in 2009, expressed in euros, was equal to (within 
1%) that in 2005, prior to the increase in 2006. While 
these data need to be interpreted with caution, it is plau-
sible that alternative cocaine trafficking methods and 
routes adopted by traffickers to counter more effective 
law enforcement efforts have corrected a short-term 
drop of cocaine availability in the European market. 
Moreover, the decline of cocaine prices expressed in 
euros over the 2006-2008 period went hand in hand 
with strongly falling value of the US dollar during that 
period, thus rendering imports, including cocaine 
imports, cheaper for the consumers. 
Africa
Cocaine seizures remained limited in Africa, amounting 
to less than 1 mt in 2009, down from 2.6 mt in 2008 
and 5.5 mt in 2007. Although this quantity is very small 
in comparison with the quantities likely to be trafficked 
in and via Africa, seizure data from other regions also 
point to a decreasing trend for Africa, notably West 
Africa, for cocaine trafficking from South America to 
Europe. Nevertheless, cocaine trafficking in West Africa 
persisted, and Africa, especially West Africa, remained 
vulnerable to a resurgence. Benin, Burkina Faso, Ethio-
pia, the Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, 
Mali, Niger, Nigeria, Senegal, South Africa and Togo 
27 Embassy of the United States to Romania, DEA and Romanian Police 
work together in stopping second cocaine shipment from Brazil to Roma-
nia, press release, 9 February 2009.
Fig. 80: Cocaine seizures in Europe (mt),  
1999-2009
* Data for 2009 for the Netherlands were unavailable; the value 
used is that corresponding to the year 2008, and is only included 
to estimate the regional total.
** Data for the United Kingdom for 2007, 2008 and 2009 are 
based on incomplete data for some jurisdictions for the financial 
years 2007/08, 2008/09 and 2009/10 respectively, and adjusted 
for the missing jurisdictions using the distribution in 2006/07.
Source: UNODC DELTA.
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The Asia-Pacific
The Asia-Pacific region continued to account for less 
than 1% of global cocaine seizures. However, there were 
signs that cocaine trafficking might be making inroads 
into new consumer markets. Seizures in the Asia-Pacific 
reached a record 1.6 mt in 2008, and stood at 766 kg in 
2009.
In Australia, seizures rose from 626 kg in 2007 to 930 
kg in 2008. In 2009, seizures in this country fell to 288 
kg, but in 2010, two large seizure cases alone brought 
the partial total to more than 700 kg.33 With reference 
to the period 1 July 2008 to 30 June 2009, Australia 
reported that nearly 70% of cocaine detections (by 
number) occurred in the postal stream, and that Mexico, 
33 Australian Federal Police, Drug syndicate smashed, 464 kg of cocaine 
seized, media release, 14 October 2010.
Colombia, Panama, Argentina, Canada, the United 
States, Brazil, the United Arab Emirates, Singapore, 
South Africa, the Plurinational State of Bolivia, Kenya 
and the Netherlands were all embarkation countries for 
the import of cocaine consignments larger than 1 kg. 
Moreover, Australia pointed to a possible shift away 
from imports of small quantities of cocaine. 
In 2008 seizures rose to 664 kg 34 in China, including 
the 69 kg that were seized in Hong Kong, China and the 
64 kg35 in Taiwan Province of China. In 2009, China 
reported seizures of 163 kg, including 112 kg in Hong 
Kong, China. According to Chinese authorities, cocaine 
was mainly smuggled from South America across the 
Pacific ocean to cities on China’s south-east coast.36 
In 2009, the Philippines registered a record level of 
cocaine seizures of 259 kg; in contrast, seizures in this 
country amounted to less than 3 kg annually over the 
period 2003-2008. The increase was partly due to a large 
quantity of cocaine that was jettisoned in December 
2009 close to the Eastern Samar province from a vessel 
on its way from South America to China. Two other 
significant cases resulted in the seizure of a total of 15.5 
kg of cocaine in the Port of Davao. The Philippines 
assessed that 30% of the total reached the Philippines 
via Germany, and an additional 30% via Malaysia, and 
that the cocaine was intended for China (40% was 
intended for Hong Kong, China).
34 UNODC, data collated by DAINAP,
35 Food and Drug Administration of Taiwan Province of China
36 National Narcotics Control Commission of China, presentation at 
the Twentieth Anti-Drug Liaison Officials’ Meeting for International 
Cooperation (ADLOMICO), October 2010
Fig. 81: Cocaine prices and purity in West and Central Europe, 2003-2009
Source: UNODC ARQ. 
Fig. 82: Cocaine seizures in selected  
countries in Africa (kg), 2008-2009
Source: UNODC DELTA.
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Table 25: Cocaine prices in Europe and the United States (not purity adjusted), 1990-2009
EUROPE 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Austria 198         180         167          120         126         156         138         118         113         93          94           78          71           90          103         101          78           99         110          97          
Belgium 80           90            68            95           82           93           90           57           55           60          55           51          50           51          51          51           60           67         72            71          
Denmark 144         135          111          90           150        176         169         108         119         165        106         120        91           122        82           82            81           74         99            93          
Finland 159         150         126         105        165        191        184        123        179         157       138        121        111         151        146         125          100         110 154 139
France 99           119          140          153         151         174         125         87           84           82          50           87          75           90          99           94            97           96         103          83          
Germany 120         103          111          95           109         103         90           77           72           68          57           58          57           68          73           79            74           86         91 87
Greece 150         120         105          54           116         111         144         91           54           82          69           72          75           96          93           79            110         110       110          104        
Ireland 141         137         120         110        100        119         32           34           32           30          28          28         94          79          87           88            88           96         103          97          
Italy 108         120          164          90           104         113         129         109         129         135       100        89          90           101        113         114          104         112       111 99
Luxembourg 150         150         150         150        172         194         127         115         110         119        119        119        107        96          114         105          106         89         89           89         
Netherlands 66           70           74            66           60          79           52           64           38           33          33          33         33          50          59          59           60          59         63            63         
Norway 176         170          255          156         145         150        153         177         133         128        114         157        165         170        155         155         151        164       154          154       
Portugal 63           57            60            57           59           66           64           57           51           43          56           48          36           47          49           55            56           55         66           66          
Spain 110         100          100          63           78           91           72           68           68           63          52           52          56           70          76           76            76           83         89            83          
Sweden 160         152         183         123        148        118         118         98           88           97          77           79          87           99          93           92            101        96         138 104
Switzerland 178         144          188          136         146         148         127         117         110         109       77           69          74           89          86          86           74          75         65            82          
United Kingdom 131         127          69            123         113         111         102         124         128         104        94           94          84           90          91           79            87          91         74            62          
Unweighted average, US$ 131         125          129          105         119         129         113         95           92           92          78           80          80           92          92           89            88           92         99            93               
Inflation adjusted, 2009 US$ 215         197          197          156         172         181         154         128         121         119        97           96          95           107        105         98            94           95         99            93               
Weighted average, US$ 117         115          118          104         112         118         105         92           92           88          70           74          72           84          88           86            86           91         94            85               
Inflation adjusted, 2009 US$ 192         180          180          154         162         166         144         123         121         113        88           90          85           97          100         95            91           95         94            85               
Weighted average in Euro 92           92            91            88           94           91           83           81           82           82          76           83          76           74          71           69            71           67         64            61               
Inflation adjusted, 2009 Euro 144         138          130          122         126         119         106         102         102         101        92           98          87           83          78           74            75           69         64            61               
Sources: UNODC ARQ data and  EUROPOL; UNODC estimates in italics
USA 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Street price in US$ 97           93            81            84           79           91           91           81           81           81          96           96          83           90          84           85            94           104       119          120             
Inflation adjusted, 2009 US$ 159         147          123          125         115         128         124         108         106         104        119         116        99           105        96           93            100         107       118          120             
Purity adjusted 167         148          120          122         119         149         124         125         117         125        155         166        119         131        122         124          127         157       215          237             
Purity and inflation adjusted, 2009$ 274         233          184          181         172         209         170         167         154         161        193         201        142         153        139         137          135         163       214          237             
EUROPE 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Austria 66,000 66,000 54,000 40,000 41,946 52,084 45,875 56,723 54,440 38,859 47,094 43,995 42,385 59,300 55,894 59,757 50,185 61,661 66,176     48,668        
Belgium 25,000 24,000 38,250 28,000 26,920 30,560 21,927 17,025 19,167 23,859 22,376 26,771 28,111 29,610 32,480 32,480 32,480 47,958 53,757     46,675        
Denmark
80,000 85,000 85,000 82,500 58,516 60,034 46,141 38,640 44,517 78,900 43,462 47,839 37,823 53,160 45,896 50,321 40,520 40,445 43,447     40,730        
Finland
79,500 75,000 62,750 52,500 82,500 95,450 91,750 61,550 89,350 78,460 68,321 59,492 51,804 62,150 68,315 68,315 56,611 61,660
66,176     62,573   
France 117,000 38,250 45,000 38,250 40,000 39,877 48,077 43,554 42,159 27,714 27,000 34,978 37,676 45,200 49,683 50,321 50,190 61,661 44,118     41,715   
Germany 69,000 53,100 60,300 54,142 57,692 54,676 53,925 45,294 41,210 39,639 33,752 33,235 34,476 40,110 44,243 46,525 45,320 48,826 54,114     57,171   
Greece 75,000 90,000 95,000 36,000 46,413 53,098 72,015 43,795 49,180 49,320 41,237 40,359 42,385 53,680 57,446 62,902 62,735 62,735 69,853     63,964   
Ireland 45,000 45,000 40,000 50,000 45,000 42,000 31,646 33,733 31,530 29,891 29,891 29,891 29,891 30,510 38,557 38,506 39,636 41107 44,118 36,161   
Italy 54,000 48,000 94,000 41,935 51,097 51,455 55,633 50,629 49,091 47,250 46,000 40,529 41,412 47,440 51,759 52,188 52,920 56,029 63,514     57,153   
Luxembourg 93,919 95,939 113,521 50,847 157,593 141,343 47,625 43,103 41,072 47,718 47,718 47,718 47,718 47,718 31,052 31,450 31,450 31,451 31,451    31,451   
Netherlands 26,500 28,000 29,500 26,500 24,680 33,232 23,894 29,698 22,355 27,500 27,500 27,500 27,500 27,400 33,775 33,775 35,000 42,409 46,691     46,691   
Norway 120,000 120,000 127,500 110,000 39,971 50,000 41,670 60,028 81,699 57,545 51,417 51,569 54,159 56,500 65,209 65,209 56,400 61,661 51,471     51,471   
Portugal 39,500 39,285 33,000 27,000 27,950 34,483 42,591 37,908 33,447 30,000 28,000 29,080 31,046 32,410 36,399 36,399 31,365 34,256 44,118     41,716   
Spain 65,000 60,000 55,000 35,000 36,434 41,322 38,760 36,806 38,924 38,898 30,882 38,898 31,511 38,830 42,167 41,321 41,210 46,274 48,709     45,941   
Sweden 80,000 85,000 91,375 61,450 73,825 55,556 59,255 45,573 50,484 48,508 38,394 34,693 35,763 43,130 39,560 40,068 39,270 51,883 72,844     45,459   
Switzerland 63,900 94,250 116,250 50,847 72,012 75,949 51,587 40,780 41,152 41,000 35,482 23,392 19,274 37,230 44,008 44,008 41,090 44,351 49,307     50,379   
United Kingdom 47,850 46,475 20,625 43,210 45,000 46,774 40,625 47,500 47,500 33,981 38,168 36,008 35,848 40,880 50,036 50,036 50,943 60,362 64,682     76,963   
Average unweighted 67,481 64,312 68,298 48,717 54,562 56,347 47,823 43,079 45,722 43,473 38,629 37,997 36,987 43,839 46,263 47,270 44,549 50,278 53,797 49,699
Inflation adjusted, 2009 US$ 110,766 101,301 104,437 72,329 78,985 79,320 65,391 57,582 60,179 55,982 48,126 46,029 44,108 51,114 52,542 51,926 47,407 52,023 53,605 49,699
Weighted average, US$ 67,639    51,835     57,493     44,032    47,117    48,204    47,823    44,011    43,456    38,510   35,592    36,089   35,941    42,308   46,898    47,739     46,963    53,390  55,261     54,577        
Weighted average, US$ per gram 68           52            57            44           47           48           48           44           43           39          36           36          36           42          47           48            47           53         55            55               
Inflation adjusted, 2009 US$ 111,026 81,648 87,915 65,373 68,208 67,858 65,391 58,829 57,195 49,591 44,343 43,718 42,861 49,330 53,262 52,442 49,977 55,242 55,065 54,577
Inflation adjusted, 2009 US$/gram 111 82 88 65 68 68 65 59 57 50 44 44 43 49 53 52 50 55 55 55
Weighted average,Euro/gram 53 42 44 38 40 37 38 39 39 36 38 40 38 37 38 38 39 39 38 39
Inflation adjusted, 2009 Euro/gram 83.1        62.2         63.4         52.0        53.3        48.4        48.4        48.6        48.3        44.3       46.3        47.4       43.9        42.2       41.7        41.0         41.1        40.4      37.7         39.2            
Sources: UNODC ARQ,  EUROPOL;  UNODC estimates in italics
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
US wholesale price 34           32            31            29           27           28           27           28           25           25          26           24          24           24          24           24            23           23         26            27               
Purity-adjusted 52           42            41            39           36           41           37           41           35           40          46           44          41           38          37           34            31           37         53            57               
Inflation and purity adjusted, 2009 dollars 85           66            62            59           51           57           50           54           46           52          57           53          49           44          42           38            33           39         53            57               
Source: ONDCP, transactions in excess of 50 grams, based on Expected Purity Hypothesis
Retail price (street price), US$/gram
Wholesale price, US$/kg
Sources: for 1990-2006, ONDCP, National Drug Control Strategy Data Supplement 2010; for 2007-2009, UNODC estimates based on ARQ (STRIDE data) and prices for 2006.
116
World Drug Report 2011 
Fig. 83: Global seizures of cocaine(a), 1999-2009
(b) Seizures as reported (no adjustment for purity).
(c) Excluding 1.9 tons of "basuco".
(a) Includes cocaine HCl, cocaine base and crack-cocaine.
(e) Data for the United Kingdom for 2009 are based on incomplete data for some jurisdictions for the financial year 2009/10, and adjusted for the missing 
jurisdictions using the latest available complete distribution (relative to the financial year 2006/07).
(d) Data relative to 2008. Data for 2009 from the Netherlands were not available.
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Fig. 84: Global seizures of cocaine, 1999-2009
COCAINE(a) INTERCEPTED - WORLD: 1999-2009  COCAINE    INTERCEPTED - ASIA: 1999-2009
COCAINE(a) INTERCEPTED - AMERICAS: 1999-2009  COCAINE(a) INTERCEPTED - EUROPE: 1999-2009
COCAINE(a) INTERCEPTED - AFRICA: 1999-2009  COCAINE(a) INTERCEPTED - OCEANIA: 1999-2009
(a) Includes cocaine HCl, cocaine base and crack-cocaine
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
M
et
ri
c 
to
n
s
0
100
200
300
400
500
600
700
800
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
M
et
ri
c 
to
n
s
0
100
200
300
400
500
600
700
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
M
et
ri
c 
to
n
s
0
25
50
75
100
125
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
M
et
ri
c 
to
n
s
0
1
2
3
4
5
6
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
M
et
ri
c 
to
n
s
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
M
et
ri
c 
to
n
s

The coca/cocaine market
119
3.5 Market analysis
Transnational cocaine trafficking has been affecting the 
Americas for the last 40 years. The size of the United 
States’ market – the single largest cocaine market for 
decades – has been shrinking in recent years, mainly due 
to a reduction of the cocaine flows from Mexico to the 
United States. The massive decline of the US cocaine 
market has been partly offset by a rise of cocaine use in 
new destination markets (mainly in areas with above 
average purchasing power) and countries caught in the 
transit flow. Cocaine trafficking and use have started to 
affect countries in the Oceania region (already showing 
high annual cocaine use prevalence rates by interna-
tional standards), countries in western and southern 
Africa affected by the transit flow, and in some parts of 
Asia (some countries in the Near and Middle East as 
well as some emerging pockets in a few countries in the 
Far East).
The most developed cocaine market outside of the 
Americas continues to be Europe, notably West and 
Central Europe. Cocaine use in East Europe, in con-
trast, is still limited. The volume of cocaine consumed 
in Europe has doubled over the last decade, even though 
data for the last few years show signs of stabilization at 
the higher levels.
While European law enforcement agencies have 
increased their efforts, traffickers continue to innovate, 
seeking novel ways of getting their product to the con-
sumer. Around 2004, South American traffickers began 
to experiment with some new trafficking routes via West 
Africa. In a few years, they managed to undermine secu-
rity and sow high-level corruption in a number of West 
African states. Recognizing the threat, the international 
community undertook a variety of interventions to 
address this flow. The novelty aspect was lost, the politi-
cal instability proved self-defeating, and some very large 
seizures were made. By 2008, there was a remarkable 
decline in the number of both large maritime seizures 
and the number of cocaine couriers detected flying from 
West Africa to Europe. Criminal intelligence work indi-
cates that the flow may have declined, but it did not 
stop. This raises the possibility that traffickers had 
simply modified their techniques, finding new methods 
for bringing cocaine to Europe, including through West 
Africa, without detection. Statistical data support this 
scenario: European cocaine seizures decreased from 121 
mt in 2006 to 57 mt in 2009. But demand has not 
dropped by half during this period. Some (but not all) 
of the decline may be explained by improved upstream 
interception efforts as a result of improved sharing of 
intelligence with counterparts in South America.37
Cocaine consumption estimates
One of the most challenging tasks is to transform esti-
mates on the number of cocaine users into quantities of 
cocaine consumed. Information on per capita use is still 
limited (a few studies conducted in North America, 
South America, Europe and Australia) and any calcu-
lated results must be treated with caution (and results 
are subject to change, whenever more reliable informa-
tion becomes available). The best reading of existing 
data and estimates suggests that some 440 mt of pure 
cocaine were consumed in 2009. This would be in line 
with a production estimate of some 1,111 mt of cocaine, 
wholesale purity-adjusted seizures of 615 mt and global 
losses of some 55 mt (5% of production).
Of the 440 mt available for consumption, around 63% 
were consumed in the Americas, 29% in Europe, 5% in 
Africa, 3% in Asia and less than 1% in Oceania. The 
largest subregional markets were found in North Amer-
ica (close to 180 mt or 41% of the total), West and 
Central Europe (123 mt or 28%) and South America 
(85 mt or 19%). These three subregions account for 
63% of global cocaine consumption. The single largest 
cocaine market – despite strong declines in recent years 
- continues to be the United States of America, with an 
estimated consumption of 157 mt of cocaine, equivalent 
to 36% of global consumption, which is still higher than 
the cocaine consumption of West and Central Europe. 
Cocaine consumption in volume terms appears to have 
declined by more than 40% over the 1999-2009 period 
in the United States to some 157 mt (range: 133-211 
mt), with most of the decline (more than a third) having 
taken place between 2006 and 2009. As compared to 
estimates for 1989, cocaine consumption in the United 
States seems to be now some 70% lower (range: -63% 
to -77%), in parts reflecting the increase in treatment 
and successes in prevention, while the latest decline over 
the 2006-2009 period was attributed more to reduced 
supply. 
37 UNODC, The Transnational Cocaine Market, April 2011.
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Fig. 85: Estimates of the amounts of cocaine consumed, by region, subregion and globally, 2009
Source: UNODC estimates based on ARQ data and the 2005 World Drug Report, as well as updates based on selected scientific studies.
 
Region/subregion 
 
Best estimates
Users  Per capita use  Consumption 
in million
in % of 
total
grams per year
 in metric 
tons 
in % of 
total
Americas 
 of which 
 South America 
 Central America 
 Caribbean 
 North America 
8.4
 
2.4
0.1
0.1
5.7
54%
 
15%
1%
1%
36%
 32.6 
 
 35.0 
 35.0 
 35.0 
 31.5 
275 
85 
 5 
6 
179 
63%
 
19%
1%
1%
41%
Europe 
 of which 
 West and Central Europe
 East and South-East Europe
4.5
 
4.1
0.5
29%
 
26%
3%
 28.4 
 
 30.3 
 12.3 
129 
123 
 6 
29%
 
28%
1%
Africa 
 of which 
 West and Central Africa 
 Southern Africa 
 North Africa 
 East Africa
1.7*
 
1.1
0.3
< 0.1
0.2
11%
 
7%
2%
<1%
1%
 12.0 
 
 12.0 
 12.0 
 12.0 
 12.0 
21 
 13 
4 
 < 1 
3 
5%
 
3%
1%
< 1%
< 1%
Asia 0.7* 4%  20.0 14 3%
Oceania 0.3 2%  7.3 2 < 1%
Total 15.6* 100%  28.1 440 100%
* Given the uncertainty of data from Asia and Africa, for the purpose of consumption estimates, a lower level of cocaine use is assumed for these 
regions.
Fig. 86: Estimates of cocaine consumption in the United States (mt), 1988-2009
Source: UNODC, World Drug Report 2010 and UNODC update for 2009.
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The opposite trend has been observed in Europe. 
Cocaine consumption in the EU and EFTA countries is 
estimated to have almost doubled, from 68 mt in 1999 
(range: 57-79 mt) to 123 mt in 2009 (range: 100-142 
mt). Between 2006 and 2009, cocaine consumption 
stabilized, and between 2007 and 2009, it may have 
slightly declined. 
Evolution of trafficking flows 
These shifts in demand have also had an impact on the 
nature of transnational cocaine trafficking. In the late 
1990s, the bulk of the world’s cocaine was shipped to 
the United States, increasingly controlled by Mexican 
groups. The Caribbean, which was the preferred transit 
zone when the Colombian cartels dominated the market, 
saw decreased trafficking as a growing share was moved 
via the Pacific through Mexico into the United States. 
Colombian traffickers, who had largely been driven 
from the more lucrative portions of the supply chain to 
North America by the Mexican cartels, increasingly 
focused on the growing European market.
Traditionally, there have been several parallel streams of 
cocaine flowing into Europe. Commercial air couriers, 
sometimes directed by West African groups in the new 
millennium, have flown to Europe from various inter-
mediate countries in the Caribbean. Colombian groups 
also made use of commercial air carriers, often in coop-
eration with groups from the Dominican Republic, with 
whom they have a long-standing relationship. Larger 
maritime consignments were often stored on board 
‘mother ships’ and transported to shore by smaller ves-
sels. The primary maritime points of entry were Spain 
(due to proximity and cultural links) and the Nether-
lands (due to the large port). These vessels typically 
transited the Caribbean.
Some time around 2004, the Colombian groups began 
experimenting with routing their cocaine shipments 
through West Africa. From 2005 to 2008, a series of 
very large cocaine seizures took place in or near West 
Africa. Many of these involved ‘mother ships’ inter-
cepted by European navies. There were also incidents 
where modified small aircraft were used. High-level 
officials were involved in some countries. There was also 
a sharp increase in the number of cocaine couriers found 
on flights from West Africa to Europe.
Around 2008, local political events (leading to the top-
pling of some of the regimes in West Africa that cooper-
ated closely with the narco-traffickers)38 coupled with 
international attention to the issue, led to in a dramatic 
reduction in the number and volume of seizures, includ-
ing both maritime shipments and commercial air couri-
ers. In parallel, the proportion of individual cocaine 
seizures in Europe that transited countries of West and 
Central Africa declined from around 25% in 2007 
(range: 21%-30%) to some 13% in 2009 (range: 11%-
17%). 
In 2008, only four large (over 100 kg) seizures were 
made, and in 2009, only one. According to IDEAS, an 
air courier database, in the second quarter of 2007, 59% 
of cocaine couriers detected were from West Africa, 
while in the third quarter of 2009, there were none. 
Since then, some increases - up to 5% of couriers 
detected - were again reported in the fourth quarter of 
2009 and, on average, 11% in 2010.
Despite this apparent reduction or even disruption, 
informal reports indicated that the trafficking contin-
ued. The use of jet aircraft, which can fly deeper inland 
in Africa, might have become an alternative method of 
moving cocaine through West Africa to Europe. 
38 UNODC, The Transnational Cocaine Market, April 2011.
Fig. 87: Estimates of cocaine consumption in the EU and EFTA countries (mt), 1998-2009
Source: UNODC ARQ; Government reports; UNODC, World Drug Report 2010; EMCDDA, Statistical Bulletin 2009.
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recent data suggest that the downward trend did not 
continue in 2009 and some early indications for 2010 
suggest that the importance of the Caribbean may have 
started to rise again. Seizures made in South American 
countries outside the Andean region, in Central America 
and the Caribbean in relation to shipments towards 
North America are estimated at slightly less than 100 mt 
(purity-adjusted). A further 100 mt of purity-adjusted 
cocaine seizures are made in North America. Thus, out 
of 380 mt exported to North America, only some 180 
are available for consumption, of which the bulk (88%) 
is consumed in the United States. 
The second largest flow is to Europe. The global shift in 
demand has also affected trafficking routes to Europe, 
with much greater volumes crossing the Atlantic by air 
and sea. Some 220 mt or 26% of total cocaine exports 
left the Andean countries for West and Central Europe 
in 2009. Of this, close to 60 mt (purity-adjusted) were 
seized in other South American countries or in the Car-
ibbean. Thus, close to 160 mt left South America for 
West and Central Europe in 2009. 
The seizures in West and Central Europe (including 
seizures on the open sea off the shores of Europe) 
amounted to some 35 mt (purity-adjusted), leaving 123 
mt for consumption in this region (range: 100–138 mt). 
This is in line with an overall prevalence rate of 0.8% of 
the population aged 15-64 and per capita use levels of 
around 30 grams of pure cocaine per user per year, for a 
total population of around 480 million people in West 
and Central Europe (EU and EFTA countries). The 
overall amount consumed in Europe is estimated at 129 
mt, suggesting that West and Central Europe (123 mt) 
accounts for 95% of the total European cocaine market. 
An analysis of individual drug seizures reported in 
Europe suggests that more than 86% of the drugs were 
trafficked directly to West and Central Europe, while 
around 13% were trafficked via West Africa. Trafficking 
via West and Central Africa would have amounted to 
some 21 mt.39 In addition, cocaine is trafficked for local 
demand to West and Central Africa – a subregion with 
a combined population of more than 400 million people, 
which may consume some 13 mt. Trafficking flows to 
39 158 mt * 13.4% = 21 mt; range: 158*10.7% to 158*16% = 17-26 
mt.
Map 22: Global cocaine ﬂows, 1998 and 2008
Source: UNODC World Drug Report 2009 and UNODC  
calculations informed by US ONDCP, Cocaine Consumption 
Estimates Methodology, September 2008 (internal paper).
Table 26: Proportion of cocaine trafﬁcked via West and Central Africa to Europe (based on individual 
drug seizures in Europe where the ‘origin’ of the shipment was known)
Source: UNODC IDS.
2004 2005 2006 2007 2008 2009
Cocaine seizure cases 2.9% 14.7% 16.4% 29.5% 23.8% 16.0%
Amounts of cocaine seized 1.1% 2.7% 13.4% 21.3% 3.6% 10.7%
Mid-point (‘best estimate’) 2.0% 8.7% 14.9% 25.4% 13.7% 13.4%
Current trafficking flows to main consumer markets
It is estimated that almost 380 mt or 45% of the total 
cocaine exports from the Andean region leave for North 
America, a region with a population of some 460 mil-
lion people. The bulk of cocaine shipments are still by 
sea across the Pacific to Mexico and on to the United 
States. In addition, Central American countries have 
gained prominence in recent years as trans-shipment 
locations. The Caribbean, in contrast, has lost signifi-
cance as a trans-shipment hub over the last decade. More 
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Table 27: Flows of cocaine, purity-adjusted*, to major consumer markets (mt), 2009
Source: UNODC estimates based on Annual Reports Questionnaire data and other government or scientific sources.
Production** 1,111
Less seizures in Andean countries -254
Less domestic consumption in Andean region -13
Potential amounts available for export out of  the Andean countries 844
Less losses in production and/or losses in global trafficking which cannot be attributed to specific regions -56
Actual exports  out of Andean countries 788
Map 23: Main global cocaine ﬂows, 2009
Source: UNODC, World Drug Report 2010, updates for 2009.
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6
West and  
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Non-Andean South Amer-
ica / Caribbean, Central 
America, Africa, Asia,  
Oceania
Amounts of cocaine leaving the Andean countries 217 378 193
Less amounts seized in non–Andean South America,  
Caribbean and Central America linked to trafficking flows  -59 -98 -64
Less  domestic consumption in non-Andean South  
America / Caribbean / Central America -83
Amounts leaving South America,  Caribbean and  
Central America  
158 
(incl. 21 mt via 
West Africa)
280 46
Less amounts seized in consumer countries outside  
South America / Central America / Caribbean -35 -101 -3
Amounts of cocaine consumed in countries outside  
South America /  Central America / Caribbean 123
179 
(incl. 157 in 
the USA)
43  
(incl. 21 Africa, 14 Asia,  
6 East and South-East Europe; 
2 Oceania)
*Purity levels tend to decline along the trafficking chain. All numbers in this table have been adjusted to pure cocaine equivalents. Seizure data were 
adjusted based on reported wholesale purity data.
** The global cocaine production in 2009 was estimated to amount to between 842 mt and 1,111 mt. Actual cocaine consumption for 2009 was esti-
mated at 440 mt. Seizures, not adjusted for purity, amounted to 732 mt in 2009.Considering purity-adjusted seizures of cocaine (unweighted average 
of all purities at retail and wholesale level reported by Member States in 2009), some 481 mt would be available for consumption and losses if the lower 
cocaine production estimate were used. If the higher cocaine production estimate were used, deducting seizures adjusted for wholesale purity (based on 
2009 purity data or the latest year available), some 496 mt would be left for consumption and losses. The upper and the lower production estimates could 
be thus sufficient to cover consumption (440 mt). For the calculation shown above, the higher production estimates and seizures adjusted at wholesale 
purities were used. This reflects the observation that wholesale seizures account for the bulk of seizures in volume terms and would support the higher 
production estimates. However, one cannot exclude the possibility that seizures may be over-estimated due to possible double-counting once several law 
enforcement agencies within or across countries have been involved in cocaine interceptions.
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West Africa could have thus amounted to some 35 mt in 
2009 (range: 21-55 mt), equivalent to 4% (range: 
2%-6%) of total cocaine exports out of the three Andean 
countries - of which almost two thirds was for subse-
quent onward transit traffic to West and Central Europe. 
Current value and money flows
The value of the global cocaine market is most certainly 
lower than it was in the mid-1990s, when prices were 
much higher and the US market was strong. In 1995, 
the global market was worth some US$165 billion, 
which had been reduced to just over half of this by 2009 
(US$85 billion; range: US$75-US$100 bn). 
North America and West and Central Europe accounted 
for 86% of the global cocaine market in economic terms 
in 2009. North America accounted for 47% and West 
and Central Europe 39% of the total. 
While the North American market shrank over the last 
two decades – due to lower volumes and lower prices - 
the European market expanded. Nonetheless, the US 
market remains the largest market globally, but the 
market of the countries of West and Central Europe 
(US$33 billion at retail level in 2009) is – in economic 
terms – now nearly as large as the US market (US$37 
billion in 2009). 
Map 24: Signiﬁcant cocaine seizures affecting West Africa, 2005-2011*
* January 2011
Source: UNODC IDS; Government sources.
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Out of the US$85 billion in income from global cocaine 
retail sales in 2009, traffickers are estimated to have 
reaped some US$84 billion (almost 99%). The rest went 
to farmers in the Andean region. The largest gross prof-
its were reaped from cocaine sales in North America 
(some US$34 billion), followed by countries of West 
and Central Europe (some US$23 billion). Expressed as 
a proportion of GDP, the cocaine profits were rather 
small (0.2% of GDP in North America and 0.1% in 
West and Central Europe). Profits from international 
trafficking to North America and Europe amount to 
some US$15 bn. This suggests that more than 85% of 
global cocaine profits were related to demand for cocaine 
Fig. 88: Value of the global cocaine retail  
market (in billion constant 2009 US$), 
1995, 2008 and 2009
Sources: UNDCP, Economic and Social Consequences of  
Drug Abuse and Illicit Trafficking, 1997 (re-valued based on 
US consumer price index); UNODC estimates on the size of 
the global cocaine market for 2009, based on ARQ data and 
other Government sources.
Fig. 89: Regional breakdown of the value of 
the global cocaine market in 2009 in 
billions of US$ (N = US$85 bn)
Source: UNODC estimates on the size of the global cocaine 
market for 2009, based on ARQ data and other Government 
sources.
in North America and West and Central Europe. 
Cocaine-related profits generated in South America, 
Central America and the Caribbean from trafficking 
cocaine to North America and West and Central Europe 
amounted to some US$18 billion in 2009, equivalent to 
0.6% of the total GDP of South America, Central 
America and the Caribbean. 
Of the cocaine trafficked to meet demand in West and 
Central Europe, UNODC estimates – based on an 
analysis of reported individual drug seizures in terms of 
volumes and number of seizure cases - that some 13% 
(range: 11%-16%) transited West Africa in 2009. 
Reports indicated that up to one third of the shipments 
is paid in kind to service providers in West Africa, who 
then traffic most of this cocaine to Europe on their own 
behalf. In addition, profits are made in supplying the 
West African cocaine market. The potential wholesale 
profits affecting West Africa in 2009 amount to US$0.8 
billion, equivalent to 0.2% of GDP in West and Central 
Africa. These figures do not include profits made by 
West African citizens engaged in European cocaine retail 
sales (often European residents, illegal immigrants or 
asylum seekers). European retail profits amount to some 
US$20 billion. Arrest statistics of West African citizens 
in relation to cocaine trafficking (for example, more 
than 23% in Portugal in 2008 and more than 16% in 
France in 2006) suggest that West African groups play 
an important role in cocaine street sales in several 
(mainly continental) European countries. Assuming that 
the West African groups reap, on average, between 5% 
and 10% of the European cocaine retail profits, this 
would amount to another US$1-2 billion in potential 
cocaine-related income. 
Fig. 90: Value of the US and West and Central 
European cocaine markets, 1989-2009 
(constant 2008 US$ billions) 
Source: UNODC, World Drug Report 2010 and updates for 
2009.
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Table 28: Estimates of gross proﬁts made by cocaine trafﬁckers (billion US$), by region, 2009
 Sources: UNODC estimates based on ARQ data and other Government or scientific sources. 
In billion US$ In % of GDP
South America, Central America, Caribbean 
 local market 
 export to North America* 
 export to Europe**
3
6
9
0.1%
0.2%
0.3%
Subtotal South America, Central America, Caribbean 18 0.6%
North America (USA, Mexico, Canada) 34 0.2%
West and Central Europe (EU-25 and EFTA) 23 0.1%
West and Central Africa (local demand and export to Europe) 0.8 0.2%
Other 8 0.04%
Total trafficking profits 84*** 0.1%
* Trafficking from producing areas in the Andean region to Mexico. 
** All trafficking to transit countries (US$4.9 bn) and from transit countries to Europe (US$6.1 bn) of which 70% (US$4.3bn) is assumed to be 
generated by trafficking groups from South America and the Caribbean; gross profits for trafficking to Europe are higher as prices in Spain (the main 
entry point into Europe) are much higher than prices in Mexico (the main entry point into North America). 
*** The difference between the total size of the global cocaine market (US$85 bn) and gross trafficking profits (US$84 bn) is income of farmers; 
farmers are estimated to earn less than US$1 bn. 
Table 29: Tentative estimates of the proﬁts reaped by West African groups out of cocaine trafﬁcking, 
2009
Source: UNODC estimates based on ARQ and IDS data.
Gross profits 
Proportion of  
(assumed) West- African 
involvement
West African cocaine 
related trafficking 
income
Profits made by importing cocaine  
from South America to West Africa  
for domestic use
US$ 0.2 bn 10% US$ 0.02 bn
Profits made by selling cocaine 
to West African customers US$ 0.4 bn 100% US$ 0.4 bn
Profits made in shipping cocaine to 
countries in West and Central Europe 
and selling it to mid-level drug dealers 
US$ 9.2 bn 13.4%*33% US$ 0.4 bn
Subtotal  US$ 0.8 bn
Retail profits made in West and  
Central Europe US$ 20 bn 5% - 10% US$ 1 bn – US$ 2 bn 
Total US$ 1.8 – US$ 2.8 bn
4. The ATS market
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4.1 Introduction
The term amphetamine-type stimulants (ATS) refers to 
a group of synthetic substances comprised of ampheta-
mines-group substances (primarily amphetamine, meth-
amphetamine and methcathinone) and ecstasy-group 
substances (MDMA and its analogues). 
ATS are available in diverse forms and purities. Meth-
amphetamine or amphetamine can be in powder, tablet, 
paste or crystalline form while ‘ecstasy’ is usually avail-
able in tablet or powder form.
4.2 Consumption
For the past two decades, the use of amphetamine type 
stimulants (ATS) has been one of the most significant 
drug problems worldwide. This section describes the 
trends in the use of amphetamines-group and ecstasy-
group substances in the different regions.
Amphetamines-group substances
In 2009, UNODC estimates that, with an annual prev-
alence ranging between 0.3% and 1.3%, between 13.7 
and 56.4 million people aged 15-64 globally had used 
amphetamines-group substances at least once in the past 
year. While these numbers reflect a slight increase over 
estimates for previous years, they do not essentially indi-
cate a significant difference in the prevalence of amphet-
amines-group substances.
The type of amphetamines-group substances used in 
different regions varies considerably. In East and South-
East Asia, methamphetamine is the primary substance 
consumed within this group, while in the Near and 
Middle East, the use of tablets sold as Captagon is 
reportedly more common. In Europe, amphetamine is 
the main substance used within this group with the 
exception of Czech Republic and Slovakia, where meth-
amphetamine has traditionally been the predominant 
amphetamines-group substance used. 
In North America as well as Australia and New Zealand, 
the use of prescription stimulants1 is as common as 
methamphetamine. In South America and the Carib-
bean, prescription stimulants are more commonly used. 
In Africa, especially in West, Central and East Africa and 
some parts of Southern Africa, the use of amphetamines-
groups substances may comprise use of prescription 
stimulants. In South Africa, methamphetamine and 
methcathinone are the most commonly used ATS. 
In 2009, out of the 69 Member States that reported 
expert perception on amphetamines-group use trends 
through the Annual Reports Questionnaire, an equal 
number of countries perceived increasing and stable 
trends in the use of ATS over the past year. In Asia, 
however - particularly in South and South-East Asia - 
the majority of countries reported a perceived increase 
in the use of ATS in their countries. 
Trends over the past 12 years in the perceived increase in 
use of ATS as reported by Member States indicate that 
since 2001, the rate of increase has been much higher 
and more substantial in the developing (non-OECD) 
countries than in the developed (OECD) countries. In 
developing countries and especially emerging econo-
1 Prescription stimulants may include substances such as amfepra-
mone, fenetylline, methylphenidate, phenmetrazine, et cetera.
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mies, there is an expanding middle class with more dis-
posable income. The association in developed countries 
of synthetic drugs, especially stimulants, with moderni-
zation and affluent lifestyles, combined with increasing 
demands for higher performance and the availability 
and reported common use of stimulants in recreational 
and entertainment settings, may be contributing to an 
increase in the use of stimulants in developing countries 
where young people within the growing middle class 
may want to emulate these lifestyles. 
Region/subregion  
(amphetamines-group)
Estimated 
number of 
users annually 
(lower)
-
Estimated 
number of 
users annually 
(upper)
Percent of 
population 
age 15-64 
(lower)
-
Percent of 
population 
age 15-64 
(upper)
Africa
East Africa
North Africa
Southern Africa
West and Central Africa
1,180,000
 
 
280,000
 
-
-
8,150,000
 
 
780,000
 
0.2
 
 
0.4
 
-
-
1.4
 
 
1.0
 
Americas
Caribbean
Central America
North America
South America
5,170,000
30,000
320,000
3,460,000
1,340,000
-
-
-
-
-
6,210,000
530,000
320,000
3,460,000
1,890,000
0.8
0.1
1.3
1.1
0.5
-
-
-
-
-
1.0
1.9
1.3
1.1
0.7
Asia
Central Asia
East/South-East Asia
Near and Middle East
South Asia
4,330,000
 
3,480,000
460,000
 
-
-
-
38,230,000
 
20,870,000
4,330,000
 
0.2
 
0.2
0.2
 
-
-
-
1.4
 
1.4
1.7
 
Europe
East/South-East Europe
West/Central Europe
2,540,000
510,000
2,030,000
-
-
-
3,180,000
1,050,000
2,120,000
0.5
0.2
0.7
-
-
-
0.6
0.5
0.7
Oceania 470,000 - 640,000 2.0 - 2.8
Global 13,690,000 - 56,410,000 0.3 - 1.3
Table 30: Annual prevalence and estimated number of amphetamines-group substances users,  
by region, subregion and globally, 2009
Fig. 91: Range of estimated number of  
amphetamines-group substance  
users by region
Source: UNODC.
Fig. 92: Range annual prevalence of  
amphetamines-group substance  
users by region
Source: UNODC.
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in 2009 in the United States. While this estimate was 
significantly higher than the estimate in 2008 (95,000), 
it is still substantially lower than the estimate for 2002 
(299,000),2 and far lower than the reported initiates for 
most other illicit drugs (except for PCP). In line with 
the annual prevalence, the number and proportion of 
people who had reported non-medical use of stimulants 
in the past 30 days (prior to the survey) increased sig-
nificantly from 904,000 (0.4%) in 2008 to 1.3 million 
2 Substance Abuse and Mental Health Services Administration, Results 
from the 2009 National Survey on Drug Use and Health: Volume I. 
Summary of National Findings, Rockville, Maryland, USA, 2010.
(0.5%) in 2009. This increase in the prevalence of stim-
ulants use is attributed in part to an increase in the 
number of methamphetamine users.3 
The recent increase in stimulant and notably in meth-
amphetamine use among the general US population was 
not reflected in prevalence data for high school students 
for 2009. Among secondary school students in the 
United States, there has been a declining trend in the 
annual prevalence of amphetamine and methampheta-
mine use between 2002 and 2008, and stable trends in 
3 Ibid.
Fig. 93: Expert perceptions of the trends in amphetamines-group substance consumption,  
2000-2009
Source: UNODC ARQ.
Fig. 94: Amphetamines-group substance use 
trends as perceived by experts of de-
veloped (OECD) and developing coun-
tries, 1998-2009 (baseline: 1998 =100)
Source: UNODC ARQ.
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Source: UNODC ARQ.
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2009.4 In 2010, annual prevalence of amphetamines use 
rose among 10th and 12th graders while it continued to 
decline among 8th graders. Use of methamphetamine, 
in contrast, increased among 8th graders, remained 
stable among 10th graders but declined among 12th 
graders in 2010. Despite some increases in ampheta-
mines use and a stable level of methamphetamine use 
4 Johnston, L. D., O’Malley, P. M., Bachman, J. G., and Schulen-
berg, J. E., Monitoring the Future national results on adolescent drug 
use: Overview of key findings, 2010, Ann Arbor, Institute for Social 
Research, The University of Michigan, USA, 2011.
among US high school students in 2010, the overall 
level in 2010 remained substantially lower than over the 
2002-2006 period. 
In contrast to an overall rising trend of ATS use in the 
United States, the annual prevalence of ATS use among 
the general population in Canada (0.7%) was signifi-
cantly lower in 2009 than in 2008 (1.5%). The annual 
prevalence of both amphetamine and methampheta-
mine was substantially lower in 2009 than a year earlier 
(0.5% and 0.1% compared to 1.3% and 0.2% respec-
tively).
In Mexico, while there has been no update in the annual 
prevalence of amphetamines-group substance use since 
the last household survey in 2008, the expert perception 
in 2009 indicates stable trends for amphetamines use 
but a great increase in the use of methamphetamine over 
the past year. In 2009, among school students aged 
12-19 in Mexico, the reported lifetime prevalence of 
amphetamine and methamphetamine use was 1.9% and 
0.7% respectively.5 In previous years, however, the life-
time prevalence among youth aged 12-17 was reported 
as 0.07% for amphetamine and 0.35% for metham-
phetamine.6 
Amphetamines-group substance use in South  
America appears to remain stable
There is no updated information on the prevalence of 
amphetamines-group substance use in South America. 
Existing information shows that the annual prevalence 
5 UNODC ARQ.
6 The information on annual prevalence in the ARQ for Mexico in 
2008 was based on the national survey conducted among the general 
population aged 12-65 with the breakdown of the estimates among 
the ages 12-17 years
Fig. 96: United States: Annual prevalence of 
stimulants and methamphetamine use 
in the population aged 12 and older, 
2002-2009
Source: Substance Abuse and Mental Health Services Adminis-
tration, Results from the 2009 National Survey on Drug Use 
and Health: Volume I, Summary of National Findings, 2010.
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of amphetamines-group substance use in South America 
remains close to the world average, with estimates rang-
ing between 0.5% and 0.7% of the population aged 
15-64 or between 1.34 and 1.89 million people in that 
age group who had used these substances in the previous 
year. Compared to 2008, most of the countries report-
ing from the region perceive trends of amphetamine and 
methamphetamine use as being stable in 2009. Brazil, 
the Bolivarian Republic of Venezuela and Argentina 
remain countries with a high prevalence and absolute 
number of users of amphetamine and methampheta-
mine in South America. 
In a national survey conducted among university stu-
dents in Brazil in 2009, the annual prevalence of 
amphetamines use among the students was reported as 
10.5%. The annual prevalence was higher among female 
students (14.1%) than male students (5.5%), and was 
also higher among the older students, that is, those who 
were 35 years or older (18.6%), followed by students 
aged between 25-34 years (13.7%).7  The use of amphet-
amine-like substances is reportedly more common 
among women due to their anorexic effects and a preva-
lent culture to use medications for weight loss purposes.8 
Although there are no recent updates on the prevalence 
of amphetamine and methamphetamine in Central 
America, as a region, it has a high prevalence of amphet-
7 Andrade, A.G., Duarte, P. and Oliveira, L. G., I Levantamento Nacio-
nal Sobre O Uso De Álcool, Tabaco E Outras Drogas Entre Universita-
rios Das 27 Capitais Brasileiras, Secretaria Nacional Politicas sobre 
Drogas, Brasilia, 2010.
8 Napp S.A., et al., ‘Use of anorectic amphetamine-like drugs by Bra-
zilian women,’ Eating Behaviors, Volume 3, Issue 2, Summer 2002, 
pages 153-1165
amines-group substance use (1.3% of the adult popula-
tion), with El Salvador (3.3%), Belize (1.4%) and 
Panama (1.2%) as the three countries with high annual 
prevalence among the general population. A large pro-
portion of the ATS use in these countries is related to 
the use of prescription stimulants. 
While most countries in Europe show stabilizing 
trends in the use of amphetamines-group  
substances, high levels of injecting amphetamines 
use are reported by a few
In 2009, more than half of European countries reported 
stable trends of ATS use in their countries. The coun-
tries that reported data show a mixed trend from previ-
ous years. The annual prevalence of amphetamines-group 
substance use in Europe is estimated between 0.5% and 
0.6%, which corresponds to an estimated 2.6 to 3.3 mil-
lion people who had used these substances in the past 
year. Like in other regions, the majority of amphetamine 
users fall within the 15-34 years age group, with a much 
higher estimated annual prevalence of 1.2%.
The amphetamines-group substance prevalence is, over-
all, higher in West and Central Europe than in East and 
South-East Europe. In most parts of Europe, ampheta-
mine is the more commonly used substance within this 
group, while the use of methamphetamine remains lim-
ited and has historically been highest in the Czech 
Republic and Slovakia. In 2009 and 2010, countries 
that reported new data on ATS prevalence include 
Cyprus, Germany, Spain, Sweden and the United King-
dom (England and Wales). Except for Germany and 
Sweden, many of these countries are showing stabilizing 
or decreasing trends in the use of amphetamines-group 
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Fig. 98: Annual prevalence of amphetamines-
group substances use in South  
America among the population aged  
15-64, latest year available
Source: UNODC ARQ.
Fig. 99: Brazil: Prevalence of amphetamine use 
among university students, 2009
Source: I Levantamento Nacional Sobre O Uso De Álcool, 
Tabaco E Outras Drogas Entre Universitarios Das 27 Capitais 
Brasileiras, Secretaria Nacional Politicas sobre Drogas, Brasilia, 
2010.
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substances. While in Germany, there was an increase in 
the annual prevalence in 2009 (0.7%) over the previous 
estimates in 2006 (0.5%), the estimate remains at lower 
levels than shown for 2003 (0.9%).
Within West and Central Europe, the Czech Republic, 
Denmark, the United Kingdom, Norway and Estonia 
remain the countries with the highest annual prevalence 
rates, while in South-East Europe, Bosnia and Herze-
govina and Bulgaria have high annual prevalence of 
amphetamines use.
In most West and Central European countries, problem 
amphetamines use represents a small fraction of overall 
problem drug use, except for the Czech Republic and 
some of the Nordic countries. Those who report 
amphetamine as their primary substance account for less 
than 5% of drug users in treatment, on average, in 
Europe. High levels of injecting use are reported from 
the Czech Republic, Estonia, Latvia, Lithuania, Sweden 
and Finland, ranging from 57% to 82% among amphet-
amines users.9
Mixed trends on use of amphetamines-group  
substances in Africa
The annual prevalence of amphetamines-group sub-
stances in Africa is estimated between 0.2% and 1.4% 
(between 1.2 and 8 million people), reflecting the fact 
that for most parts of Africa, there is either limited or no 
recent or reliable data available on the prevalence or 
trends of amphetamines-group substance use, resulting 
9 European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA), Annual Report 2010: The State of the drugs problem in 
Europe, Lisbon, 2010
in a wide range and uncertainty of the estimates. The 
only valid estimates that can be derived in the region are 
for Southern Africa where the annual prevalence is esti-
mated between 0.4% and 1% of the population aged 
15-64. 
Among the limited number of countries that have 
reported expert opinion on trends in the use of amphet-
amines-group substances in Africa, nearly half of the 
countries report that the trend has increased while a 
similar proportion report stable trends over the past year. 
In most parts of Africa, prescription amphetamines 
comprise the primary substances used within this group. 
South Africa is one country in the region from which 
there is more consistent and recent information available 
on drug use trends. Such data – based on treatment 
demand - showed a strong increase in the importance of 
amphetamines until the second half of 2006, followed 
by a stabilization or small downward trend since. The 
importance of amphetamines increased again temporar-
ily in the first half of 2009, before falling back in the 
second half of the year to the levels reported in 2008. 
The past 3 months prevalence of amphetamines-group 
substances in South Africa was reported at 0.7% in 2008 
for the population aged 15 and above. Based on this 
information, the annual prevalence of amphetamines-
group substance use was estimated by UNODC at 
between 0.7% to 1.4% of the adult population (aged 
15-64) in South Africa. 
In contrast to the patterns in other parts of Africa, meth-
amphetamine and methcathinone are the main sub-
stances used within the amphetamines-group substances. 
Fig. 100: Trends in amphetamines-group substances in selected European countries, various years
Sources: EMCDDA; UNODC.
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In South Africa, methamphetamine or ‘tik’ as it is locally 
known, remained the primary substance of use for which 
people were seeking treatment, mainly in Cape Town. In 
other parts of the country, the proportion has remained 
very low.10 For the other countries in Africa, for which 
information on treatment demand is available, amphet-
amines-group substances as the primary substance of 
abuse among persons treated in the region averaged 
around 5% of all treatment demand. This ranges from 
30% of all treatment admissions reported in Niger to 
around 2% in Nigeria.
Increasing trends of amphetamines-group sub-
stances use in Asia with injecting methamphetamine 
and its associated negative health consequences 
reported as an increasing problem in East and  
South-East Asia
The annual prevalence of amphetamines-group sub-
stance use in Asia ranges between 0.2%-1.4% or from 4 
to 38 million people aged 15-64 who are estimated to 
have used these substances in the past year. The wide 
range and uncertainty in the estimates derive from miss-
ing information on the extent and pattern of use from 
large countries in Asia, particularly China and India. 
Due to a lack of recent or reliable estimates from many 
countries in the region, estimates cannot be calculated 
for the subregions of Central and South Asia. 
Nevertheless, among the Asian countries reporting 
through the ARQ, experts in more than half of the 
countries, mainly in East and South-East Asia, perceived 
10 Pluddemann A., Parry C., et al. Alcohol and Drug Abuse Trends: July 
– December, 2009 (Phase 27), South African Community Epidemiol-
ogy Network on Drug Use (SACENDU) Update June 2010.
an increase in the use of amphetamines-group sub-
stances, compared to less than a quarter of countries in 
which experts perceived the problem to have stabilized 
or decreased over the past year. Outside East and South-
East Asia,11 Armenia, Georgia, Jordan, Pakistan and 
Qatar are five countries that have reported a perceived 
increase in the use of amphetamine-type stimulants over 
the past years.
In East and South-East Asia, the annual prevalence of 
amphetamines-group substances ranges between 0.2%-
1.4% of the adult population aged 15-64.12 Metham-
phetamine, both in pill and crystalline forms, is the 
main substance used within this group. The Philippines 
(2.1%), Thailand (1.4%) and the Lao People’s Demo-
cratic Republic (1.4%) are the countries in the subre-
gion with prevalence of methamphetamine use higher 
than the global average.
On average, the countries in South-East Asia in 2009 
reported a 250% increase in the number of metham-
phetamine-related arrests since 2004. The highest 
increase reported was from Lao People’s Democratic 
Republic, whereas Japan has reported a decline in meth-
amphetamine-related attests.13 
11 The countries and areas reporting increases in ATS use in 2009 
include China (and Macao, China), Indonesia, Lao People’s Demo-
cratic Republic, Malaysia, Myanmar and Viet Nam. On the other 
hand, Hong Kong China, Kazakhstan, the Republic of Korea and 
Lebanon have reported decreasing use of ATS.
12 In East and South-East Asia, most of the information on ampheta-
mines-group substances is available through the UNODC SMART 
programme that assists the countries in the region to monitor drug 
trends with a particular focus on use of amphetamine-type stimu-
lants.
13 UNODC Patterns and Trends of Amphetamine-Type Stimulants and 
Fig. 101: Trends in treatment demand for  
methamphetamine as the primary sub-
stance in Western Cape (Cape Town), 
South Africa, 2005-2009 (biannual data)
Source: Alcohol and Drug Abuse Trends: July – December, 
2009 (Phase 27), South African Community Epidemiology 
Network on Drug Use (SACENDU) Update June 2010.
Fig. 102: Percentage of ATS-group substances 
among primary substance of abuse in 
treatment in  Africa, 2009 or latest  
year available
Source: UNODC ARQ.
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The treatment demand for methamphetamine in East 
and South-East Asia has also increased considerably over 
the last decade. It rose from on average a quarter of all 
treatment demand in 1998 to nearly half of all treatment 
admissions in 2009. The treatment demand for meth-
amphetamine in 2009, or the latest year for which data 
is available, varied considerably across the countries and 
areas, ranging from nearly the entire treatment demand 
for methamphetamine use in Brunei Darussalam, the 
Republic of Korea and the Lao People's Democratic 
Republic to only 9% in Indonesia and Hong Kong, 
China.
Heroin and methamphetamine are the two common 
substances being injected in East and South-East Asia, 
with increasing trends reported of injecting metham-
phetamine in the subregion. In Thailand, injecting is the 
second most common method for using crystalline 
methamphetamine and the third most common method 
for abuse of methamphetamine pills.14 In 2009, Indo-
nesia reported an increasing trend in injecting heroin 
and crystalline methamphetamine, while Malaysia 
reported injecting of crystalline methamphetamine for 
the first time in 2009.15 As a consequence, many coun-
tries in East and South-East Asia also have concentrated 
HIV epidemics that are in large part driven by sharing 
of contaminated needles and syringes among the inject-
ing drug users. 
 
Other Drugs, Asia and Pacific, Global SMART Programme, 2010.
14 Pills are crushed, dissolved and injected.
15 UNODC, Patterns and Trends of Amphetamine-Type Stimulants and 
Other Drugs, Asia and Pacific, Global SMART Programme, 2010
Infection with the hepatitis C virus (HCV), another 
major health consequence of injecting, is also reportedly 
high in the countries of East and South-East Asia. 
Among the countries and areas that reported prevalence 
of HCV among injecting drug users, this ranged between 
50% in Macao, China to over 80% in Indonesia, Myan-
mar and Hong Kong, China.16
16 UNODC ARQ.
Fig. 103: Trends in methamphetamine-related 
arrests in selected countries in East 
and South-East Asia, 2004-2009
Source: UNODC, Patterns and Trends of Amphetamine-Type 
Stimulants and Other Drugs, Asia and Pacific, Global SMART 
Programme, 2010.
0
100
200
300
400
500
600
2004 2005 2006 2007 2008 2009
B
as
el
in
e 
(2
00
4)
Indonesia Japan
Republic of Korea Thailand
Lao PDR
9
9
12
19
22
27
55
59
82
90
95
98
99
0 20 40 60 80 100
Hong Kong, China
Indonesia
Malaysia
China
Taiwan, Prov. of China
Singapore
Japan
Philippines
Thailand
Cambodia
Lao PDR
Korea (Republic of)
Brunei Darussalam
Primary drug of abuse among those treated (%)
Fig. 104: Percentage of methamphetamine  
as the primary substance of abuse 
among those treated (%), 2009 or  
latest year available
Source: UNODC ARQ.
0
20,000
40,000
60,000
80,000
100,000
120,000
140,000
160,000
180,000
In
do
ne
si
a
Th
ai
la
nd
M
ya
nm
ar
C
am
bo
di
a
M
al
ay
si
a
V
ie
t 
N
am
Ph
ili
pp
in
es
N
u
m
b
er
 o
f 
ID
U
0
10
20
30
40
50
60
H
IV
 p
re
va
le
n
ce
 (
%
)
Injecting drug users
HIV among IDU (%)
Fig. 105: East and South-East Asia: Number  
of injecting drug users and HIV  
prevalence among IDU in selected 
countries, 2009 or latest year available
Source: United Nations Regional Task Force on Injecting Drug 
use and HIV and AIDS for Asia and the Pacific.
136
World Drug Report 2011 
Prevalence of amphetamines-group substances 
remains highest in Oceania but with declining 
trends in Australia and New Zealand
Oceania as a region reportedly has the highest preva-
lence rate of amphetamines-group substances, ranging 
between 2% to 2.8% of the population aged 15-64. 
Marshall Islands, Australia and New Zealand, with 
annual prevalence rates of 2.7%, 2.7% and 2.1% respec-
tively, remain the countries with the highest prevalence 
rates. The Pacific island states and territories in the 
region with available data report high prevalence rates of 
amphetamines-group substances.
The annual prevalence of meth/amphetamine use 
among the population aged 14 and above in Australia 
declined from 3.4% in 2001 to 2.3% in 2007. Although 
there is no updated information on annual prevalence of 
amphetamines use among the general population since 
2007, available information points to a continuing 
decline in the trends of amphetamines use reported 
through different indicators. 
Among Australian students aged 12-17 there has been a 
significant decline in both the lifetime and past month 
prevalence of amphetamines use from 2002 to 2005 and 
further to 2008.17 The lifetime prevalence among the 
students had declined to 3.7% in 2008 from the 6.6% 
reported in 2002.18
17 White V., Smith G., Australian secondary school students’ use of tobacco, 
alcohol, and over-the-counter and illicit substance in 2008, Drug Strat-
egy Branch, Australian Government Department of Health and 
Ageing, September 2009.
18 Like in other countries, the lifetime and past month prevalence of 
amphetamines use among students aged 16-17 is higher (6.2% and 
2.4% respectively) than those aged 12-15 years (2.7% and 1.2% 
respectively). 
The monitoring among detainees who were tested for 
drug use in Australia in 2008 revealed that 22% of 
detainees tested positive for methamphetamine use, 
down from 27% in 2007. This proportion was lower 
than at any point in time since 2000.19
Among the injecting drug users who were interviewed as 
part of the Illicit Drug Reporting System (IDRS), the 
19 Gaffney A., et al Drug Use Monitoring in Australia: 2008 Annual 
Report on drug use among police detainees, Australian Institute of 
Criminology, 2010
Fig. 106: Annual prevalence of amphetamines-
group substances in selected areas in 
Oceania, 2007/2008*
* In the case of New Zealand the estimates are for 2008, while  
for the rest of the countries they are from 2007.
Source: UNODC.
Fig. 107: Australia: Prevalence of amphetamine 
use among students, 2002, 2005 and 
2008
Source: Australian secondary school students’ use of tobacco, 
alcohol, and over-the-counter and illicit substance in 2008, 
Drug Strategy Branch, Australian Government Department of 
Health and Ageing, September 2009.
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Fig. 108: Australia: Proportion of detainees  
testing positive for use of ampheta-
mines, 2000-2008
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proportion of injecting drug users who had used any 
form of methamphetamine in the preceding six months 
declined each year between 2006 and 2010, and in 2010 
reached its lowest level since 2003. The proportion of 
injectors who had used methamphetamine in the pre-
ceding six months dropped from 79% in 2006 to 74% 
in 2007 and continued to decline to 67% in 2009 and 
60% in 2010.20
The prevalence of Hepatitis C among injecting drug 
users has remained stable at 61-62% over the period 
2005-2008 in Australia, and is lower among those who 
reported using methamphetamine compared to those 
who reported heroin as the last drug injected. The HIV 
prevalence has also remained low at 1.5% among inject-
ing drug users, but the prevalence is higher among drug 
users reporting methamphetamine as the last drug 
injected compared to those who reported last injecting 
heroin.21
The prevalence of amphetamines-group substances in 
New Zealand is among the highest in the world, where 
2.1% of the population aged 16-64 had used ampheta-
mine in the past year (2007/2008). Methamphetamine 
is also injected. About 0.5% of the population had used 
prescription stimulants for recreational purposes in the 
past year.22 As part of the drug use monitoring among 
arrestees in New Zealand (NZ-ADAM), amphetamines 
were reported as the second most common drug (10%) 
 
20 Illicit drug reporting system (IDRS), Australian Drug Trends 2010: 
Key Findings – Drug Trend Conference Handouts, Australian Govern-
ment Department of Health and Ageing.
21 National Centre in HIV Epidemiology and Clinical Research., Aus-
tralian NSP Survey National Data Report 2005-2009, The University 
of New South Wales, Sydney, 2010. 
22 Ministry of Health, Drug Use in New Zealand: Key Results of the 
2007/08 New Zealand Alcohol and Drug Use Survey, 2010.
after cannabis, followed by methamphetamine (9%) 
among those tested for drug use in 2008.23 
In contrast to Australia, methamphetamine use figures 
seem to be still rising in New Zealand. Among frequent 
injecting drug users the proportion of those who injected 
methamphetamine increased from 40% in 2006 to 50% 
in 2009. Frequent methamphetamine users, that is, 
those who had used the drug in the past 6 months, 
interviewed as part of Illicit Drug Monitoring System in 
New Zealand in 2009, were more likely to have injected 
methamphetamine in 2009 than in 2008 (35% vs. 
23%).24 
23 Hales J and Manser J., Annual report 2008- New Zealand Police NZ-
ADAM, Health Outcomes International Pvt. Ltd., October 2008.
24 Wilkins C., et al, Recent Trends in Illegal Drug Use in New Zealand, 
2006-20009: Findings from the 2006, 2007,2008 and 2009, Illicit 
Drug Monitoring System (IDMS), Massey University, July 2010.
Fig. 109: Australia: proportion of injecting drug users who reported use of methamphetamine  
in the preceding six months, 2003-2010
Source: Illicit drug reporting system (IDRS), Australian Drug Trends 2010: Key Findings – Drug Trend Conference Handouts, Australian 
Government Department of Health and Ageing.
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America has the highest prevalence rate of 1.4% of 
‘ecstasy’ use among the general population. 
Around 1.1 million people initiated their drug use with 
‘ecstasy’ in the United States in 2009, signalling a sig-
nificant increase over the previous year (894,000 people 
in 2008). Most (66.3%) of the ‘ecstasy’ users who had 
initiated in 2009 were aged 18 years or older, with an 
average age of 20.2 among those using ‘ecstasy’ for the 
first time in 2009.26
26 Substance Abuse and Mental Health Services Administration. (2010). 
Results from the 2009 National Survey on Drug Use and Health: Volume 
Since the decline in prevalence of ‘ecstasy’ use in 2002, 
the trends remained stable between 2003 and 2008, but 
began to register an increase in 2009.
A similar trend was observed among secondary school 
students, where the annual prevalence of ‘ecstasy’ use 
among students in the 8th, 10th and 12th grades, after 
having remained stable between 2003 and 2008, regis-
tered a clear increase over the 2008-2010 period, nota-
bly among the younger age groups, the 8th and 10th 
I. Summary of National Findings, Rockville, Maryland, USA.
Region/subregion
Estimated 
number of 
users annually 
(lower)
-
Estimated 
number of users 
annually (upper)
Percent of 
population 
age 15-64 
(lower)
-
Percent of 
population 
age 15-64 
(upper)
Africa
East Africa
North Africa
Southern Africa
West and Central Africa
390,000
190,000
-
-
1,900,000
300,000
0.1
0.2
-
-
0.3
0.4
Americas
Caribbean
Central America
North America
South America
3,770,000
20,000
20,000
3,210,000
520,000
-
-
-
-
-
4,020,000
240,000
30,000
3,210,000
530,000
0.6
0.1
0.1
1.1
0.2
-
-
-
-
-
0.7
0.9
0.1
1.1
0.2
Asia
Central Asia
East/South-East Asia
Near and Middle East
South Asia
2,390,000
1,480,000
-
-
17,330,000
6,920,000
0.1
0.1
-
-
0.6
0.5
Europe
East/South-East Europe
West/Central Europe
3,680,000
1,190,000
2,490,000
-
-
-
3,920,000
1,370,000
2,560,000
0.7
0.5
0.8
-
-
-
0.7
0.6
0.8
Oceania 850,000 - 920,000 3.6 - 4.0
Global 11,080,000 - 28,090,000 0.2 - 0.6
Table 32: Annual prevalence and estimated number of ‘ecstasy’ users, by region, subregion  
and globally, 2009
Region
Member  
States  
providing  
perception  
data
Member 
States  
perception 
response  
rate
Use  
problem 
increased*
Percent  
use  
problem 
increased*
Use  
problem 
stable
Percent  
use  
problem 
stable
Use  
problem 
decreased*
Percent  
use  
problem 
decreased*
Africa 3 6% 1 33% 2 67% 0 0%
Americas 6 17% 1 17% 5 83% 0 0%
Asia 17 38% 6 35% 3 18% 8 47%
Europe 24 53% 8 33% 13 54% 3 13%
Oceania 1 7% 0  1  0  
Global 51 27% 16 31% 24 47% 11 22%
*Identifies increases/decreases ranging from either some to strong, unweighted by population.
Table 33: Expert perceptions of trends in ‘ecstasy’ use, 2009
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graders.27 US data among high school students did not 
indicate any increase in the availability of ‘ecstasy.’ The 
increase of ‘ecstasy’ use went, however, hand in hand 
with reduced risk perceptions of the harmfulness of 
using the substance. 
By contrast, in Canada, ‘ecstasy’ use declined in 2009 
compared to the previous year. The annual prevalence of 
‘ecstasy’ use among the population aged 15-64 was 
reported at 1.1% in 2009, down from 1.7% in 2008.28 
The annual prevalence among young people, aged 
15-19, was 3% in 2009.29
For Mexico there are no recent quantitative estimates on 
‘ecstasy’ use. Expert perceptions indicate an increasing 
‘ecstasy’ use trend in the country.
In Central and South America, ‘ecstasy’ use remains 
low in the general population but higher among 
youth.
There is no update on ‘ecstasy’ use in Central and South 
America. Available information suggests, however, that 
the annual prevalence among the general population 
remains much lower in these subregions than the world 
average, ranging between 0.1% in Chile and 0.5% in 
Argentina. El Salvador, Peru and Trinidad and Tobago 
reported a perceived increase in ‘ecstasy’ use over the 
past year. As in other countries, information on ‘ecstasy’ 
27 Johnston, L. D., et al., Monitoring the Future national results on ado-
lescent drug use: Overview of key findings, 2010, Institute for Social 
Research, The University of Michigan, Ann Arbor, Michigan, USA.
28 UNODC ARQ.
29 For prevalence among youth, Canada reported only the annual preva-
lence among young people in 2008 as 6.2% among young people 
aged 12-17, while in 2009, the annual prevalence was reported at 
4.5% and last year prevalence at 3% among those aged 15-19.
use among school children in South and Central Amer-
ica shows much higher prevalence rates than for the 
general population. The latest information (2008 or 
2009) on lifetime prevalence of ‘ecstasy’ shows the prev-
alence rates ranging from 0.5% in the Bolivarian Repub-
lic of Venezuela to 3.7% in Chile. 
In Brazil, the annual prevalence of ‘ecstasy’ use accord-
ing to a national survey conducted among university 
students in 2009 was 3.1%, clearly exceeding UNODC’s 
general population estimates of around 0.2%. Like in 
the rest of the world, ‘ecstasy’ use was found to be more 
common among male than female students. The annual 
and past 30 days prevalence was higher among students 
aged 18-24 than for any other age group.30 
30 Andrade, A.G., Duarte, P. and Oliveira, L.G., I Levantamento Nacio-
Fig. 111: United States: Trends in prevalence of 
‘ecstasy’ use among the population 
aged 12 years or older, 2002-2009
Source: Substance Abuse and Mental Health Services Adminis-
tration, Results from the 2009 National Survey on Drug Use 
and Health: Volume I. Summary of National Findings.
Fig. 112: United States: Trends in annual  
prevalence of ‘ecstasy’ use among 
secondary school students, 2002-2010
Source: Monitoring the Future: national results on  
adolescent drug use: Overview of key findings, Institute for 
Social Research, The University of Michigan, USA.
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‘Ecstasy’ use is reported to be stabilizing in Europe, 
but use patterns are becoming more polarized 
among club-goers and the general population
The annual prevalence of ‘ecstasy’ use in Europe is esti-
mated at 0.7% of the adult population. Between 3.7 and 
4 million people aged 15-64 years used ‘ecstasy’ in the 
past year in Europe. The ‘ecstasy’ use prevalence rate is 
still higher in West and Central Europe (0.8%) than in 
East and South-East Europe (0.6%). 
Most of the countries in Europe are now reporting sta-
nal Sobre O Uso De Álcool, Tabaco E Outras Drogas Entre Universi-
tarios Das 27 Capitais Brasileiras, Secretaria Nacional Politicas sobre 
Drogas, Brasilia 2010.
bilizing trends of ‘ecstasy’ use. Updated or new estimates 
for ‘ecstasy’ use were available from some countries in 
Europe, including Belgium, Cyprus, Germany, Spain 
Sweden and the United Kingdom (England and Wales, 
and Scotland). Many of these countries have reported a 
decline in the annual prevalence in their current surveys 
compared to previous years. This is in line with reports 
of manufacturing difficulties in a number of European 
countries in recent years, and thus the use of various 
other substances than MDMA in ‘ecstasy’ tablets. The 
Czech Republic, Latvia, Slovakia and the United King-
dom remain countries with high ‘ecstasy’ use prevalence 
rates in the general population.
Like in other parts of the world, most of the ‘ecstasy’ 
users are young people aged 15-34. The EMCDDA in 
its annual report for 2010 mentions that practically all 
of the estimated 2.5 million ‘ecstasy’ users who had used 
‘ecstasy’ in the past year were between 15 and 34 years 
old. 
Targeted surveys in nightlife settings in European coun-
tries suggest that the prevalence and patterns of stimu-
lants and ‘ecstasy’ use, together with alcohol, remains 
high. Some studies even suggest that drug use patterns 
among club-goers are becoming increasingly ‘polarized,’ 
that is, showing ever higher prevalence rates, in sharp 
contrast to the situation among the general population.31
Lack of information from Africa makes it difficult 
to determine any trends in ‘ecstasy’ use in the region
Based on very limited country information, the an - 
nual prevalence of ‘ecstasy’ use – based on UNODC’s 
31 EMCDDA, The State of the Drugs Problem in Europe: Annual Report 
2010, 2010.
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Fig. 115: Europe: trends in ‘ecstasy’ use in selected countries and areas, various years
Source: EMCDDA; UNODC ARQ.
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standard model - is estimated between 0.1% and 0.3% 
in Africa. The actual figures are probably closer to the 
lower end of the range or perhaps even below that range, 
as ‘ecstasy’ use in Africa is still primarily a phenomenon 
of youth from the upper classes and/or concentrations in 
some tourist resorts where the prime target group is 
foreigners from overseas. The wide range in the esti-
mates is due to missing data or information on ‘ecstasy’ 
use from most of the region. Only three countries in 
Africa - Algeria, Morocco and South Africa - reported 
expert opinions on ‘ecstasy’ use trends through the ARQ 
in 2009. While Morocco reported an increase in ‘ecstasy’ 
use, Algeria and South Africa reported stabilizing trends 
for 2009.
Mixed trends on ‘ecstasy’ use reported from Asia 
In 2009, nearly half (47%) of the Asian countries report-
ing expert opinion on ‘ecstasy’ use through the ARQ 
considered its trends to be decreasing, while one third of 
the countries reported increasing trends in the past year. 
The annual prevalence of ‘ecstasy’ use in Asia is esti-
mated between 0.1% and 0.6% of the population aged 
15-64, or some 2.4 to 17 million people who could have 
used ‘ecstasy’ at least once in the previous year. The wide 
range in the estimates reflects the uncertainty due to lack 
of information on ‘ecstasy’ use for most parts of Asia.
‘Ecstasy’ use in New Zealand and Australia  
remains high
Oceania (primarily Australia and New Zealand) has the 
highest prevalence of ‘ecstasy’ use in the world, with 
annual prevalence ranging from 3.6% to 4% of the adult 
population. This corresponds to between 850,000 and 
920,000 people who had used ‘ecstasy’ at least once in 
the preceding year.
The annual prevalence of ‘ecstasy’ use among the popu-
lation aged 16-64 in New Zealand ranged from 2% to 
3%, or an estimated 67,000 people which reported 
having used ‘ecstasy’ in the previous year (2007/2008). 
The highest prevalence, like in other countries, was 
reported among the 18-24 year age group; higher among 
men than women (annual prevalence of 8.9% among 
men and 4.9% among women in this age group). Most 
of the ‘ecstasy’ users in New Zealand were reported to 
have used it with alcohol (78.9%), cannabis (42.8%) 
and benzylpiperazine (BZP) party pills32 (13.5%).33
In Australia, ‘ecstasy’ use was estimated at around 4.2% 
of the population aged 15-64 in 2007. Since then, there 
has been no update on drug use prevalence in Australia. 
However, in 2010, a survey carried out among 974 ath-
letes indicated that one quarter had been offered or had 
the opportunity to use ‘ecstasy’ in the past 12 months. 
This was a higher proportion than for cannabis (22%) 
and cocaine (17%). Past year ‘ecstasy’ use was reported 
by 3.2% of the sample.34
32 Products containing benzylpiperazine (BZP) and related substances, 
with stimulant and euphoric effects.
33 Ministry of Health Drug Use in New Zealand: Key Results of the 
2007/08, New Zealand Alcohol and Drug Use Survey, 2010.
34 Dunn, M. and Thomas, J.O., ‘Attitudes toward, knowledge of, and 
prevalence of recreational drug use among elite Australian athletes,’ 
EDRS Drug Trends Bulletin, April 2010, Sydney: National Drug and 
Alcohol Research Centre, University of New South Wales.
Decrease Stable Increase
China Korea  (Republic of) Armenia
Hong Kong, 
China Kuwait Georgia
Macao, China Malaysia Israel
Indonesia Lebanon
Japan Pakistan
Kazakhstan Viet Nam
Singapore
Thailand
Table 34: Asia: countries and areas reporting  
expert perception in ‘ecstasy’ use in 
2009
Source: UNODC ARQ.
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In 2009, the global number of methamphetamine labo-
ratories increased significantly, by 22%, to almost 
10,200, up from 8,300 in 2008. The numbers of 
reported methamphetamine laboratories have continued 
to increase since 2007, but are still significantly lower 
than their peak in 2004. While the overall number of 
dismantled methamphetamine laboratories increased at 
the global level in 2009, the increase was largely concen-
trated in the United States. The number of dismantled 
(and reported) laboratories outside the United States 
declined in 2009 from a year earlier, but was still at the 
second highest level so far. 
Significant manufacturing locations
Methamphetamine is manufactured in all North Ameri-
can countries. Over the last decade - and notably in 
2009 - Mexico has become an important manufacturing 
location. In 2009, Mexico reported the dismantling of 
191 laboratories, up from 21 in 2008. The upward trend 
in manufacturing appears to have continued in 2010, 
with 63 laboratories dismantled up to May 2010.37 
While the number of laboratories seized in Mexico is 
still substantially lower than in the United States, the 
Mexican operations tend to manufacture large quanti-
ties of end products, whereas many laboratories in the 
United States appear to be manufacturing the substance 
on a far smaller scale. There are also increasing incidents 
of methamphetamine-related manufacturing occurring 
throughout Central and South America. In 2010, for 
instance, authorities in Nicaragua dismantled a large 
clandestine methamphetamine laboratory. 
Another important region in terms of illicit metham-
phetamine manufacture is East and South-East Asia, 
37 US Department of State, International Narcotics Control Strategy 
Report, March 2011.
where a significant number of clandestine metham-
phetamine laboratories have been dismantled over the 
past several years.38 Previously, illicit ATS manufactur-
ing laboratories were primarily large industrial-scale 
operations. In recent years, however, several countries 
reported seizures of a significant number of smaller 
laboratories, a trend that continued in 2009. 
China reported the seizure of 391 clandestine synthetic 
drug laboratories and storage facilities in 2009. Most of 
these were in Guangdong, Sichuan and Hubei provinces 
and were primarily manufacturing crystalline metham-
phetamine and ketamine. In 2008, a total of 244 
unspecified laboratories were dismantled in China. ATS 
manufacture is becoming increasingly diversified in 
China with different stages of manufacturing being 
divided across provinces. 
Indonesia seized 35 clandestine synthetic drug-manufac-
turing laboratories in 2009, the highest figure reported 
to date. These included 25 large-scale and 10 small-scale 
laboratories. 
Clandestine ATS manufacture in Hong Kong, China 
has been dominated by tableting and repackaging oper-
ations. In 2009, two small-scale manufacturing facilities 
for crystalline methamphetamine were reported in Hong 
Kong, China.39 
Over the past five years, Malaysia has become a signifi-
cant methamphetamine manufacturing location. In 
38 For East and South-East Asia, most ATS data is available through the 
UNODC Global Synthetics Monitoring: Analyses, Reporting and 
Trends (SMART) Programme, which assists countries in the region 
in the monitoring of drug trends, with a particular focus on ATS. 
39 UNODC, Patterns and trends of amphetamine-type stimulants and 
other drugs- Asia and the Pacific, Global SMART Programme, 
November 2010.
Fig. 116:  Total number of ATS laboratory incidents, 1999-2009
Source: UNODC DELTA.
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2009, 11 clandestine ATS manufacturing laboratories 
were seized. Most of the laboratories were located in 
Kuala Lumpur and southern Malaysia.40 
In the Philippines, illicit manufacture of crystalline 
methamphetamine was first reported in 1996, and in 
1997, the first industrial-scale clandestine manufactur-
ing facility was reported. The manufacture of crystalline 
methamphetamine continues in the Philippines, with 9 
manufacturing laboratories detected in 2009. Clandes-
tine methamphetamine manufacturing laboratories have 
been seized across the country in recent years and have 
been located in both rural and urban areas. The labora-
tories have also shifted from large and medium-sized 
facilities in previous years to smaller ‘kitchen type’ facil-
ities in 2009.41 In 2009, most of the seized clandestine 
laboratories were again located in urban areas.42 
Myanmar main source of methamphetamine pills  
in South-East Asia 
Myanmar is the primary source of the region’s metham-
phetamine in pill form. Reported seizures of clandestine 
manufacturing laboratories in Myanmar in previous 
years have mainly consisted of tableting operations. This 
is inconsistent, however, with the vast number of pills 
seized throughout the region. Extensive forensic profil-
ing of methamphetamine seized in Thailand suggests 
that there are likely 12 large-scale methamphetamine 
manufacturing operations in the ‘Golden Triangle’ 
40 UNODC, Patterns and trends of amphetamine-type stimulants and 
other drugs- Asia and the Pacific, Global SMART Programme, 
November 2010.
41 Communication with the Philippine Drug Enforcement Agency, 
August 2010.
42 Philippine Drug Enforcement Agency, Philippine National ATS 
Situation 2008-2009, presented at the Global SMART Programme 
Regional Workshop, Bangkok, 5-6 August 2010. 
region. While there have been no facilities seized for 
crystalline methamphetamine manufacture, authorities 
in both Myanmar and Thailand confirm that manufac-
ture occurs in Myanmar and has been the source of most 
crystalline methamphetamine seized in the northern 
part of Thailand in the past few years.
In Japan, the illicit manufacture of ATS is rare. In June 
2010, however, police arrested two nationals of the 
Islamic Republic of Iran on suspicion of manufacturing 
methamphetamine. This was the first such incident in 
the country since 1995. 
Australia and New Zealand report methampheta-
mine manufacture; little data from the Pacific Island 
states and territories
In Oceania, ATS manufacture has been reported from 
Australia and New Zealand. Australia reported the dis-
mantling of 316 ATS manufacturing laboratories in 
2009. Most of the laboratories were identified as manu-
facturing methamphetamine and amphetamine. New 
Zealand reported that a total of 135 laboratories were 
dismantled in 2009, primarily for methamphetamine. 
Further increases in the number of laboratories might be 
recorded in 2010 due to the increased efforts of the 
Government of New Zealand to tackle methampheta-
mine.43 
Little data is available from the Pacific Island states and 
territories, which remain vulnerable to illicit manufac-
ture of amphetamine-type stimulants, given the fact that 
several of the countries are not parties to the 1988 
United Nations Convention Against Illicit Traffic in 
Narcotic Drugs and Psychotropic Substances.44
43 Monthly Illicit Drug Assessment, National Drug Intelligence Bureau 
(NDIB), Wellington, January 2010.
44 These include Kiribati, Nauru, Palau, Papua New Guinea, Solomon 
Fig. 117: Number of reported methamphetamine laboratory incidents, 1999-2009 
 Source:  UNODC DELTA.
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Level of methamphetamine manufacture in Europe 
comparatively low
Compared to most other regions of the world, illicit 
manufacture of methamphetamine in Europe is fairly 
low. Until recently, methamphetamine manufacture was 
largely confined to the Czech Republic, where some 
300-400 mostly small-scale manufacturing sites are 
being dismantled every year. These are so-called kitchen 
laboratories, which typically manufacture a few grams of 
drugs at a time. Seizures of methamphetamine manufac-
turing facilities were also reported to Europol in neigh-
bouring countries such as Slovakia, Germany, Poland 
and Austria. The second hub of methamphetamine 
supply is centred around the Baltic countries, particu-
larly Lithuania and Estonia.45 
Methamphetamine manufacture is rarely reported from 
Africa, except for South Africa and Egypt. In 2009, 10 
methamphetamine laboratory incidents were reported 
from South Africa, compared to 20 such incidents 
reported for 2008.
The global number of dismantled amphetamine  
laboratories remains stable
In 2009, 44 amphetamine laboratories were reported, 
remaining essentially stable compared to 2008. Most of 
these laboratories continue to be reported in Europe, 
particularly West, Central and East Europe.
According to the European Monitoring Centre on 
Drugs and Drug Addiction, most amphetamine seized 
in Europe is manufactured, in order of importance, in 
the Netherlands, Poland and Belgium, and to a lesser 
extent in Estonia, Lithuania and the United Kingdom. 
In 2007, 29 sites involved in the production, tableting 
or storage of amphetamine were discovered in the Euro-
pean Union and reported to Europol. 
The relatively low number of amphetamine laboratories 
reported is inconsistent with the high number of global 
amphetamine seizures which have continued to rise over 
the past two years.
Increase in seizures of precursors for  
methamphetamine and amphetamine manufacture
Ephedrine and pseudoephedrine are the main precursors 
for methamphetamine and both substances are control-
led in Table I of the 1988 United Nations Convention 
Against Illicit Traffic in Narcotic Drugs and Psycho-
tropic Substances. Seizures of these precursors can pro-
vide some indications about manufacturing trends. In 
2009, 41.9 mt of ephedrine and 7.2 mt of pseudoephe-
drine were seized, compared to 18.2 mt of ephedrine 
Islands and Tuvalu, status as of 7 April 2011.
45 EMCDDA, Amphetamine and methamphetamine use in Europe, 
Lisbon, November 2010.
and 5.1 mt of pseudoephedrine in 2008.46 Recently, 
there has been a shift from bulk substances to pharma-
ceutical preparations used in the illicit manufacture of 
methamphetamine.
46 International Narcotics Control Board, Precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs and psychotropic 
substances, E/INCB/2010/4, March 2011.
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Fig. 118: Number of seized amphetamine  
laboratories, 1999-2009 
Source: UNODC ARQ.
Fig. 119: Global seizures of ephedrine and 
pseudoephedrine, 2005-2009* 
* The chart is based on data on domestic seizures and on seizures 
effected at points of entry or exit. They do not include reported 
seizures of substances where it is known that the substances were 
not intended for the illicit manufacture of drugs. Stopped ship-
ments are also not included.
Source: INCB.
0
10,000
20,000
30,000
40,000
50,000
60,000
2005 2006 2007 2008 2009
Q
u
an
ti
ty
 [
kg
]
Ephedrine Pseudoephedrine
150
World Drug Report 2011 
Traffickers adopt alternative strategies to evade 
stricter control measures
As awareness, restrictions and enforcement against illicit 
ATS manufacture increases, manufacturing operations 
tend to move to more vulnerable countries. When con-
trols over precursors were strengthened in the United 
States, manufacture shifted to Mexico. As Mexico has 
responded with strong counter-methamphetamine ini-
tiatives, manufacturing activities are increasingly 
reported from countries in Central and South America. 
Traffickers also resort to substitute chemicals. As Gov-
ernments have restricted the availability of ephedrine 
and pseudoephedrine, some traffickers could turn to 
other chemicals such as norephedrine which can replace 
these two chemicals with only slight modifications to 
the illicit manufacturing process. Traffickers have also 
attempted to divert the ephedra plant - a natural source 
of ephedrine - for illicit ATS manufacture. In addition, 
there have been reports that traffickers transform exist-
ing precursors into new uncontrolled chemicals, which 
are subsequently converted back to the original precur-
sor chemical once in the final destination country. 
A precursor chemical commonly used in the illicit man-
ufacture of methamphetamine and amphetamine is 
1-phenyl-2-propanone (P-2-P). The diversion of this 
chemical may be fuelling the market for amphetamine 
in the Near and Middle East, where amphetamine is 
often sold as Captagon on illicit markets. In 2009 and 
2010, Jordan reported the world’s highest annual legiti-
mate requirement of P-2-P to the International Narcot-
ics Control Board, accounting for half of the global 
total. The high legitimate need is based on the pur-
ported formulation of P-2-P into cleaning and disinfec-
tion products. The volume represents a significant risk 
of diversion into illicit manufacture, however, particu-
larly as P-2-P is not an essential ingredient in the formu-
lation of cleaning and disinfection products and 
alternative chemicals exist. 
Number of reported ecstasy-group laboratories 
remains essentially stable
In 2009, 52 ecstasy-group laboratories were reported, 
compared to 53 in 2008. The highest number of dis-
mantled laboratories was reported from Asia and Oce-
ania, namely Indonesia (18) and Australia (19). This 
might indicate that Indonesia has replaced Europe as the 
main source for ‘ecstasy’ used in South-East Asia. 
In the past, ecstasy-group substances used to be manu-
factured predominantly in West Europe. Manufacture 
peaked in 2000, when 50 laboratories were reported as 
having been dismantled in Europe. Since that time, 
however, manufacture of ecstasy-group substances has 
shifted away from the region to a number of other mar-
kets around the world. Large-scale manufacturing oper-
ations are more frequently being dismantled in East and 
South-East Asia, the Americas and Oceania. In 2008, 
only four laboratories were reported from Europe; for 
Notable ephedrine & pseudoephedrine
trafficking route cases
Routes identified in 2008-2010
Established trafficking routes
Note: The boundaries and names shown and the designations used on this map do not imply official endorsement or acceptance by the United Nations. Lines represent origin and intended destination, not necessarily exact 
route, and include completed or stopped trafficking attempts. Modes of transport include by air, sea, overland, or any combination thereof.
Other government sources include: ACC (2010), DEA-ODC (2008), INSCR (2011), NDIB (2009), RCMP (2010 and previous years) and WCO (2010 and previous years)
Map 34: Routes of notable ephedrine/pseudoephedrine diversion, 2008-2010
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2009, there was only one reported to have been seized 
in Belgium.
Shift in ecstasy manufacture
Manufacture of ecstasy increasingly takes place in 
regions other than Europe, such as East and South-East 
Asia, North America, Oceania and Latin America. Illicit 
manufacture of ecstasy has been reported in Argentina, 
Belize, Brazil, Guatemala, Mexico and Suriname. In 
Brazil, a small-scale laboratory was seized in 2008 and 
another, more commercial-size operation in 2009, which 
included the seizure of 20,000 tablets.47 
Precursors for ecstasy-group substances include safrole 
(including in the form of safrole-rich oils), isosafrole, 
piperonal, and 3,4—MDP-2-P, which are all controlled 
in Table 1 of the 1988 United Nations Convention 
Against Illicit Traffic in Narcotic Drugs and Psycho-
47  UNODC, Global SMART Update, vol.2, October 2009.
tropic Substances. Reported global seizures of these 
precursors have strongly declined, reflecting the declin-
ing availability of ecstasy in Europe, one of the main 
markets for the substance.
However, in January 2010, authorities in Australia 
uncovered the country’s first clandestine laboratory for 
the domestic extraction and processing of safrole-rich oil 
for the manufacture of ‘ecstasy’. 
Significant increase in other synthetic drug  
manufacture incidents 
For the first time, the number of other synthetic drug 
manufacture incidents reported to UNODC through 
the ARQ has surpassed those of ‘ecstasy’. This is due to 
a significant number of incidents relating to unspecified 
ATS precursors reported from the United States. Such 
cases also appear to occur in other parts of the world.
Fig. 120: Distribution of global annual legitimate 
requirement for P-2-P, 2010
Source: INCB.
Fig. 121: Number of seized ecstasy-group  
laboratories by region, 1999-2009
Source: UNODC DELTA.
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
ATS precursors 0 5 0 0 2 0 0 22 1 3 40
Fentanyl 0 0 0 0 0 0 0 1 1 1 0
Gamma-Hydroxybutyric 
acid (GHB)
0 1 0 9 21 17 8 10 8 12 9
Ketamine 0 0 0 0 0 0 0 0 44 0 0
Lysergic acid  
diethylamide (LSD)
1 1 1 0 1 0 1 1 1 0 1
Methaqualone 0 4 5 6 15 16 5 3 4 1 4
Phencyclidine (PCP) 1 1 4 6 16 0 11 4 0 16 7
Total 2 12 10 21 55 33 25 41 59 33 61
Table 35: Other synthetic drug manufacture incidents, 1999-2009 
Source: UNODC DELTA.
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The number of GHB laboratory incidents decreased 
from 12 in 2008 to 9 in 2009. No ketamine laboratory 
was reported through the ARQ. As ketamine is not 
under international control, however, the extent of man-
ufacture is probably underreported. Government sources 
in China indicate that ketamine laboratories are regu-
larly dismantled in that country. 
Seizures of precursors used in the  
illicit manufacture of ATS
Chemical precursors are necessary for the synthesis of 
amphetamine-type stimulants, and many of the chemi-
cals are controlled internationally through the 1988 
United Nations Convention Against Illicit Traffic in 
Narcotic Drugs and Psychotropic Substances. Their 
seizures are reported to the International Narcotics Con-
trol Board and can provide some indications about 
trends in illicit manufacture.
Seizures in 2009 included:
Amphetamines-group
 • Methamphetamine: 41,931 kg of ephedrine and 
7,241 kg of pseudoephedrine, suﬃcient to manufac-
ture 32.7 mt of methamphetamine.
 • Amphetamine: 4,885 litres of phenyl-2-propoanone 
(P-2-P), suﬃcient for 2.4 mt of amphetamine or 
methamphetamine.
 • 195 kg of norephedrine, suﬃcient to manufacture 
130 kg of amphetamine.
Ecstasy-group
 • 40 litres of 3,4-MDP-2-P, enough to manufacture 33 
kg of MDMA;
 • 1048 l of safrole oil, suﬃcient to manufacture 222 kg 
of MDMA;
 • 4.3 mt of piperonal which could be converted into 
1.6 mt of MDMA; and
 • 5 l of isosafrole, which could be used in the manufac-
ture of 2.36 kg of MDMA.
The low amounts of precursor chemicals seized are 
inconsistent with the size of the consuming market, sug-
gesting that much of the trafficking of precursors needed 
for ATS manufacture goes undetected. Criminal organi-
zations adopt several strategies to avoid control by traf-
ficking precursors through new locations, such as Africa, 
by relocating manufacturing operations to new coun-
tries and by changing precursor chemicals. 
Seizure data for precursors can only provide a partial 
picture of precursor availability. Diversions and stopped 
shipments are not included in the traditional seizure 
statistics, neither are domestic diversions followed by 
onward smuggling. 
These figures largely represent raw chemical seizures and 
in some cases pharmaceutical preparations, and thus are 
not representative of all precursors seized.
No amphetamines-group seizures
reports (2005-2009)
Amphetamines-group seizures (2005 - 2009)
Main routes
  Methamphetamine
  Amphetamine
Other/ notable routes
   Methamphetamine
   Amphetamine
Methamphetamine
Amphetamine
Amphetamines-group seizures
Known notable locations of
manufacture/tableting
Notable trafficking routes
Other government sources include: ACC (2010), DCHIRI (2008), ICPO (2010), INSCR (2011), JNPA (2010), LDECB (2008), RCMP (2010), TKOM (2008-2009), and WCO (2010)
Note: The boundaries and names shown and the designations used on this map do not imply official endorsement or acceptance by the United Nations. Lines represent origin and intended desnaon, not necessarily exact 
route, and include completed or stopped traﬃcking aempts. Modes of transport include by air, sea, overland, or any combinaon thereof.
Map 35: Notable locations of manufacture and main trafﬁcking routes of ATS
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No ecstasy seizures reported to
UNODC (2005-2009)
Ecstasy seizures reported to
UNODC (2005-2009)
Note:  The boundaries and names shown and the designations used on this map do not imply official endorsement or acceptance by the United Nations. Lines represent origin and intended desnaon, not necessarily exact 
route, and include completed or stopped traﬃcking aempts. Modes of transport include by air, sea, overland, or any combinaon thereof.
Main routes
Other/ notable routes
Notable trafficking routesKnown notable sources of 
manufacture/ tableting
Ecstasy-group 
Ecstasy-group seizures
Other government sources include: ACC (2010), DCHIRI (2008), ICPO (2010), INSCR (2011), JNPA (2010), LDECB (2008), RCMP (2010), TKOM (2008-2009), and WCO (2010)
Map 36: Notable locations of manufacture and main trafﬁcking routes of ecstasy-group substances
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4.4 Trafficking
Global ATS seizures
In 2009, global seizures of ATS rose significantly (by 
16%), slightly exceeding the high level of 2007 (follow-
ing a dip of 9% in 2008). The increase was driven by the 
quantities of seized methamphetamine, which rose 
markedly to 31 mt (from 22 mt in 2008) and ampheta-
mine, which rose more moderately (33 mt, up from 30 
mt in 2008). Seizures of ecstasy amounted to 5.4 mt, 
remaining below the reduced level of 2008. The increases 
in methamphetamine and amphetamine were also partly 
offset by a drop in seizures of non-specified ampheta-
mines, so that total ATS seizures in 2009 amounted to 
71 mt. Due to the paucity of data from some countries, 
the decline in non-specified amphetamines is not statis-
tically significant, and the total for amphetamine, meth-
amphetamine and ecstasy rose by 22% in 2009.
Seizures of amphetamine-type stimulants are reported 
by weight (in kg), by volume (in litres, usually when the 
seized drugs are in liquid form) and by number of tab-
lets, doses or ‘units’. Although UNODC maintains and 
publishes records to reflect - as closely as possible - sei-
zure quantities as reported by countries, it is often useful 
to aggregate data of different types to compare over time 
or across countries and regions. For the purposes of this 
aggregation, conversion factors are used to convert the 
quantities into ‘kilogram equivalents.’
The aggregate statistics used in this report depend on 
the conversion factors used, and the impact of these 
conversion factors can be especially pronounced in the 
case of amphetamine-type stimulants, as a significant 
share of seizures of these drug types are quantified by 
number of tablets. In previous editions of the World 
Drug Report the conversion factors used were intended 
to reflect the amount of psychoactive ingredient in the 
seized tablets. In order to enhance the comparability 
with seizures reported by weight, which are quantified 
by bulk weight and can only be adjusted for purity in a 
minority of cases where the availability of data allows, 
UNODC has revised the conversion factors used for 
amphetamine-type stimulants to reflect the bulk weight 
of the seized tablets. The new factors are based on foren-
sic studies and range between 90 mg and 300 mg per 
tablet, depending on the region as well as the drug type. 
These factors are subject to revision as the available 
information improves; details can be found in the meth-
odology section. 
Although trafficking in and consumption of ampheta-
mine-type stimulants has come to affect all regions of 
the world, different types of ATS prevail in different 
regions. In past years, seizures of ATS in Europe have 
been dominated by ecstasy and amphetamine; however, 
ecstasy seizures in Europe fell sharply between 2007 and 
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2009, while methamphetamine seizures reached a record 
level by European standards in 2009. Ecstasy accounted 
for only 10% of ATS seizures in Europe in 2009, 
compared with 6% for methamphetamine. In North 
America, seizures continue to be dominated by metham-
phetamine and ‘ecstasy’. In relative terms, seizures of 
‘ecstasy’ remained important also in Central and South 
America and the Caribbean, although the majority of 
reported ATS seizures in this region consisted of amphet-
amine in 2009. The market in Oceania remained diver-
sified among the various types of amphetamine-type 
stimulants. In the Near and Middle East/South-West 
Asia, seizures of amphetamine-type stimulants are 
mainly in the form of Captagon, believed to contain 
amphetamine as the main psychoactive ingredient. 
Methamphetamine seizures have been reported from 
Nigeria and South Africa. For 2009, however, only 
South Africa reported seizures of methamphetamine, 
out of a total of four African countries reporting any 
ATS seizures in the ARQ. Approximately one half of the 
ATS seized in Africa referred to amphetamine. The pau-
city of the data thus does not allow for a reliable charac-
terization for the continent as a whole. 
Fig. 123: Seizures of ATS by type
Source: UNODC DELTA.
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North America: Increase in the supply  
of methamphetamine
In 2009, North America accounted for 44% of global 
seizures of methamphetamine, due to continued high 
seizures in the United States (7.5 mt, compared with 7.4 
mt in 2008) as well as a sharp increase in methampheta-
mine seizures in Mexico, which reached a comparable 
level (6.1 mt, up from 341 kg in 2008). This was in 
sharp contrast to prior years; over the period 2001-
2008, annual seizures in the United States ranged 
between 5 and 21 times the level in Mexico.
Methamphetamine in the United States’ consumer 
market continued to be supplied by manufacture of 
methamphetamine in Mexico as well as the United 
States. Following a substantial decline in 2007, the avail-
ability of methamphetamine in the United States appears 
to have rebounded. According to the United States 
Department of Justice,48 methamphetamine availability 
in the United States seems to be directly related to meth-
amphetamine production trends in Mexico. The decline 
in availability in 2007, possibly triggered by more strin-
gent import restrictions of methamphetamine precur-
sors in Mexico, was reflected in reduced seizures and 
48 US Department of Justice, National Drug Threat Assessment 2010, 
February 2010.
Fig. 125: Methamphetamine laboratories and seizures of methamphetamine in the United States  
and Mexico, 2001-2009
Sources: UNODC DELTA; US Department of Justice.
Fig. 126: Mean price and purity of methamphetamine purchases by law enforcement agencies  
in the United States, 2006-2009
Source: UNODC ARQ.
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increased prices, and may have led to an increase in 
manufacture of methamphetamine in the United States. 
The number of methamphetamine laboratories detected 
in the United States rose from 3,049 in 2007 to 3,873 
in 2008 and 5,286 in 2009. The increase was mainly 
attributable to the number of small-scale laboratories. 
Moreover, some Mexican drug trafficking organizations 
shifted their production operations from Mexico to the 
United States, particularly to California.
Since 2007, manufacture of methamphetamine in 
Mexico appears to have grown significantly. Mexico 
reported 191 methamphetamine laboratories in 2009, 
up from 21 in 2008. In 2009, the laboratories were 
discovered in the central Pacific region (in particular, the 
states of Michoacan, Jalisco and Sinaloa). Between 2007 
and 2009, seizures of methamphetamine by United 
States authorities along the border with Mexico increased 
by at least 87%, as the partial total for 2009 amounted 
to 3,478 kg (compared with 1,860 kg in 2007).49 The 
increased availability in the United States is also visible 
in price and purity data. Between the fourth quarter of 
2007 and the fourth quarter of 2009, the average price 
per pure gram of methamphetamine followed a gener-
ally decreasing trend, falling from US$284 to US$119, 
while the average purity followed a distinct increasing 
trend, rising from 39% to 72%.50 
The rising purity and falling price are, however, also due 
to a less potent product being manufactured – a racemic 
‘d/l methamphetamine’. The loss in potency of this infe-
rior product can, however, be compensated by higher 
purity levels – and this is currently happening. It appears 
that the reduced availability of ephedrine and pseu-
doephedrine (which would be required for the manufac-
ture of the more potent ‘d-methamphetamine’) in 
Mexico had led to an increased use of alternative meth-
ods for the manufacture of methamphetamine. Such 
techniques either synthesize these chemicals from others 
more easily available or bypass their use entirely, employ-
ing for example the 1-phenyl-2-propanone (P-2-P) 
method, or its pre-precursor, phenylacetic acid (PAA). 
The product obtained from the use of PAA or P-2-P is 
a less potent racemic ‘d/l methamphetamine,’ unless an 
additional purification step is added on to obtain again 
the traditional ‘d-methamphetamine.’ Mexico made 
large seizures of phenylacetic acid (31 mt in 2009), 
which can be used to obtain P-2-P, as well as other 
closely related chemicals, including some which are not 
under international control (such as esters of phenylace-
tic acid in 200851 and phenylacetyl amide in 2009). In 
49 Ibid.
50 US Department of Justice, National Drug Threat Assessment 2010. 
Based on data extracted from System To Retrieve Information on 
Drug Evidence (STRIDE).
51 International Narcotics Control Board, Precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs and psychotropic 
2010 and 2011, Mexican authorities continued to make 
seizures of esters of phenylacetic acid.52 
Increasing seizures of MDMA in the United States 
and Canada
For the second year in a row, North America accounted 
for more than half of global ‘ecstasy’ seizures in 2009. 
The United States alone accounted for 63% of the 
global total. Contrary to the trend in global seizures, 
which essentially remained at the significantly reduced 
level of 2008, in 2009, seizures in North America sus-
tained the increased levels of 2007 and 2008. According 
to the United States Department of Justice,53 the resur-
gence of MDMA availability in the United States was 
fuelled by the manufacture of MDMA in Canada and 
subsequent smuggling into the United States across the 
northern border. MDMA seizures at the northern border 
more than doubled between 2007 and 2008.
Canada reported 23 methamphetamine laboratories and 
12 MDMA laboratories in 2009. Although ‘ecstasy’ 
seizures in Canada fell for the second year in a row – 
from 1 mt in 2007 to 715 kg in 2008 and 405 kg in 
2009 – Canada reported an increased amount of powder 
MDMA shipments destined for foreign countries and 
an apparent expansion of international consumer mar-
kets for Canadian-produced MDMA. Destinations for 
MDMA shipments seized in or en route from Canada 
included the Philippines, Malaysia, Taiwan Province of 
China, Mexico and Jamaica. While cross-border meth-
amphetamine trafficking between Canada and the 
United States continued to be limited in comparison 
with cross-border MDMA trafficking, a slight increase 
was registered in the number of methamphetamine ship-
ments intercepted in both directions.
Central America, South America and the Caribbean
In this region, seizures of amphetamine-type stimulants 
are limited. In recent years however, illicit manufacture 
of amphetamine-type stimulants has emerged in several 
countries with little or no previous history of reported 
manufacture. 
In Argentina, seizures of ‘ecstasy’ tablets rose from 
11,072 in 2008 to 136,550 in 2009.54 Argentina also 
seized 20 kg of methamphetamine in 2008, and small 
quantities of methamphetamine tablets in 2008 and 
2009. Argentina reported the seizure of one ‘ecstasy’ 
laboratory in 2008. In August 2009, Argentine authori-
ties seized 4.2 mt of ephedrine (a precursor for metham-
substances, 2008, February 2009. 
52 Procuraduría General de la República, Mexico, Secretaría de Marina, 
Mexico.
53 US Department of Justice, National Drug Threat Assessment 2010, 
February 2010.
54 In addition, Argentina also reported 15 grams and 10 grams of 
‘ecstasy’ seized in 2008 and 2009 respectively.
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phetamine) in two operations in the outskirts of Buenos 
Aires. Although manufacture in Argentina cannot be 
ruled out, it is likely that the large quantity of precursor 
chemical was intended for other destinations, possibly 
Mexico.55 
In 2010, Brazil seized 2,740 ‘ecstasy’ tablets and 5,910 
units of methamphetamine.56 Brazilian authorities 
seized one ‘ecstasy’ laboratory in 200857 in the state of 
Paraná, and, according to preliminary data, one ‘ecstasy’ 
laboratory, again in Paraná, as well as one metham-
phetamine laboratory in the state of Santa Catarina, in 
2009.58 Chile seized one laboratory manufacturing mes-
caline59 in 2009. Seizures and investigations by Chilean 
authorities also point to trafficking of ephedrine from 
Chile to Mexico.60 Colombia seized 126,573 ATS tab-
lets in 2009, including 23,477 ‘ecstasy’ tablets.61 
In the Dominican Republic – for years an important 
trans-shipment location of ecstasy – seizures of ‘ecstasy’ 
tablets fell from 20,861 units in 2007 to 17,885 
in 200862 and 10,166 in 2009. In August 2009, author-
ities in the Dominican Republic intercepted more 
than 409,000 pseudoephedrine tablets in a shipment en 
route to Guatemala and originating in Bangladesh.63 
55 UNODC, Global SMART Update, Volume 2, October 2009. 
56 Brazil Federal Police.
57 Brazil Federal Police. Dados Estatísticos apreensão de drogas, Coorde-
nação Geral Polícia de Repressão a Entorpecentes. December 2010.
58 UNODC, Global SMART Update, Volume 2, October 2009. 
59 Although mescaline is not classified as an amphetamine-type stimu-
lant, it is a psychotropic substance and a hallucinogen.
60 UNODC, Global Smart Update, Volume 2, October 2009.
61 Observatorio de Drogas de Colombia.
62 In addition, in 2008, 49 grams of ‘ecstasy’ were seized in the Domini-
can Republic.
63 UNODC, Global Smart Update, Volume 2, October 2009.
Guatemala reported the seizure of one ATS laboratory 
in 2008 and three in 2009, as well as the seizure of 12 
mt of pseudoephedrine in 2009. In 2008, Honduran 
authorities discovered some establishments used for 
extracting pseudoephedrine. In Nicaragua, police dis-
covered a laboratory manufacturing illicit synthetic 
drugs in February 2010, and seized a small quantity of 
amphetamine. This represented the third reported ATS 
laboratory in Nicaragua.64
64 UNODC, Global Smart Update, Volume 3, March 2010.
Fig. 127: Ecstasy seizures in the United States and by region, 2001-2009
Source: UNODC DELTA.
Fig. 128: Distribution of global ecstasy  
seizures, by region, 2000-2009
Source: UNODC DELTA.
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In 2009, small quantities of amphetamine-type stimu-
lants were also seized in Costa Rica (methamphetamine 
and ‘ecstasy’), Chile (amphetamine and ‘ecstasy’) Cuba 
(methamphetamine and unspecified ATS), the Bahamas 
(‘ecstasy’) and El Salvador (amphetamine).
Near and Middle East/South-West Asia:  
Rise in amphetamine seizures
Countries in the Near and Middle East/South-West Asia 
continued to be affected by trafficking of Captagon on 
a large scale. The content of tablets bearing the Capta-
gon logo is not always clear, but the main psychoactive 
ingredient in such tablets is now amphetamine (rather 
than fenetylline, the active ingredient in the licit phar-
maceutical preparation some 15 years ago). Caffeine is 
also frequently found in such tablets. 
Seizures of amphetamine in the Near and Middle East/ 
South-West Asia increased steadily between 2000 and 
2007, appeared to stabilize in 2008, amounting to 19.6 
mt, and resumed the increasing trend in 2009, reaching 
24.8 tons. The long-term growth in seizures in this region 
was driven mainly by seizures in Saudi Arabia, which rose 
consistently over the period 2000-2007, reaching 13.9 
mt65 in 2007. Seizures in this country  have remained 
stable since then, amounting to 12.8 mt in 2008 and 
13.4 mt66 in 2009. Saudi Arabia has a significant con-
sumer market for Captagon tablets. In January 2010, 
eight million Captagon pills were confiscated in a single 
seizure in Saudi Arabia. The traffickers were believed to 
65 Data relative to the period 2002-2007 and 2009 were sourced from 
the World Customs Organization and ICPO/INTERPOL.
66 World Customs Organization.
have ties to an amphetamine manufacturing and distri-
bution ring that was broken in Turkey a few months 
earlier.67 Turkey is believed to be mainly a transit country 
for Captagon, and a gateway for illicit trafficking from 
South-East Europe to the Middle East.
Replies to the Annual Reports Questionnaire from the 
Near and Middle East identified Saudi Arabia as a major 
destination for amphetamine (specifically Captagon) 
trafficked on their territory. It also appeared that Egypt 
had become a point of departure for amphetamine ship-
ments. In a single seizure at Dhuba seaport, Saudi Ara-
bian Customs seized over 1.3 million tablets that were 
concealed on board a vessel that had arrived from 
Egypt.68 
Jordan registered significant increases in amphetamine 
seizures in 2008 and again in 2009. Seizures in this 
country averaged 11 million tablets over the period 
2004-2007, and rose to 14 million tablets in 2008 and 
29 million tablets (specifically Captagon tablets) in 
2009. Seizures also continued to increase in the Syrian 
Arab Republic, from 12 million tablets in 2007 and 
2008 to 22 million tablets in 2009. 
Turkey reported seizures of 2.8 million Captagon tablets 
in 2009,69 in addition to 479 kg of amphetamine, of 
which 473 kg70 were seized at a Captagon laboratory 
67 UNODC, Global SMART Update, Volume 3, March 2010.
68 World Customs Organization, Customs and Drugs Report 2009. June 
2010.
69 Turkey also confirmed that, in 2009, Captagon tablets contained 
amphetamine rather than fenetylline. 
70 Ministry of Interior, Turkish National Police, Department of Anti-
Smuggling and Organized Crime. Turkish Report on Drugs and 
Fig. 129: Seizures of amphetamine in the Near 
and Middle East/South-West Asia and 
worldwide, 2000-2009
Source: UNODC DELTA.
Fig. 130: Distribution of amphetamine seizures 
in the Near and Middle East/South- 
West Asia, 2009 (kg equivalents)
Source: UNODC DELTA.
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discovered in Istanbul in September 2009. According to 
Turkish authorities,71 such establishments, which are 
discovered sporadically, carry out the conversion into 
tablet form, rather than the chemical process whereby 
amphetamine is manufactured from other substances. In 
2010 seizures of Captagon tablets fell to 1.1 million.72
Increased seizures of methamphetamine in the 
Islamic Republic of Iran
Starting in 2005, the Islamic Republic of Iran has seized 
increasing quantities of methamphetamine. In the first 
nine months of 2010, the country seized 883 kg of 
methamphetamine, up from 571 kg in 2009.73 The 
results of research in the country, as reported by the 
Drug Control Headquarters74, indicate that the use of 
methamphetamine has increased. The Islamic Republic 
of Iran reported that, in 2009, methamphetamine traf-
ficked on its territory originated in North-West Asia, 
South-East Asia and northern and western Europe, with 
1% manufactured domestically. It also reported the 
detection of six ‘kitchen’ laboratories manufacturing 
methamphetamine. In 2009, the Islamic Republic of 
Iran registered legitimate requirements of 55 mt75 of the 
precursor pseudoepehedrine, the fourth largest level 
worldwide for that year. 
According to Thai authorities,76 there was an emergent 
trend of Iranian nationals trafficking methamphetamine 
into the region. This pattern was also observed in Japan, 
where Iranian nationals accounted for one fifth of arrests 
of non-resident foreigners related to methampheta-
mine.77 In two incidents in July 2009 and February 
2010, a total of five Iranian nationals were arrested in 
Malaysia for attempting to traffic a total of 75 kg of 
methamphetamine on flights from the United Arab 
Emirates.78 In August 2010, police in Sri Lanka arrested 
three Iranian nationals, confiscating 16 kg of metham-
Organized Crime 2009.
71 Ibid.
72 Ministry of Interior, Turkish National Police, Department of Anti-
Smuggling and Organized Crime. Turkish Report on Drugs and 
Organized Crime 2010.
73 Drug Control Headquarters, Islamic Republic of Iran, Drug Control 
in 2010, Annual Report. 
74 Drug Control Headquarters, Islamic Republic of Iran. Drug control 
in 2008, Annual Report and Rapid Situation Assessment, 
75 International Narcotics Control Board, Precursors and chemicals fre-
quently used in the illicit manufacture of narcotic drugs and psychotropic 
substances, Report of the International Narcotics Control Board for 
2009 on the Implementation of Article 12 of the United Nations 
Convention against Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances of 1988, E/INCB/2009/4. February 2010.
76 Office of the Narcotics Control Board of Thailand, presentation at 
the Twentieth Anti-Drug Liaison Officials’ Meeting for International 
Cooperation (ADLOMICO), October 2010, Seoul, Republic of 
Korea.
77 Fifteenth Asia-Pacific Operational Drug Enforcement Conference, 
February 2010, Tokyo, Japan. Country report by Japan.
78 UNODC, Global SMART Update, Volume 3, March 2010. 
phetamine.79 Turkey, which registered methampheta-
mine seizures for the first time in 2009, also reported 
that methamphetamine was smuggled overland from the 
Islamic Republic of Iran into Turkey and then trafficked 
by air to countries in East and South-East Asia such as 
Indonesia, Japan, Malaysia and the Republic of Korea. 
Indonesia also mentioned the Islamic Republic of Iran 
as a source country for methamphetamine in 2009, and 
Turkey as a transit country. Trafficking of metham-
phetamine from the Islamic Republic of Iran via Turkey 
was also confirmed by Philippine authorities.80 
Asia-Pacific: Increased seizures of  
methamphetamine 
The Asia-Pacific region - notably the area encompassing 
Cambodia, the Lao People’s Democratic Republic, 
Myanmar, Thailand, Viet Nam and bordering provinces 
of south China - continued to be affected by manufac-
ture, trafficking and consumption of methamphetamine 
on a large scale. In 2009, seizures in East and South-East 
Asia rose by more than one third, from 11.6 mt in 2008 
to 15.8 mt, mainly due to the quantities seized in Myan-
mar. In relative terms, Thailand recently also registered 
significant increases. The largest seizures in the Asia-
Pacific region continued to be made by China, while 
East and South-East Asia as a whole continued to 
account for approximately one half of global seizures of 
methamphetamine. Moreover, there were signs of diver-
sification in trafficking routes, with methamphetamine 
reaching the region from Africa and the Islamic Repub-
lic of Iran.
In China, aggregate seizures of methamphetamine were 
remarkably stable over the period 2005-2009, ranging 
between 6.1 mt and 6.8 mt (6.6 mt in 2009). According 
to Chinese authorities,81 there was an increase in traf-
ficking of amphetamine-type stimulants from neigh-
bouring countries (referred to as the ‘Golden Triangle’) 
into Yunnan province. Methamphetamine seizures in 
this province rose from 2.2 mt in 2008 to 3.2 mt in 
2009. There was also an increase in the domestic manu-
facture of illicit drugs, with the number of dismantled 
clandestine laboratories rising from 244 in 2008 to 391 
in 2009. Manufacture occurred in particular in the 
provinces of Guangdong, Sichuan and Hubei, and the 
substances involved were mainly amphetamine-type 
stimulants and ketamine.
 
79 UNODC, Global SMART Update, Volume 4, October 2010.
80 Twentieth Anti-Drug Liaison Officials’ Meeting for International 
Cooperation (ADLOMICO), October 2010, Seoul, Republic of 
Korea. Country report by the Philippines.
81 National Narcotics Control Commission of China, presentation at 
the Twentieth Anti-Drug Liaison Officials’ Meeting for International 
Cooperation (ADLOMICO), October 2010, Seoul, Republic of 
Korea.
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In 2009, a notable increase in methamphetamine sei-
zures was registered in Myanmar, where annual seizures 
of methamphetamine averaged 528 kg over the period 
2003-2008 and rose to 3.4 mt in 2009. This increase 
was concurrent with a similar increase in heroin seizures 
in the same country and may reflect a strengthened pres-
ence of law enforcement agencies in parts of Myanmar.
Thailand continues to constitute a major market for 
methamphetamine, and there were signs that trafficking 
methamphetamine was on the rise. According to data 
collated by the Drug Abuse Information Network for 
Asia and the Pacific, seizures of methamphetamine tab-
lets rose from 14 million in 2007 to 22 million in 2008 
and 27 million in 2009, while seizures of crystalline 
methamphetamine increased from 47 kg in 2007 and 53 
kg in 2008 to 209 kg in 2009.82 According to Thai 
authorities,83 manufacture of illicit substances was very 
limited in Thailand, and methamphetamine was traf-
ficked into Thailand from neighbouring countries. Thai-
land was also being used by traffickers as a transit point 
for methamphetamine intended for other markets. 
Large quantities of methamphetamine were seized in the 
Philippines in 2008 and 2009. The Philippines also 
dismantled 10 methamphetamine laboratories in 2008 
(including four ‘kitchen’ laboratories) and nine in 2009 
82 In its reply to the Annual Reports Questionnaire for 2009, Thailand 
reported seizures of 2.4 mt of methamphetamine pills and 210 kg of 
crystalline methamphetamine. 
83 Office of the Narcotics Control Board of Thailand, presentation at 
the Twentieth Anti-Drug Liaison Officials’ Meeting for International 
Cooperation (ADLOMICO), October 2010, Seoul, Republic of 
Korea.
(including eight ‘kitchen’ laboratories), and further 
reported an increase of 36% in the average price of 
methamphetamine hydrochloride in 2009, as compared 
to that in 2008, suggesting an increased demand for the 
substance. 
Methamphetamine seizures in Malaysia amounted to 
1.1 mt in 2008 and 1.2 mt in 2009.84 These levels are 
significantly higher than those registered prior to 2008. 
In a single seizure in May 2009, Malaysian police seized 
978 kg of high purity crystalline methamphetamine in 
the city of Johor Bahru.85 
Methamphetamine seizures in Indonesia, in contrast, 
fell to the lowest level since 2004. Indonesia also reported 
the seizure of five ‘kitchen’ methamphetamine laborato-
ries in 2008 and 17 in 2009.
The general declining trend in ecstasy seizures prevalent 
worldwide since 2007 (with the exception of North 
America) was also to be seen in several countries in the 
Asia-Pacific region. By 2009, ecstasy seizures in China, 
Indonesia, Japan, Malaysia and Thailand had fallen sig-
nificantly by comparison with the level in 2007. How-
ever, Indonesia reported that nine ‘kitchen’ laboratories 
manufacturing ecstasy were seized in 2008 and 18 in 
2009.
Oceania continued to be affected by trafficking of 
amphetamine, methamphetamine and ecstasy, with no 
single type dominating the market. In 2009, Australia 
seized 56 kg of amphetamine, 150 kg of methampheta-
mine and 59 kg of ecstasy. The number of laboratories 
dismantled in Australia rose significantly, from 11 ATS 
laboratories in 2007-2008 to 316 in 2008-09, of which 
19 were manufacturing primarily MDMA and the rest 
were manufacturing amphetamine or methampheta-
mine. New Zealand also seized smaller quantities of 
amphetamine, methamphetamine and ecstasy; however, 
all 135 seized laboratories reported by New Zealand 
were manufacturing methamphetamine.
Africa: Few countries report seizures
The variety of substances, combinations of substances, 
precursor chemicals and chemical processes for manu-
facturing ATS hinders the collection of good quality 
data, in particular the proper identification and classifi-
cation of seized controlled substances, especially in 
countries lacking laboratory services for forensic pur-
poses, and this is an issue of concern especially in Africa. 
The vast majority represent seizures whose precise nature 
is unknown. Several African countries appear to be 
affected by trafficking in, and consumption of, diverted 
or counterfeit prescription drugs containing controlled 
substances whose nature is not always clear, possibly 
84 Data collated by DAINAP.
85 UNODC, Global SMART Update, Volume 2. October 2009.
Fig. 131: Methamphetamine seizures in China, 
East and South-East Asia, North  
America and worldwide, 2001-2009
Source: UNODC DELTA.
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including amphetamine-type stimulants as well as seda-
tives and tranquillisers.
Nigeria reported seizures of 712 kg of psychotropic sub-
stances in 2009, up from 530 kg of psychotropic sub-
stances in 2008. Burkina Faso reported seizures of 3,403 
kg of ‘médicaments de la rue’ in 2008. Morocco reported 
seizures of 48,293 units of psychotropic substances in 
2008, rising to 61,254 in 2009 and 105,940 in 2010.86 
South Africa reported aggregate seizures of 48 kg of 
amphetamine-type stimulants in 2009, including 37 kg 
of methamphetamine. Algeria reported aggregate sei-
zures of 90,630 tablets of sedatives and tranquillisers in 
2009. Côte d’Ivoire seized 43 kg of amphetamine in 
2008, as well as 17,155 amphetamine tablets (in addi-
tion to seizures of clonazepam and diazepam tablets).87 
In 2009, seizures of amphetamine in Côte d’Ivoire fell 
to 1,200 tablets. The World Customs Organization also 
reported that Sudanese officials foiled an attempt to 
smuggle 18.3 kg of stimulant tablets at Khartoum air-
port. 
Every year from 2000 to 2009, Egyptian authorities 
seized small quantities of ‘ecstasy tablets’. Seizures 
exceeded 10,000 tablets in 2006, but had fallen to 203 
tablets by 2008 to 76 tablets in 2009. In April 2010,88 
one methamphetamine laboratory was seized in Egypt.
According to South African authorities, amphetamine-
type stimulants, in particular methamphetamine and 
club drugs such as ecstasy and cathinone, continued to 
be used in South Africa.89 These drugs, with the excep-
tion of ecstasy, were manufactured locally in clandestine 
laboratories, while ecstasy was mainly smuggled in from 
Europe by air freight and parcel post. Over the period 
1 April 2008 to 31 March 2009, 20 clandestine 
laboratories manufacturing methamphetamine were 
dismantled,90 while 10 methamphetamine laboratories 
and six cathinone laboratories were dismantled during 
2009. South Africa also reported that an increase of 
methamphetamine trafficking allowed for a decrease in 
prices.
86 Official communication from the Government of Morocco. The 
replies to the Annual Reports Questionnaire for the year 2009 and 
2010 from the Kingdom of Morocco were not available at the time 
of preparation of the present report. 
87 Country report by Côte d’Ivoire to the Nineteenth Meeting of Heads 
of National Drug Law Enforcement Agencies, Africa. The replies to 
the ARQ for 2008 from Côte d’Ivoire were not available at the time 
of preparation of the present report.
88 UNODC, Global SMART Update Volume 4.
89 Country report by South Africa to the Nineteenth Meeting of Heads 
of National Drug Law Enforcement Agencies, Africa.
90 South African Police Service, Annual Report 2008/2009. In the replies 
to the ARQ for 2008, South Africa did not report any clandestine 
laboratories.
Methamphetamine trafficking from Africa to Japan 
One emerging trend identified by Japanese authorities91 
was that of methamphetamine trafficking from Africa to 
Japan. The proportion of methamphetamine seized in 
Japan that was sourced from Africa increased from 7.4% 
in 2009 to 36% in the first half of 2010. The West and 
Central African countries of Benin, Nigeria, Cameroon 
and Senegal were prominent among the source countries 
in Africa. It is unclear whether West Africa, already a 
hub for cocaine trafficking, was beginning to see the 
emergence of local ATS manufacture, or is simply serv-
ing as a transit point for methamphetamine manufac-
tured elsewhere, possibly in South Africa. Nevertheless 
this trend, together with reports from other countries in 
the region, suggests that African trafficking syndicates 
active in the Asia-Pacific region may be expanding their 
activities to include trafficking of methamphetamine in 
addition to heroin and cocaine.
Countries in West Africa, which have assumed an 
important role in the trafficking of cocaine, are also 
vulnerable to a potentially increased role in the traffick-
ing or manufacture of other drugs, including ampheta-
mine-type stimulants. In July 2009, large quantities of 
chemicals and equipment that could be used in the 
manufacture of illicit drugs were discovered in multiple 
facilities in Guinea. Among the seized materials were 
more than 5,000 litres of sassafras oil and 80 litres of 
91 Japan Customs Intelligence and Targeting Centre, presentation at 
the Twentieth Anti-Drug Liaison Officials’ Meeting for International 
Cooperation (ADLOMICO), October 2010, Seoul, Republic of 
Korea.
Fig. 132: Number of methamphetamine and 
cathinone/methcathinone laboratories 
seized in South Africa (all sizes),  
2002-2009
Source: UNODC DELTA.
*Covers the period 1 April 2008 to 31 March 2009
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3,4-MDP-2-P, which can be used to manufacture 
MDMA. In a separate single seizure, also in July 2009, 
Nigerian officials seized 10 kg of crystalline metham-
phetamine and 10 kg of amphetamine along with 57 kg 
of the precursor chemical ephedrine. The seizure was 
made at the departure concourse of a flight en route to 
South Africa.92 (The methamphetamine seizures were, 
however, not reported separately in the ARQ but 
included in the broad category of psychotropic sub-
stances seizures). In 2010, Nigeria seized 75 kg of meth-
amphetamine: over the nine-month period May 2010 
– January 2011, 11 out of 150 seizures made by author-
ities at Murtala Muhammed International Airport 
involved methamphetamine, intended predominantly 
for the Asia-Pacific region.93 
Europe: Amphetamine seizures appear to recede
Europe, notably West and Central Europe, continues to 
be an important market for amphetamine, in terms of 
both manufacture and consumption. Amphetamine 
seizures in West and Central Europe reached a record 
level (8.2 mt) in 2007, and essentially sustained this 
level in 2008 (7.9 mt). In 2007 and 2008, the Nether-
lands, the United Kingdom and Germany collectively 
accounted for more than 70% of annual amphetamine 
seizures in West and Central Europe, and in 2009 the 
United Kingdom and Germany accounted for the larg-
est and second largest seizure levels in Europe, respec-
tively. Seizure data from the Netherlands for 2009 were 
not available; however, a comparison of seizure totals for 
2008 and 2009 excluding the Netherlands indicates a 
decline of 20%.
92 UNODC, Global SMART Update, Volume 2, October 2009.
93 National Drug Law Enforcement Agency of Nigeria.
A sharp drop in seizures in the United Kingdom, from 
the high level of 2008, was partly offset by increased 
seizures in France, while seizures in Germany continued 
the gradually increasing trend that can be traced back to 
2002. Among all countries worldwide, the Netherlands 
continued to be the most frequently mentioned country 
of origin for amphetamine as well as ‘ecstasy’. Poland 
continued to be the second most frequently mentioned 
country of origin for amphetamine: Poland dismantled 
eight amphetamine laboratories in 2009, and identified 
Germany, Scandinavia and the United Kingdom as the 
main destinations for amphetamine manufactured in 
Poland.
Ecstasy seizures continue to decline
Seizures of ecstasy in Europe have declined sharply, 
standing at 1.8 mt in 2008 – approximately one third 
the prior levels – and appearing to decline by a further 
59% in 2009 (excluding seizures in the Netherlands). 
The decreases were prevalent throughout Europe but 
were more pronounced in some countries than others; 
due to recent decreases in countries which historically 
accounted for a dominant portion of European ‘ecstasy’ 
seizures (notably the United Kingdom and, up till 2008, 
the Netherlands), in 2009 the largest ‘ecstasy’ seizures 
reported by European countries were made in Turkey 
(432,513 tablets) and Spain (404,334 tablets), while 
Poland registered seizures comparable with the quanti-
ties seized in the United Kingdom (6% of the European 
total). Poland assessed that some of the `ecstasy’ on 
its territory originated in Poland itself, as well as the 
Netherlands. According to Colombian authorities,94 a 
94 Dirección Nacional de Estupefacientes, Ministerio del Interior y de 
Justicia, Colombia.
Fig. 133: Amphetamine seizures in Europe, 2000-2009
* Data for 2009 for the Netherlands were unavailable; the value used is that corresponding to the year 2008, and is only included to estimate the 
regional total.
** Data for the United Kingdom for 2007, 2008 and 2009 are based on incomplete data for some jurisdictions for the financial years 2007/08, 
2008/09 and 2009/10 respectively, and adjusted for the missing jurisdictions using the distribution in 2006/07.
Source: UNODC DELTA.
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shipment of 15 million ‘ecstasy’ tablets seized in Poland 
and intended for Colombia suggested that Colombian 
syndicates were accepting payment for cocaine in the 
form of ‘ecstasy’ tablets manufactured in Europe. Similar 
arrangements were also reported from other European 
countries in the past. 
Methamphetamine emerging in Europe
While the European ATS market has in the past been 
dominated by amphetamine and ‘ecstasy’, recent years 
have seen the emergence of methamphetamine manu-
facture, trafficking and consumption in parts of Europe. 
Between 2004 and 2009, there was a five-fold increase 
of methamphetamine seizures in West and Central 
Europe, driven mainly by seizures in Norway, Sweden 
and Lithuania. Over the period 2002-2009, Lithuania 
and the Netherlands were the European countries most 
frequently mentioned as a country of origin for meth-
amphetamine, followed by Poland, the Czech Republic 
and Slovakia. Lithuania assessed that methamphetamine 
on its territory originated entirely in Lithuania itself in 
2009, while the percentage of domestic manufacture 
was estimated at 98% by Slovakia and 95% by the 
Czech Republic. The Czech Republic reported seizures 
of a large number of methamphetamine laboratories 
(342); one methamphetamine laboratory was also dis-
mantled in Lithuania and an unspecified number in 
Slovakia.
Fig. 134: Seizures of ecstasy in Europe, 2000-2009
* Data for the United Kingdom for 2007, 2008 and 2009 are based on incomplete data for some jurisdictions for the financial years 2007/08, 2008/09 
and 2009/10 respectively, and adjusted for the missing jurisdictions using the distribution in 2006/07.
** Data for 2009 for the Netherlands were unavailable; the value used is that corresponding to the year 2008, and is only included to estimate the 
regional total.
Source: UNODC DELTA.
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Fig. 135: Methamphetamine seizures in West and Central Europe, 2000-2009
Source: UNODC DELTA.
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4.5 Emerging trends
Market expansion for ATS markets in  
East and South-East Asia 
Established markets for amphetamine-type stimulants in 
East and South-East Asia have seen an expansion over 
the past year. Expert perceptions confirm that ATS - 
notably methamphetamine - play a significant role in 
the region. ATS may even have overtaken the use of 
plant-based drugs in some countries over the past few 
years. Methamphetamine in pill form has been reported 
as the primary drug of use in the Lao People’s Demo-
cratic Republic and Thailand, while methamphetamine 
in crystalline form has been reported as the primary 
drug of use in Brunei Darussalam, Cambodia, Japan, 
the Republic of Korea and the Philippines. Metham-
phetamine in pill and crystalline form ranked as the 
second most commonly used drug type in China, with 
‘ecstasy’ ranking third. In Indonesia, crystalline meth-
amphetamine and ‘ecstasy’ ranked as the second and 
third most commonly used drugs, respectively. Crystal-
line methamphetamine ranked as the third most com-
monly used drug in Malaysia and Singapore. 
Over the past few years, several expanding markets have 
emerged in the region. For example, the market for 
methamphetamine in Viet Nam has grown as the coun-
try becomes an attractive target for traffickers due to its 
large, increasingly affluent and urban population. The 
use of crystalline methamphetamine, in particular, has 
increased among young people in major cities and sei-
zures of methamphetamine pills have increased signifi-
cantly over the past three years. Viet Nam also reports 
the existence of drug storage points along the northern 
border with the Lao People’s Democratic Republic.
In Indonesia, crystalline methamphetamine use has 
been increasing each year since 2003 according to 
experts, and the drug now ranks as the second most 
commonly used drug, after having ranked fifth in 2005. 
Over the past five years, Indonesia - hitherto primarily a 
transit country for methamphetamine - has become a 
manufacturing centre for crystalline methamphetamine. 
Malaysia is a key transit country for crystalline metham-
phetamine trafficking in the region and in recent years 
has seen seizures of several small and large-scale manu-
facturing laboratories, echoing the same pattern as some 
other countries.
Another trend is the increasing trafficking and use of 
ketamine which is often sold in the traditional ATS 
markets of South-East Asia. In 2009, 6.9 mt of ketamine 
was seized in East and South-East Asia. Almost 90% of 
this was seized in China, which, along with India, is one 
of the major source countries for ketamine in the region. 
Ketamine seizure figures are almost certainly under-
reported, particularly in Asia. Ketamine is not under 
international control and only some countries in the 
region have imposed restrictions on its availability. Use 
is reportedly increasing in several countries and areas, 
and in Hong Kong, China, it was the main drug of use, 
with 2009 seizures reaching five times their 2007 level. 
One reason for its growing popularity is that ketamine 
is cheaper than other drugs such as MDMA and its licit 
use makes it widely available for diversion for illicit pur-
poses in many countries in the region.
Ketamine is also frequently trafficked in South Asia, 
particularly from India. Seizures of ketamine in India 
have increased from 60 kg in 2005 to more than 1 mt 
in 2009. Ketamine has been trafficked to countries in 
East and South-East Asia as well as to North America 
(notably Canada) and some European countries (nota-
bly the United Kingdom and the Netherlands).
The emergence of analogue substances in 
established ATS markets
The appearance of several new unregulated synthetic 
compounds in established ATS markets, particularly in 
0
200
400
600
800
1,000
1,200
2005 2006 2007 2008 2009
Q
u
an
ti
ty
 (
kg
)
Fig. 136: Seizures of ketamine in India,  
2005-2009
Source: Directorate of Revenue Intelligence and Narcotics 
Control Board, India.
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Europe, the United States, Canada, Australia and New 
Zealand, has been an important trend observed over the 
past years. Many of these substances are marketed as 
‘legal highs’ and substitute for illicit stimulant drugs 
such as cocaine or ecstasy. 
In Europe, the emergence of these substances coincided 
with the gradual disappearance of ecstasy from the illicit 
drugs market. Seizures of ecstasy precursors have con-
tinually declined over the past five years. Seizures of the 
main ecstasy precursor 3,4-MDP-2-P (also known as 
piperonyl methyl ketone) steeply declined after 2004. 
The slow and steady disappearance of MDMA from the 
illicit market coincided with a decline in laboratory 
activity. In 2009, only one ecstasy-related laboratory 
incident was reported in Europe. 
At the same time, other synthetic substances, notably 
piperazines, have been sold as ‘ecstasy’ to meet the 
demand from the illicit market. Manufacturers and traf-
fickers have started to exploit the lack of national and 
international control over piperazines and other new 
synthetic substances. Piperazines are not under interna-
tional control although many countries have introduced 
national controls over BZP and taken other action to 
prevent their sale and distribution. 
As a result, other substances have emerged, notably 
mephedrone. Mephedrone, 4-methylmethcathinone 
(4-MMC), first appeared on the illicit market around 
2007. The substance has no medical use in either 
humans or animals and has been associated with a 
number of fatalities in European countries. In Decem-
ber 2010, mephedrone was banned in the countries of 
the European Union. But it is still available in illicit 
drug markets and has also appeared on markets in devel-
oped countries outside Europe, including the United 
States and Australia. 
Methamphetamine trafficking from Africa 
Africa poses one of the greatest emerging threats with 
regard to trafficking of amphetamine-type stimulants. 
Trafficking of methamphetamine from Africa was 
reported first at the end of 2008 and reports of such 
trafficking have continued since. West Africa, in particu-
lar, is emerging as a source of methamphetamine for 
illicit markets in East Asia, with couriers transiting 
Europe, western Asia or East Africa. Few countries in the 
region have the capacity and governance structures to 
address the problem. 
Methamphetamine manufacture is not entirely new to 
Africa. South Africa has had increasing reports since 
2004 and Egypt reported a case as recently as April 
2010. There are also indications that ATS manufacture 
could occur in West Africa. In July 2009, equipment 
that could be used in ATS manufacture was discovered 
in Guinea. In June 2010, the United States Government 
indicted members of a large international cocaine traf-
ficking organization for, inter alia, the intent to establish 
large-scale manufacture of crystalline methamphetamine 
in Liberia. 
Precursor chemicals are frequently trans-shipped through 
the region. The International Narcotics Control Board 
(INCB) identified Africa as the region with the greatest 
number of diversions or attempted diversions of ATS 
precursor chemicals in 2008. Countries import precur-
sors in considerable excess of legitimate annual needs 
and are targets for organized crime. For example, a single 
shipment to Uganda of 300 kg of pseudoephedrine was 
seized upon arrival in 2008. At the same time, the INCB 
notes that precursor trafficking patterns in Africa stand 
in sharp contrast to the low number of seizures made by 
Governments in the region. Only two cases were 
reported in 2009: 1.25 mt of ephedrine to the Central 
African Republic and 1 mt of pseudoephedrine to 
Kenya, both of which can be used in the manufacture of 
methamphetamine. 
The World Customs Organization (WCO) noted a 
small number of methamphetamine trafficking cases 
from Africa (southern) to East Asia in mid-2008 with no 
prior cases reported. The year 2009 saw both the number 
of seizures and their quantities originating from Africa 
more than triple. This trend appears to be growing and 
spreading. Cases of methamphetamine trafficking have 
emerged from various West African nations. Trafficking 
of methamphetamine originating in or transiting 
through Benin, Cameroon, Côte d’Ivoire, Ghana, 
To East Asia via Europe
To East Asia 
and Gulf area
To Oceania
Methamphetamine laboratories
Methamphetamine traffic
since 2009 reported
Routes (arrow indicates source
and routing reported in 2009/2010
Source: Global SMART Update Vol 4, October 2010
Note: The boundaries and names shown and the designations used on this map do not imply official endorsement or acceptance by 
the United Nations. Lines represent origin and intended destination, not necessarily exact route, and include completed or stopped 
trafficking attempts. Modes of transport include by air, sea, overland, or any combination thereof.
Map 37: Trafﬁcking routes of  
methamphetamine in Africa
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Guinea, Senegal and in particular Nigeria have all been 
reported since 2009. 
The most common destinations for methamphetamine 
have been outside the region, primarily Japan, followed 
by the Republic of Korea, with new reports from Malay-
sia and Thailand. Cases are typically multi-kilo and 
transported via air passengers hidden in luggage or by 
body concealment resembling methods employed by 
West African syndicates for other drugs. Couriers transit 
via Gulf countries, East African as well as European 
countries. Significantly larger shipments have also been 
reported. For example, in May 2010, Nigerian authori-
ties stopped two separate cargo shipments totalling 63 
kg of methamphetamine and amphetamine to Japan and 
South Africa. In July 2009, 10 kg of crystalline metham-
phetamine, 10 kg of amphetamine and 57 kg of ephe-
drine were seized in Nigeria en route to South Africa. 
The infrastructure established by transnational cocaine 
and heroin traffickers in West Africa is readily adaptable 
to accommodate the flexibility of ATS manufacture. 
While the capacity to report on the situation in the 
region remains limited, initial indications suggest that 
the products are a threat for lucrative markets around 
the world. This raises the need for a truly global effort 
to address the synthetic drugs problem.
ATS in South Asia
Located at the crossroads of drug supply between the 
sources in South-East and South-West Asia, South Asia 
has traditionally been affected by illicit manufacture, 
trafficking and use of drugs, mostly opiates. Over the 
past few years, however, South Asia has emerged as a 
source for amphetamine-type stimulants (ATS) and the 
precursors needed to manufacture them.
The geographical proximity to East and South-East 
Asian source countries of illicit methamphetamine is 
one of several factors which makes South Asia a vulner-
able target for illicit manufacture of amphetamine-type 
stimulants. The first clandestine ATS manufacture oper-
ation was detected in India in May 2003. Since then, 
several additional facilities have been uncovered. In 
August 2010, a methamphetamine laboratory was dis-
covered in India. However, attempts at illicit ATS man-
ufacture are not limited to India, they have also been 
reported from Bangladesh and Sri Lanka. In Sri Lanka, 
for example, a large-scale methamphetamine laboratory 
was dismantled in May 2008.
In addition, South Asia has become one of the main 
regions used by drug traffickers to obtain ephedrine and 
pseudoephedrine for the illicit manufacture of metham-
phetamine. India is one of the world’s largest manufac-
turers of precursor chemicals and Bangladesh also has a 
growing chemical industry. Despite efforts to control 
precursor chemicals, both countries have been identified 
in a number of cases as the source of diverted precursor 
chemicals for a range of drugs, including methampheta-
mine. Several significant seizures of pseudoephedrine in 
Central America and the Caribbean (such as the Domin-
ican Republic, Guatemala and Honduras) are believed 
to have originated in Bangladesh. Many countries in 
Central America and the Caribbean are vulnerable as 
destinations for these shipments. Africa also remains at 
risk at being used by traffickers to obtain precursor 
chemicals.
Amphetamine, methamphetamine and ecstasy have 
been regularly seized in South Asia over the past five 
years. Methamphetamine pills originating from Myan-
mar are trafficked into Bangladesh, India and Nepal. 
The recent upsurge of methamphetamine seizures origi-
nating from Myanmar may therefore be felt acutely in 
the region.
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Fig. 137: Global seizures of amphetamines(a), 2001-2009
(a) Amphetamine, methamphetamine and related non-specified amphetamines.
Year 2001 2002 2003 2004 2005 2006 2007 2008 2009
Metric ton 
equivalents(b) 33        33        42        42        50        56        51        55        65        
(b)  This quantity reflects the bulk weight of seizures, with no adjustment for purity. Seizures of amphetamines-group substances reported in tablets or similar 
units are converted using assumed bulk tablet weights between 90mg and 300 mg, depending on the region and specific drug type, and based on 
information currently available to UNODC. This differs from the approach adopted in earlier editions of the World Drug Report.
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SEIZURES OF AMPHETAMINES-GROUP SUBSTANCES as % of world total and 
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(b) Data for the United Kingdom for 2009 are based on incomplete data for some jurisdictions for the financial year 2009/10, and adjusted for the missing 
jurisdictions using the latest available complete distribution (relative to the financial year 2006/07).
(c) Data relative to 2008. Data for 2009 from the Netherlands were not available.
(a)  This quantity reflects the bulk weight of seizures, with no adjustment for purity. Seizures of amphetamines-group substances reported in tablets or similar 
units are converted using assumed bulk tablet weights between 90mg and 300 mg, depending on the region and specific drug type, and based on 
information currently available to UNODC. This differs from the approach adopted in earlier editions of the World Drug Report.
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Fig. 138: Interception of amphetamines-group substances, 2001-2009
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Fig. 139: Global seizures of ‘ecstasy’-group(a) substances, 2001-2009
Year 2001 2002 2003 2004 2005 2006 2007 2008 2009
Kilogram 
equivalents 10,895 13,049  9,410 12,727 9,729  9,776  16,595 5,991  5,435  
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** data refer to
2003.           
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(a)  Includes substances believed to be ecstasy (e.g. MDMA, MDA, MDE) which may not have been confirmed by forensic testing. 
 (b) This quantity reflects the bulk weight of ecstasy seizures, with no adjustment for purity. Seizures of ecstasy reported in tablets or 
similar units are converted using assumed bulk tablet weights between 200mg and 300mg, depending on the region and based on 
information currently available to UNODC. This differs from the approach adopted in earlier editions of the World Drug Report.
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(c)
 (a) This quantity reflects the bulk weight of ecstasy seizures, with no adjustment for purity. Seizures of ecstasy reported in tablets or similar 
units are converted using assumed bulk tablet weights between 200mg and 300mg, depending on the region and based on information 
currently available to UNODC. This differs from the approach adopted in earlier editions of the World Drug Report.
(b) Data relative to 2008. Data for 2009 from the Netherlands were not available
(c) Data for the United Kingdom for 2009 are based on incomplete data for some jurisdictions for the financial year 2009/10, and adjusted for 
the missing jurisdictions using the latest available complete distribution (relative to the financial year 2006/07).
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Fig. 140: Interception of ‘ecstasy’-group substances, 2001-2009
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5.1 Introduction
Cannabis remains the most widely produced and con-
sumed illicit substance globally. The extent of the global 
cannabis problem did not change significantly in 2009, 
though the consumption estimates show a wider range. 
This is the result of some increases in cannabis use in the 
United States of America, Africa, South and Central 
America and Asia, though consumption in Canada, 
western Europe and Oceania remained stable or showed 
a decline. 
In Europe, cannabis resin seizures are now at their lowest 
level for the last 10 years, whereas seizures of resin in 
North Africa have increased. The major cannabis resin-
producing countries showed little evidence of changes in 
the production levels. Global herbal cannabis seizures 
have increased, principally due to increased seizures in 
the United States of America and Mexico, where data on 
use and cultivation also point to an increase in the avail-
ability of cannabis herb in the market. 
There is more and more evidence that intensive expo-
sure to cannabis products with high potency levels 
increases the risk of psychotic disorders (see text box). 
Some recent studies show that the average concentration 
of the major psychoactive substance in cannabis prod-
ucts (THC) is nowadays at higher levels than 10-15 
years ago; however, data for the past five years show a 
stable trend in some countries although the pattern is 
not consistent for all products and all countries. 
From a market perspective, both cannabis producers and 
users are apparently searching for more diversified prod-
ucts which are not only determined by different THC 
concentrations, but also by choices in ‘flavours.’ This 
diversification is illustrated by the rise of synthetic can-
nabinoids (‘spice’). In a short time, these products have 
become popular among young adults and teenagers in 
Europe and the United States. While there are some 
indications that these products might cause more 
damage to the health of users, there is a need for more 
pharmacological and toxicological research in this area. 
At the same time, the large number of products being 
marketed as cannabinoids also challenges the control 
measures taken by regulatory authorities in the Member 
States, the World Health Organization, the Interna-
tional Narcotics Control Board and the Commission on 
Narcotic Drugs.
5.2 Consumption
UNODC estimates that in 2009, between 2.8% and 
4.5% of the world population aged 15-64, correspond-
ing to between 125 and 203 million people, had used 
cannabis at least once in the past year. Compared to the 
previous year, the lower and upper levels of the estimates 
have increased, thereby widening the range.1 This is in 
part due to greater uncertainty in the estimates as there 
are limited recent or reliable prevalence data available 
from many countries in Asia and Africa.
1 In 2008, the annual prevalence was estimated between 2.9% and 
4.3% of the population aged 15-64.
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In 2009, among the Member States who provided expert 
perceptions on the trends of cannabis use in their coun-
tries, nearly half of the countries reported a stable trend. 
This number was even higher in countries in the Amer-
icas (67%). Less than half of Member States (44%), 
mainly in Africa, Asia and to a lesser extent Europe, 
reported that cannabis use had increased in their coun-
tries. As an overall trend, over the past 10 years, an 
increasing number of countries have been reporting 
stable trends for the use of cannabis.
Table 36: Annual prevalence and estimated number of cannabis users, by region, subregion  
and globally, 2009
Fig. 141: Estimated number of cannabis users 
by region, 2009
Source: UNODC.
Fig. 142: Annual prevalence of cannabis users 
by region, 2009
Source: UNODC.
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Region/subregion
Estimated 
number of users 
annually  
(lower)
-
Estimated 
number of users 
annually 
(upper)
Percent of 
population 
age 15-64 
(lower)
-
Percent of 
population 
age 15-64 
(upper)
Africa
East Africa
North Africa
Southern Africa
West and Central Africa
21,630,000
2,340,000
4,780,000
3,130,000
11,380,000
-
-
-
-
-
59,140,000
8,870,000
10,620,000
7,810,000
31,840,000
3.8
1.7
3.6
3.9
5.2
-
-
-
-
-
10.4
6.5
8.0
9.8
14.6
Americas
Caribbean
Central America
North America
South America
40,950,000
440,000
550,000
32,520,000
7,410,000
-
-
-
-
-
42,860,000
2,060,000
610,000
32,520,000
7,630,000
6.7
1.6
2.2
10.7
2.9
-
-
-
-
-
7.0
7.6
2.5
10.7
3.0
Asia
Central Asia
East/South-East Asia
Near and Middle East
South Asia
31,340,000
1,950,000
5,440,000
6,060,000
16,830,000
-
-
-
-
-
67,970,000
2,260,000
24,160,000
12,360,000
28,110,000
1.2
3.8
0.4
2.4
1.9
-
-
-
-
-
2.5
4.4
1.6
4.8
3.1
Europe
East/South-East Europe
West/Central Europe
28,730,000
5,980,000
22,750,000
-
-
-
29,250,000
6,380,000
22,860,000
5.2
2.6
7.1
-
-
-
5.3
2.6
7.1
Oceania 2,160,000 - 3,460,000 9.3 - 14.8
Global 124,810,000 - 202,680,000 2.8 - 4.5
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Cannabis users
The typology presented below is based on selected 
behavioural studies undertaken in a few developed 
countries (including the United States, Australia and 
the United Kingdom). It gives an indication of the risk 
factors and cannabis use patterns in some high-preva-
lence countries.
Experimental:
Experimental cannabis users typically try the drug for 
the first time in adolescence. They constitute a group of 
people who want to experience illegal drugs, but for the 
majority of these people, experience with cannabis suf-
fices. A stage pattern suggests that ‘experimenters’ begin 
with alcohol and tobacco, followed by cannabis or inha-
lants.
Poor relations with parents, depression symptoms, 
exposure to drug-using peers and accessibility of drugs 
are important factors for initiation into illicit drugs. 
However, adolescents’ beliefs and values favourable to 
the use of cannabis and association with cannabis-using 
peers are the strongest predictors of cannabis experi-
mentation. Sensation-seeking in adolescence represents 
a propensity toward novel experiences and could also 
lead to the experimental use of cannabis. A number of 
experimental users may continue to use cannabis more 
regularly for recreational purposes or long-term to 
become chronic or dependent users.
Recreational: 
During the last quarter of the twentieth century, recrea-
tional use of cannabis increased greatly across the world 
and came to be seen by larger numbers of young people 
as a normal leisure activity. Recreational users use can-
nabis mostly on weekends, are likely to have used or use 
other drugs and have a more active night life in the city 
than other users. These users report that the main pur-
pose of their use of cannabis is to reach a ‘social high’ 
and that they also use it to relax, enhance activity, 
decrease boredom, increase confidence, reduce anxiety 
or feel better. These young people do not contact public 
or private addiction counselling services because they 
are at times unaware of their existence, do not consider 
themselves dependent or feel these services are not 
designed for their specific needs. Early repeated use of 
cannabis during adolescence may be a risk factor for 
chronic cannabis use.
Long-term or chronic: 
People who start using cannabis at an early age and 
those who used other illicit drugs are more likely to 
continue using cannabis in their mid-30s or beyond, 
suggesting that cannabis use is part of their routine 
lifestyle choices. Lower income and marital rates, higher 
unemployment rates and having cannabis-using friends 
in young adulthood are commonly reported among this 
population. 
Long-term cannabis users express lower levels of satis-
faction on measures of quality of life. They report using 
cannabis to enhance positive feelings and perceive the 
drug as having calming effects, and may use it for stress-
coping purposes. They also report using cannabis to 
escape from problems, alleviate anger or frustration, and 
'get through the day'. Greater antisocial behaviour dis-
tinguishes chronic users from experimental and recrea-
tional users. It has been reported that psychosocial 
factors, antisocial personality disorder and alcohol 
dependence could predict long-term cannabis use. A 
social taboo against chronic drug use among women 
may be a protective factor, which is reflected in lower 
long-term female use rates.
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Cannabis use in the United States shows a  
resurgence, while there is a decrease in Canada 
The annual prevalence of cannabis use in North Amer-
ica is estimated at around 10.7% of the adult popula-
tion aged 15-64. These estimates are higher than the 
annual prevalence of 9.9% reported in the 2010 World 
Drug Report, and essentially reflect the increase in the 
annual prevalence of cannabis use in the United States 
of America.
In the United States, cannabis remained the most 
common illicit drug used in the past year. The annual 
prevalence of cannabis use that had been declining stead-
ily between 2002 and 2007 begun to show an increase 
over the past two years, and in 2009 was estimated 
slightly higher than the prevalence in 2002.2 Compara-
2 Substance Abuse and Mental Health Services Administration, Results 
from the 2009 National Survey on Drug Use and Health: Volume I. 
Summary of National Findings, 2010, Rockville, Maryland, USA.
ble trends of cannabis use have been observed both 
among the general population and high school stu-
dents.
In 2009, among the people who had initiated drug use 
in the past year in the United States, the largest number 
- 2.4 million people aged 12 years or older - had used 
cannabis as their first drug. This was followed by the 
non-medical use of pain relievers (2.2 million). Among 
the estimated 22.5 million drug users who were classi-
fied with substance dependence or abuse in the past 
year, the highest number was among cannabis users (4.3 
million people aged 12 or older).3 
Past month prevalence of cannabis use among the US 
population aged 12 or older increased from 6.1% in 
2008 to 6.6% in 2009. The rate of current illicit drug 
use, including cannabis, among the older population 
3 Ibid.
Table 37: Expert perceptions of trends in cannabis use by region, 2009
Source: UNODC ARQ.
Region
Member 
States 
providing 
perception 
data
Member 
States 
perception 
response 
rate
Use  
problem 
increased
Percent  
use  
problem 
increased
Use  
problem 
stable
Percent 
use  
problem 
stable
Use  
problem 
decreased
Percent use 
problem 
decreased
Africa 11 21% 7 64% 3 27% 1 9%
Americas 15 43% 5 33% 10 67% 0 0%
Asia 22 49% 11 50% 8 36% 3 14%
Europe 30 67% 12 40% 14 47% 4 13%
Oceania 1 7% 0 0% 1 100% 0 0%
Global 79 41% 35 44% 36 46% 8 10%
Fig. 143: Expert perceptions of trends in cannabis use, 2000-2009
Source: UNODC ARQ.
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(aged 50-59) has also increased from 2.7% in 2002 to 
6.2% in 2009,4 mainly due to the ageing cohort of baby 
boomers5 that have had high rates of illicit drug use. 
Among secondary school students in grades 8, 10 and 
12, after some decreases observed between 2002 and 
2006, there has been a steady increase in the annual 
prevalence of cannabis use since 2007. Use is still not 
reaching the levels reported in 2002, however.6 The 
reversal in cannabis trends from 2006 onwards is in part 
attributed to a softening of the perceptions related to the 
risks of cannabis use among the student population,7 
which coincided with a period of public debates around 
an initiative aiming at the legalization of cannabis in one 
US state. 
In 2009, among emergency department visits related to 
cannabis use, the rate was slightly higher for the popula-
tion aged 20 years or younger (125.3 visits per 100,000 
people) compared to those aged 21 or older (121.5 visits 
per 100,000 people).8 For all other illicit drugs, the rate 
4 Substance Abuse and Mental Health Services Administration, Results 
from the 2009 National Survey on Drug Use and Health: Volume I. 
Summary of National Findings, 2010, Rockville, Maryland, USA.
5 Baby boomers refers to the cohort of persons born in the United 
States between 1946 and 1964.
6 Johnston, L. D., O’Malley, P. M., Bachman, J. G. and Schulenberg, J. 
E., Monitoring the Future, national results on adolescent drug use: Over-
view of key findings, 2010, Institute for Social Research, University of 
Michigan, 2011, Ann Arbor, Michigan, USA. 
7 NIDA, Research Report Series: Marijuana Abuse, US Department of 
Health and Human Services, National Institutes of Health, Septem-
ber 2010.
8 Substance Abuse and Mental Health Services Administration, Centre 
for Behavioural Health Statistics and Quality, The DAWN Report: 
Highlights of the 2009 Drug Abuse Warning Network (DAWN) Find-
ings on Drug-Related Emergency Department Visits, December 2010, 
of emergency department visits was much lower among 
the younger population.
In Canada, the annual prevalence of cannabis use among 
the adult population remains at levels comparable to 
those in the United States, although the annual preva-
lence has been declining since 2004. In 2009 the annual 
prevalence was reported at 12.6%, a decrease from 
13.6% in 2008 and 14.1% in 2004.9 There has also 
been a decline in the annual prevalence of cannabis use 
among youth aged 15-24, from 37% in 2004 to 26.3% 
in 2009.10 
There is no update on the extent of cannabis use in 
Mexico, but experts perceive an increase since 2008 
when use was reported at 1% among the adult popula-
tion. Cannabis use in Mexico remains at much lower 
levels than in the United States or Canada.
Some countries in South and Central America 
report increases in cannabis use
Cannabis use patterns and trends in the Caribbean, 
South and Central America remain unchanged, with the 
prevalence of cannabis use at comparable levels in these 
subregions. One third of the countries that reported 
expert opinions on trends of drug use considered that 
cannabis use in their countries had increased. Countries 
with high prevalence of cannabis use among the adult 
Rockville, Maryland, USA.
9 UNODC ARQ.
10 Health Canada, Canadian Alcohol and Drug Use Monitoring Survey: 
Summary Results for 2009, 2010.
Fig. 144: United States: Trends in the annual  
prevalence of cannabis use among  
the population aged 12 or older,  
2002-2009
Source: Substance Abuse and Mental Health Services Adminis-
tration, Results from the 2009 National Survey on Drug Use 
and Health: Summary of National Findings.
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Fig. 145: United States: Trends in the annual  
prevalence of cannabis use among 
secondary school students,  
2002-2010
Source: Monitoring the Future: national results on adolescent 
drug use.
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population in these regions include Argentina, Belize, 
the Plurinational State of Bolivia, Chile and Guatemala. 
As observed in other regions, the prevalence of cannabis 
use in Central and South America tends to be higher 
among youth than in the general population. One 
exception is Guatemala, where the prevalence of canna-
bis use is higher in the adult population aged 15-64 
(4.8%) than in the 12-19 age group (1%). In Argentina, 
the annual prevalence of cannabis use among the popu-
lations aged 15-64 and 13-17 is almost identical (7.2% 
and 7.6%, respectively). 
Profile of clients in treatment with cannabis as the primary drug  
of concern in the United States (2000-2008) 
Contrary to the general belief that cannabis use can result in little harm to users, in recent years, an increasing 
number of people in many regions have entered treatment for problems related to cannabis use. Presented below are 
some characteristics of a typical cannabis user entering treatment services in the United States, using data aggregated 
over the years 2000-2008. Based on this information, it can be inferred that cannabis users in treatment: 
1. Are most likely adolescents or young adults, single and male with secondary-level schooling.  
One third of clients are less than 17 years old. 
2. Are most likely not in the workforce, that is, unemployed or students.
3. Initiated their use of cannabis at a very young age - more than half by the age of 14 and almost  
90% before the age of 18. 
More than a quarter were daily users immediately prior to entering treatment, although more than a third had ceased 
use in the month prior to admission. The majority of referrals came through the criminal justice system.
Characteristic % of total
Age 12-17
18-24
25+
32.5
32.5
34.9
Gender Male
Female
74.4
25.6
Marital status Never married 80.5
Education 12 years or less 90.4
Employment status Full time
Part time
Unemployed
Not in labour force
(of which 55.4% are students)
19.2
9.2
25.3
46.3
Frequency of cannabis use No use in past month
1-3 times in past month
1-2 times in past week
3-6 times in past week
daily
35.0
16.4
10.4
11.8
26.4
Age at first use 11 and under
12-14
15-17
18-20
21+
13.6
42.3
31.2
8.5
4.4
Source of referral Individual (includes self-)
Healthcare provider
School
Employer
Community referral
Court/criminal justice system
16.1
10.3
3.9
1
11.5
57.1
DSM diagnosis Cannabis dependence
Cannabis abuse
40.8
28.8
Psychiatric problem in addition to cannabis problem 23.2
Source: SAMHSA, Treatment Episode Data Set (TEDS).
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Most countries in Europe have shown stable or 
declining levels of cannabis use, but it is reportedly 
on the increase in eastern Europe 
In some countries in eastern Europe, cannabis use 
exceeds the prevalence levels in western Europe. New 
data are available from a few countries in Europe, and 
they confirm the stabilization of cannabis use in West 
Europe. The Czech Republic, Estonia, Italy, Slovakia, 
Spain and the United Kingdom remain countries with 
high levels of cannabis use among the general popula-
tion and among young adults with perceived trends of 
increasing use reported in recent years.11
In Europe, the annual prevalence of cannabis use is esti-
mated at 5.2%-5.3% of the population aged 15-64. The 
prevalence of cannabis use is much higher in West and 
11 A new household survey in Italy indicates a strong decline in annual 
prevalence from 14.3% in 2008 to 5.2% in 2009 as well as a parallel 
decline in the lifetime prevalence of cannabis use among the general 
population. The comparability of the findings between these two 
surveys, however, is uncertain. 
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Source: UNODC ARQ.
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Fig. 147: Europe: Trends in annual prevalence of cannabis use in countries with new* data
* This refers to new or most recent data provided by Member States in 2010, either through the ARQ or in survey reports.
Source: UNODC ARQ; Government reports.
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Although there is not much reliable information on 
the extent of cannabis use in Africa, it is perceived 
to be widespread, and most countries reporting 
expert opinion consider that cannabis use continues 
to increase 
The estimated annual prevalence rates of cannabis use 
for Africa is the second highest in the world, with esti-
mates ranging between 3.8% and 10.4% of the popula-
tion aged 15-64, or between 21.6 and 59.1 million 
people. Higher levels of cannabis use are estimated for 
West and Central Africa compared to other subregions.
In Kenya, a 2009 survey conducted among 4,500 house-
holds in the coastal provinces indicated that the overall 
lifetime prevalence of cannabis use was 10.6% among all 
Central Europe (7.1%) than in East and South-East 
Europe (2.6%). The use of cannabis is in large part con-
centrated among young people, with the highest annual 
prevalence reported among those aged 15-24 (13.9%), 
compared to an average annual prevalence of 10% 
among the population aged 15-34 in West, Central and 
South-East Europe. 
The individual risk related to cannabis use seems lower 
than for heroin or cocaine, but health problems do exist 
and due to the high prevalence of use, the impact of 
cannabis on public health may be significant.12 On aver-
age, cannabis was reported as the primary drug in treat-
ment for 21% of cases in West and Central Europe and 
14% of cases in East and South-East Europe. Cannabis 
was also reported as a secondary drug by 24% of all 
outpatient clients in Europe. Among the younger drug 
users (aged 15-19) in treatment, a much higher propor-
tion (83%) were in treatment for primary cannabis 
use.13 As reported by EMCDDA, many cannabis clients 
also report the use of alcohol or other drugs. Based on 
data collected in 14 EU member states, 65% of the can-
nabis users had taken another substance – mostly alco-
hol or cocaine – and some reported the use of both 
alcohol and cocaine in the previous year. 
12 European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) Annual Report 2010: The State of the drugs problem in 
Europe, Lisbon, 2010. 
13 Ibid.
Fig. 148: Trends in annual prevalence of cannabis use in high prevalence countries 
Source: EMCDDA; UNODC ARQ.
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Cannabis use and psychosis
Evidence suggests that cannabis and other cannabinoids 
can produce a range of transient psychotic symptoms 
and cognitive deficits, such as transient deficits in learn-
ing, short-term memory, working memory, executive 
function, abstract ability, decision-making and atten-
tion. Increasing evidence also suggests that early onset 
and heavy cannabis exposure could increase the risk of 
developing a psychotic disorder such as schizophrenia. 
In a case control study conducted by Di Forti et al. in 
the United Kingdom (2009), it was reported that 
patients with a first episode of psychosis were more 
likely to have smoked higher potency cannabis (that is, 
cannabis with higher THC content) with greater fre-
quency and for a longer period. The study found that 
78% of the case groups used the high potency cannabis 
(Sinsemilla or Skunk with THC concentrations ranging 
between 12-18% and 0% cannabidiol) compared with 
37% of the control group (that smoked cannabis resin 
with both THC concentration and cannabidiol of 
3.4%) (AOR* 6.8); were daily users (AOR = 6.4), and 
had smoked cannabis for more than 5 years (AOR 2.1). 
Recent studies also indicate that cannabidiol reduces the 
acute cognitive effects of THC, an important aspect 
since the potency of cannabis has increased in Europe 
during the last 10 years and THC has been associated 
with the detrimental effects of cannabis on the mental 
health of at-risk users.
A recently published 10-year follow-up cohort study 
investigated the relationship between cannabis use and 
the subsequent development of psychosis over time and 
concluded that cannabis use was a risk factor for the 
development of incident psychotic symptoms. The 
study also concluded that continued cannabis use might 
increase the risk of psychotic disorder by impacting on 
the persistence of symptoms.
* AOR stands for Adjusted Odds Ratio, meaning that adjusting for 
age, gender, ethnicity, et cetera, those who had smoked higher THC 
content cannabis were 6.8 times more likely to report psychosis than 
the other group.  
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ages, with a much higher prevalence among the urban 
(11%) than the rural population (4%). The lifetime 
prevalence was at similar levels for all age groups except 
the 12-17 year olds, whereas the current use,14 reported 
at 5.3% among all age groups, was fairly consistent.15
In terms of treatment demand, compared to the other 
regions, cannabis remains the most common primary 
drug for which drug users seek treatment in Africa. This 
proportion varies from nearly all treatment admissions 
in countries such as Botswana, Malawi and Ghana to 
around one third of treatment admissions in Kenya, 
Mozambique and South Africa.
14 Defined as use in the past 4 weeks before the interview.
15 National Campaign Against Drug Abuse Authority (NACADA), 
Report of Survey on Drug and Substance Abuse in Coast Province Kenya 
– Main Report, March 2010.
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For New Zealand, the latest information on cannabis 
use dates from 2008, when the annual prevalence was 
estimated between 13.4% and 15.7% of the population 
aged 16-64. As commonly observed, men (21%) were 
more likely to have used cannabis in the past year than 
women (13.9%). Among the adult population, the past 
year cannabis use was highest among younger age groups 
and decreased with increasing age in the adult popula-
tion. The highest past year use prevalence was among 
men in the 18-24 year age group and for women in the 
16-17 and 18-24 year age groups.18
As shown in previous years, high annual prevalence of 
cannabis use is reported from many Pacific Island states 
and territories, ranging from 24.2% in Palau or 22.2% 
in Northern Mariana Islands to around 5% in Fiji and 
Marshall Islands. 
The emergence of synthetic cannabinoids  
in herbal products 
In 2008, several synthetic cannabinoids were detected in 
herbal smoking blends which were sold on the internet 
and in specialized shops under a variety of brand names 
such as ‘Spice Silver,’ ‘Spice Gold,’ ‘Spice Diamond,’ 
‘Yucatan Fire’ and ‘Smoke.’ These colourful and profes-
sionally designed herbal products typically contain about 
3 grams of finely cut plant material to which one or 
more synthetic cannabinoids have been added. 
Before 2008, the use of these herbal products seemed to 
be restricted to a small number of experimental users. 
However, in 2008,19 these products achieved immense 
popularity in Germany and other European countries 
through the internet and subsequent media reports, 
where they were referred to as ‘legal alternatives’ to can-
nabis, thus unintentionally promoting the use of these 
drugs.
The synthetic cannabinoids are generally administered 
by smoking either as a joint or in a water-pipe. These 
products do not contain tobacco or cannabis but when 
smoked were claimed to be able to produce cannabis-
like effects. 
Although so far, relatively little is known about the phar-
macology and toxicology of the various (and frequently 
changing) synthetic cannabinoids that are added to the 
herbal mixtures, a number of these substances may have 
a higher addictive potential compared to cannabis due 
to quicker development of tolerance (see text box).
Monitoring Reports 09, Australian Institute of Criminology.
18 Drug use in New Zealand, Key Results 2007/08 New Zealand Alcohol 
and Drug Use Survey, Ministry of Health, 2010.
19 Although a recent study showed a sharp decline in the use of spice in 
Germany, from 3% to 1% in 2009 (source: Abschlussbericht, Spice, 
Smoke, Sence & Co. – Cannabinoidhaltige Räuchermischungen: 
Konsum und Konsummotivation vor dem Hintergrund sich wandel-
nder Gesetzgebung, Goethe-Universität).
Currently, none of the synthetic cannabinoids found in 
these herbal products are internationally controlled 
under the 1961 or 1971 UN drug control conventions 
and at present, the control status of these compounds 
differ significantly from country to country. Most coun-
tries are challenged by the sheer number of synthetic 
cannabinoids constantly emerging, which means that 
control measures targeting individual compounds can 
be easily circumnavigated. Some Member States, for 
example, the United Kingdom, Ireland and Luxem-
bourg, have adopted a more generic approach to con-
trolling synthetic cannabinoids of similarly structured 
compounds. Nevertheless, effective implementation of 
control measures could be hampered by the lack of ana-
lytical data and reference samples, as well as methodolo-
gies for toxicological identification of metabolites in 
biological specimens.
Fig. 153: New Zealand: annual prevalence 
of cannabis use by gender and age 
group, 2008
Source: Drug use in New Zealand, Key Results 2007/08 New 
Zealand Alcohol and Drug Use Survey, Ministry of Health 
2010. 
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Chemistry and effects of synthetic 
cannabinoids 
Chemistry
Synthetic cannabinoids are typically synthetic cannabi-
noid agonists that function similarly to D9-tetrahydro-
cannabinol (THC), the principal psychoactive 
component in cannabis. Like THC, synthetic cannabi-
noids have structural features that allow binding to one 
of the known cannabinoid receptors, that is, CB1 or 
CB2, in the brain and other organs to produce canna-
bis-like pharmacological activity. Currently, there are 
many compounds with chemically unrelated structures 
that fall under this definition and could be classified as 
follows:*
i) Classical cannabinoids (for example, HU-210, 
AM-906, AM-411, O-1184)
ii) Nonclassical cannabinoids (for example, CP-
47,497-C8, CP-55,940, CP-55,244)
iii) Hybrid cannabinoids (for example, AM-4030)
iv) Aminoalkylindoles (for example, JWH-018, JWH-
073, JWH-398, JWH-015, JWH-122, JWH-210, 
JWH-081, WIN-55,212, JWH-250, JWH-251, 
pravadoline, AM-694, RSC-4)
v) Eicosanoids (for example, anandamide, methanan-
damide)
vi) Others (for example, Rimonabant®, JWH 307, 
CRA-13)
Synthesis and precursors
A number of methods for synthesizing synthetic can-
nabinoids have been described in detail in the scientific 
literature.** Precursor chemicals can also be obtained 
from commercial chemical suppliers. In general, synthe-
ses of classical, nonclassical or hybrid cannabinoids are 
much more elaborate and complicated due to the pres-
ence of asymmetric centres in these compounds. As a 
result, stereoselective synthesis or elaborate separation of 
stereoisomers are often necessary to isolate the desired 
compound. As for compounds without asymmetric 
centres like most aminoalkylindoles, a vast variety of 
similar compounds could be easily synthesized by the 
addition of a halogen, alkyl, alkoxy or other substituents 
to one of the aromatic ring systems, or other small 
changes could be made, such as variation of the length 
and configuration of the alkyl chain.
Most of the aminoalkylindoles can be easily synthesized 
with standard laboratory equipment and readily availa-
ble reagents. The synthesis of nonclassical cannabinoids 
requires more elaborate equipment and technical know-
how, but it should be feasible for a chemist with a sound 
basic training in organic synthesis.
Medicinal use 
Some synthetic cannabinoids are commercially available 
for medicinal purposes such as Nabilone (Cesamet®) for 
treatment of cancer patients under chemotherapy and 
Dronabinol (Marinol®) which is a synthetically pro-
duced pure THC applied in multiple sclerosis and pal-
liative care.
Pharmacology and toxicity
So far, little is known about the pharmacology and 
toxicology of these compounds. Some case reports have 
shown that health-related problems associated with the 
use of these herbal products seem to be very similar to 
problems reported after cannabis use.*** Cardiovascular 
problems and psychological disorders such as panic 
attacks were among the frequently reported symptoms. 
A number of these substances may have a higher addic-
tive potential compared to cannabis due to quicker 
development of tolerance. Some synthetic cannabi-
noids, for example, HU-210, CP-55,940 and WIN-
55,212-2, which act as full agonists at the CB1 receptor, 
could possibly cause severe or even life-threatening 
intoxications when overdosed. Furthermore, due to its 
structural features in certain aminoalkylindoles, some 
carcinogenic potential could also be possible.
* Howlett et al., ‘International Union of Pharmacology. XXVII. 
Classification of cannabinoid receptors,’ Pharmacol Rev, 2002. 
54(2): p. 161‒202. 
** Huffman et al., ‘Structure-activity relationships for 1-alkyl-3-
(1-naphthoyl)indoles at the cannabinoid CB1 and CB2 recep-
tors: steric and electronic effects of naphthoyl substituents. New 
highly selective CB2 receptor agonists,’ Bioorganic and Medicinal 
Chemistry, 2005, 13(1): pp. 89‒112.
*** Vardakou et al., ‘Spice drugs as a new trend: mode of action, 
identification and legislation,’ Toxicology Letters, 2010. 197(3): 
pp. 157‒62.
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5.3 Production
Cannabis is produced in practically every country of the 
world, making it the most widely produced illicit drug. 
Cannabis herb is mostly produced for domestic or 
regional markets, whereas cannabis resin is trafficked 
over larger distances. The major countries identified as 
sources by the cannabis resin consumer markets are 
Afghanistan, Morocco, Lebanon and Nepal/India. 
Attempts to estimate cannabis production encounter 
severe deficiencies in the data, which were extensively 
described in former World Drug Reports and is reflected 
in the reporting. In the 2009 World Drug Report, it was 
estimated that the production of cannabis herb ranged 
from 13,300-66,100 mt and of cannabis resin from 
20 UNODC, Afghanistan cannabis survey 2010 (preliminary).
21 OAS, Mecanismo de Evaluación Multilateral, Evaluación del progreso 
de control de drogas 2007-2009.
22 US Department of State, International Narcotics Control Strategy 
Report, 2011.
2,200-9,900 mt. The resulting total area under cannabis 
cultivation was estimated at 200,000-641,800 ha. The 
calculations were based on the minimum and maximum 
levels from reported cultivation and production, seizures 
and user prevalence rates. In 2010, these indicators did 
not show significant changes that would justify an 
update of the production estimates, taking into account 
the large minimum and maximum levels. Therefore, the 
production estimates were not updated for this World 
Drug Report. This chapter focuses on some production 
trends found in the last year, with a focus on trends in 
potency.
23 Note Verbale to UNODC, 27 December 2010.
24 Calculated from the harvestable area, number of harvests and yield 
figures in UNODC, ARQ 2009.
25 US Department of Justice, Drug Enforcement Administration, 2009.
Table 39: Update of available information on the extent of cannabis cultivation and production  
in major producing countries, 2009* 
Source: UNODC ARQ 2009 unless otherwise specified.
Country Cultivated  area (ha)
Eradication Harvestable 
area (ha)
 Production (mt)
Area (ha) Plants Resin Herb
Afghanistan20 9,000-29,000 (2010)
 9,000-29,000 
(2010)
Belarus 300 300
Bolivia21 1,910,857 (kg) 1,200-3,700 (2010)
Guatemala 429,610 (kg)
India 4,265 4,265 0
Lebanon 1,310 1,310 0
Mexico 16,547 17,50022
Morocco  47,50023
Nigeria 925
Philippines 477,927 (kg)
South Africa 880 567 313 65724
Spain  29
Sri Lanka 500
Swaziland 542 
USA25 9,980,038 outdoor plants/ 414,604 indoor plants
* Or other year, if mentioned.
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Cannabis cultivation in some major  
producing countries 
In 2010, UNODC and the Government jointly carried 
out a survey in an important cannabis resin producing 
country, Afghanistan. The results of the first cannabis 
survey in 2009 indicated that Afghanistan is among the 
major cannabis resin producing countries and that can-
nabis has become a competitor to opium poppy as a 
lucrative crop for farmers in the country. The prelimi-
nary 2010 survey gave no indications for major changes 
in the levels of cultivation and production compared to 
2009. It showed a cultivation range of 9,000 to 29,000 
hectares, compared to 10,000-24,000 hectares in 2009. 
Resin production ranged between 1,200 and 3,700 mt, 
compared to 1,500 to 3,500 mt in 2009. 
The importance of Afghanistan as a cannabis resin pro-
ducer is reflected in the seizures reported by other coun-
tries. 10% of all countries reporting cannabis seizures 
mentioned Afghanistan as the source of cannabis. The 
Government of Morocco reported a reduction of cultiva-
tion area to 47,500 ha,26 however, Morocco continued 
to be mentioned as source by the majority of countries 
reporting cannabis resin seizures to UNODC (19%). 
This suggests that Morocco continued to be a major 
producer of cannabis resin. Data on seizures and prices 
in Europe suggest that the supply of cannabis resin from 
Morocco to the region has remained the same or slightly 
decreased.
Other countries were increasingly reported as sources of 
 
26 The last joint survey by UNODC and the Moroccan Government 
was carried out in 2005.
27 US Department of Justice, National Drug Threat Assessment 2010.
28 US Department of Justice, Drug Enforcement Administration, 2009.
cannabis, including Lebanon, Spain (as a transit country 
for Moroccan cannabis), Turkey and India. India also 
reported substantial cannabis cultivation and subse-
quent eradication of 4,265 ha.
The amount of cannabis herb produced in the United 
States is unknown but believed to be high and rising. 
The rise is illustrated by the continuing increase of 
eradicated cannabis plants, mainly grown on public 
lands by foreign criminal groups (attributed to Cauca-
sian, Asian, Cuban and Mexican criminal groups/drug 
trafficking organizations.27) The indoor production is 
believed to be increasing as well; however, the number 
of eradicated indoor-grown plants is stable.28 
Although the Mexican Government does not estimate 
its national production level,29 reports from the United 
States suggest that cannabis cultivation in Mexico has 
increased. The US estimates suggest that cultivation 
in Mexico has increased from 5,600 ha in 2005 to 
17,500 ha in 2009. According to the US sources, the 
increase may be a result of a shifting law enforcement 
focus from reduction of illicit crop cultivation to public 
security tasks.30 
Cannabis production in Europe is believed to be 
in creasing,31 mostly in indoor settings and increasingly 
controlled by organized crime groups. Herbal cannabis 
is now commonly produced inside Europe (29 Euro-
pean countries reported domestic cultivation in 2008), 
closer to its intended market and therefore less likely to 
be intercepted.32 
29 Currently, the Mexican Government is preparing to conduct its own 
cannabis production surveys in cooperation with UNODC.
30 US Department of State, International Narcotics Control Strategy 
Report, 2011.
31 EMCDDA, Annual Report 2010.
32 Ibid.
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Fig. 154: Main source* countries of cannabis resin reported to UNODC in the periods 2007-2009  
and 2004-2006**
* Source countries might not always mean the country where it was produced and might also indicate the latest known transit country.  
** Number of times that countries were identified as source countries, represented as proportion of countries reporting. 
Source: UNODC ARQ.
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Changes in THC concentrations
In the recent past there were claims of strong increases in 
THC concentrations (frequently referred to as ‘potency’) 
of cannabis, the main active component of cannabis. 
Cannabis THC contents have changed frequently in dif-
ferent countries. The most systematic and standardized 
collections of THC content are performed in the United 
States, the Netherlands and Germany33 and are pre-
sented below. 
33 Measured from samples: in the USA, from 46,211 samples confis-
cated by law enforcement agencies; in the Netherlands, from yearly 
collected samples from 50 randomly selected coffeeshops; in Ger-
many, calculated from seizure data, in 2009 from 9,250 samples.
THC concentration in herbal cannabis in the  
United States, the Netherlands and Germany
At the end of the 1990s/beginning of the 2000s, both 
the US and the Netherlands experienced an increase of 
the average THC contents in their herbal cannabis prod-
ucts. In the US, the average THC concentration of sin-
semilla doubled from 6% to 13% from the early 1990s 
to the late 1990s, after which the level decreased and 
became practically stable around 11% over the past 
decade.34 At the same time, THC contents of the more 
34 These are average values and the ranges of potency have not changed. 
High potency cannabis was also available in the past, however, it was 
less common. 
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Fig. 155: Eradicated cannabis plants at indoor 
and outdoor cultivation sites in the 
United States, 2003-2009
Source: US Department of Justice, Drug Enforcement  
Administration, 2009.
Fig. 156: Cultivation and eradication ﬁgures 
for Mexico, 2005-2009
Sources: UNODC ARQ; US International Narcotics Control 
Strategy Reports.
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commonly grown marijuana are significantly lower since 
the consumed marijuana in the USA is mainly produced 
outdoors; THC contents in marijuana show a consistent 
but slowly increasing trend in the 15-year period. 
In the Netherlands, yearly analyses have been performed 
since 2000, and the results show a sharp increase in 
THC concentration of sinsemilla in the early 2000s, 
from nearly 9% to 19%. This is attributed to the increas-
ingly common use of improved breeds, indoor cultiva-
tion and the use of sophisticated techniques. Although 
these techniques were already available in the 1980s, the 
profile of the cultivators has changed to organized pro-
fessionals. Nevertheless, since 2004, the general trend 
was downwards to 15% in 2009. In Germany, the THC 
concentration of marijuana, which is a broader group 
than sinsemilla alone, shows a similar trend, doubling its 
THC content from 5% in 1997 to more than 10% in 
2004, dropping back again to around 8% in 2009. The 
similar patterns probably reflect similar production 
sources. Reports from other countries are fragmented 
and less systematic; the European countries that reported 
sufficient data for herbal cannabis reported divergent 
trends for the period 2003-2008. Six countries reported 
an increase, four a decrease.35 
THC concentration in cannabis resin
In the Netherlands, THC contents of cannabis resin 
show a growth trend similar to that of sinsemilla. The 
level in the Netherlands increased from 20% to almost 
40% in the early 2000s, after which it dropped to around 
30% during 2005-2010. In Germany, the THC con-
tents have been fluctuating around 8%, without show-
ing a long-term change. The THC contents of cannabis 
resin in other European countries followed divergent 
patterns, with some countries showing an increase and 
others a decrease. 
35 EMCDDA, Annual Report 2010.
Fig. 157: THC concentrations for different cannabis products in the Netherlands, United States  
and Germany, with varying time series
Sources: THC-concentraties in wiet, nederwiet en hasj in Nederlandse coffeeshops 2009-2010; THC-concentraties in wiet,  
nederwiet en hasj in Nederlandse coffeeshops 2005-2006.; Mehmedic, Z. et al, ‘Potency Trends of 9-THC and Other Cannabinoids 
in Confiscated Cannabis Preparations from 1993 to 2008,’ Journal of Forensic Sciences, September 2010, Vol. 55, No.5, pp.  
1209-1217; 2010 national report (2009 data) to the EMCDDA by the Reitox National Focal Point for Germany.
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5.4 Trafficking
Among the four major drug groups, cannabis derivatives 
constitute the most widely trafficked and most easily 
available class of illicit drugs. Reports of cannabis sei-
zures refer mainly to cannabis herb and cannabis resin, 
but also cannabis plant, cannabis oil and cannabis seed. 
Large quantities of cannabis herb are seized worldwide, 
while seizures of cannabis resin are concentrated mainly 
in Europe, North Africa and the Near and Middle East/
South-West Asia, reflecting the locations of production 
and main consumer markets for cannabis resin. The fact 
that production of cannabis resin occurs to a large extent 
in countries removed from the main consumer markets 
brings about the necessity for trafficking of cannabis 
resin across different regions, in contrast with the more 
localized trafficking patterns of cannabis herb.
Cannabis herb
Following a slight drop (8%) in 2008, in 2009, global 
cannabis herb seizures returned to the levels of 2006 and 
2007, amounting to 6,022 mt. North America accounted 
for 70% of global seizures, followed by Africa (11%), 
South America (10%), Asia (6%) and Europe (3%).
Given the relative ease of cannabis cultivation, the 
supply of cannabis herb can often be locally sourced, 
with the result that the trafficking patterns tend to be 
rather localized in comparison with cannabis resin or 
other drugs. In the ARQ replies for 2009, out of 68 
countries that provided information about the country 
of origin of cannabis herb trafficked in their territories, 
44 countries assessed that some or all cannabis herb 
originated in their own country. For these countries, on 
average 75% of all herb originated from their own coun-
try.36
Cannabis herb retail prices displayed significant inter-
regional as well as intra-regional variation, even when 
adjusted for purchasing power parity. Retail prices 
appear to be driven both by the availability of cannabis 
herb, which is in turn linked to domestic production 
levels, as well as the disposable income of consumers. 
Overall, prices were significantly lower in Africa and in 
Central and South America and the Caribbean. Some of 
the lowest prices were registered in Togo, India, Guate-
mala and the United Republic of Tanzania, while the 
highest price was registered in Japan. The low prices in 
some of these countries could be partly due to high 
production, but income levels likely also play a signifi-
cant role. Similarly, the price in Japan may be high 
partly because of the high income level of consumers 
and partly because, contrary to the common pattern in 
other countries, a significant share of cannabis herb in 
Japan appears to be imported. 
36 Calculated based on the 33 countries that gave a percentage. The 
other 11 countries pointed to their own country without specifying 
the proportion.
Fig. 158: Cannabis herb seizures worldwide, 1999-2009
Source: UNODC DELTA.
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Americas
Cannabis herb seizures in North America rose from 
3,205 mt in 2008 to 4,189 mt in 2009, driven by 
increases in both Mexico and the United States, which 
continued to report the largest cannabis herb seizures 
worldwide. Large quantities of cannabis herb are pro-
duced in Mexico and trafficked to the United States. 
Seizures in the United States rose to a record level of 
2,049 mt in 2009, up by one third on the previous year, 
and a similar increase was registered in Mexico, with 
seizures rising from 1,658 mt in 2008 to 2,105 mt in 
2009.
Seizures in Mexico were made mainly close to the areas 
of cultivation or close to the border with the United 
States. In 2009, the contiguous states of Sinaloa, 
Durango, Chihuahua and Sonora accounted for 75% of 
cannabis herb seizures, while Sinaloa, Chihuahua and 
Durango accounted for 76% of eradication, with the 
states of Nayarit, Jalisco, Michoacán, Guerrero and 
Oaxaca on the Pacific coast accounting for an additional 
20% of eradication.
The supply of cannabis herb in the consumer market in 
the United States is partly locally produced and partly 
trafficked into the country from Mexico as well as, to a 
smaller extent, from Canada. In 2008, border seizures of 
cannabis herb made by US authorities amounted to 
1,253 mt on the US-Mexico border and 3 mt on the 
US-Canada border; based on partial data for 2009, sei-
zures on both borders rose in 2009, but they remained 
concentrated on the US-Mexico border. According to 
US authorities, cannabis herb in Mexico was widely 
available, in part due to rising production there.37
37 US Department of Justice, National Drug Threat Assessment 2010.
The United States also reported that foreign drug traf-
ficking organizations were increasingly engaging in 
indoor and outdoor cannabis cultivation, and their dis-
tribution networks were growing. Canada reported that 
Asian organized crime groups continued to specialize in 
cannabis cultivation while Indo-Canadian and East 
European organized crime groups were involved in 
cross-border smuggling.
Large quantities of cannabis herb, as well as cannabis 
plants, continued to be seized in South America. Sei-
zures in this region peaked at 946 mt in 2007 and since 
then fell twice in succession, standing at 598 mt in 
2009. The largest seizures were registered in Colombia, 
where seizures declined from 255 mt in 2008 to 209 mt, 
and in Brazil, where seizures also fell, from 187 mt in 
2008 to 131 mt. In relative terms, a significant increase 
was registered in the Bolivarian Republic of Venezuela, 
where seizures rose by 58% in 2009, reaching 33 mt – 
the highest level since 1990.
Considering seizures of the various forms of cannabis 
collectively (cannabis herb, plant, resin, oil and seed), 
the Plurinational State of Bolivia recorded a consistent 
increase over the period 1998-2009. The reported quan-
tities, which include predominantly cannabis plant, 
amounted to 320 kg in 1998, 28 mt in 2004 and 1,937 
mt in 2009. According to preliminary data, seizures 
receded to 1,073 mt in 2010. 
The recent high levels of cannabis plant seizures in the 
Plurinational State of Bolivia are comparable with can-
nabis plant seizures registered in Paraguay in 2007 and 
2008 – 4,667 mt in 2007 and 5,185 mt in 2008. Sei-
zures of very large numbers of cannabis plants have also 
been reported by Guatemala: 10.8 million in 2008 and 
4.3 million in 2009.
Fig. 159: Cannabis herb retail prices worldwide, by region, 2009
Source: UNODC DELTA.
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Africa
Seizures of cannabis herb in Africa have fluctuated con-
siderably in recent years, but have followed a generally 
decreasing trend since the peak level of 2004. In 2009, 
total seizures in Africa fell to 640 mt, from 936 mt in 
2008. The decline was partly due to a significant drop 
in Nigeria.
Although cannabis herb continues to be trafficked 
throughout Africa, seizures tend to be concentrated in a 
small number of countries. Over the period 2000-2009, 
UNODC collated records of cannabis herb seizures 
from 48 countries in Africa. However, seizures in seven 
of these countries (Egypt, Kenya, Malawi, Morocco, 
Nigeria, South Africa and the United Republic of Tan-
zania) accounted for 90% or more of the annual total for 
Africa each year from 2000 to 2009 and for 94% of the 
quantity seized in Africa over the entire period.
In 2007 and 2008, the largest annual seizures of can-
nabis herb in Africa were reported by Nigeria. However, 
in 2009 seizures in this country fell by almost two thirds, 
to 115 mt, from 336 mt in 2008. Nigeria assessed that, 
in 2009, cannabis herb on its territory originated entirely 
in Nigeria itself, but was destined for the Netherlands 
(50%), Japan (30%) and Italy (20%). Nigeria also 
reported a notable increase in the farm-gate price of can-
nabis – from 8,000 Naira per kg in 2008 to 35,000 
Naira per kg in 2009. Both the decline in seizures and 
the increase in price were attributed to the destruction 
of cannabis farms by law enforcement operatives in 
Nigeria. 
Morocco continued to seize large quantities of ‘kif,’ 
selected parts of herbal cannabis which can be further 
processed into cannabis resin.38 However, Morocco has 
also been mentioned by other countries as a country of 
origin for cannabis herb, sometimes in addition to can-
nabis resin. Seizures of ‘kif ’ amounted to 223 mt in 
2009 to 187 mt in 2010. In 2009, seizures of cannabis 
herb declined in Egypt, from 81 mt in 2008 to 63 mt, 
and in the United Republic of Tanzania, from 70 mt in 
2008 to 56 mt. 
38 Stambouli, H., El Bouri, A., Bellimam, M. A., Bouayoun, T. and El 
Karn, N., ‘Cultivation of Cannabis sativa L. in northern Morocco,’ 
Bulletin on Narcotics, Volume LVII, Nos. 1 and 2, 2005.
Fig. 160: Growth of aggregate cannabis*  
seizures in selected South American 
countries, 1997-2009 (baseline: 1997)
*Cannabis herb, plant, resin, oil and seed. For the purposes of 
aggregation, one cannabis plant is assumed to have a weight of 
100 grams.
Source: UNODC DELTA.
Fig. 161: Africa: seizures of cannabis herb  
by subregion, 1999-2009
Source: UNODC DELTA.
Fig. 162: Africa: cannabis herb seizures,  
by country, 2009
Source: UNODC DELTA.
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South Africa continued to be a source, consumer and 
transit country for cannabis herb. It appears that the 
ports of South Africa provide a gateway for cannabis 
herb produced in neighbouring countries, as well as 
South Africa itself, and exported to consumer markets 
outside Africa. This reflects the role of this country as a 
major trans-shipment hub for legitimate trade. South 
Africa assessed that, in 2009, 80% of cannabis herb on 
its territory originated in neighbouring countries 
(Lesotho and Swaziland). Moreover, an estimated 30% 
were destined for the consumer markets of Europe. Sei-
zures in South Africa amounted to 126 mt in 2009. In 
the ARQ replies for 2007-2009, South Africa was men-
tioned eight times by other countries as a country of 
origin for cannabis herb. Contrary to the prevalent trend 
of localized trafficking patterns for cannabis herb, seven 
of these mentions were by countries outside Africa.
Asia-Pacific
In 2009, the Asia-Pacific region accounted for 5.5% of 
global cannabis herb seizures. Seizures in this region rose 
for the second year in a row, standing at 333 mt in 2009. 
The increases were mainly due to the amounts seized in 
India and Indonesia, which reported the largest seizures 
in this region by far. 
In 2008, seizures in Indonesia reached a record level of 
141 mt. In 2009, seizures fell to 111 mt, but remained 
high in comparison with historical levels, which aver-
aged 20 mt over the 2003-2007 period. Indonesia 
assessed that 99% of cannabis herb on its territory orig-
inated in Indonesia itself. The increased levels were 
attributed to improvements in law enforcement efforts, 
and the decline in 2009 to the success of alternative 
development programmes.
In 2009, cannabis herb seizures in India rose by almost 
two thirds, from 103 mt in 2008 to 171 mt – the high-
est level since 1994. India assessed that 81% of the can-
nabis seized on its territory in 2009 originated in India 
itself, with the remainder originating in Nepal. An 
unspecified proportion was intended for Bangladesh. In 
2008, seizures of cannabis herb in Nepal rose to 9.6 mt 
(the highest level since 1987), and increased by a further 
73% in 2009, reaching 17 mt.39 
According to Thai authorities,40 cultivation of cannabis 
herb in Thailand had been drastically reduced over a 
period of 20 years, and recent trafficking patterns for 
cannabis herb involved smuggling into Thailand from 
39 Fifteenth Asia-Pacific Operational Drug Enforcement Conference, 
February 2010, Tokyo, Japan, country report by Nepal.
40 Fifteenth Asia-Pacific Operational Drug Enforcement Conference, 
February 2010, Tokyo, Japan, country report by Thailand and Office 
of the Narcotics Control Board of Thailand, presentation at the 
Twentieth Anti-Drug Liaison Officials’ Meeting for International 
Cooperation (ADLOMICO), October 2010, Seoul, Republic of 
Korea.
the Lao People’s Democratic Republic and out of Thai-
land into Malaysia. Cannabis herb seizures in Thailand 
amounted to 19 mt in 2008 and 18 mt in 2009. Sig-
nificant quantities were also seized in 2009 in Malaysia 
(2.4 mt, up from 875 kg in 200841) and the Philippines 
(1.9 mt, down from 3.7 mt in 2008).
In Japan, seizures declined from 504 kg in 2007 to 207 
kg in 2009. Japan attributed the decline to a decrease in 
cases of illegal importation accompanied by an increase 
in domestic illicit cultivation of cannabis. According to 
Japanese authorities, one case of large-scale indoor culti-
vation of cannabis was discovered in Japan and involved 
six Vietnamese and one Japanese national.42 Moreover, 
the number of arrests for cannabis cultivation rose from 
207 in 2008 to 243 in 2009, while the number of arrests 
for smuggling of cannabis fell from 85 in 2008 to 48 in 
2009.43 Nevertheless, in 2009 cannabis herb also con-
tinued to be smuggled into Japan from other countries, 
such as Botswana, France, South Africa and the United 
States.44 
Seizures of cannabis herb in Oceania have declined sig-
nificantly since the peak level of 2001, mainly due to 
Australian seizures. In 2009 seizures in New Zealand 
amounted to 759 kg, while in Australia seizures amounted 
41 Data collated by DAINAP.
42 International Intelligence Division, Narcotics Control Department, 
Japan. Presentation at the Twentieth Anti-Drug Liaison Officials’ 
Meeting for International Cooperation (ADLOMICO), October 
2010, Seoul, Republic of Korea.
43 Drugs and Firearms Division, National Police Agency, Japan. Pres-
entation at the Twentieth Anti-Drug Liaison Officials’ Meeting for 
International Cooperation (ADLOMICO), October 2010, Seoul, 
Republic of Korea.
44 Twentieth Anti-Drug Liaison Officials’ Meeting for International 
Cooperation (ADLOMICO), October 2010, Seoul, Republic of 
Korea, country report by Japan.
Fig. 163: Cannabis herb seizures in the  
Asia-Paciﬁc region, 1999-2009
Source: UNODC DELTA.
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to 629 kg45 in 2009 and 745 kg in 2008, significantly 
less than previous levels in this country, which averaged 
6.1 mt over the 2001-2003 period. Despite the high 
prevalence rate of cannabis use in Australia, the seized 
quantities are relatively low, even when compared on a 
per capita basis with similar consumer markets such as 
Europe and the United States.
Rest of the world
In Central Asia, the largest quantities of cannabis herb 
continued to be seized by Kazakhstan (26 mt in 2009) 
where cannabis was partially supplying the domestic 
market and partially intended for other markets such as 
the Russian Federation where significant seizures were 
also registered (33 mt, up from 25 mt in 2008). Seizures 
in West and Central Europe amounted to 101 mt, essen-
tially sustaining the increased level of 2008. 
In recent years, seizures of cannabis herb in Turkey have 
followed a notable increasing trend, rising six-fold over a 
period of 5 years, from 6.8 mt in 2004 to a record level 
of 42 mt in 2009. According to Turkish authorities,46 
the increase in cannabis trafficking was attributable to 
illicit cultivation taking place in some rural parts of the 
country. 
Cannabis resin
Global cannabis resin seizures reached a record of 1,648 
mt in 2008, and in 2009 declined to 1,261 mt - a level 
comparable to those registered in previous years. Every 
year from 2001 onwards, West and Central Europe, the 
45 This figure represents an aggregate of 624 kg of cannabis herb 
together with 11,042 seeds or bags, converted assuming a weight of 
half a gram per unit. 
46 Ministry of Interior, Turkish National Police, Department of Anti-
Smuggling and Organized Crime, Turkish Report on Drugs and 
Organized Crime 2009.
Near and Middle East/South-West Asia and North 
Africa together accounted for 95% or more of global 
cannabis resin seizures. The proportion attributable to 
West and Central Europe declined gradually from 73% 
in 2004 to 48% in 2009. The year 2009 marked a sig-
nificant shift in cannabis resin seizures, away from the 
consumer market of West and Central Europe and 
toward North Africa, an important source region for 
cannabis resin reaching Europe. 
The high level of 2008 was partly due to increases in the 
Near and Middle East/South-West Asia; in particular a 
single extraordinarily large seizure of 236.8 mt47of can-
nabis resin made by Afghan authorities in Kandahar 
province in June 2008. A less pronounced increase in 
seizures was registered in West and Central Europe in 
2008; however, in 2009 seizures fell in both West and 
Central Europe and the Near and Middle East/South-
West Asia, and the drop was partially offset by seizures 
in North Africa. 
In contrast with cannabis herb, the demand for which 
tends to be met by production occurring in relative 
proximity to consumption, large quantities of cannabis 
resin are trafficked significant distances to reach con-
sumer markets.
Europe and North Africa
Spain continued to report the largest annual seizures of 
cannabis resin worldwide. Large quantities of cannabis 
resin are trafficked from the source country of Morocco 
to Spain, and on to other countries in Europe. In 2009, 
47 International Security Assistance Force, Press Release 11 June 
2008 (http://www.nato.int/isaf/docu/pressreleases/2008/06-june/
pr080611-246.html) and UNODC press release, 12 June 2008 
(http://www.unodc.org/unodc/en/press/releases/2008-06-12.html).
Fig. 164: Global cannabis resin seizures, by region, 1999-2009
Source: UNODC DELTA.
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seizures of cannabis resin in Spain fell to 445 mt – the 
lowest level since 1999 (431 mt) - while seizures in 
Morocco rose from 114 mt in 2008 to 188 mt in 2009 
– the highest level on record. Over the period 1999-
2009, approximately one half of significant individual 
drug seizures reported by Spain involved cannabis resin. 
Among these seizure cases, Morocco was practically the 
only country of origin48 for the seized cannabis resin. 
However, Morocco is likely not the only source country 
for cannabis resin reaching Europe, and Spain assessed 
48 This excludes mentions of Spain itself as the country of ‘origin,’ 
which likely refer to the point of departure of the consignment rather 
than the actual country of origin of the drug.
that the drop in the total quantity of resin seized in 
Spain was due to the European market drawing from 
another supplier than Morocco. In 2010, seizures in 
Morocco fell back to 118 mt.
Increases in cannabis resin seizures were also observed in 
other North African countries. In Algeria and Egypt, 
seizures more than doubled in 2008, reaching a record 
level of 38 mt in Algeria and a level of 12.8 mt – the 
highest since 1989 - in Egypt. In 2009, seizures in Egypt 
appeared to stabilize, amounting to 11.4 mt, but sei-
zures in Algeria rose even further, registering the fourth 
consecutive year-on-year increase. Indeed, seizures in 
Algeria amounted to 74.6 mt in 2009, compared with 
1.7 mt in 2005. Algeria reported that in 2009 cannabis 
resin and cannabis herb in its territory originated entirely 
in Morocco.
Seizure data and, to some extent, price data support the 
flow of cannabis resin from North Africa into western 
Europe via Spain. Apart from Spain, which reports the 
largest cannabis seizures in Europe by far, the largest 
seizures among European countries in 2009 were 
reported by France and Portugal, followed by Italy and 
Belgium. The decrease in seizures in Spain in 2009 was 
reflected in similar decreases in the four European coun-
tries which seized the largest quantities in 2008 (apart 
from Spain): France (-21%), Portugal (-62%), Italy 
(-43%) and the United Kingdom (-61%). Seizures in 
Belgium have fluctuated considerably, amounting to 
18.7 mt in 2009 (up from 1.5 mt in 2008).
Fig. 165: Signiﬁcant individual seizures of  
cannabis resin in Spain originating in 
Morocco, 1999-2009
Source: UNODC IDS.
Fig. 166: Wholesale cannabis resin prices in Europe, 2009
Source: UNODC DELTA.
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China and India overland. Cannabis resin was further 
distributed from India to other destinations via cargo 
couriers.
Near and Middle East/South-West Asia
Seizures of cannabis resin in Pakistan rose for two years 
running, reaching 205 mt in 2009 – the highest level 
since 1995. Pakistan continued to assess the share of 
cannabis resin originating in Afghanistan at 98%. Over 
the period 1999-2009, 41% of significant individual 
drug seizures reported by Pakistan involved cannabis 
resin; the country of origin for these consignments was 
identified almost exclusively as Afghanistan.
In the Islamic Republic of Iran, seizures of cannabis 
resin fell twice in succession, from the record level of 
2007 (90 mt) to 69 mt in 2009. Based on data for the 
first nine months of the year, it appears that the decreas-
ing trend continued into 2010. The Islamic Republic of 
Iran assessed that, in 2009, one quarter of cannabis resin 
trafficked on its territory was intended for the country 
itself, with the remainder intended for Arab countries, 
Turkey and Europe. 
Seizures in Afghanistan fell from the record level of 2008 
(271 mt) to the relatively low level of 10.5 mt in 2009, 
representing slightly less than 1% of the global total for 
2009. Seizures in Afghanistan averaged 56 mt over the 
2002-2007 period. 
North America
Seizures of cannabis resin in the Americas remained 
limited. In 2009, seizures rose significantly but at 10.8 
mt, remained below 1% of the global total. Neverthe-
less, Canada has a significant consumer market for can-
nabis resin. In 2008, almost one half of cannabis resin 
seizures in the Americas were made by Canada (899 kg). 
In 2009, Canada seized a much larger quantity - 9.7 mt 
- in 2,045 individual seizures, two of which together 
accounted for 82% of the total. Moreover, the traffick-
ing routes for cannabis resin reaching Canada appeared 
to undergo significant changes. Canada identified the 
Caribbean, North Africa and South-East Asia as the 
origin for cannabis resin reaching its territory in 2008, 
but these were replaced by Southern Africa and South-
West Asia in 2009. 
In the United States, seizures rose from 367 kg in 2008 
to 811 kg in 2009. The United States also assessed that, 
in 2008, cannabis resin was trafficked both to the United 
States via Canada (from North Africa), and to Canada 
via the United States (of Caribbean origin). Seizures of 
cannabis resin in Mexico rose from 6 kg in 2007 to 297 
kg in 2008 – the highest level since 1995. However, 
seizures fell to 11 kg in 2009. In Brazil, cannabis resin 
seizures tripled between 2006 and 2008, reaching the 
record level of 301 kg in 2008, but fell to 204 kg in 
2009.
Fig. 167: Significant individual seizures of  
cannabis resin in Pakistan originating 
in Afghanistan, 1999-2009
Source: UNODC IDS.
Significant individual drug seizures of cannabis resin in 
Pakistan originating in Afghanistan, 1999-2009
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Fig. 168: Global seizures of cannabis herb, 1999-2009
Year 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Metric tons 4,042   4,680   5,504    5,076    6,295    6,739    4,901    5,932    5,982    5,510   6,022    
(b) Data for the United Kingdom for 2009 are based on incomplete data for some jurisdictions for the financial year 2009/10, and adjusted for the missing 
jurisdictions using the latest available complete distribution (relative to the financial year 2006/07).
(a) Data relative to 2008. Data for 2009 from the Netherlands were not available.
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Fig. 169: Global seizures of cannabis herb, 1999-2009
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Fig. 170: Global seizures of cannabis resin, 1999-2009
Year 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Metric tons 891      1,051   942      1,088   1,392 1,472 1,274 1,008 1,303   1,648   1,261 
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Fig. 171: Global seizures of cannabis resin, 1999-2009
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Statistical annex Consumption
6.1.1.3 Cannabis
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6.1.3.2 Hepatitis C among injecting drug users
 
 -+ P'$(
 + ?@@D ::
 ?@@= D@


 ?@@B BD
  ?@@B ?
	 ?@@C <B
N ?@@: B<
G

 ?@@= ??
 E)O ?@@D A@
H$	 ?@@= :=
L ?@@B :@
 ?@@B CB
,	 ?@@= C?
,$ ?@@C ::
K ?@@= AD
E> ?@@B <@

)$ ?@@= C@

! ?@@C =@
M) ?@@B ?
 ?@@D DB
 ?@@D ?D
P> ?@@D ?@
+
 $) ?@@< ??

 ?@@D =?
H$
 ?@@C =B
H	LE' ?@@< <D
H
$ ?@@B </
 ?@@B =?
E
)$ ?@@B A@
&$	 ?@@C /
& ?@@C =@
I ?@@C A<
I ?@@= </
L
 ?@@B ?=
,$	 ?@@D D@
,$ ?@@B :B
M' ?@@D D=
M
 ?@@C B:
M
N)
 ?@@: C/
	&- ?@@B /C
$ ?@/@ AB
#$	 ?@@C D<
P$	 ?@@B =C
P
$ ?@@B ?B
 ?@@B :D

&	 ?@@B =C
$'> ?@@D /=
$' ?@@C ??
!E$	 ?@@D /=

> ?@@A /:
G		 ?@@C =@
 
$ ?@@C <A
#!S$	 ?@@D D@
6.2 PRODUCTION
241
2009 Change on 2009 2010
Net opium cultivation (after eradication)2 123,000 ha (102,000-137,000) 0%
123,000 ha 
(104,000-145,000)
Cannabis cultivation3 10,000-24,000 ha * 9,000-29,000 ha
No. of poppy-free provinces4 
No. of provinces affected by opium cultivation
20 
14
No change 
No change
20 
14
No. of provinces affected by cannabis cultivation5 17 +2 19
Opium poppy eradication 5,351 -57% 2,316 ha
Weighted average opium yield 56.1 kg/ha -48% 29.2 kg/ha
Average cannabis resin (garda) yield 143 kg/ha -12% 128 kg/ha
Potential production of opium 
 in % of global potential opium production
6,900 mt 
88%
-48% 3,600 mt 
74%
Potential production of cannabis resin (garda)6  1,500-3,500 mt * 1,200-3,700 mt
No. of household involved in opium cultivation7 
 in % of total population
245,200 
6%
+1% 248,700 
6%
No. of households involved in cannabis cultivation 40,000 (25,000-60,000) +18%
47,000 
(27,000-88,000)
Average farm-gate price (weighted by production) of dry opium  
at harvest time US$ 64/kg +164% US$ 169/kg
Average farm-gate price of cannabis resin (best quality, weighted by 
production) at the time of resin processing US$ 35/kg +146% US$ 86/kg
Total farm-gate value of opium production 
in % of GDP8
US$ 438 million 
4%
+38% US$ 605 million 
5%
Total farm-gate value of cannabis resin (garda) production US$ 39-94 million * US$ 85-263 million
Potential gross export value of opiates 
in % of GDP
US$ 2.8 billion 
26%
-50% US$ 1.4 billion 
11%
Potential net export value of opiates 
in % of GDP8  
US$ 2.3 billion 
21%
-48% US$ 1.2 billion 
9%
Average yearly gross income from opium of opium growing households US$ 1,786 +36% US$ 2,433
Average yearly gross income from cannabis of cannabis  
growing households US$ 1,553 +93% US$ 3,000
Income from opium per ha (gross/net) US$ 3,600 / 2,005 +36% / +45% US$ 4,900 / 2,900
Income from cannabis per ha (gross/net) US$ 3,900 / 3,341 +131% / +150% US$ 9,000 / 8,341
* Due to the uncertainty associated with the estimate, a change rate could not be calculated.
1 The information in this section comes from the Afghanistan Opium 
Survey 2010 (UNODC/Ministry of Counter Narcotics) and can 
also be found at http://www.unodc.org/unodc/en/crop-monitoring/
index.html, and the preliminary Afghanistan Cannabis Survey 2010. 
Source unless otherwise indicated: National Monitoring System sup-
ported by UNODC.
2 Figures in brackets represent the upper and lower bounds of the 
estimation range. 
3 Cannabis cultivation was defined as mono-crop cannabis cultivated 
in fields. Small-scale and mixed cultivation could not be considered. 
4 Out of 34 provinces of Afghanistan. Poppy-free provinces are those 
which are estimated to have less than 100 ha of opium cultivation. 
5 Cannabis cultivation was defined as mono-crop cannabis cultivated 
in fields. Small-scale and mixed cultivation could not be considered. 
6 Garda is the local term used in Afghanistan for the powder obtained 
by threshing and sieving the harvested and dried cannabis plants. 
This process is repeated several times and results in different quality 
of garda (first, second, …) with varying proportions of resin and 
other plant matter. Garda is further processed into hashish.
7 Estimates are based on a population of 24.0 million a for 2009  and a 
population of 24.5 million for 2010 and an average household size of 
6.2 persons. Source: Gov. of Afghanistan, Central Statistical Office.
8 Nominal GDP of the respective year. Source: Gov. of Afghanistan, 
Central Statistical Office. 
6.2.1 Afghanistan
Fact Sheet – Afghanistan Opium and Cannabis Surveys 20101
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Afghanistan, regional distribution of opium poppy cultivation (ha), 2009 to 2010
Region 2009 (ha) 2010 (ha) Change on 2009
2010 (ha)  
as % of total
Southern 103,014 100,247 -3% 82%
Western 18,800 19,909 6% 16%
Eastern 593 1,100 97% 1%
North-eastern 557 1,107 87% 1%
Central 132 152 15% 0.1%
Northern Poppy-free Poppy-free NA NA
Rounded Total 123,000 123,000 0% 100%
Afghanistan, opium poppy cultivation at provincial level, 2008-2010
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6.2.2 Bolivia (Plurinational State of)
2009 Change on 2009 2010
Coca cultivation 
Of which in the Yungas of La Paz
 in Chapare
 in Apolo
Of which permitted by Bolivian law 1008
30,900 ha
20,900 ha
9,700 ha
300 ha
12,000 ha 12,000 ha
Production of sun-dried coca leaf 54,800 mt
Potential production of cocaine HCl n.a.
National weighted average farm-gate price of coca leaf 
(outside state market)
US$ 4.9/kg
Total farm-gate value of coca leaf production
GDP10 
Farm-gate value of coca leaf production in per cent of GDP
Farm-gate value of coca leaf production in per cent of GDP  
of agricultural sector
US$ 265 million
US$ 13.0 billion
2%
 
14%
Reported eradication of coca bush* 6,341 ha +29% 8,200 ha
Reported seizure of sun-dried coca leaves* 1,624 mt -37% 1,016 mt
Reported seizure of cocaine base* 21,970 kg +17% 25,714 kg
Reported seizure of cocaine HCl* 4,922 kg -31% 3,390 kg
Reported destruction of coca laboratories11* 4,888 +21% 5,922
* As reported by the Government of the Plurinational State of Bolivia. Eradication: includes voluntary and forced eradication.
Fact Sheet – Bolivia Coca Survey 20109
The figures from the 2010 report on coca cultivation were not yet available at the time of printing  
of this report.
9 The information in this section comes from the report on Coca Cul-
tivation in Bolivia (UNODC/Government of Bolivia, June 2010), 
and can also be found on the internet ( http://www.unodc.org/
unodc/en/crop-monitoring/index.html). Source unless otherwise 
indicated: National Monitoring System supported by UNODC.
10 Source: Instituto Nacional de Estadística de Bolivia (INE).
11 Including installations producing cocaine base, HCl or “recycling” 
precursors. Excluding coca leaf maceration pits.
Statistical Annex Production
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6.2.3 Colombia
Fact Sheet - Colombia Coca Survey 201012
2009
Change on 
2009
2010
Net coca cultivation (on 31 Dec, rounded)
Without adjustmenfor small fields
With adjustment for small fields13
Of which14 Pacific region
 Central region
 Putumayo-Caquetá region
 Meta-Guaviare region
 elsewhere
68,000 ha
73,000 ha
27,020 ha
18,050 ha
9,620 ha
13,130 ha
5,320 ha
-16%
-15%
-5%
-15%
-23%
-34%
-11%
57,000 ha
62,000 ha
25,680 ha
15,310 ha
7,360 ha
8,710 ha
4,750 ha
Potential production of cocaine (100% purity)
Based on area without adjustment for small fields
Based on area with adjustment for small fields
410 mt 
n.a.
n.a. 
n.a.
n.a. 
350 ml (350-400)
Average farm-gate price of coca paste
Average wholesale price of cocaine*  
(of unknown purity in major cities)
US$956/kg
COP2,047,970/kg
 
US$2,147/kg
COP 4,587,000/kg
-6%
-6%
 
+14%
+1%
US$1,015/kg
COP1,923,000/kg
 
US$2,439/kg
COP4,623,000/kg
Total farm-gate value of the production of coca leaf 
and its derivatives US$496 million n.a.
 in per cent of GDP15 
 in per cent of agricultural sector
0.2%
3%
n.a.
n.a.
Reported aerial spraying of coca bush*
Reported manual eradication of coca bush*
Reported seizure of cocaine*
Reported destruction of coca processing laboratories*
 Of which cocaine HCl processing lab.
104,771 ha
60,544 ha
203 mt
2,888
278
-3%
-28%
-9%
-9%
101,939 ha
43,792 ha
215 mt
2,623
254
Reported opium poppy cultivation* 356 ha -3% 346 ha
Potential opium latex production** 26 mt
Potential heroin production (rounded) ** 1.1 mt
Average farm-gate price of opium latex*
Average wholesale heroin price*
US$358/kg
US$9,993/kg
+37%
+7%
US$489/kg***
US$10,667/kg***
Reported seizure of heroin* 732 kg -54% 337 kg
Note: Due to the introduction of an adjustment factor for small fields, 2009 figures are being revised.
* As reported by the Government of Colombia. 
** Own calculations based on regional yield figures and conversion ratios from US Government/DEA scientific studies.
*** Preliminary, refers to January to October 2010, only. 
12 The information in this section comes from the report on Coca 
Cultivation in Colombia (UNODC/Government of Colombia, June 
2011), and can also be found on the internet (http://www.unodc.
org/unodc/en/crop-monitoring/index.html). Source unless otherwise 
indicated: National monitoring system supported by UNODC. 
13 The spatial resolution of the satellite images (“pixel size”) used for 
coca monitoring limits the detection of small fields below 0.25 ha. 
Based on studies with very high resolution imagery, a correction 
factor was calculated to minimize this effect and improve the accu-
racy of the estimate. 
14 Regional area figures refer to area adjusted for small fields. 
15 GDP of the respective year as reported by the Government.
246
World Drug Report 2011 
0
1,000
2,000
3,000
4,000
5,000
6,000
Pr
ic
e 
p
er
 k
g
'000 COP/kg (nominal) 4,155 4,567 4,580 4,587 4,623
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US$/kg (nominal) 1,762 2,198 2,348 2,146 2,439
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Colombia, nominal and constant annual wholesale prices for cocaine HCl* (US$/kg and '000 COP/kg), 
2006 to 2010
*Cocaine of unknown purity. 
Source: DIRAN.
Colombia, annual farm-gate prices* for opium latex, 2006 to 2010
*Nominal prices. Source: DIRAN.
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Heroin (wholesale), '000 COP/kg  23,822  22,294  19,560  21,422  20,187 
Heroin (wholesale), US$/kg  10,103  10,780  9,950  9,993  10,667 
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Colombia, annual wholesale price of heroin,* 2006 to 2010
*Nominal prices for heroin of unknown purity. Source: DIRAN.
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Colombia, coca cultivation by region (ha), 2006-2010
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6.2.4 Lao People's Democratic Republic
Fact Sheet – Lao People’s Democratic Republic Opium Survey 201016
2009 Change on 2009 2010
Opium poppy cultivation 1,900 ha (900-3,000) +58%
3,000 ha 
(1,900-4,000)
Average dry opium yield17  6 kg/ha na 6 kg/ha
Potential production of dry opium 11 mt (5.4-18) +58%
18 mt 
(11.4-24.0)
Average retail/wholesale price of opium18  US$ 1,327 (350-2,440) +26%
US$ 1,670  
(580-2,700)
Eradication19  651 ha -11% 579 ha
Lao People’s Democratic Republic, annual opium prices (US$/kg), 2002 to 2010
Source: LCDC, Provincial authorities survey.
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16 The information in this section comes from the report on Opium 
Poppy Cultivation in South-East Asia (UNODC/Governments of 
Lao PDR and Myanmar), and can also be found on the internet 
(http://www.unodc.org/unodc/en/crop-monitoring/index.html). 
Source unless otherwise indicated: National monitoring system sup-
ported by UNODC. Figures in brackets represent the upper and 
lower bounds of the 90% confidence interval unless otherwise indi-
cated. 
17 In the absence of a recent yield survey, the yield per hectare estimated 
in 2007 was used.
18 Source: LCDC, Provincial authorities survey. Due to the limited 
market for opium, a clear distinction between farm gate, wholesale 
and retail prices could not be established. The range refers to the 
lowest and highest provincial price observed.
19 Source: LCDC. Eradication campaigns were conducted during and 
after the survey. 
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6.2.5 Myanmar
Fact Sheet - Myanmar Opium Survey 201020
2009
Change 
on 2009
2010
Opium poppy cultivation in Myanmar 
 
 Of which in Shan State
31,700 ha 
(24,000 - 42,900)
30,000 ha
(24,000 - 40,000)
+20%
 
+17% 
38,100 ha 
(23,200 - 53,900)
35,000 ha
(22,700 - 50,100)
Average opium yield (weighted by area) 10.4 kg/ha +46% 15.2 kg/ha
Potential production of dry opium
330 mt
(214 - 447)
+76%
580
(350 - 820)
Opium poppy eradication21 4,087 ha +102% 8,268 ha
Average farm-gate price of opium at harvest time US$ 317/kg -4% US$ 305/kg
Total potential farm-gate value of opium production22 
US$ 105 million
(68 - 142)
+68%
US$ 177 million
(107 - 250)
Estimated number of households involved in opium 
poppy cultivation 
 Of which in the Shan State
192,000
(160,000 - 225,000)
176,500
(141,200 - 235,300)
+17%
+17%
224,000 
(102,000 - 342,000)
206,000
(134,000 - 295,000)
Opium-producing households in Shan State: 
 Average yearly household income 
 Income from opium sales
 Per capita income
US$ 700
US$ 160
US$ 125
+19%23 
+125%
+19%
US$ 830
US$ 360
US$ 155
Non-opium poppy producing households in Shan State
 Household average yearly income 
 Per capita income
US$ 750
US$ 133
+13%24 
+17%
US$ 850
US$ 155
Numbers in brackets refer to the lower and upper bound of the 95% confidence interval.
20 The information in this section comes from the report on Opium 
Poppy Cultivation in South East Asia (UNODC/Governments of 
Lao PDR and Myanmar, December 2010), and can also be found 
on the internet (http://www.unodc.org/unodc/en/crop-monitoring/
index.html).
21 Source: CCDAC.
22 The farm-gate value should calculated with the price of dry opium. 
However, the price of dry opium is difficult to establish in Myanmar 
because of the selling and storing practices of the farmers. The farm-
gate value here is calculated with the price of fresh opium. This result 
in a lower estimate. 
23 This is equivalent to a 10% increase in constant 2009 Kyats.
24 This is equivalent to a 5% increase in constant 2009 Kyats.
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Myanmar, opium poppy cultivation by region (ha), 2008-2010
Myanmar, reported eradication of opium poppy by region (ha), 2006-2010
Region 2008 2009 2010
% of total area  
of opium poppy  
cultivation
East Shan 
9,300
(6,800 to 11,800)
11,900
(8,100 to 15,000)
12,100 
(6,200 to 19,000)
32%
North Shan
800
(400 to 1,200)
1,600
(390 to 2,900)
3,700 
(1,500 to 6,700)
10%
South Shan
15,500
(9,500 to 21,500)
16,500
(10,900 to 22,600)
19,200 
(9,400 to 31,500)
50%
Shan State total 25,300
30,000 
(24,000 to 40,000)
35,000
(22,700 to 50,100)
92%
Kachin
1,500
(1,100 to 1,900)
1,400
(1,100 to 1,700)
3,000
(500 to 3,800)
8%
Kayah
1,800
(1,800 to 2,500)
30025 
(60 to 700)
100 0.3%
National total 
(rounded)
28,500
(17,900 to 37,000) 
31,700
(20,500 to 42,800)
38,100
(23,200 to 53,900)
100%
Numbers in brackets refer to the lower and upper bound of the 95% confidence interval.
Region 2006 2007 2008 2009 2010
East Shan 32 1,101 1,249 702 868
North Shan 76 916 932 546 1,309
South Shan 3,175 1,316 1,748 1,466 3,138
Shan State total 3,283 3,333 3,929 2,714 5,316
Kachin 678 189 790 1,350 2,936
Kayah 0 12 12 14 13
Total within the surveyed area 3,961 3,534 4,731 4,078 8,265
Magwe 0 45 0 1 1
Chin 0 10 86 5 2
Mandalay 9 0 3 2 0
Sagaing 0 9 0 1 0
Other states 9 64 0 0 0
Total (national) 3,970 3,598 4,820 4,087 8,268
25 The estimates in Kayah for 2008 and 2009 are not directly compara-
ble due to a change in methodology.
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Myanmar, opium poppy cultivation (ha), 2006-2010
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6.2.6 Peru
Fact Sheet - Peru Coca Survey 201026
2009
Change on 
2009
2010
Coca cultivation
Of which in Alto Huallaga
 Apurímac-Ene
 La Convención-Lares
 Elsewhere
59,900 ha
17,500 ha
17,500 ha
13,200 ha
11,700 ha
+2%
-26%
+13%
+1%
+29%
61,200 ha
13,000 ha
19,700 ha
13,300 ha
15,200 ha
Weighted average sun-dried coca leaf yield 2,200 kg/ha -5% 2,100 kg/ha
Potential production of sun-dried coca leaf27 128,000 mt +1% 129,500 mt
Potential production of sun-dried coca leaf available for 
cocaine production
119,000 mt 
(102,400-134,200) +1%
120,500 mt 
(103,000-
136,300)
Average farm-gate price of sun-dried coca leaf
Average farm-gate price of sun-dried coca leaf 
(weighted by production)28 
Average farm-gate price of coca paste
Average price of cocaine HCl in coca cultivating regions
US$ 3.2/kg
US$ 3.0/kg 
US$ 778/kg
US$ 1,021/kg
-3%
-7%
-1%
-7%
US $ 3.1/Kg
US $ 3.1/Kg
US $ 784/Kg
US $ 947/Kg
Potential farm-gate value of sun-dried coca leaf29 US$ 384 million
Reported eradication of coca cultivation* 10,025 ha +2% 12,239 ha
Reported seizure of sun-dried coca leaves* 1,031 mt
Reported seizure of coca paste* 9,914 kg +34% 13,238 kg
Reported seizure of cocaine HCl* 10,744 kg +63% 17,544 kg
Reported destruction of coca laboratories30* 1,242 +6% 1,317
Of which cocaine HCl processing laboratories 25 21
* As reported by the Government of Peru. 
26 The information in this section comes from the report on Coca 
Cultivation in Peru (UNODC/Government of Peru, June 2011), 
and can also be found on the Internet (http://www.unodc.org/unodc/
en/crop-monitoring/index.html). Source unless otherwise indicated: 
National monitoring system supported by UNODC.
27 Includes all coca leaf potentially produced. For the calculation of coca 
leaf available for cocaine production, 9,000 mt of sun-dried coca leaf 
were deducted from this figure, which, according to Government 
sources, is the amount used for traditional purposes. 
28 The weighted average price takes into account that different amounts 
of coca leaf are sold in different regions at different price levels. 
29 Takes into account all coca leaf produced, irrespective of its use. 
For the calculation, the weighted average coca leaf price was used. 
30 Excluding coca leaf macerations pits.
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2.3 Annual prevalence
Methodology
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Considerable efforts have been made over the years to 
improve the estimates present d in the World Drug 
Report, which rely, to a large extent, on information 
submitted by Member States through the Annual Report 
Questionnaire (ARQ). Nonetheless, challenges remain 
in making such estimates because of data gaps and the 
varying quality of the available data. One major problem 
is the irregularity and incompleteness in ARQ reporting 
by Member States. Irregular reporting may result in 
absence of data for some years, and may influence the 
reported trend in a given year. Secondly, submitted 
questionnaires are not always complete or comprehen-
sive, and thirdly, much of the data collected are subject 
to limitations and biases. These issues affect the reliabil-
ity, quality and comparability of the information 
received. 
Sources of information
Under the International Drug Conventions, Member 
States are formally required to provide national drug 
control-related information annually to the ‘Secretary-
General’ of the United Nations (that is, to UNODC). 
The Commission on Narcotic Drugs, the UNODC 
governing body on illicit drug issues, developed the 
Annual Reports Questionnaire (ARQ) to collect this 
information. The 2011 World Drug Report is based pri-
marily on data obtained from the ARQs submitted by 
Governments over the period March 2010 to December 
2010. The data collected during this period normally 
refer to the drug situation in 2009. UNODC distrib-
uted the questionnaire to 194 countries, as well as 15 
territories, and received 107 replies to its questionnaire 
on Drug Abuse (Part II) and 106 replies to its question-
naire on Illicit Supply of Drugs (Part III). The best 
coverage was from countries in Europe (80% of coun-
tries filled in Part II and 88% filled in Part III), Asia 
(64% of countries filled in Part II and 62% Part III) and 
the Americas (59% of countries filled in Part II and 53% 
Part III). In the case of Africa, 27% of countries submit-
ted Part II and 25% Part III, and for Oceania, 12% of 
countries submitted Part II and Part III. 
In general, the quantity of information provided on 
illicit drug supply is significantly better than data pro-
vided on drug use. While 90% of the responses to Part 
III of the ARQ were ‘substantially’ completed, this was 
true for just 53% of the Part II. (ARQs which were more 
than 50% completed were classified as having been ‘sub-
stantially filled in’; less than 50% completion was classi-
fied as ‘partially filled in’). In order to analyse the extent 
to which Member States provided information, a 
number of key questions in the ARQs were identified:
 • For Part II, Drug Abuse, the key questions referred 
to: trends in drug use (78% of the countries return-
ing the ARQ), lifetime prevalence among the general 
population (54%), youth prevalence (54%), treatment 
(68%), prevalence of Hepatitis C (47%), HIV (48%) 
and  Hepatitis B (41%) among injecting drug users, 
and drug-related mortality (34%).
 • For Part III, the Supply of Drugs, this included the 
questions on: quantities of illicit drugs seized (95% 
of the countries returning the ARQ), traﬃcking (ori-
gin, routes and destination) (80%), prices and purity 
(85%), and drug-related arrests (91%). 
While the ARQ information forms the basis for the 
estimates and trend analysis provided in the World Drug 
Report, often, this is not sufficient to provide a compre-
hensive picture of the world’s illicit drug markets. When 
necessary and where available, ARQ data are supple-
mented with data from other sources. As in previous 
years, seizure data was complemented primarily with 
data and reports from international organizations such 
as INTERPOL, the World Customs Organization, 
Europol, the Organization of American States /Inter-
American Drug Abuse Control Commission (CICAD) 
as well as data provided by the Heads of National Law 
Enforcement Agencies at their regional meetings, and 
UNODC’s ‘Drug Use Information Network for Asia 
and the Pacific’ (DAINAP). In addition, Government 
reports and online resources were used. Other sources 
included data published by the United States Depart-
ment of State’s Bureau for International Narcotics and 
Law Enforcement Affairs in its International Narcotics 
Control Strategy Report. Price and purity data for 
Europe was complemented with data from the Euro-
pean Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) and Europol, whereas precursor data are 
from the International Narcotics Control Board. 
Demand-related information was obtained through a 
number of additional sources, including the drug con-
trol agencies participating in the DAINAP network, as 
well as various national and regional epidemiological 
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networks such as EMCDDA and CICAD. National 
government reports and scientific literature were also 
used.
Data on drug consumption
Overview
UNODC estimates of the extent of illicit drug use in the 
world have been published periodically since 1997. 
Assessing the extent of drug use (the number of drug 
users) is a particularly difficult undertaking because it 
involves measuring the size of a ‘hidden’ population. 
Margins of error are considerable, and tend to increase 
as the scale of estimation is raised, from local to national, 
regional and global levels. Regional and global estimates 
are reported as ranges to reflect the information gaps. 
The level of confidence expressed in the estimates varies 
across regions and drug types. 
A global estimate of the level of use of a specific drug 
involves the following steps:
1. Identiﬁcation and analysis of appropriate sources 
(starting from the ARQ);
2. Identiﬁcation of key benchmark ﬁgures for the level of 
drug use in all countries where data are available (an-
nual prevalence of drug use among the general popu-
lation aged 15-64) which then serve as ‘anchor points’ 
for subsequent calculations;
3. ‘Standardization’ of existing data if reported with a 
diﬀerent reference population than the one used for 
the World Drug Report (for example, from age group 
12 and above to a standard age group of 15-64) ;
4. Adjustments of national indicators to estimate an an-
nual prevalence rate if such a rate is not available (for 
example, by using the lifetime prevalence or current 
use rates; or lifetime or annual prevalence rates among 
the student population). This includes the identiﬁca-
tion of adjustment factors based on information from 
neighbouring countries with similar cultural, social 
and economic situations where applicable;
5. Imputation for countries where data is not available, 
based on data from countries in the same subregion. 
Ranges are calculated by considering the 10th and 
90th percentile of the subregional distribution;
6. Extrapolation of available results for a subregion were 
calculated only for subregions where prevalence esti-
mates for at least two countries covering at least 20% 
of the population were available. If, due to a lack of 
data, subregional estimates were not extrapolated, a 
regional calculation was extrapolated based on the 
10th and 90th percentile of the distribution of the 
data available from countries in the region.
7. Aggregation of subregional estimates rolled-up into 
regional results to arrive at global estimates.
For countries that did not submit information through 
the ARQ, or in cases where the data were older than 10 
years, other sources were identified, where available. In 
nearly all cases, these were government sources. Many 
estimates needed to be adjusted to improve comparabil-
ity (see below). 
In cases of estimates referring to previous years, the 
prevalence rates were left unchanged and applied to new 
population estimates for the year 2009. Currently, only 
two countries measure drug prevalence among the gen-
eral population on an annual basis. The remaining 
countries that regularly measure it - typically the more 
economically developed - do so usually every three to 
five years. Therefore, caution should be used when inter-
preting any change in global prevalence figures, as 
changes may in part reflect newer reports from countries 
or the exclusion of older reports, rather than actual 
changes in use at the global level.
Detailed information is available from countries in 
North America, a large number of countries in Europe, 
a number of countries in South America, the two large 
countries in Oceania and a limited number of countries 
in Asia and Africa. One key problem in national data is 
the level of accuracy, which varies strongly from country 
to country. Not all estimates are based on sound epide-
miological surveys. In some cases, the estimates simply 
reflect the aggregate number of drug users found in drug 
registries, which cover only a fraction of the total drug 
using population in a country. Even in cases where 
detailed information is available, there is often consider-
able divergence in definitions used, such as chronic or 
regular users; registry data (people in contact with the 
treatment system or the judicial system) versus survey 
data (usually extrapolation of results obtained through 
interviews of a selected sample); general population 
versus specific surveys of groups in terms of age (such as 
school surveys), special settings (such as hospitals or 
prisons), et cetera. 
To reduce the error margins that arise from simply 
aggregating such diverse estimates, an attempt has been 
made to standardize - as a far as possible - the heteroge-
neous data set. All available estimates were transformed 
into one single indicator – annual prevalence among the 
general population aged 15 to 64 - using transformation 
ratios derived from analysis of the situation in neigh-
bouring countries, and if such data were not available, 
using global average estimates. The basic assumption is 
that though the level of drug use differs between coun-
tries, there are general patterns (for example, lifetime 
prevalence is higher than annual prevalence; young 
people consume more drugs than older people; males 
consume more drugs than females; people in contact 
258
World Drug Report 2011 
with the criminal justice system show higher prevalence 
rates than the general population, et cetera) which apply 
to most countries. It is also assumed that the difference 
between lifetime prevalence and annual prevalence 
among the general population or between lifetime prev-
alence among young people and annual prevalence 
among the general population, except for emerging drug 
trends, do not vary greatly among countries with similar 
social, cultural and economic situations. 
Indicators used
The most widely used indicator at the global level is the 
annual prevalence rate: the number of people who have 
consumed an illicit drug at least once in the last twelve 
months prior to the study. Annual prevalence has been 
adopted by UNODC as one of key indicators to meas-
ure the extent of drug use. It is also part of the Lisbon 
Consensus on core epidemiological demand indicators 
which has been endorsed by the Commission on Nar-
cotic Drugs. The key indicators are:
1. Drug consumption among the general population 
(prevalence and incidence);
2. Drug consumption among the youth population 
(prevalence and incidence);
3.  High-risk drug use (number of injecting drug users 
and the proportion engaged in high-risk behaviour, 
number of daily drug users);
4. Utilization of services for drug problems;
5. Drug-related morbidity (prevalence of HIV, hepati-
tis B virus and hepatitis C virus among illicit drug 
consumers);
6. Drug-related mortality (deaths directly attributable to 
drug consumption).
Efforts have been made to present the drug situation 
from countries and regions based on these key epide-
miological indicators.
The use of annual prevalence is a compromise between 
lifetime prevalence data (drug use at least once in a life-
time) and data on current use (drug use at least once 
over the past month). The annual prevalence rate is usu-
ally shown as a percentage of the youth and adult popu-
lation. The definitions of the age groups vary, however, 
from country to country. Given a highly skewed distri-
bution of drug use among the different age cohorts in 
most countries, differences in the age groups can lead to 
substantially diverging results. 
Applying different methodologies may also yield diverg-
ing results for the same country. In such cases, the 
sources were analysed in-depth and priority was given to 
the most recent data and to the methodological 
approaches that are considered to produce the best 
results. For example, it is generally accepted that nation-
ally representative household surveys are reasonably 
good approaches to estimating cannabis, ATS or cocaine 
use among the general population, at least in countries 
where there are no adverse consequences for admitting 
illicit drug use. Thus, household survey results were usu-
ally given priority over other sources of prevalence esti-
mates. 
When it comes to heroin use (or drug injecting), or 
problematic use of cocaine and ATS, annual prevalence 
data derived from national household surveys tend to 
grossly under-estimate such use, because heroin or other 
problem drug users often belong to marginalized or less 
socially integrated groups, and may not be identified as 
living in a ‘typical’ household (they may be on the 
streets, homeless or institutionalized). Therefore, a 
number of ‘indirect’ methods have been developed to 
provide estimates for this group of drug users, including 
benchmark and multiplier methods (benchmark data 
may include treatment demand, police registration or 
arrest data, data on HIV infections, other services utili-
zation by problem drug users or mortality data), cap-
ture-recapture methods and multivariate indicators. In 
countries where there was evidence that the primary 
‘problem drug’ was opiates, and an indirect estimate 
existed for ‘problem drug use’ or injecting drug use, this 
was preferred over household survey estimates of heroin 
use. 
For other drug types, priority was given to annual prev-
alence data found by means of household surveys. In 
order to generate comparable results for all countries, 
wherever needed, the reported data was extrapolated to 
annual prevalence rates and/or adjusted for the preferred 
age group of 15-64 for the general population.

Extrapolation methods used
Adjustment for differences in age groups
Member States are increasingly using the 15-64 age 
group, though other groups are used as well. Where the 
age groups reported by Member States did not differ 
significantly from 15-64, they were presented as 
reported, and the age group specified. Where studies 
were based on significantly different age groups, results 
were typically adjusted. A number of countries reported 
prevalence rates for the age groups 15+ or 18+. In these 
cases, it was generally assumed that there was no signifi-
cant drug use above the age of 64. The number of drug 
users based on the population age 15+ (or age 18+) was 
thus shown as a proportion of the population aged 
15-64. 
Extrapolation of results from lifetime prevalence to 
annual prevalence 
Some countries have conducted surveys in recent years 
without asking the question whether drug consumption 
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took place over the last year. In such cases, results were 
extrapolated to reach annual prevalence estimates. For 
example, country X in West and Central Europe reported 
a lifetime prevalence of cocaine use of 2%. Taking data 
for lifetime and annual prevalence of cocaine use in 
countries of West and Central Europe, it can be shown 
that there is a strong positive correlation between the 
two measures (correlation coefficient R = 0.94); that is, 
the higher the lifetime prevalence, the higher the annual 
prevalence and vice versa. Based on the resulting regres-
sion curve (y = annual prevalence and x = lifetime prev-
alence) it can be estimated that a country in West and 
Central European with a lifetime prevalence of 2% is 
likely to have an annual prevalence of around 0.7% (see 
figure). Almost the same result is obtained by calculating 
the ratio of the unweighted annual prevalence rates of 
the West and Central European countries and the 
unweighted lifetime prevalence rate (0.93/2.61 = 0.356) 
and multiplying this ratio with the lifetime prevalence of 
the country concerned (2% * 0.356 = 0.7%).
A similar approach was used to calculate the overall ratio 
by averaging the annual/lifetime ratios, calculated for 
each country. Multiplying the resulting average ratio 
(0.334) with the lifetime prevalence of the country con-
cerned provides the estimate for the annual prevalence 
(0.387 * 2% = 0.8%). There is a close correlation 
observed between lifetime and annual prevalence (and 
an even stronger correlation between annual prevalence 
and monthly prevalence). Solid results (showing small 
potential errors) can only be expected from extrapola-
tions done for a country in the same region. If instead 
of using the West and Central European average (0.387), 
the ratio found in the USA was used (0.17), the estimate 
for a country with a lifetime prevalence of cocaine use of 
2% would decline to 0.3% (2% * 0.17). Such an esti-
mate is likely to be correct for a country with a drug 
history similar to the USA, which has had a cocaine 
problem for more than two decades, as opposed to West 
and Central Europe, where the cocaine problem is 
largely a phenomenon of the last decade. Therefore, data 
from countries in the same subregion with similar pat-
terns in drug use were used, wherever possible, for 
extrapolation purposes.
Both approaches—the regression model and the ratio 
model—were used to determine upper and lower uncer-
tainty range estimates calculated at a 90% confidence 
interval among those aged 15-64 years in the given 
country. The greater the range, the larger the level of 
uncertainty around the estimates. The range for each 
country is reported in the statistical annex, where avail-
able. 
Extrapolations based on school surveys
Analysis of countries which have conducted both school 
surveys and national household surveys shows that there 
is, in general, a positive correlation between the two 
variables, particularly for cannabis, ATS and cocaine. 
The correlation, however, is weaker than that of lifetime 
and annual prevalence or current use and annual preva-
lence among the general population. But it is stronger 
than the correlation between opiate use and injecting 
drug use-related HIV cases, and between treatment and 
drug use.
These extrapolations were conducted by using the ratios 
between school surveys and household surveys of coun-
tries in the same region or with similar social structure 
where applicable. As was the case with extrapolation of 
results from lifetime prevalence to annual prevalence, 
two approaches were taken: a) the unweighted average 
of the ratios between school and household surveys in 
the comparison countries with an upper and lower 
uncertainty range estimate calculated at a 90% confi-
dence interval; and b) a regression-based extrapolation, 
using the relationships between estimates from the other 
countries to predict the estimate in the country con-
cerned, with an upper and lower uncertainty range esti-
mate calculated at a 90% confidence interval. The final 
uncertainty range and best estimate are calculated using 
both models, where applicable.
Extrapolations based on treatment data
For a number of developing countries, the only drug 
use-related data available was treatment demand. In 
such cases, other countries in the region with a similar 
socio-economic structure were identified, which reported 
annual prevalence and treatment data. A ratio of people 
treated per 1,000 drug users was calculated for each 
country. The results from different countries were then 
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averaged and the resulting ratio was used to extrapolate 
the likely number of drug users from the number of 
people in treatment. 
Making regional and global estimates of the 
number of people who use drugs and the 
health consequences
For this purpose, the estimated prevalence rates of coun-
tries were applied to the population aged 15-64, as 
provided by the United Nations Population Division for 
the year 2009. 
Ranges have been produced to reflect the considerable 
uncertainty that arises when data are either extrapolated 
or imputed. Ranges (not absolutes) are provided for 
estimated numbers and prevalence rates in the Report. 
Larger ranges are reported for subregions and regions 
with less certainty about the likely levels of drug use – in 
other words, those regions for which fewer direct esti-
mates are available, for a comparatively smaller propor-
tion of the region’s population.
Countries with one published estimate (typically those 
countries with a representative household survey, or an 
indirect prevalence estimate that did not report ranges) 
did not have uncertainty estimated. This estimate is 
reported as the ‘best estimate’. 
To account for populations in countries with no pub-
lished estimate, the 10th and 90th percentile in the 
range of direct estimates was used to produce a lower 
and upper estimate. For example, there are three coun-
tries in the North Africa subregion with past year preva-
lence estimates for cannabis use: Algeria (a range from 
5.2 – 6.4), Egypt (2.9 – 9.6) and Morocco (4.2, a point 
estimate). These are extrapolated to the population of 
the remaining three countries without prevalence data, 
namely the Libyan Arab Jamahiriya, Sudan and Tunisia. 
The 10th percentile of the lower bound of the uncer-
tainty range (5,2, 2.9, and 4.2) is 3.2 and the 90th 
percentile of the upper bound (6.4, 9.6, and 4.2) is 8.9. 
The 3.2 and 8.9 figures are applied to the population of 
the remaining three countries without prevalence data 
for a subregional total lower and upper estimate. 
In some cases, not all of a region’s subregions had esti-
mates due to a lack of country level data. For example, 
past year amphetamines-group prevalence was calcu-
lated for East and South-East Asia and the Near and 
Middle East/South West Asia, however the remaining 
subregions – South Asia and Central Asia – had no esti-
mates. To calculate an overall Asia lower and upper 
estimate for populations in subregions with no pub-
lished estimate, all of the countries throughout the 
region were considered using the 10th and 90th percen-
tile of the regional distribution. These results were then 
combined with those subregions where an estimate was 
possible. One exception was South Asia’s subregional 
opiate and cannabis estimates. In this case, India’s popu-
lation accounts for 85% of the six countries in the sub-
region, but reliable estimates of drug use for India were 
not available. Instead of using all prevalence estimates 
for Asia (that is, estimates from the Near and Middle 
East to East Asia) to determine India’s contribution to 
the subregional uncertainty, it was determined that 
India’s contribution was best reflected by its neighboring 
countries. 
This produces conservative (wide) intervals for subre-
gions where there is geographic variation and/or vari-
ance in existing country-level estimates; but it also 
reduces the likelihood that skewed estimates will have a 
dramatic effect on regional and global figures (since 
these would most likely fall outside the 10th and 90th 
percentile). 
Estimates of the total number of people who used 
illicit drugs at least once in the past year
This year’s Report used the same approach as last year. 
Two ranges were produced, and the lowest and highest 
estimate of each the approaches were taken to estimate 
the lower and upper ranges, respectively, of the total 
illicit drug using population. This estimate is obviously 
tentative given the limited number of countries upon 
which the data informing the two approaches were 
based. The two approaches were as follows:
Approach 1.
The global estimates of the number of people using each 
of the five drug groups in the past year were added up. 
Taking into account that people use more than one drug 
type and that these five populations overlap, the total 
was adjusted downward. The size of this adjustment was 
made based upon household surveys conducted in the 
USA, Canada, Australia, the United Kingdom, Italy, 
Brazil, Mexico, Germany, Spain, Argentina, Chile, the 
Plurinational State of Bolivia, Peru, Indonesia and the 
Philippines, which assessed all five drug types, and 
reported an estimate of total illicit drug use. Across these 
studies, the extent to which adding each population of 
users overestimated the total population was a median 
value of 126%. The summed total was therefore divided 
by 1.26. 
Approach 2. 
This approach was based on the average proportion of 
the total drug using population that comprises cannabis 
users. The average proportion was obtained from house-
hold surveys conducted in the same countries as for 
Approach 1 Across all of these studies, the median pro-
portion of total drug users that comprised cannabis users 
was 75%. The range of cannabis users at the global level 
was therefore divided by 0.75.
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Estimates of the number of ‘problem drug users’
It is useful to make estimates of the number of drug 
users whose use is particularly problematic as this sub-
group of drug users is most likely to come to the atten-
tion of health and law enforcement. Moreover, this 
subgroup’s drug use has been estimated to cause the 
main public health and public order burden. 
The number of problem drug users is typically estimated 
with the number of dependent drug users. Sometimes, 
an alternative approach is used. The EMCDDA uses 
‘injecting or long duration use of opioids, ampheta-
mines or cocaine’ to guide country-level indirect preva-
lence estimation studies of problem drug use.
In this Report, as in previous years, each of the five range 
estimates of the number of people using each of the five 
drug groups was converted into a ‘heroin user equiva-
lent’. This was calculated through the use of ‘relative risk 
coefficients’ (see table) derived from the UNODC Harm 
Index. This method enables the aggregation of results 
from different drugs into one reference drug
A lower range was calculated by summing each of the 
five lower range estimates; the upper end of the range 
was calculated by summing the upper range of the five 
estimates. 
To obtain an estimate of the number of ‘problem drug 
users’, these totals were multiplied by the proportion of 
past year heroin users in the United States National 
Survey on Drug Use and Health (range 53-68% over the 
past six years of this survey). Hence, The LOW estimate 
of is the lower proportion (53%) multiplied by the lower 
estimated size of the heroin use equivalent population 
(28.6 million heroin user equivalents). The HIGH esti-
mate is the higher proportion (68%) multiplied by the 
higher estimated size of the heroin use equivalent popu-
lation (57.5 million heroin user equivalents). This gives 
a range of 15 to 39 million problem drug users globally.
Estimates of the prevalence of hepatitis C virus 
among injecting drug users
The prevalence of hepatitis C among injecting drug 
users is reported directly by Member States. The number 
of injecting drug users is obtained from the Reference 
Group to the UN on HIV and Injecting Drug Use1 
(preferred source), or otherwise as reported via the ARQ. 
To obtain an estimate of the prevalence at the regional 
and global level, country-level rates were weighted by 
the number of injecting drug users.
Estimates of the number of drug-related deaths
Drug-related deaths include those directly or indirectly 
caused by the intake of illicit drugs, but it may also 
include deaths where the use of illicit drugs was a con-
tributory cause, including cases where drug use was 
involved in the circumstances of the deaths (for exam-
ple, violence and traffic accidents). Member States 
report on drug-related deaths according to their own 
definitions and therefore care should be taken in making 
country comparisons.
The total number of drug-related deaths reported by 
Member States were aggregated at the regional level. To 
account for non-responding countries, an upper and 
lower estimate of the number of deaths was made using 
the 10th and 90th percentiles of the mortality rates for 
countries that did report within the same region. In 
North America, all countries reported and therefore, no 
range was given. In Oceania, only Australia reported on 
the number of deaths, and therefore, no variation in 
mortality rates across the region could be determined. 
Because of the lack of reported information on drug-
related deaths in Africa, an alternative source was used.2 
The global estimate of the number of drug-related 
deaths is the sum of the regional estimates. The overall 
estimated number of deaths for a region was presented 
as a range to account for uncertainty, and also presented 
as a rate per 1 million population aged 15-64 to allow 
for some degree of comparison across regions.
1 Mathers BM, Degenhardt L, Phillips B, et al. (November 2008). 
“Global epidemiology of injecting drug use and HIV among people 
who inject drugs: a systematic review”. Lancet 372 (9651): 1733–45
2 Degenhardt L, Hall W, Warner-Smith M, Lynskey M. Chapter 13: 
Illicit drug use. In: Ezzati M, Lopez A, Rodgers A, Murray CJL, 
eds. Comparative quantification of health risks: global and regional 
burden of disease attributable to selected major risk factors. Geneva, 
World Health Organization, 2003.
 
Treatment 
index
IDU Toxicity Deaths index
Relative risk 
 coefficient
  Index Index  (average treatment, IDU, toxicity, death)
Opiates 100 100 100 100 100
Cocaine 85.3 47.8 88 18.5 59.9
Amphetamines 20.1 59.5 32 6.8 29.6
Ecstasy 3.8 6.1 20.7 1 7.9
Cannabis 9 0 1.5 0.6 2.8
Relative risk coefﬁcient
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Drug cultivation, production and 
manufacture
Data on cultivation of opium poppy and coca bush and 
production of opium and coca leaf for the main produc-
ing countries (Afghanistan, Myanmar and the Lao Peo-
ple’s Democratic Republic for opium and Colombia, 
Peru and the Plurinational State of Bolivia for coca) are 
mainly derived from national monitoring systems sup-
ported by UNODC in the framework of its Global 
Illicit Crop Monitoring Programme (ICMP). Estimates 
of cannabis cultivation in 2009 and 2010 in Afghani-
stan, as well as cannabis cultivation in 2003, 2004 and 
2005 in Morocco, have also been produced by the 
ICMP-supported national monitoring systems. Esti-
mates for other countries have been drawn from ARQ 
replies and various other sources, including reports from 
Governments, UNODC field offices and the United 
States Department of State’s Bureau for International 
Narcotics and Law Enforcement Affairs.
A full technical description of the methods used by 
UNODC-supported national monitoring systems can 
be found in the respective national survey reports avail-
able at http://www.unodc.org/unodc/en/crop-monitor-
ing/index.html .
Net cultivation
Not all the fields on which illicit crops are planted are 
actually harvested and contribute to drug production. 
For Afghanistan, a system of monitoring opium poppy 
eradication is in place which provides all necessary infor-
mation to calculate the net cultivation area. In Myanmar 
and the Lao People’s Democratic Republic, the eradi-
cated area of opium poppy is partly taken into account 
for the estimation of the net cultivation area. Not 
enough information is available to consider eradication 
carried out after the time of the annual opium survey. 
A major difference between coca and other narcotic 
plants such as opium poppy and cannabis is that the 
coca bush is a perennial plant which can be harvested 
several times per year. This longevity of the coca plant 
should, in principle, make it easier to measure the area 
under coca cultivation. In reality, the area under coca 
cultivation is dynamic, changes all the time and it is dif-
ficult to determine the exact amount of land under coca 
cultivation at any specific point in time or within a given 
year. There are several reasons why coca cultivation is 
dynamic, including new plantation, reactivation of pre-
viously abandoned fields, abandonment, manual eradi-
cation and aerial spraying.3 
Depending on the purpose, different concepts of area 
3 Plant disease and pests are not considered here as their impact is likely 
to be captured in the coca leaf yield estimates.
under coca cultivation can by useful, taking into account 
some or all of the factors described above. From a gov-
ernment’s perspective, it may be interesting to monitor 
illicit cultivation attempts in a given year, by trying to 
capture all coca fields irrespective of whether they existed 
the whole year or only part of it (gross cultivation 
area). For estimating potential coca leaf and cocaine 
production, it would be necessary to measure the pro-
ductive area and how long the fields were productive in 
the course of a year (net productive area). For other 
reasons, the area under cultivation at a specific cut-off 
date may be chosen, for example, to monitor the effect 
of law enforcement activities implemented in the pre-
ceding period (area under cultivation at date x). By 
definition, the net productive area and the area under 
cultivation at point x will be smaller than the gross cul-
tivation area. 
The area affected by coca cultivation in a given year, or 
gross coca cultivation, can be defined as the totality of 
all coca fields existing in that year, irrespective of whether 
they were newly planted, reactivated, abandoned, eradi-
cated or sprayed during the course of that year. 
For the calculation of the net productive area, two 
dimensions should be considered: the duration over 
which the field was in existence and productivity. The 
area of fields which did not exist over the full 12 months 
of a year should be subtracted from the gross cultivation 
figure, by a factor expressing their reduced productive 
time. In addition to the time factor, the reduced produc-
tivity of certain field types and the effects of eradication 
and spraying need to be taken into account. 
 • Young plants in new coca ﬁelds are not as productive 
as mature coca bushes. 
 • Eradicated coca ﬁelds may be replanted but have a 
lower yields as plants are not mature
 • Coca bushes in a ﬁeld sprayed with herbicide may ei-
ther die (all or some) or have a reduced yield for some 
months.
 • A reactivated ﬁeld with mature coca bushes may reach 
full productivity faster than a newly planted ﬁeld but 
still be less productive than a well maintained ﬁeld
The effect on productivity could be added to the effect 
of time. For example, 20 ha which were eradicated after 
six months would only count as 10 productive hectares. 
Similarly, a factor can be introduced to reflect the 
reduced productivity as a result of aerial spraying. Efforts 
are being made to improve the estimation of the net 
productive area in the context of improving the accuracy 
of the cocaine production estimate. 
In 2010, for the first time, the net productive area was 
estimated in addition to the net cultivation on 31 
December, using information on manual eradication 
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and spraying of coca bush and other sources to model 
the permanence (that is, the productive time span) of 
coca fields. Permanence factors for abandoned, sprayed 
and eradicated coca fields were established and applied. 
The resulting area was considerably larger than the net 
area on 31 December. In addition, the previous approach 
of using the average net area on 31 December of the two 
last surveys was used to calculate coca leaf production to 
maintain comparability with previous years. More 
research is needed on the permanence of coca fields and 
the consequences for coca leaf yield to improve the net 
productive area estimate. 
In Colombia, an adjustment factor was introduced to 
include small coca fields into the area estimate, which 
could not be captured due to technical limitations. This 
was necessary as studies showed that the proportion of 
undetectable small fields below 0.25 ha has been increas-
ing in recent years. The adjustment for small fields leads 
to a higher area estimate and is considered more accu-
rate. Area figures for 2009 and 2010 were calculated 
with and without adjustment for small fields for compa-
rability reasons. The adjustment varies from year to year, 
depending on the proportion of small fields present in 
each cultivation region, and the contribution of each 
region to the total in a specific year. Thus, the adjust-
ment factor has to be calculated for each year separately. 
Efforts are under way to recalculate the time series for 
Colombia with the adjustment factor. As of now, the 
adjusted figures are only available for 2009 and 2010. 
In the Plurinational State of Bolivia and Peru, the coca 
area as estimated from satellite imagery in the second 
half of the year was used as a proxy for the net produc-
tive area. Thus, eradication of coca bush is partly taken 
into account for the estimation of the net cultivation 
area. Not enough information is available to also con-
sider eradication carried out after the time of the annual 
survey. 
For countries not covered by UNODC’s Illicit Crop 
Monitoring Programme, the reported net cultivation 
figure is used. 
Yield4 and production
To estimate potential production of opium, coca leaf 
and cannabis (herb and resin), the number of harvests 
per year and the total yield of primary plant material has 
to be established. The UNODC-supported national 
surveys take measurements in the field and conduct 
interviews with farmers, using results from both to pro-
duce the final data on yield.
Opium yield surveys are complex. Harvesting opium 
with the traditional lancing method can take up to two 
weeks as the opium latex that oozes out of the poppy 
capsule has to dry before harvesters can scrape it off and 
several lancings take place until the plant has dried. To 
avoid this lengthy process, yield surveyors measure the 
number of poppy capsules and their size in sample plots. 
Using a scientifically developed formula, the measured 
poppy capsule volume indicates how much opium gum 
each plant potentially yields. Thus, the per hectare 
opium yield can be estimated. Different formulas were 
developed for South-East and South-West Asia. In 
Afghanistan and Myanmar, yield surveys are carried out 
annually.
For coca bush, the number of harvests varies, as does the 
yield per harvest. In the Plurinational State of Bolivia 
and Peru, UNODC supports monitoring systems that 
conduct coca leaf yield surveys in several regions, by 
4 Further information on the methodology of opium and coca leaf 
yield surveys conducted by UNODC can be found in United 
Nations (2001): Guidelines for Yield Assessment of Opium Gum and 
Coca Leaf from Brief Field Visits, New York (ST/NAR/33).
 Net area (31 Dec 2010)* Average area 2009/2010 Net productive area 2010
Area under coca 
cultivation (ha)* 62,000 67,500 77,500
Application Used for area trend analysis
Used for coca leaf/cocaine  
estimate 
 (lower bound of range)
Used for coca leaf/cocaine 
estimate 
 (upper bound of range)
Colombia, area concepts used for coca cultivation and production estimates, 2010
* All rounded and adjusted for small fields
 2009 2010 Change on 2009
Area without adjustment 68,000 57,000 -16%
Adjustment for small fields 5,000 5,000 0%
Area with adjustment 73,000 62,000 -15%
 Colombia, adjustment of coca area for small ﬁelds, 2009-2010 (ha)
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harvesting sample plots of coca fields over the course of 
a year, at points in time indicated by the coca farmer. In 
Colombia, where the security situation does not allow 
for surveyors to return to the sample fields, only one 
harvest was measured, and the others were estimated 
based on information from the farmer. In all three coca 
cultivating countries, yield surveys are carried out only 
occasionally, due to the difficult security situation in 
many coca regions, and because of funding constraints. 
Conversion factors
The primary plant material harvested - opium in the 
form of gum or latex from opium poppy, coca leaves 
from coca bush, and the cannabis plant - undergo a 
sequence of extraction and transformation processes, 
some of which are done by farmers onsite, others by 
traffickers in clandestine laboratories. Some of these 
processes involve precursor chemicals and may be done 
by different people in different places under a variety of 
conditions, which are not always known. In the case of 
opium gum, for example, traffickers extract the mor-
phine contained in the gum in one process, transform 
the morphine into heroin base in a second process, and 
finally produce heroin hydrochloride. In the case of 
cocaine, coca paste is produced from either sun-dried (in 
the Plurinational State of Bolivia and Peru) or fresh coca 
leaves (in Colombia), which is later transformed into 
cocaine base, from where cocaine hydrochloride is pro-
duced.
The results of each step, for example, from coca leaf to 
coca paste, can be estimated with a conversion factor. 
Such conversion factors are based on interviews with the 
people involved in the process, such as farmers in 
Colombia, who report how much coca leaf they need to 
produce 1 kg of coca paste or cocaine base. Tests have 
also been conducted where so-called ‘cooks’ or ‘chemists’ 
demonstrate how they do the processing under local 
conditions. A number of studies conducted by enforce-
ment agencies in the main drug-producing countries 
have provided the orders of magnitude for the transfor-
mation from the raw material to the end product. This 
information is usually based on just a few case studies, 
however, which are not necessarily representative of the 
entire production process. Farmer interviews are not 
always possible due to the sensitivity of the topic, espe-
cially if the processing is done by specialists and not by 
the farmers themselves. Establishing conversion ratios is 
complicated by the fact that traffickers may not know 
the quality of the raw material and chemicals they use, 
which may vary considerably; they may have to use a 
range of chemicals for the same purpose depending, on 
their availability and costs; and the conditions under 
which the processing takes place (temperature, humid-
ity, et cetera) differ.
It is important to take into account the fact that the 
margins of error of these conversion ratios – used to 
calculate the potential cocaine production from coca leaf 
or the heroin production from opium - are not known. 
To be precise, these calculations would require detailed 
information on the morphine content of opium or the 
cocaine content of the coca leaf, as well as detailed infor-
mation on the efficiency of clandestine laboratories. 
Such information is limited. This also applies to the 
question of the psychoactive content of the narcotic 
plants. 
UNODC, in cooperation with Member States, is cur-
rently reviewing coca leaf to cocaine conversion ratios as 
well as coca leaf yields and net productive area esti-
mates.5 More research is needed to establish comparable 
data for all components of the cocaine production esti-
mate. 
Many cannabis farmers in Afghanistan and Morocco 
conduct the first processing steps themselves, either by 
removing the upper leaves and flowers of the plant to 
produce cannabis herb or by threshing and sieving the 
plant material to extract the cannabis resin. The herb 
and resin yield per hectare can be obtained by multiply-
ing the plant material yield with an extraction factor. 
The complex area of cannabis resin yield in Afghanistan 
was investigated in 2009 and 2010. The yield study 
included observation of the actual production of resin, 
which is a process of threshing and sieving the dried 
cannabis plants. In Morocco, this factor was established 
by using information from farmers on the methods used 
and on results from scientific laboratories. Information 
on the yield was obtained from interviews with cannabis 
farmers.6 The estimate of global cannabis herb and resin 
5 More detailed information on the ongoing review of conversion fac-
tors was presented in the 2010 World Drug Report, p.251 ff.
6 For greater detail on studies with cannabis farmers, see: UNODC, 
Enquête sur le cannabis au Maroc 2005, Vienna, 2007.
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production was not updated in 2010, given the high 
level of uncertainty and the continuing lack of informa-
tion in many cannabis-cultivating countries.
Potential production 
‘Potential’ heroin or cocaine production shows the total 
production of heroin or cocaine if all the cultivated 
opium or coca leaf were transformed into the end prod-
ucts in the respective producer country in the same year. 
However, part of the opium or coca leaf is directly con-
sumed in the producing countries or in neighbouring 
countries, prior to the transformation into heroin or 
cocaine. In addition, significant quantities of the inter-
mediate products, coca paste or morphine, are also con-
sumed in the producing countries. Some products such 
as opium can be stored for extended periods of time and 
be converted into intermediate or final products long 
after the harvest year. These factors are partly taken into 
account: for example, consumption of coca leaf consid-
ered licit in the Plurinational State of Bolivia and Peru 
is not taken into account for the transformation into 
cocaine. Other factors, such as the actual amount of 
illicit coca paste or opium consumption and storage, are 
difficult to estimate and were not taken into account. 
For cocaine, potential production of 100% pure cocaine 
is estimated. In reality, clandestine laboratories do not 
produce 100% pure cocaine but cocaine of lower purity 
which is often referred to as ‘export quality’. For heroin, 
not enough information is available to estimate the pro-
duction of heroin of 100% purity. Instead, potential 
production of export quality heroin is estimated, whose 
exact purity is not known and may vary. 
Although it is based on current knowledge on the alka-
loid content of narcotic plants and the efficiency of 
clandestine laboratories, ‘potential production’ is a 
hypothetical concept and is not an estimate of actual 
heroin or cocaine production at the country or global 
level. The concept of potential production is different 
from the theoretical maximum amount of drug that 
could be produced if all alkaloids were extracted from 
opium and coca leaf. The difference between the theo-
retical maximum and the potential production is 
expressed by the so-called laboratory efficiency, which 
describes which proportion of alkaloids present in plant 
material clandestine laboratories are actually able to 
extract. 
Colombia
In 2010, for the first time, the net productive area was 
estimated, in addition to the previous approach of using 
the average area under coca cultivation of the reporting 
year and the previous year. For reasons of comparability, 
the latter was presented as the point estimate. A range 
was calculated whereby the estimate based on the previ-
ous methodology forms the lower bound, and the 
cocaine estimate based on the net productive area the 
upper bound. For years before 2010, the net productive 
area had not yet been calculated at the time of printing.7
Peru
Potential cocaine production in Peru is estimated from 
potential coca leaf production after deducting the 
amount of coca leaf estimated to be used for traditional 
purposes according to Government sources (9,000 mt of 
sun-dry coca leaf ). 
The Plurinational State of Bolivia
Potential cocaine production in the Plurinational State 
of Bolivia is estimated from potential coca leaf produc-
tion after deducting the amount of coca leaf produced 
on 12,000 ha in the Yungas of La Paz where coca cultiva-
tion is authorized under national law. 
Drug trafficking
Seizures
The analysis presented in this report is mainly derived 
from the ARQ responses covering the March 2010–
December 2010 period. Including information from 
other sources, UNODC was able to obtain seizure data 
from 143 countries and territories for 2009. Seizures are 
thus the most comprehensive indicator of the drug situ-
ation and its evolution at the global level. Although sei-
zures may not always reflect trafficking trends correctly 
at the national level, they tend to show reasonable repre-
sentations of trends at the regional and global levels. 
Countries may report seizures of drugs using a variety of 
units, primarily by weight (kg) but also in litres, tablets, 
doses, blotters, capsules, ampoules, et cetera. When 
reporting about individual countries in individual years 
UNODC endeavours to be as faithful as possible to the 
reports received, but often it is necessary to aggregate 
data of different types for the purposes of comparison. 
For the purposes of aggregation, conversion factors are 
used to convert the quantities into ‘kilogram equiva-
lents’ (or ‘ton equivalents’). 
The conversion factors affect seizure totals of ampheta-
mine-type stimulants in particular, as a significant share 
of seizures of these drug types is reported in number of 
tablets. In previous editions of the World Drug Report, 
the factors used for ATS ranged between 30 mg and 100 
mg per tablet, and were intended to reflect the amount 
of controlled substance in the tablet; these factors 
depended on the drug type but not on the reporting 
country. 
7 More information on the results of the two approaches and the 
methodology used can be found in the report on coca cultivation 
in Colombia (UNODC/ Government of Colombia, June 2011) 
available on the internet at http://www.unodc.org/unodc/en/crop-
monitoring/index.html.
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Apart from seizures of ATS tablets, drug seizures are 
mainly reported to UNODC by weight. This includes 
seizures of ATS which are not seized in tablet form (for 
example, crystalline methamphetamine, ATS in powder 
form) as well as seizures of other drug types, such as 
heroin and cocaine. Moreover, ATS seizures made in 
tablet form are also sometimes reported by weight, and 
in some cases, the reported total weight possibly includes 
ATS seized in different forms. Reports of seizures by 
weight usually refer to the bulk weight of seizures, 
including adulterants and diluents, rather than the 
amount of controlled substance. Moreover, given the 
availability of data, accurate purity adjustments for bulk 
seizure totals in individual countries are feasible in a 
small minority of cases, as they would require informa-
tion on purity on a case by case basis or statistically 
calibrated data, such as a weighted average or a distribu-
tion. The bulk weight of tablets is easier to obtain and 
less variable.
To improve the comparability of seizure totals across 
different years and countries, UNODC has revised the 
conversion factors used for ATS tablets to reflect the 
bulk weight of the tablets rather than the amount of 
controlled substance. The factors used in this edition of 
the World Drug Report are based on available forensic 
studies and range between 90 mg and 300 mg, depend-
ing on the region and drug type. The change has been 
implemented for all years up to and including 2009 (see 
table). The conversion factors remain subject to revision 
as the information available to UNODC improves. 
All other conversion ratios remained unchanged from 
previous editions. Seizures quantified by volume (litres) 
are aggregated using a conversion ratio of  1 kilogram 
per liter, which applies to all drug types. Cannabis plants 
are assumed to have a weight of 100 grams. 
Moreover, at various points in the analysis, purity adjust-
ments are made where relevant and where the availabil-
ity of data allows.
UNODC continues to record and report the disaggre-
gated raw data, which are available in the seizure listings 
published online.8 In these tables, seizure quantities are 
reproduced as reported. In the rest of the Report, seizure 
data are often aggregated and transformed into a unique 
measurement: seizures in ‘kilogram equivalents’. For the 
purposes of the calculations a ‘typical consumption unit’ 
was assumed to be for cannabis herb, 0.5 g; for cannabis 
resin, 0.135 g; cocaine and morphine, 0.1 g; heroin, 
0.03 g; LSD, 0.00005 g (50 micrograms); and opium, 
0.3 g. For opiate seizures (unless specified differently in 
the text), it was assumed that 10 kg of opium were 
equivalent to 1 kg of morphine or heroin. Though these 
transformation ratios can be disputed, they provide a 
means of combining the different seizure reports into 
one comprehensive measure. The transformation ratios 
have been derived from those normally used by law 
enforcement agencies, in the scientific literature and by 
the International Narcotics Control Board, and were 
established in consultation with UNODC’s Laboratory 
and Scientific Section.
Trafficking routes and volumes
Information of trafficking routes was mainly obtained 
from analyses of individual drug seizures reported to 
UNODC, as well as analyses of trafficking routes 
reported by Member States. 
To calculate the volumes of drugs trafficked, the retail 
market size of each country was established by multiply-
ing the number of drug users with best estimates on per 
capita drug consumption, derived from local studies. 
There is, however, still a lack of scientific studies on per 
8 See http://www.unodc.org/unodc/en/data-and-analysis/WDR.html
Ecstasy 
(MDMA or analogue)
Amphetamine Methamphetamine
Non-specified  
amphetamines
Africa 271 250 250 250
Asia (excluding Near 
and Middle East/ 
South-West Asia)
300 250 90 250
Europe 271 253 225 250
Central and  
South America and 
the Caribbean
271 250 250 250
Near and Middle East/ 
South-West Asia 237 170 250 250
North America 250 250 250 250
Oceania 276 250 250 250
Weight of tablets in mg
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capita consumption and results must be treated as pre-
liminary. Based on the estimates of the volumes con-
sumed and knowing the main origins of the drugs and 
the seizures made, the volumes of the main drug flows 
were established
Market analysis
Drug price and purity data
Price and purity data, if properly collected and reported, 
can be powerful indicators of market trends. Trends in 
supply can change over a shorter period of time when 
compared with changes in demand and shifts in prices 
and purities are good indicators for increases or declines 
of market supply. Research has shown that short-term 
changes in the consumer markets are first reflected in 
purity changes while prices tend to be rather stable over 
longer periods of time. UNODC collects its price data 
from the ARQ, and supplements this data with other 
sources such as DAINAP, EMCDDA and Government 
reports. Prices are collected at farm-gate level, wholesale 
level (‘kilogram prices’) and at retail level (‘gram prices’). 
Countries are asked to provide minimum, maximum 
and typical prices and purities. When countries do not 
provide typical prices/purities, for the purposes of cer-
tain estimates, the mid-point of these estimates is calcu-
lated as a proxy for the ‘typical’ prices/purities (unless 
scientific studies are available which provide better esti-
mates). What is generally not known is how data were 
collected and how reliable it is. Although improvements 
have been made in some countries over the years, a 
number of law enforcement bodies have not yet estab-
lished a regular system for collecting purity and price 
data. 
Size and value of the market
Multiplying the volumes of drugs consumed in a coun-
try with the purity-adjusted retail prices gives the value 
of the market. In case no country-specific per capita use 
rates were available, regional estimates were used. Simi-
larly, in case no country-specific prices were available, 
average subregional prices were used as a proxy. The 
same principle was applied to purities. Average subre-
gional purities were used for countries that were not in 
a position to assess the purities of the drugs seized. 
Given the large number of assumptions in deriving the 
various country estimates from subregional or regional 
averages,  all sizes of the market estimates must be 
treated with caution. 
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